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The two mammalian sphingosine kinases, SK1 and SK2, produce the bioactive signalling 
lipid sphingosine-1-phosphate (S1P), which generally promotes cell survival, proliferation 
and migration. In line with this, SK1 is often found to be upregulated in human cancers, and 
overexpression of SK1 leads to neoplastic transformation of cells and tumour growth. 
However, despite generating the same product, most evidence to date suggests that SK2 acts 
in an opposing manner to promote cell death. In contrast, knockout mouse models indicate 
that there is at least some functional redundancy between the two SK isoforms, and 
targeting SK2 via genetic or pharmacological approaches in cancer models results in 
reduced tumour growth. Clearly, the roles of SK2 are poorly understood, but it is apparent 
that these unique and complex functions of SK2 are largely dictated by its differential 
subcellular localisation. SK1 is generally a cytoplasmic protein, but it can also be 
translocated to the plasma membrane where it mediates cell survival, proliferation and 
oncogenic signalling through the production of S1P. SK2, however, has been reported to 
localise to the nucleus, endoplasmic reticulum and mitochondria, and at these locations it 
appears to possess anti-proliferative and pro-apoptotic functions. SK2 has also been 
reported to localise to the plasma membrane, but its specific roles here have not been well 
characterised. Therefore, the main aims of this study were to explore the roles of SK2 in 
cancer, and to characterise novel mechanisms that regulate SK2 subcellular localisation, 
such as interacting proteins and post translational modifications, in order to gain a better 
understanding of this complex enzyme and the potential benefits of targeting SK2 in cancer.  
 
To explore the roles of SK2 in cancer, we examined the expression of SK2 in various 
human tumour samples using publically available datasets, and found that SK2 shows 
statistically significant upregulation in many cancers, but only to modest levels up to 2.5-
fold over normal tissues. As high-level SK2 overexpression has been previously shown to 
cause cell death, we explored the effects of low, close to physiological levels of SK2 
overexpression. By engineering a series of human and mouse cell lines overexpressing 
graded levels of SK2, we found that low-level SK2 overexpression increased cell survival 
and proliferation, and activated oncogenic signalling pathways. Notably, low-level SK2 
overexpression (5- to 10-fold over endogenous levels) was sufficient to induce neoplastic 
transformation of mouse fibroblasts, resulting in efficient tumour formation in vivo. These 
findings coincided with decreased nuclear localisation and increased plasma membrane 
xiv 
 
localisation of SK2, as well as increases in extracellular S1P formation. Hence, we have 
shown for the first time that SK2 can have a direct role in promoting oncogenesis. 
 
Furthermore, the Pitson laboratory previously identified a novel SK2-interacting protein, 
cytoplasmic dynein 1 intermediate chain 2 (IC-2), through a yeast two-hybrid screen, and 
characterising this interaction formed another part of these studies. We confirmed that SK2 
interacts physiologically with the dynein complex in cells via the IC subunit, and being a 
retrograde-directed transport motor complex, we found that dynein mediates the 
translocation of SK2 away from the plasma membrane. Interestingly, although IC-2 was 
identified in the yeast two-hybrid screen, SK2 interacts more robustly with the highly-
related IC-1 isoform, which is abundantly expressed in the brain. Strikingly, we found that 
IC-1 is downregulated 17-fold in glioblastoma multiforme (GBM) patient samples, which 
correlated with poorer survival of patients with this form of brain tumour. In line with a role 
for dynein in transporting SK2, low IC-1 expression in GBM cells coincided with more SK2 
localised to the plasma membrane, where we had found it to accumulate in an oncogenic 
setting. Re-expression of IC-1 in these cells reduced plasma membrane localised-SK2 and 
extracellular S1P formation, and notably, decreased tumour growth and tumour-associated 
angiogenesis in vivo. Thus, these findings demonstrate a novel tumour-suppressive function 
of dynein IC-1, and uncover new mechanistic insights into SK2 regulation. 
 
Through previous mass spectrometric analyses performed by the Pitson laboratory, it is 
evident that SK2 contains multiple uncharacterised phosphorylation sites that are not shared 
with SK1. We explored the function of one such site, Ser363, and found it to potentially 
regulate nuclear localisation of SK2. Furthermore, we identified SK2 as a bona fide 
substrate of glycogen synthase kinase 3 (GSK3) in vitro and in cells, involving residues 
Ser437 and Ser441, and we found that other phosphorylation events may act to regulate SK2 
catalytic activity. 
 
Overall, the studies outlined here have revealed a previously unreported role for SK2 in 
driving oncogenesis, and have described the characterisation of novel mechanisms that 
regulate the subcellular localisation of SK2. Therefore, these findings support the use of 
SK2 inhibitors as promising anti-cancer therapeutic agents. Furthermore, as the opposing 
functions of SK2 are largely dictated by it subcellular localisation, these findings may also 
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Chapter 1. Introduction 
 
Sphingolipids have emerged as important signalling molecules that can regulate a vast range 
of cellular processes, including cell survival, proliferation, migration, differentiation and 
inflammatory responses (Hannun & Obeid, 2008; Maceyka et al, 2009; Pitson & Pebay, 
2009). Although many enzymes are involved in regulating the relative levels of the 
sphingolipids, the sphingosine kinases (SKs), SK1 and SK2, are of particular interest as 
their activity can be dynamically regulated by external stimuli (Pitson, 2011). As a result, 
altering the levels or activity of the SKs can play a key role in controlling cell fate, making 
them attractive targets in the development of therapeutics for many diseases, particularly 
cancer (Cuvillier et al, 2010; Edmonds et al, 2011; Gault & Obeid, 2011; Newton et al, 
2015; Pitman & Pitson, 2010; Pitson, 2011; Pyne & Pyne, 2010). Indeed, given its 
unequivocal role in promoting cell survival and proliferation, targeting SK1 has proven 
effective in attenuating tumour growth and progression in a range of cancer models 
(reviewed in Pitman & Pitson (2010) and Pitman et al (2016)). However, investigating the 
therapeutic potential of targeting SK2 in cancer has only recently gained momentum, and 
although the findings are promising, the mechanisms behind SK2 function and regulation 
remain poorly understood. Indeed, the current literature focuses largely on SK1, and 
although the exact cellular roles of SK2 are yet to be fully deciphered, what is currently 
known about this isoform suggests that its functions and mechanisms of regulation are 
extremely complex. Therefore, this thesis examines the function of SK2, specifically in the 
context of neoplastic transformation, and also how SK2 is regulated within the cell by 
interacting proteins and post-translational modifications. 
 
 
1.1 Sphingosine-1-phosphate and sphingolipid signalling 
 
Sphingosine-1-phosphate (S1P) is a biologically active phospholipid that is derived from a 
network of sphingolipid synthesis and degradation pathways (Pitson, 2011). Ceramide 
resides at the centre of this network and can be deacylated by ceramidases to form 
sphingosine, which can in turn be phosphorylated by SKs to produce S1P (Figure 1.1). The 
aforementioned reactions are reversible and the only exit point from the cycle is the 
irreversible degradation of S1P to hexadecenal and phosphoethanolamine.  
Figure 1.1: Sphingolipid synthesis and degradation pathways 
Sphingolipid structures are shown with the key enzymes that catalyse their synthesis and 




S1P acts as both an extracellular and intracellular signalling molecule through a range of 
different pathways (Strub et al, 2010). Although export of the SKs from cells has been 
reported (Soldi et al, 2007; Venkataraman et al, 2006; Waters et al, 2003; Weigert et al, 
2010), the vast majority of S1P appears to be formed within cells (Tani et al, 2007). 
Intracellular S1P can then be transported out of the cell where it exists in high nanomolar 
concentrations in the blood (Sensken et al, 2010; Yatomi et al, 1997). This export is 
mediated by the transporter spinster homolog 2 (Spns2) (Hisano et al, 2012), as well as by 
members of the ABC transporter family (Sato et al, 2007; Takabe et al, 2010). Upon exit 
from the cell, S1P can bind to and activate a family of five G protein coupled receptors 
(GPCRs), referred to as S1P1-5 (Chun et al, 2010), to elicit autocrine or paracrine signalling 
(Figure 1.2). Interestingly, evidence suggests that S1P may engage its GPCRs by lateral 
diffusion within the outer leaflet of the plasma membrane, rather than directly from the 
extracellular space (Hanson et al, 2012). The S1P receptors are coupled to various 
heterotrimeric G proteins, which subsequently activate or inhibit a number of downstream 
signalling pathways via the modulation of extracellular signal-regulated kinases 1/2 
(ERK1/2), small GTPases (Rac and Rho), the phosphoinositide 3-kinase (PI3K)/AKT 
pathway, adenylyl cyclase (AC)/cyclic AMP, Jun N-terminal kinase (JNK), and 
phospholipase C (PLC) (Figure 1.2), ultimately promoting cell proliferation, survival and 
migration (Meyer zu Heringdorf & Jakobs, 2007; Nagahashi et al, 2014; Pyne & Pyne, 
2010). These responses can vary in a cell- or tissue-specific manner as a result of the 
differential expression of the S1P receptors and the various G proteins they couple to 
(Rosen et al, 2009). Notably, although S1P is present at high levels in blood, it is in 
relatively low abundance in tissues, resulting in an S1P gradient owing to differences in 
levels of S1P metabolic enzymes and substrate availability (Hla et al, 2008). 
 
In addition to its extracellular signalling roles, S1P can also act directly on a number of 
intracellular targets. Specifically, S1P has been shown to directly inhibit histone deacetylase 
(HDAC) 1/2 activity (Hait et al, 2009), bind to and stabilise human telomerase reverse 
transcriptase (hTERT) (Panneer Selvam et al, 2015), function as a co-activator to the 
transcription factor peroxisome proliferator-activated receptor (PPAR)γ (Parham et al, 
2015), interact with prohibitin 2 to mediate mitochondrial respiration (Strub et al, 2011) and 
possibly modulate the activity of p21-activated kinase 1 (Maceyka et al, 2008). 
Furthermore, upon induction of endoplasmic reticulum (ER)-stress, S1P was found to 
mediate NF-κB activation by directly binding to the heat shock proteins HSP90α and
Figure 1.2: Sphingosine-1-phosphate receptors
Downstream signalling pathways initiated by the sphingosine-1-phosphate (S1P) receptors.
S1P is a ligand for five G protein coupled receptors: S1P1, S1P2, S1P3, S1P4 and S1P5. Each
S1P receptor is coupled to different G-proteins, which individually regulate different
downstream signalling pathways, including adenylyl cyclase (AC)/cyclic AMP,
extracellular signal-regulated kinase (ERK), phospholipase C (PLC), phosphatidylinositol
3-kinase (PI3K), Rho family small GTPases, and Jun N-terminal kinase (JNK). Figure




GRP94, an interaction dependent on the presence of IRE1α (Park et al, 2016). It has also 
been described that S1P produced specifically by SK1 can directly bind to and activate the 
E3 ubiquitin ligase activity of TNF receptor-associated factor 2 (TRAF2), leading to the 
activation of NF-κB signalling (Alvarez et al, 2010). However, recent studies have since 
reported that SK1 genetic knockout does not recapitulate the disruption of TNF and NF-κB 
signalling observed as a result of the genetic deletion of TRAF2 in fibroblasts and 
keratinocytes (Etemadi et al, 2015; Xiong et al, 2013). Additionally, other studies were 
unable to detect an interaction between S1P and TRAF2 (Park et al, 2016). Therefore, the 
true function of S1P as a co-activator of TRAF2 will require further examination, as this 
role may be dependent on cell/tissue type and specific signalling events. Another study has 
suggested that S1P may contribute to cytochrome c release from mitochondria via 
modulation of BAK, although it should be noted that in this study a direct interaction of S1P 
with BAK was not demonstrated (Chipuk et al, 2012). 
 
Through the activation of these varied signalling pathways, S1P can act to promote cell 
survival, proliferation and migration, as well as regulate differentiation, angiogenesis and 
inflammation (Pebay et al, 2007; Pyne & Pyne, 2010; Spiegel & Milstien, 2003). 
Interestingly, an intracellular role for the S1P5 GPCR has also been proposed, where the co-
localisation of the receptor and SKs to centrosomes may indicate a novel function in 
regulating cell division (Gillies et al, 2009). Somewhat surprisingly, exogenously-expressed 
S1P2 was found to translocate to the nucleus of MDA-MB-231 breast cancer cells and 
consequently reduce cell growth, but only when SK2 or S1P4 were blocked (Ohotski et al, 
2014), suggesting that SK2-mediated signalling through S1P4 can block this anti-
proliferative nuclear function of S1P2. 
 
In contrast to S1P, the sphingolipids ceramide and sphingosine, which both lie directly 
upstream of S1P in the sphingolipid biosynthetic pathway (Figure 1.1), are promoters of 
apoptosis. Ceramide has been found to directly modulate a number of protein targets that 
appear to facilitate its pro-apoptotic functions, including protein phosphatases PP1 (Chalfant 
et al, 2004), PP2A (Chalfant et al, 2004) and PP2C (Perry et al, 2012), protein kinase C 
(PKC)ζ (Muller et al, 1995; Wang et al, 2005), the kinase suppressor of ras (KSR) (Zhang et 
al, 1997), cathepsin D (Heinrich et al, 2004), mixed lineage kinase (MLK) (Sathyanarayana 
et al, 2002), and inhibitor 2 of PP2A (I2PP2A/SET) (Mukhopadhyay et al, 2009; Saddoughi 
et al, 2013). Through these interactions, ceramide has been found to activate the stress-
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activated protein kinase pathway, mediate the dephosphorylation of Bcl-2, AKT, 
retinoblastoma protein and c-Jun, and trigger caspase-3 activation and mitochondrial-
mediated apoptosis (Hannun & Obeid, 2008; Modrak et al, 2006). It has also been suggested 
that ceramide itself can form pores in mitochondrial membranes, resulting in membrane 
permeabilisation and release of pro-apoptotic proteins (Siskind, 2005). Furthermore, the 
pro-apoptotic effects of sphingosine have, to date, been attributed to its ability to strongly 
inhibit PKC (Taha et al, 2006b), as well as to bind to the pro-survival adaptor protein 14-3-3 
and promote its phosphorylation and inactivation by kinases such as PKA and a cleaved 
fragment of PKCδ (Woodcock et al, 2010). Sphingosine has been shown to mediate 
inhibition of the ERK and AKT pathways, as well as induce caspase-dependent apoptosis 
via Bid cleavage, cytochrome c release and effector caspase activation (Taha et al, 2006b).  
 
Given these opposing functions, the current dogma is that a delicate balance must be 
maintained between the relative levels of pro-apoptotic ceramide and sphingosine and pro-
survival S1P, with this equilibrium, referred to as the ‘sphingolipid rheostat’, playing an 
important role in dictating cell fate (Cuvillier et al, 1996; Newton et al, 2015; Pyne & Pyne, 
2010). Sphingosine kinase is a central regulator of this equilibrium, residing at the critical 
junction between pro-proliferative, pro-survival S1P and pro-apoptotic sphingosine and 
ceramide (Figure 1.1). Therefore, understanding how the SKs are regulated is important to 
understand not only their role in controlling cell fate, but also in aberrant survival and 
proliferative signalling in disease states like cancer. Indeed, there are a multitude of studies 
that implicate S1P and the SKs in cancer development, survival and metastasis, and this 
field has been extensively reviewed (Cuvillier et al, 2010; Edmonds et al, 2011; Gault & 
Obeid, 2011; Newton et al, 2015; Pitman et al, 2016; Pitman & Pitson, 2010; Pitson, 2011; 
Pitson et al, 2011; Pyne & Pyne, 2010; Taha et al, 2006a). 
 
 
1.2 Sphingosine kinases 
 
Two SKs exist in mammalian cells, namely SK1 and SK2. In humans they are generated 
from two distinct genes, SPHK1 and SPHK2, which are located on chromosome 17 
(17q25.2) and 19 (19q13.2), respectively. All known eukaryotic SKs share five highly 
conserved regions within their sequence (termed C1 to C5; see Figure 1.3), which appear to 
encompass the regions necessary for ATP binding and catalysis 
SK1    1 ------------------------------------------------------------ 1 
SK2    1 MAPPPPPLAASTPLLHGEFGSYPARGPRFALTLTSQALHIQRLRPKPEARPRGGLVPLAE 60 
 
SK1    1 ------------------------------------------------------------ 1 
SK2   61 VSGCCTLRSRSPSDSAAYFCIYTYPRGRRGARRRATRTFRADGAATYEENRAEAQRWATA 120 
 
SK1    1 ----------MDPAGGPRGVLPRPCRVLVLLNPRGGKGKALQLFRSHVQPLLAEAEISFT 50  
SK2  121 LTCLLRGLPLPGDGEITPDLLPRPPRLLLLVNPFGGRGLAWQWCKNHVLPMISEAGLSFN 180 
 
SK1   51 LMLTERRNHARELVRSEELGRWDALVVMSGDGLMHEVVNGLMERPDWETAIQKPLCSLPA 110 
SK2  181 LIQTERQNHARELVQGLSLSEWDGIVTVSGDGLLHEVLNGLLDRPDWEEAVKMPVGILPC 240 
 
SK1  111 GSGNALAASLNHYAGYEQVTNEDLLTNCTLLLCRRLLSPMNLLSLHTASGLRLFSVLSLA 170 
SK2  241 GSGNALAGAVNQHGGFEPALGLDLLLNCSLLLCRGGGHPLDLLSVTLASGSRCFSFLSVA 300 
 
SK1  171 WGFIADVDLESEKYRRLGEMRFTLGTFLRLAALRTYRGRLAYLPVGRVGSKT-PA----- 224  
SK2  301 WGFVSDVDIQSERFRALGSARFTLGTVLGLATLHTYRGRLSYLPATVEPASPTPAHSLPR 360 
 
SK1  224 ------------------------------------------------------------ 224 
SK2  361 AKSELTLTPDPAPPMAHSPLHRSVSDLPLPLPQPALASPGSPEPLPILSLNGGGPELAGD 420 
 
SK1  225 --------------------SP------------------------------VVVQQGPV 234 
SK2  421 WGGAGDAPLSPDPLLSSPPGSPKAALHSPVSEGAPVIPPSSGLPLPTPDARVGASTCGPP 480 
 
SK1  235 DAHLVPLEEPVPSHWTVVPDEDFVLVLALLHSHLGSEMFAAPMGRCAAGVMHLFYVRAGV 294 
SK2  481 DHLLPPLGTPLPPDWVTL-EGDFVLMLAISPSHLGADLVAAPHARFDDGLVHLCWVRSGI 539 
 
SK1  295 SRAMLLRLFLAMEKGRHMEYECPYLVYVPVVAFRLEPKDGKGVFAVDGELMVSEAVQGQV 354 
SK2  540 SRAALLRLFLAMERGSHFSLGCPQLGYAAARAFRLEPLTPRGVLTVDGEQVEYGPLQAQM 599 
 
SK1  355 HPNYFWMVSG---CVEPPPSWKPQQMPPPEEPL 384 










Figure 1.3: Sequence alignment of SK1 and SK2  
A, Amino acid sequence alignment of the human SK1a and SK2a isoforms, with the five 
evolutionarily conserved regions, C1 to C5, indicated by black lines. Sequence alignment 
was performed using the Clustal Omega program via UniProt. B, The sphingosine kinases 
share 45% overall sequence identity within the regions that are conserved in both iso-
forms (grey shaded area). Unshaded regions represent sequences unique to each isoform. 




(Leclercq & Pitson, 2006; Pitman et al, 2015; Pitson, 2011). Although human SK1 and SK2 
vary considerably in size (384 and 618 amino acids for SK1a and SK2a, respectively) (Liu 
et al, 2000), they share 80% similarity and 45% overall sequence identity, with almost all of 
the polypeptide sequence of SK1 aligning with regions of the larger SK2 (Figure 1.3). The 
additional residues present in SK2 result from both its extended N-terminus and additional 
central proline-rich region not found in SK1, or in any other protein.  
 
Both SK1 and SK2 have multiple splice variants. Human SK1 has three known isoforms; 
SK1a, SK1b and SK1c, possessing 384, 402 and 470 amino acids, respectively. SK1a is the 
best characterised of the SK1 isoforms, and it is the main isoform referred to in the 
literature. SK1b and SK1c both contain N-terminal extensions with respect to SK1a, and are 
less well characterised. Human SK2 has four reported isoforms, two of which are well 
documented (SK2a and SK2b) and two are only putative (SK2c and SK2d). The SK2 splice 
isoforms will be discussed in more detail later in the chapter.  
 
The crystal structure for SK1 was only recently solved (Wang et al, 2013), but there is 
currently no crystal structure available for SK2, making comparisons between the two SKs 
difficult. However, the central proline-rich region of SK2 appears to coincide with the 
sphingosine-binding region of these enzymes (Pitson, 2011), and consistent with this, 
biochemical information regarding substrate specificity and inhibition of the two SKs 
suggest significant differences exist in their sphingosine binding regions. As discussed 
below, SK2 is more promiscuous than SK1 in the substrates it can phosphorylate, and 
several isoform-selective inhibitors that target the sphingosine binding site of these enzymes 
have been developed (French et al, 2010; Gao et al, 2012; Patwardhan et al, 2015). 
Interestingly, despite the high degree of sequence conservation in the putative ATP-binding 
regions of the SKs (Pitman et al, 2015), an ATP competitive inhibitor has been reported that 
shows high selectivity for SK1 over SK2 (Gao et al, 2012). Experimental evidence has 
revealed that the single point mutant G212E completely abolishes SK2 catalytic activity 
(Maceyka et al, 2005) just like the comparable G82D mutation in SK1 (Pitson et al, 2000b), 
via interfering with ATP binding (Pitson et al, 2002).  
 
While the activity of both SK isoforms can be enhanced by various cytokines and growth 
factors (discussed further below), both enzymes also possess intrinsic catalytic activity 
independent of eukaryotic post-translational modifications, that results in cellular SK 
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activity even in the absence of agonist stimulation (Kono et al, 2002; Pitson et al, 2000a). 
This basal SK activity has been proposed to facilitate a housekeeping role in maintaining 
cellular sphingosine and ceramide levels (Chan & Pitson, 2013). Although both SK 
isoforms are ubiquitously expressed in all human tissues and cells, some differential 
expression is apparent, with SK1 most highly expressed in lung, spleen and leukocytes 
(Melendez et al, 2000) whereas SK2 is highest in the kidney and liver (Liu et al, 2000). 
Furthermore, while both SKs are expressed throughout embryonic development in the 
mouse, SK1 expression peaks earlier (E7-E11), with SK2 being more strongly expressed in 
the later stages (E15-E17) (Liu et al, 2000).  
 
 
1.2.1 Roles and regulation of SK1 
 
Of the two SKs, SK1 is by far the most well studied. SK1 has been widely described as a 
pro-survival, pro-proliferative enzyme, demonstrated initially by studies showing that 
overexpression of SK1 increases cell survival and proliferation (Olivera et al, 1999) and 
induces neoplastic transformation (Xia et al, 2000). Numerous studies have implicated SK1 
in cancer development and progression, where expression levels of SK1 are found to be 
upregulated in a number of human solid tumours (Bayerl et al, 2008; French et al, 2003; 
Johnson et al, 2005; Kawamori et al, 2006; Li et al, 2008; Malavaud et al, 2010; Van 
Brocklyn et al, 2005), and higher SK1 expression in tumours is correlated with poor patient 
prognosis (Facchinetti et al, 2010; Li et al, 2008; Li et al, 2015; Li et al, 2009; Liu et al, 
2010; Long et al, 2010; Meng et al, 2014; Pan et al, 2011; Ruckhaberle et al, 2008; Sinha et 
al, 2011; Van Brocklyn et al, 2005; Zhang et al, 2014). Notably, targeting SK1 by chemical 
inhibition or genetic ablation has successfully reduced the growth of a wide variety of 
tumours in mice (Endo et al, 1991; French et al, 2003; French et al, 2006; Kawamori et al, 
2009; Kohno et al, 2006; Park et al, 1994; Pchejetski et al, 2008; Ponnusamy et al, 2012; 
Shirai et al, 2011; Sinha et al, 2011).  
 
The oncogenic signalling mediated by SK1 is dependent upon its activation and 
translocation to the plasma membrane (Pitson et al, 2005). SK1 is a cytoplasmic protein 
that, upon agonist stimulation, can be phosphorylated by ERK1/2 at Ser225, which results in 
a 14-fold increase in its catalytic activity (Pitson et al, 2003). SK1 can be transported to the 
plasma membrane via binding to calcium- and integrin-binding protein 1 (CIB1) (Jarman et 
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al, 2010). Interestingly, other mechanisms of SK1 translocation to the plasma membrane 
have also been documented, involving Gq-coupled receptor activation (ter Braak et al, 
2009) and constitutively-active oncogenic K-RasG12V (Gault et al, 2012). At the plasma 
membrane, SK1 catalyses the formation of S1P from plasma membrane-associated 
sphingosine, which appears to facilitate both the efficient release of S1P to act 
extracellularly on cell surface S1P receptors, as well as interaction with intracellular targets 
to mediate downstream signalling and promote cell survival, proliferation, migration, 
differentiation, angiogenesis and inflammation (Maceyka et al, 2009; Pitson & Pebay, 2009; 
Pyne & Pyne, 2010).  
 
 
1.2.2 Roles of SK2 
 
1.2.2.1    Apoptosis and cell cycle arrest  
 
Contrary to the roles of SK1 in pro-proliferative, pro-survival signalling, many of the early 
studies examining SK2 function found that its over-expression induced cell cycle arrest and 
apoptosis (Igarashi et al, 2003; Maceyka et al, 2005; Okada et al, 2005). A putative BH3 
domain was identified within SK2, which has been proposed to mediate its pro-apoptotic 
functions, at least in part, through  interaction with Bcl-xL, a pro-survival Bcl-2 family 
member (Liu et al, 2003). Since this SK2-Bcl-xL interaction was only demonstrated 
following SK2 overexpression, however, the physiological significance of this proposed 
association remains unclear. More recently, mitochondrial localisation of SK2, and 
specifically S1P generation at this site, was shown to contribute to BID-mediated activation 
of BAK, and subsequent mitochondrial membrane permeabilisation and cytochrome c 
release (Chipuk et al, 2012). Another study demonstrated that nuclear S1P and dihydro-S1P 
produced specifically by SK2 inhibited HDAC1/2 activity, leading to increased histone 
acetylation at distinct promoters, and resulting in enhanced transcription of cyclin-
dependent kinase inhibitor p21 and transcriptional regulator c-fos (Hait et al, 2009). While 
this is likely to contribute to the growth arrest previously associated with SK2, the notion 
that SK2 can act as an epigenetic and transcriptional regulator suggests that there may be 
other downstream effects of its nuclear activity yet to be elucidated. Indeed, as outlined 
below (section 1.2.2.2), S1P-mediated regulation of HDAC activity may also contribute to 
cell survival and proliferation. 
12 
 
While a number of the initial studies describing pro-apoptotic effects of SK2 are based on 
data from forced overexpression of this protein, several studies also suggest this role for 
endogenous SK2. For example, siRNA-mediated knockdown of endogenous SK2 in 
HEK293 cells or mouse embryonic fibroblasts prevented the induction of apoptosis by 
TNFα (Chipuk et al, 2012; Okada et al, 2005), while mesangial cells taken from Sphk2-/- 
mice displayed greater resistance to staurosporine-induced apoptosis than wildtype or 
Sphk1
-/- cells (Hofmann et al, 2008). Thus, these studies support the notion that SK2 can 
have an opposite role to SK1 in the control of cell survival. Indeed, the tissue distribution 
and developmental expression of the SKs would also suggest that they may have at least 
some differing roles.  
 
 
1.2.2.2    Cell survival, proliferation and cancer 
 
Although, as outlined above, there is compelling evidence to suggest that SK2 can have a 
physiological role in inducing apoptosis, there are now many studies also supporting a role 
for SK2 in promoting cell survival and proliferation, much like SK1. Indeed, there appears 
to be some functional redundancy between the two enzymes, as deletion of either Sphk1 or 
Sphk2 in mice produces no gross phenotype (Allende et al, 2004; Mizugishi et al, 2005; 
Zemann et al, 2007), and yet a double knockout of both genes is embryonic lethal as a result 
of defects in neurological and vascular development (Mizugishi et al, 2005). siRNA-
mediated knockdown of SK2 has been shown to enhance apoptosis and decrease 
chemotherapeutic resistance in a number of cancer cell types (Nemoto et al, 2009; Sankala 
et al, 2007; Schnitzer et al, 2009; Sun et al, 2015; Van Brocklyn et al, 2005). Notably, 
targeting SK2 in some cancer cell lines can have more of an anti-cancer effect than targeting 
SK1 (Gao & Smith, 2011; Van Brocklyn et al, 2005). Furthermore, a number of in vivo 
studies have reported that tumour growth can be significantly attenuated following the 
genetic ablation of SK2 in MCF-7 breast tumour xenografts (Weigert et al, 2009), or the 
pharmacological inhibition of SK2 in a range of cancer models in mice, including leukaemia 
(Liu et al, 2013; Wallington-Beddoe et al, 2014), multiple myeloma (Venkata et al, 2014), 
breast (Antoon et al, 2012; Antoon et al, 2011; French et al, 2010; Liu et al, 2013), kidney 
(Beljanski et al, 2011a), pancreatic (Beljanski et al, 2011a), liver (Beljanski et al, 2011b), 
lung (Panneer Selvam et al, 2015) prostate (Schrecengost et al, 2015) and colon cancer 
(Chumanevich et al, 2010; Xun et al, 2015). Increased SK2 expression levels have also been 
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shown to correlate with disease progression in non-small cell lung cancer (NSCLC) (Wang 
et al, 2014b) and multiple myeloma (Venkata et al, 2014), and poorer survival in NSCLC 
patients (Wang et al, 2014b).  
 
More recently, functional studies are beginning to uncover the mechanisms whereby SK2 
may be mediating cell survival and proliferation. It has been proposed that nuclear S1P, 
produced by SK2, can act as an antagonist to the retinoic acid receptor β (RARβ), 
attenuating ligand-stimulated tumour suppressor effects of this nuclear receptor in human 
colon carcinoma cells (Sun et al, 2012). Furthermore, the known role of SK2 in epigenetic 
regulation via HDAC1/2 inhibition has recently been shown to facilitate the upregulation of 
c-Myc mRNA and protein levels in acute lymphoblastic leukaemia (ALL) (Wallington-
Beddoe et al, 2014). Notably, S1P produced by nuclear-localised SK2 has also recently been 
proposed to bind to and stabilise hTERT, preventing telomere damage, delaying cell 
senescence and promoting tumour development (Panneer Selvam et al, 2015).  
 
SK2 has also been shown to play a role in TGFβ-induced migration of esophageal cancer 
cells (Miller et al, 2008), epidermal growth factor (EGF)-induced migration of breast cancer 
cells (Hait et al, 2005), and the migration and invasion of colorectal cancer cells (Zhang et 
al, 2016), suggesting a potential role for SK2 in metastasis. Indeed, it was recently 
demonstrated that SK2 is required for EGF-induced cancer cell invasion, by facilitating 
activation of ezrin-radixin-moesin (ERM) proteins through intracellular S1P production 
(Adada et al, 2015). Interestingly, a recent study proposed that the transcription factor 
CREB binds to the 5’ promoter region of SK2, and under conditions of serum-deprivation, 
SK2 is upregulated at the mRNA and protein level as a result of increased CREB binding, in 




1.2.2.3    Inflammation and immune cell regulation 
 
The role of the SKs in inflammation and immune cell function has been widely investigated, 
with most studies focusing on SK1 and its role in promoting inflammation. SK1 can be both 
post-translationally activated and transcriptionally upregulated by a number of inflammatory 
signalling molecules such as TNF-α, IL-1β, IFN-γ, IgE and C5a (Billich et al, 2005; Snider 
14 
 
et al, 2010; Xia et al, 1998), and shown to regulate monocyte, macrophage and neutrophil 
function during the inflammatory response (Snider et al, 2010). However, despite SK1 
having a clear role in promoting/enhancing inflammation, the role of SK2 in the 
inflammatory response is controversial, with many of the studies suggesting that SK2 may 
in fact be anti-inflammatory. For example, it was demonstrated, using a breast cancer 
xenograft model, that MCF-7 cells with stable shRNA-mediated SK2 knockdown had 
increased levels of pro-inflammatory cytokines and decreased levels of anti-inflammatory 
IL-10, which coincided with a decrease in tumour growth (Weigert et al, 2009). 
Furthermore, unlike SK1, siRNA-mediated knockdown of SK2 in a murine collagen-
induced arthritis model led to more aggressive disease and production of pro-inflammatory 
cytokines (Lai et al, 2009). Notably, Samy et al employed an adoptive transfer model of 
inflammatory bowel disease (IBD) where T cell-deficient C.B-17 scid mice were injected 
with Sphk2-/- T cells. They found that mice receiving these cells had increased levels of pro-
inflammatory cytokines and worsened intestinal inflammation than those receiving wildtype 
T cells, seemingly due to enhanced IL-2 responsiveness and increased expression of 
activated pSTAT5 (Samy et al, 2007). Therefore, SK2 may play a role in negatively 
regulating IL-2 signalling by attenuating STAT5 activation. 
 
In contrast to the studies described above, the pharmacological inhibition of SK2 by 
ABC294640 demonstrated anti-inflammatory effects in murine models of IBD (Maines et 
al, 2008; Maines et al, 2010) and in rodent models of inflammatory arthritis (Fitzpatrick et 
al, 2011a), suggesting that SK2 can promote inflammation. However, it is intriguing that 
opposite effects are observed only with the pharmacological inhibition of SK2 when 
compared to genetic ablation and RNAi, suggesting either that the loss of SK2 protein elicits 
a different effect than its inhibition, or that the purported ‘SK2-specific’ inhibitor may be 
having off-target effects on other pathways. Indeed, as discussed further below, the 
commonly used SK2 inhibitor ABC294640 is now known to modulate other targets in 
addition to SK2 (Pitman et al, 2016), suggesting that it may not be an ideal tool to 
interrogate SK2 function. 
 
It also appears that SK2 may have opposite roles to SK1 in mast cell function, but 
interestingly these roles seem to vary across species despite the sequences for both SK1 and 
SK2 being highly conserved between human and mouse. Upon IgE-mediated cross-linking 
of the FcεRI receptor, the Src family kinases Lyn and Fyn facilitate the activation and 
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translocation of the SKs to the plasma membrane (Olivera et al, 2006). In murine mast cells, 
SK2 has emerged as the major producer of intracellular S1P and, unlike SK1, appears to 
mediate calcium influx and initiate downstream activation of PKCα, PKCβ, and NF-κB, 
leading to degranulation and the production of eicosanoids and cytokines by these cells 
(Olivera et al, 2007). However, in human mast cells SK1 appears to be more important, 
initiating degranulation, migration and cytokine production, with the roles of SK2 
seemingly limited to the production of TNF-α and IL-6 (Oskeritzian et al, 2008). This 
variation in SK function between species is intriguing, in particular as exogenous S1P 
strongly induces degranulation of human mast cells (where SK1 is more important) but only 
weakly in murine mast cells (where SK2 plays more of a prominent role) (Olivera et al, 
2007; Oskeritzian et al, 2008). It has, therefore, been suggested that SK2 may function as an 
intrinsic regulator of mast cell responses, independent of the S1P receptors, whereas SK1, 
which is largely responsible for the production of circulating S1P, may regulate extrinsic 
mast cell responsiveness (Olivera et al, 2007; Oskeritzian et al, 2008). Indeed, sphingosine 
is reported to inhibit calcium influx (Blom et al, 2005; Mathes et al, 1998) and so SK2 may, 
at least in murine mast cells, function by decreasing the intracellular levels of sphingosine, 
thus allowing for calcium entry and the subsequent activation of downstream signalling 
pathways. 
 
S1P plays an important role in immune cell function by regulating lymphocyte egress from 
lymphoid tissues, and it appears that SK2 may mediate this response by regulating the 
transport and circulation of S1P between tissues. A study by Sensken et al (2010) 
demonstrated that the uptake of blood-borne S1P into peripheral tissues is SK2-dependent, 
and suggested that intracellular SK2 may play a role in importing S1P into cells and 
directing it to S1P lyase for degradation and maintenance of an S1P gradient. In agreement, 
Sphk2
-/- mice resist lymphopenia induced in wildtype mice by the inhibition of S1P lyase in 
lymphoid tissues (Sensken et al, 2010). This is an intriguing concept, particularly as a 
number of groups have reported that Sphk2-/- mice, surprisingly, have significantly increased 
levels of plasma S1P compared to wildtype mice (Kharel et al, 2012; Liang et al, 2013; 
Olivera et al, 2007; Sensken et al, 2010; Zemann et al, 2006). Another obvious explanation 
for this phenomenon is that SK1 may be upregulated as a compensatory mechanism for SK2 
ablation, and indeed this has been examined with somewhat conflicting results. Some 
studies have found no differences in SK1 mRNA levels or activity in Sphk2-/- mice, 
compared to wildtype mice (Sensken et al, 2010; Zemann et al, 2006). Conversely, a more 
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recent study found increased SK1 mRNA and protein levels in Sphk2-/- mice (Liang et al, 
2013), which was proposed to arise from a compensatory mechanism involving the 
reduction of HDAC1/2 inhibition by SK2, leading to a decrease in histone acetylation and 
an indirect transcriptional upregulation of SK1 (Hait et al, 2009; Liang et al, 2013). Notably, 
however, transgenic mice with ubiquitous overexpression of SK1 (approximately 20-fold 
over endogenous) did not show a significant increase in blood S1P levels (Takuwa et al, 
2010). 
 
Interestingly, murine SK2 was found to interact with the cytoplasmic region of the murine 
IL-12 receptor β1, mediating downstream IL-12 signalling and production of interferon-γ 
(Yoshimoto et al, 2003). It still remains to be elucidated if this interaction and function of 
SK2 also occurs in humans. 
 
 
1.2.2.4    Other diseases 
 
SK2 also appears to be influential in a number of other disease states. It has been 
demonstrated that the inhibition or downregulation of SK2 resulted in decreased proteolytic 
activity of beta-secretase 1 (BACE1), the rate-limiting enzyme for amyloid β (Aβ) peptide 
production (Takasugi et al, 2011). Targeting SK1 also had the same effect, although the role 
of SK2 in this process appeared more prominent. Interestingly, SK2 activity was also found 
to be upregulated in the brain of Alzheimer's disease patients, suggesting a role for SK2 in 
this disease (Takasugi et al, 2011).  
 
There are conflicting reports on the role of SK2 in ischemia-reperfusion (IR) injury, 
although generally it appears to play a protective role. The genetic deletion of SK2, but not 
SK1, in mice significantly increased kidney damage following renal IR (Jo et al, 2009), and 
SK2 was found to mediate the protective effects of ischemic preconditioning in cerebral 
(Wacker et al, 2009; Yung et al, 2012) and myocardial (Gomez et al, 2011; Ng et al, 2010; 
Vessey et al, 2011) IR injury. Interestingly, the protective effects of hypoxic 
preconditioning in cerebral ischemia appear to result, at least in part, from SK2-dependent 
upregulation of junctional proteins and concomitant increases in blood-brain barrier 
integrity, which is lost in Sphk2-/- mice (Ishizawa et al, 2015). Furthermore, cerebral 
ischemia was found to increase SK2 mRNA levels in the brain (Blondeau et al, 2007) and 
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hypoxic preconditioning rapidly and transiently upregulated SK2 activity and protein levels 
in cerebral microvessels (Wacker et al, 2009). Conversely, however, SK2 inhibition greatly 
reduced liver injury and improved survival following hepatic IR, coinciding with a 
reduction in liver S1P levels and mitochondrial permeabilisation (Shi et al, 2012), 
suggesting that the role of SK2 in IR injury may be tissue-specific.  
 
It has also been reported that the pharmacological inhibition of SK2 resulted in reduced 
disease severity in rodent models of osteoarthritis (Fitzpatrick et al, 2011b), rheumatoid 
arthritis (Fitzpatrick et al, 2011a), Crohn’s disease (Maines et al, 2010), ulcerative colitis 
(Maines et al, 2008) and diabetic retinopathy (Maines et al, 2006). It, therefore, appears that 
the roles of SK2 are complex and as such, the dysregulation of SK2 can facilitate the 
development of a number of highly varied disease states. In this regard, SK2 is emerging as 
a promising therapeutic target in many of these diseases. 
 
 
1.2.3 SK2 isoforms 
 
Two isoforms of SK2 have been described and characterised (Liu et al, 2000; Okada et al, 
2005). Unless otherwise specified, in the literature ‘SK2’ generally refers to the shorter 
isoform (SK2a or SK2-S), which is consequently the best characterised. The larger isoform 
(SK2b or SK2-L) has an additional 36 amino acids at the N-terminus and appears to arise 
from the use of an alternate start codon (Figure 1.4). While not expressed in mice (Okada et 
al, 2005), SK2b appears the predominant form of SK2 in several human cell lines and 
tissues. This may suggest that in fact SK2b is physiologically the more important human 
SK2 isoform, although very few studies have specifically examined its functions. It has been 
demonstrated that serum deprivation leads to an increase in SK2b expression and promotes 
the translocation of SK2b to the nucleus where it can inhibit DNA synthesis (Okada et al, 
2005). Furthermore, SK2b appears to phosphorylate some of its substrates at a higher rate 
than SK2a, including sphingosine (1.3-fold increase) and the sphingosine-like 
immunomodulatory pro-drug FTY720 (4-fold increase) (Billich et al, 2003). This trend 
would suggest that the N-terminal extension of SK2b may introduce a conformational 
change that promotes SK2 catalytic activity or stability (Billich et al, 2003). 
 




All known SKs possess five evolutionarily conserved regions (labelled C1 to C5) important for catalytic activity (Pitson et al, 2002). There are
two confirmed human SK2 isoforms (SK2a and SK2b) and two further putative or predicted SK2 isoforms. Compared to SK2a (Genbank
accession number AF245447), SK2b (RefSeq NM_020126) has an additional 36 amino acids at the N-terminus and appears to be the most
abundant human isoform (Okada et al, 2005). SK2c (Genbank accession number EF107108) has an additional N-terminal extension as well as
an extended C-terminus, however this putative isoform has only been detected at the mRNA level in some human cells (Alemany et al, 2007). A
fourth SK2 isoform (bottom) has been predicted by in silico analyses (Genbank accession number AK000599) which varies considerably at
the C-terminus compared to SK2a. The expression of this isoform has not been examined, but since it does not possess the conserved C4 and C5





A third isoform of SK2 (SK2c; Genbank accession number EF107108) has been reported, 
which possesses an N-terminal extension and an additional C-terminal sequence (Alemany 
et al, 2007) (Figure 1.4). SK2c mRNA has been reported to be detected in some human 
cells, but no other analysis of this putative SK2 isoform has been described (Alemany et al, 
2007). In silico analysis has predicted a fourth SK2 splice variant (Genbank accession 
number AK000599) that differs from SK2a at the C-terminus (from residue 256; see Figure 
1.4), although there is yet no physical evidence for the existence of this SK2 isoform. 
Notably, this putative SK2 variant does not possess the C4 and C5 regions proposed to 
contain the sphingosine binding and catalytic residues, respectively (Pitson, 2011; Yokota et 
al, 2004), which have previously shown to be essential for SK activity (Pitson et al, 2002). 
Therefore, even if this SK2 variant was expressed it is unlikely to have SK activity. 
 
 
1.2.4 SK2 substrate specificity 
 
Both SK1 and SK2 can utilise D-erythro-sphingosine and D-erythro-dihydrosphingosine as 
substrates, however SK2 appears to be more promiscuous and can phosphorylate a range of 
other biological and synthetic lipids with much greater efficiency than SK1 (Pitman & 
Pitson, 2010). These substrates include phytosphingosine (Liu et al, 2000), ω-biotinyl D-
erythro-sphingosine (Roberts et al, 2004), and surprisingly, the SK1-specific inhibitor D,L-
threo-dihydrosphingosine (Liu et al, 2000). SK2 is also responsible for phosphorylating the 
immunosuppressive agent FTY720, converting it to its active form FTY720-P (Billich et al, 
2003; Paugh et al, 2003; Sanchez et al, 2003). Although SK1 can also phosphorylate 
FTY720 in vitro, albeit less efficiently than SK2 (Billich et al, 2003; Kharel et al, 2005; 
Paugh et al, 2003), levels of FTY720-P in Sphk2-/- mice administered FTY720 are 
negligible, indicating that SK1 does not significantly contribute to FTY720 phosphorylation 
in vivo (Kharel et al, 2005). The ability of SK2 to phosphorylate a larger pool of substrates 
would suggest that the sphingosine binding pockets of SK1 and SK2 differ slightly in 
conformation. Although the functional significance of this is currently unknown, it has 
allowed for these subtle structural differences to be exploited in the generation of isoform-





1.2.5 SK2-specific inhibitors 
 
A number of SK inhibitors have been generated that show potential for development as 
therapeutics for cancer and some other diseases (Pitman et al, 2016; Pitman & Pitson, 2010). 
The majority of these either specifically inhibit SK1 or both SK isoforms. Within the last 
seven years, however, several SK2-selective inhibitors have emerged, some of which 
demonstrate promising therapeutic properties. These inhibitors have been previously 
reviewed in detail (Neubauer & Pitson, 2013; Pitman et al, 2016), and so here, those that 
have been well characterised, show promising therapeutic effects and/or closely mimic 
genetic depletion of SK2 will be discussed. 
 
The first described SK2-selective small molecule inhibitor, ABC294640, acts in a 
sphingosine-competitive manner and has been shown to significantly decrease tumour 
growth in vivo in an array of different tumour models in mice (Antoon et al, 2012; Antoon 
et al, 2011; Beljanski et al, 2011a; Beljanski et al, 2011b; Chumanevich et al, 2010; French 
et al, 2010; Panneer Selvam et al, 2015; Schrecengost et al, 2015; Venant et al, 2015; 
Venkata et al, 2014; Wallington-Beddoe et al, 2014; Xun et al, 2015). There are conflicting 
reports on the mode of action whereby ABC294640 induces cell death, with some studies 
demonstrating that apoptotic pathways are activated (Antoon et al, 2012; French et al, 
2010), and others describing the presence of autophagy markers (Beljanski et al, 2010; Gao 
et al, 2012). However, it has been noted that, in addition to SK2 inhibition, ABC294640 can 
act as a weak antagonist to the estrogen receptor (ERα) (Antoon et al, 2010), and more 
recently, inhibit dihydroceramide desaturase (Des1) activity and induce its proteasomal 
degradation (McNaughton et al, 2016; Venant et al, 2015). Furthermore, ABC294640 has 
been reported to promote the degradation of SK1, c-Myc, androgen receptor and Mcl-1 
(McNaughton et al, 2016; Venant et al, 2015; Venkata et al, 2014), although the 
mechanisms by which it achieves this are unclear. Most notably, administration of 
ABC294640 in vivo resulted in reduced levels of circulating S1P (Beljanski et al, 2011b), 
which is in stark contrast to the striking increase in circulating S1P levels observed in 
Sphk2
-/- mice (Kharel et al, 2012; Liang et al, 2013; Olivera et al, 2007; Sensken et al, 2010; 
Zemann et al, 2006). Therefore, the anti-tumour effects of ABC294640 may not be entirely 
attributed to SK2 inhibition, and its off-target actions will need to be considered when 




Despite this, ABC294640 also seems to have therapeutic potential for a number of other 
diseases, where attenuated disease progression was observed in rodent models of 
osteoarthritis (Fitzpatrick et al, 2011b), rheumatoid arthritis (Fitzpatrick et al, 2011a), 
Crohn’s disease (Maines et al, 2010), ulcerative colitis (Maines et al, 2008) and diabetic 
retinopathy (Maines et al, 2006). Hence, ABC294640 appears to have significant 
therapeutic potential and as such, this compound has successfully passed Phase I clinical 
trials in patients with advanced solid tumours, and is now commencing Phase I/II clinical 
trials for the treatment of refractory/relapsed diffuse large B-cell lymphoma. Additional 
Phase II clinical trials using ABC294640 are also planned to commence for the treatment of 
multiple myeloma and advanced hepatocellular carcinoma. 
 
A more recently developed SK2-specific inhibitor, K145, is also demonstrating promising 
anti-cancer properties. K145 also acts in a competitive manner with respect to sphingosine, 
and shows no significant inhibition of SK1 or ceramide kinase at concentrations up to 10 
µM (Liu et al, 2013). Cellular studies demonstrated that K145 can inhibit growth and induce 
apoptosis in U937 human leukaemia cells. In vivo, K145 was found to reduce tumour 
volume in JC mammary adenocarcinoma and U937 leukaemia xenograft models (Liu et al, 
2013), with comparable anti-tumour activity by both oral administration (50 mg/kg) and i.p. 
injection (15 mg/kg).  
 
SLR080811 has also been described as a sphingosine-competitive SK2-specific inhibitor 
(Kharel et al, 2012). Interestingly, SLR080811 was not found to have significant effects on 
survival or proliferation of U937 human leukaemia cells, despite reducing S1P generation 
and total S1P levels in these cells (Kharel et al, 2012). The reasons for this unexpected 
finding remain unclear, with further studies required to examine if this is specific to this cell 
line or a more general effect. Notably, unlike other purported SK2-specific inhibitors, 
administration of SLR080811 in vivo resulted in an increase in blood S1P levels in wildtype 
mice, which is the same phenomenon observed in Sphk2-/- mice (Kharel et al, 2012). 
Therefore, SLR080811 may be a useful tool to study SK2 biology as it seems to more 
closely recapitulate the genetic deletion of SK2. Recently, the same group reported another 
SK2-specific inhibitor, SLP120701, which also caused decreased S1P levels and increased 
sphingosine levels in U937 cells, as well as increased circulating S1P levels in vivo 
(Patwardhan et al, 2015). However, again this inhibitor was not found to induce any 
cytotoxic effects on U937 cells in vitro (Patwardhan et al, 2015). 
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The Pitson Laboratory also recently developed a dual SK1/SK2 inhibitor, MP-A08, which is 
a first-in-class ATP-competitive small molecule inhibitor (Pitman et al, 2015). MP-A08 
inhibits SK2 with somewhat higher affinity than SK1, with Ki values of 6.9 µM and 27 µM, 
respectively. In vitro, MP-A08 decreased the proliferation and neoplastic growth of a 
number of human cancer cell lines, whilst not affecting the growth of untransformed human 
fibroblasts (Pitman et al, 2015). Furthermore, MP-A08 significantly reduced tumour burden 
in vivo in A549 human lung adenocarcinoma xenografts in mice, owing to increased 
apoptosis and decreased angiogenesis within the tumour (Pitman et al, 2015). 
 
Interestingly, recently developed potent SK1-selective inhibitors have demonstrated 
surprisingly limited anti-cancer properties compared to less isoform-specific SK inhibitors 
(Gao et al, 2012; Kharel et al, 2011; Schnute et al, 2012). This notion, coupled with the 
promising anti-cancer effects of the current SK2-specific inhibitors, suggests that in some 
cancers SK2 may be a more important target for cancer therapy.  
 
 
1.2.6 Regulation of SK2  
 
1.2.6.1    SK2 activation 
 
Like SK1, the catalytic activity of SK2 can be rapidly increased upon stimulation by a 
number of agonists, including EGF (Hait et al, 2005), TNFα (Mastrandrea et al, 2005), IL-
1β (Mastrandrea et al, 2005), cross-linking of the IgE receptor FcεRI (Olivera et al, 2006), 
and phorbol esters (Hait et al, 2005). Hypoxia was also found to rapidly activate SK2 in vivo 
(Wacker et al, 2009) and in cultured lung cancer cells (Schnitzer et al, 2009). Like SK1, the 
mechanism of SK2 activation involves phosphorylation by ERK1/2 (Hait et al, 2007). In 
cells, agonist-induced activation of SK2 increases its catalytic activity by 2- to 6-fold (Hait 
et al, 2005), which is comparable to that observed for SK1 (Pitson et al, 2003). Interestingly, 
however, in vitro phosphorylation of SK2 by ERK1 resulted in a modest doubling of 
catalytic activity of this enzyme (Hait et al, 2007), which is less than the 14-fold increase 






1.2.6.2    Post-translational modifications of SK2 
 
Although the activating phosphorylation site in SK1 (Ser225) occurs within a region that is 
divergent in SK2, studies have shown that SK2 catalytic activity also increases following 
phosphorylation by ERK1/2 (Hait et al, 2007). This activation of SK2 has been suggested to 
involve the phosphorylation of Ser351 and/or Thr578 on SK2a (Ser387 and Thr614 on 
SK2b) (Hait et al, 2007), although direct evidence for this is lacking. For example, in this 
study, Hait and colleagues demonstrated that mutating Ser351 or Thr578 to alanine reduced 
ERK1-mediated phosphorylation of SK2, and they showed that ERK1 can modestly activate 
SK2 in vitro, but they did not then examine or compare the ability of SK2 S351A or T578A 
mutants to be activated by ERK1 (Hait et al, 2007). Furthermore, mutation of Ser351 to 
alanine resulted in the same level of activity as wildtype SK2 (Hait et al, 2007), and Ser351 
is not conserved in mouse or rat SK2, making its role in SK2 activation doubtful. Therefore, 
further characterisation of the activating phosphorylation site on SK2 is still required. 
Phosphorylation of SK2 also appears to regulate its nuclear/cytoplasmic shuttling, with 
protein kinase D (PKD)-mediated phosphorylation of either Ser419 or Ser421 within the 
NES of SK2 promoting its nuclear export (Ding et al, 2007).  
 
Mining of global phosphoproteome studies and the PhosphositePlus resource (Hornbeck et 
al, 2012) has revealed 13 other Ser/Thr phosphorylation events in endogenous human SK2, 
most of which occur within unique regions of SK2 not conserved in SK1 (Figure 1.5). Nine 
of these residues are conserved in mouse and rat, while another three phosphorylations have 
been detected in mouse and rat SK2 (see Figure 1.5) but have yet to be confirmed in human 
(Huttlin et al, 2010). No functional studies have been performed to define the regulatory 
significance of these novel phosphorylation sites. However, it is possible that these 
modifications play a role in the isoform-specific regulation of SK2 and may therefore 
provide an elegant yet undoubtedly complex mechanism to allow for the emerging 
functional complexity of SK2. 
 
 
1.2.6.3    SK2 subcellular localisation 
 
The subcellular localisation of the SKs, and hence the compartmentalisation of generated 









Figure 1.5: SK2 post-translational modifications and regulatory domains 
SK2 contains two unique regions within its sequence not conserved in SK1, or in any other 
protein. These regions, the N-terminus and the central proline-rich region (white), have been 
expanded to show the amino acid sequence. The five evolutionarily conserved regions, C1 
to C5, are shown in purple. The SK2b isoform is shown here. SK2 possesses a nuclear 
localisation signal (NLS) within the N-terminus and a nuclear export signal (NES) within 
the central region. Data from direct analysis of SK2 or from global phosphoproteomic 
studies have identified a number of SK2 phosphorylation sites. Phosphorylation events 
detected in human SK2 where the site is conserved in mouse or rat SK2 sequence are shown 
in red, while those not conserved in rodent SK2 are shown in white. Phosphorylation events 
detected in mouse or rat SK2 where the site is conserved in the human sequence are shown 
in yellow. Ser355, Thr359 and Thr371 were identified in untreated HeLa cells (Hornbeck et 
al, 2012). Ser105 and Ser107 were identified in HeLa cells treated with rapamycin and EGF 
(Chen et al, 2009). Ser387, Ser389, Thr404, Ser414 and Ser484 were identified in HeLa 
cells treated with double thymidine block (G1- or S-phase) or nocodazole (M-phase) (Daub 
et al, 2008; Dephoure et al, 2008). Ser399, Ser414, Ser473 and Ser477 were identified in 
HEK293 cells stably transfected with angiotensin II (Ang II) type 1 receptor treated with 
Ang II ligand (Christensen et al, 2010). Thr402 was identified in Jurkat cells treated with 
calyculin and pervanadate (Hornbeck et al, 2012). Ser419, Ser421, Ser387 and Thr614 were 
identified by direct analysis of overexpressed SK2 and validated by mutagenesis (Ding et al, 




(Siow & Wattenberg, 2011; Wattenberg, 2010). It is well established that in order for SK1 
to mediate pro-survival, pro-proliferative and oncogenic signalling it must re-localise from 
the cytoplasm to the plasma membrane (Pitson et al, 2005). By comparison, the subcellular 
localisation of SK2 appears to be much more complex than for SK1, in line with its more 
complex functions. SK2 possesses nuclear localisation (NLS) and export (NES) signals 
(Ding et al, 2007; Igarashi et al, 2003), with the NLS positioned within the N-terminus and 
the NES located within the central proline-rich region that is not conserved in SK1 (Figure 
1.5). Interestingly, when localised to the nucleus, SK2 has been shown to inhibit DNA 
synthesis (Igarashi et al, 2003), as well as regulate epigenetic modifications via interaction 
with and modulation of HDAC1/2, to increase p21 and c-fos transcription (Hait et al, 2009). 
SK2 localisation also appears to vary according to both cell type and cell density. For 
example, SK2 predominantly localises to the nucleus in HeLa cells whereas in HEK293 
cells it is mainly cytoplasmic (Igarashi et al, 2003). Moreover, it has been described that as 
COS-7 fibroblasts became more confluent in culture, the proportion of SK2 localised to the 
nucleus increased (Igarashi et al, 2003), suggesting this may represent a response to contact 
inhibition to decrease cell proliferation.  
 
It has also been demonstrated that under stress conditions SK2 localises to the ER (Maceyka 
et al, 2005). S1P production at the ER can fuel the sphingosine salvage pathway driven by 
ER-localised S1P phosphatases and ceramide synthases, to ultimately generate pro-
apoptotic ceramide (Maceyka et al, 2005). Interestingly, artificially targeting SK1 to the ER 
or nucleus can allow the otherwise pro-survival enzyme to promote apoptosis (Igarashi et al, 
2003; Maceyka et al, 2005). Moreover, mitochondrial localisation of SK2 has been shown 
to promote apoptosis via S1P and BAK-dependent membrane permeabilisation and 
cytochrome-c release (Chipuk et al, 2012; Strub et al, 2011). It should be noted that a lipid 
binding domain has been identified within the N-terminal region (residues 1-175) of SK2, 
not conserved in SK1 (Don & Rosen, 2009). This domain was shown to be a requirement 
for SK2 to interact with phosphoinositides, which may facilitate its differential localisation 
at internal membranes (Don & Rosen, 2009). 
 
As such, it has long been accepted in the field that the pro-apoptotic functions of SK2 not 
shared with SK1 seem to be mediated by its localisation to intracellular membranes like the 
ER, mitochondria and nucleus. However, this notion is now being challenged by more 
recent studies to demonstrate that nuclear SK2 can seemingly also promote cancer cell 
27 
 
survival and proliferation. Specifically, S1P produced by nuclear-localised SK2 has been 
implicated in hTERT stabilisation and delayed cell senescence in A549 lung cancer cells 
(Panneer Selvam et al, 2015), maintaining MYC expression through epigenetic regulation in 
ALL (Wallington-Beddoe et al, 2014), and antagonising the tumour-suppressive effects of 
all-trans retinoic acid through retinoic acid receptor β (RARβ) down-regulation in HT-29 
colon cancer cells (Sun et al, 2012). Whether this role for nuclear SK2 in promoting cell 
survival and proliferation is restricted to a cancer setting, or is cell and tissue specific, 
remains to be elucidated. 
 
The subcellular localisation of SK2 also influences substrate availability, and recent 
findings suggest that this may be another major contributor to the pro-apoptotic function of 
SK2. Both SK1 and SK2 can utilise dihydrosphingosine (dhSph) as a substrate (Liu et al, 
2000; Pitson et al, 2000a). Since dhSph is generated at internal membranes such as the ER, 
SK1 targeted to the plasma membrane cannot utilise this substrate pool (Siow et al, 2011; 
Siow et al, 2010). Unlike S1P, the specific role of dihydro-S1P (dhS1P) in oncogenic 
signalling is not well characterised. Interestingly, however, Hait et al (2009) demonstrated 
that dhS1P and S1P generated by SK2 in the nucleus can both inhibit HDAC1/2 and 
regulate epigenetic modifications to inhibit proliferation. Furthermore, a recent study 
reported that the anti-tumour efficacy of ‘PhotoImmunoNano’ therapy is directly attributed 
to the production of dhS1P specifically by SK2 (Barth et al, 2013). This technology utilises 
tumour-infiltrating nanoparticles loaded with indocyanine green (ICG), which can be 
excited by near-infrared light to produce damaging oxidation and cell death. Use of this 
novel technology in murine models of breast cancer, pancreatic cancer and metastatic 
osteosarcoma resulted in dhS1P production by SK2, leading to a reduction in immune 
suppressive myeloid cells expanded in response to tumour-associated inflammation (Barth 
et al, 2013). Notably, this study also demonstrated that administering dhS1P alone to 
tumour-bearing mice prevented tumour growth and increased survival of the mice, as 
opposed to S1P which increased tumour growth (Barth et al, 2013). Therefore, dhS1P and 
S1P appear to have opposing roles in oncogenic signalling, dependent on their differential 
cellular compartmentalisation. Again, this highlights the importance of the subcellular 
localisation of SK2 and consequent access to substrates in relation to its function. 
 
Interestingly, only one study has shown SK2 to mediate pro-proliferative S1P receptor 
signalling when localised to the plasma membrane (Weigert et al, 2010). This process, 
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however, appears linked to the activation of caspase-1 in apoptotic cells, which cleaves the 
N-terminus of SK2 and allows it to be exported from the cell, potentially mediated by the 
flipping of phosphatidylserine following interaction of the enzyme with the plasma 
membrane (Weigert et al, 2010).   
 
Overall, the roles of SK2 are clearly complex (as illustrated in Figure 1.6), and much work 
is still required to uncover and understand the true functions of SK2, particularly in regards 
to its involvement in cancer. Interestingly, all of the studies demonstrating a functional role 
for SK2 in promoting survival and proliferation have been conducted in a cancer setting, 
using cancer cell lines or in vivo xenograft models in mice. This begs the question of 
whether the true physiological role of SK2 in normal cells and tissues is to mediate cell 
death, but it is somewhat hijacked by transformed cells to drive survival and proliferation. 
This would have clear implications in targeting SK2 as a cancer therapeutic, and would 
stress the importance of understanding how the dual functions of SK2 are regulated. Clearly 
SK2 function is largely dictated by its subcellular localisation, however the mechanisms by 
which SK2 is localised with the cell, and the factors involved in regulating those 
mechanisms, are virtually unknown. Hence, the studies outlined in this thesis aim to better 
understand the true functions of SK2 and how it is regulated. 
 
 
1.3 Cytoplasmic dynein 1 intermediate chain 2 is a novel SK2-interacting protein 
 
In order to identify novel SK2-interacting proteins, the Pitson Laboratory previously 
performed a yeast two-hybrid screen using full-length SK2b as the bait and a C-terminal 
human normalised cDNA library as the prey, under stringent conditions. One putative SK2-
interacting protein was discovered from this screen and identified as cytoplasmic dynein 1 
intermediate chain 2. As the characterisation of this interaction is a major focus of this 
thesis, cytoplasmic dynein has been reviewed in detail below. 
 
 
1.4 Cytoplasmic Dynein 
 
Cytoplasmic dynein is a microtubule minus end-directed transport motor that has a diverse 








Figure 1.6: Signalling and regulation of SK2 
Activation of SK2 is mediated by ERK1/2 phosphorylation in response to a range of growth 
factors and cytokines. SK2 can undergo nuclear-cytoplasmic shuttling, regulated by nuclear 
localisation and nuclear export signals. The latter is regulated by PKD-mediated 
phosphorylation, which promotes the nuclear export of SK2. In the nucleus, SK2 can 
interact with histone H3-HDAC1/2 complexes following phorbol ester treatment of cells, 
and S1P produced by SK2 here can inhibit HDAC1/2-mediated deacetylation of histone H3 
and promote transcription of cyclin-dependent kinase inhibitor p21 and the transcriptional 
regulator c-fos. SK2 can also localise to the ER in response to serum deprivation or cell 
density, and S1P produced here can fuel a sphingolipid ‘salvage’ pathway that ultimately 
results in the generation of pro-apoptotic ceramide via ER-localized S1P phosphatase and 
ceramide synthase. Mitochondrial localisation of SK2, and subsequent S1P production, can 
mediate apoptosis via BAK-dependent membrane permeabilisation and cytochrome-c 
release. SK2 contains a putative BH3 domain through which it can interact with, and 
presumably sequester, the pro-survival molecule Bcl-xL, to induce apoptosis. The release of 
active SK2 from the cell can occur following cleavage at the N-terminus by caspase-1, 
which can then allow for the production of extracellular S1P. Upon IgE-mediated cross-
linking of the FcεRI receptor, Lyn and Fyn can mediate the activation and translocation of 
SK2 to the plasma membrane to initiate downstream mast cell responses. Murine SK2 has 
also been found to interact with the IL-12 receptor β1 (IL-12R), mediating downstream IL-












however, cytoplasmic dynein 2 is almost exclusively found within cilia and flagella to 
function in retrograde intraflagellar transport for axoneme maintenance and assembly 
(Allan, 2011; Hook & Vallee, 2006). Therefore, all microtubule minus end-directed 
transport of cargoes through the cytoplasm, as well as other important mitotic and structural 
functions, are carried out solely by cytoplasmic dynein 1 (herein referred to simply as 
dynein) (Cianfrocco et al, 2015). This is quite unique, as the other cytoskeletal motors (plus 
end-directed kinesins and actin-based myosins) have evolved as part of large families of up 
to 45 genes (in the case of mammalian kinesin), each specific to different cargoes and 
cellular functions (Hirokawa et al, 2010). As discussed further below, the vast array of 
functions achieved by this single dynein motor are thought to be made possible through the 
use of multiple isoforms of various subunits, post-translational modification of specific 
subunits, and through differential binding to a range of interacting regulatory 
proteins/complexes (Cianfrocco et al, 2015; Kardon & Vale, 2009; Pfister, 2015). 
 
 
1.4.1   Functions of dynein 
 
Dynein transports a diverse range of cargoes in a retrograde direction along microtubules, 
accumulating at the microtubule-organising centre (MTOC) (Figure 1.7). For fibroblasts, the 
MTOC is next to the nucleus in the cell centre, but for some other cell types, like polarised 
epithelial cells and neuronal dendrites, the plus ends can be oriented towards the nucleus or 
they can have mixed polarity (Allan, 2011). Dynein cargoes can include proteins, 
RNA/protein complexes, vesicles and membranous organelles such as endosomes, 
peroxisomes, autophagosomes, lysosomes and mitochondria (a list of various dynein 
cargoes is provided in Table 1.1) (Allan, 2011; Flores-Rodriguez et al, 2011; Tan et al, 
2011). Viruses - specifically adenovirus, the α herpes viruses HSV-1 and PrV, and the 
retrovirus HIV-1 - are also able to hijack the dynein motor for retrograde-directed transport 
towards the nucleus (Dodding & Way, 2011). Dynein also has important functions during 
mitosis, including the transport of chromosomes along microtubules required for 
chromosome alignment during metaphase (Li et al, 2007; Yang et al, 2007), as well as 
removing spindle assembly checkpoint (SAC) proteins from kinetochores to initiate 
anaphase (Wang et al, 2014c), both of which involve a number of dynein-interacting 
proteins described below. The ability of dynein to attach to a ‘fixed’ cellular structure, like 
the cell cortex, and use it as leverage to pull on microtubules can facilitate correct
Figure 1.7: Dynein transports its cargo in a retrograde direction
Cytoplasmic dynein can transport various cargoes, such as proteins, vesicles and
organelles, through the cytoplasm. It achieves this by binding to microtubules and moving
in a retrograde direction (towards the minus ends of the microtubules), ultimately
accumulating at the microtubule-organising centre (MTOC) which is generally located in
close proximity to the nucleus. Cargoes can also be transported in an anterograde direction








Table 1.1: Selected dynein-cargo interactions 
Key examples of direct interactions between dynein subunits and various cargoes are listed. 
Adapted from Allan (2011). 
 
Dynein subunit Cargo Reference 
IC Lysosomes/autophagosomes in neurons (Cai et al, 2010) 
IC, LIC Adenovirus particles (Bremner et al, 2009) 
IC β-catenin (Ligon et al, 2001) 
IC Kinetochores (Whyte et al, 2008) 
IC PLAC-24 (Karki et al, 2002) 
LIC, LC8 Endosomes 
(Horgan et al, 2010; Traer et 
al, 2007) 
LIC1 Centrosomes (Tynan et al, 2000) 
LIC2, LC8 Cell cortex 
(Manneville et al, 2010; 
Schmoranzer et al, 2009) 
LIC Nuclei (Malone et al, 2003) 












positioning of the mitotic spindle as well as reorganisation of the cell during cell migration 
(Allan, 2011). Furthermore, dynein can facilitate the sliding of intermediate filaments along 
microtubules as well as the sliding of microtubules with respect to each other, for instance 
within the mitotic spindle (Allan, 2011). It has also been well described that dynein binds to 
the nuclear envelope to maintain correct cellular positioning of the nucleus through 
association with the MTOC, as well as to mediate nuclear envelope breakdown during 
mitosis by essentially peeling open the nuclear membranes (Burke & Roux, 2009; Starr, 
2009).  
 
In order for dynein to perform retrograde-directed transport, it often appears to require 
microtubule plus end localisation to collect its cargo (Cianfrocco et al, 2015). Significant 
research has been undertaken to understand how this is achieved, and it is apparent that 
multiple mechanisms are at play. Firstly, it has been shown that dynein can interact, either 
directly (Ligon et al, 2004) or indirectly via other proteins (Yamada et al, 2010), with the 
plus end-directed kinesin motor. It appears that dynein and kinesin can engage in a ‘tug-of-
war’ along the microtubules, resulting in overall anterograde-directed transport of dynein as 
a consequence of kinesin recruiting factors that increase its processivity (Roberts et al, 
2014). Secondly, dynein can be recruited to the microtubule plus ends through the 
coordinated assembly of microtubule plus end binding proteins (+TIPs), such as 
cytoplasmic linker protein 170 (CLIP-170), end-binding proteins (EBs), and dynactin 
(Moughamian et al, 2013). These +TIPs bind to the plus ends of polymerising microtubules 
and can initiate dynein-mediated retrograde transport, although this mechanism seems to 
only be utilised in specific cell types, such as neurons and Xenopus melanophores, where 
perhaps high-flux trafficking events are required (Lomakin et al, 2009; Moughamian et al, 
2013). Interestingly, it has also been suggested that the mRNA of dynein subunits and 
regulators can be transported to the microtubule plus ends as messenger ribonucleoprotein 
particles (mRNPs), where they can then be locally translated (Cianfrocco et al, 2015; 
Preitner et al, 2014). 
 
 
1.4.2   Dynein complex structure 
 
The large ~1.4 MDa dynein complex is made up of multiple subunits: heavy chains (HC), 
light intermediate chains (LIC), intermediate chains (IC) and light chains (LC) (Figure 1.8).
Figure 1.8: The cytoplasmic dynein complex 
The cytoplasmic dynein complex is composed of multiple subunits bound as dimers. 
These subunits include the heavy chains (HC), light intermediate chains (LIC), intermedi-
ate chains (IC), and the three light chain subunits (LC; Roadblock, LC8 and Tctex-1). The 
HC dimers contain ring-shaped motor domains, microtubule-binding domains (MBD), 
and a long tail domain where all other subunit dimers bind. A, Schematic of the dynein 
complex bound to microtubules, adapted from Hook & Vallee (2006). B, Surface features 
are rendered based upon atomic resolution structures where available, and appear as 
smooth images for domains of unknown structure. The IC spans a large portion of the HC 
tail, making contacts with the three LCs as well as interacting with the dynein regulator, 
dynactin, at the N-terminal end. Adapted from Vale (2003). 


















Two copies of the HC form the backbone of the complex, and importantly, possess the C-
terminal microtubule binding domains and motor domains. The HC is the largest subunit 
(~500 kDa) and is a member of the ATPases associated with various cellular activities 
(AAA+) superfamily (Neuwald et al, 1999). The AAA+ ATPase motor domain of the HC is 
comprised of six AAA+ modules that fold to form a hexameric ring structure, and the HC is 
a unique member of this superfamily in that its AAA+ domains are linked in a single large 
polypeptide (Neuwald et al, 1999). Interestingly, of the six AAA+ domains, AAA1 is the 
predominant site of ATP hydrolysis and is essential for dynein motility (Kon et al, 2004). 
Although AAA2 is able to bind to ATP, it has lost the residues required for ATP hydrolysis 
(Cianfrocco et al, 2015). Mutations in the ATP binding site of AAA3 also reduced dynein 
motility, as did mutations in AAA4 but to a lesser extent (Cho et al, 2008; Kon et al, 2004), 
suggesting that these domains may also be important for the motor function of the HC. The 
remaining two AAA+ modules, AAA5 and AAA6, are poorly conserved and have lost the 
residues required for ATP binding (Neuwald et al, 1999), however they have been shown to 
play an important structural role in generating force and movement of the motor by 
transmitting conformational changes through the AAA+ ring (Schmidt et al, 2015).  
 
The tail domain at the N-terminus of the HC allows for the binding of the five non-catalytic 
dynein subunits, and it is this end of the dynein complex that is responsible for cargo 
binding and specificity. Binding as dimers, the LICs and the ICs interact directly with the 
HC, and three LC subunits (t-complex testis-expressed - Tctex1, LC8 and Roadblock/LC7) 
then bind as dimers to the ICs (see Figure 1.8). Interestingly, where dynein usually recruits 
the large multi-subunit complex, dynactin, to facilitate in cargo binding and transport 
(discussed below), there is evidence that dynein can also bind directly to some cargoes via 
the LICs, ICs and LCs. In vertebrates, there are two genes for each of the five non-catalytic 
subunits (Pfister et al, 2006). The two LICs, LIC1 and LIC2, are only able to homodimerise 
within the dynein complex, resulting in two distinct subsets of dynein: LIC1-containing 
complexes and LIC2-containing complexes (Tynan et al, 2000). There is evidence in favour 
of the idea that the distinct dynein subsets containing either LIC1 or LIC2 may provide 
some cargo specificity, as LIC1 has been shown to selectively interact with the centrosomal 
protein pericentrin (Tynan et al, 2000), whereas only LIC2 can bind to the polarity protein 
Par3 (Schmoranzer et al, 2009). However, there also appears to be some functional 
redundancy between the two isoforms in binding to other cargoes, as well as functioning in 
spindle assembly and organelle positioning (reviewed in Allan, 2011; Jones et al, 2014).  
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The dynein LC subunits are unique in that they are the only subunits that have been 
described to have additional functions independent of the dynein motor. The LC8 family 
have over 60 validated protein interacting-partners (Rapali et al, 2011), including the 
myosin 5a heavy chain (Espindola et al, 2000), and as such it was thought that the LCs must 
play an important role in the direct tethering of cargo to the dynein and myosin 5a 
complexes. However, it has since been noted that LC8 has many interacting partners that are 
not involved in intracellular transport (Rapali et al, 2011), and it seems to be structurally 
unlikely that LC8 could link cargo to these complexes (Williams et al, 2007). Furthermore, 
LC8 is highly evolutionarily conserved and is expressed in some lineages (e.g. plants) where 
all other dynein components have been lost (Wickstead & Gull, 2007). Indeed, it is now 
emerging that the true function of LC8 is to act as a ‘molecular glue’, binding to many 
cellular proteins in inherently disordered regions to promote their dimerisation and 
stabilisation, and the dynein complex is one such example (Barbar, 2008). Nevertheless, the 
dynein light chains are essential components of the dynein complex (Dick et al, 1996), and 
loss of either LC8 or Tctex from the complex, or mutations in Roadblock/LC7 have been 
shown to disrupt a number of dynein-mediated cellular processes (Bowman et al, 1999; 
Varma et al, 2010). 
 
As the dynein ICs are a major focus of this thesis, they are discussed in greater detail below. 
 
 
1.4.3  Dynein intermediate chains 
 
The dynein ICs act as scaffolds within the complex, binding both the HCs and the LCs (see 
Figure 1.8) as well as playing critical roles in cargo binding and specificity. Many of the 
regulator proteins/complexes that mediate dynein function bind to the motor via the ICs 
(Pfister, 2015). There have also been reports of the ICs directly binding to cargoes, such as 
β-catenin (Ligon et al, 2001), PLAC-24 (Karki et al, 2002), adenovirus (Bremner et al, 
2009), circovirus (Cao et al, 2015), and kinesin light chains 1 and 2 (Ligon et al, 2004). 
Somewhat surprisingly, the characterisation of the ICs has been best studied in rat, not 
human, and consequently the majority of the literature documenting IC distribution and 
expression, as well as structural domains and protein interactions refers to rat IC. This may 
be due to the relative ease of obtaining rat tissues, particularly brain where dynein function 
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is important and highly studied. However, as rat IC shares 97% sequence identity with 
human IC, it is likely to be a good representation of human IC.  
 
The N-terminal coiled-coil region of the IC is where binding to dynein regulators dynactin 
and NudE occurs (see Figure 1.9) (McKenney et al, 2011; Vaughan & Vallee, 1995). 
Downstream of the coiled-coil domain are the binding sites for the three LCs as well as the 
IC dimerisation site (Lo et al, 2006; Lo et al, 2001; Mok et al, 2001; Susalka et al, 2002). 
The remainder of the C-terminus is composed of seven WD40 repeat domains that form a 
beta propeller structure, and it is this region of the IC that is responsible for binding to the 
HC (Figure 1.9) (Pfister, 2015). 
 
There are two vertebrate IC genes: IC-1 and IC-2 (Pfister et al, 2006). They are highly 
conserved, sharing 76% amino acid sequence identity, and they are able to both homo- and 
heterodimerise as determined by overexpression as well as endogenous systems (Lo et al, 
2006; Zhang et al, 2013). Both genes are alternatively spliced at two conserved regions 
within the N-terminus (Figure 1.9) to generate a subset of splice isoforms, but the number of 
isoforms expressed for each gene seems to be species specific. In human and rat, there are 
three splice isoforms of IC-1 and three of IC-2 (see Figure 1.10), as each has a full-length 
transcript as well as two shorter transcripts that are spliced at one or both of the two 
conserved regions (Myers et al, 2007). Interestingly, a large scale analysis of mouse IC 
isoforms revealed five IC-1 isoforms and six IC-2 isoforms (Kuta et al, 2010). Although it 
was found that splicing in the mouse IC genes still occurs at the same two regions as in 
human and rat, it appears that the size of the spliced regions can vary (Kuta et al, 2010). 
 
Notably, in mouse and rat, the only isoform that is ubiquitously expressed in all cell types 
and tissues is the IC-2C isoform, whereas all other isoforms seem to be restricted to brain 
and nervous tissues, except for IC-1C, which is also detected in ovary and testis (Kuta et al, 
2010; Myers et al, 2007). This suggests that the IC-2C isoform is sufficient for dynein to 
achieve its functions in most cells, whereas cells in the brain and CNS require the increased 
complexity of multiple dynein IC isoforms. In rat, IC-2B was also reported to be expressed 
in many tissues (Myers et al, 2007). Interestingly, however, although less well studied, it has 
been reported that in human cells and tissues IC-1 may actually be more widely expressed, 
with the highest levels found in brain, heart and skeletal muscle, and low but significant 
levels of IC-1 mRNA detected in pancreas, kidney, liver, lung, placenta, colon, small
Figure 1.9: Domain and interaction map of the dynein intermediate chain 
Domain map shown is of the dynein intermediate chain (IC), with the N-terminus on the 
left. Domains and interactions were characterised using rat IC, however rat IC shares 97% 
sequence identity with human IC. Characterised domains include: coiled-coil motif 
(yellow), two alternative splicing regions (red; A1 and A2), serine-rich region (S; green), 
IC dimerisation domain (blue), and seven WD40 domain repeats (purple; A-E’). The IC 
interaction sites for the three light chains (Tctex-1, LC8 and Roadblock) are depicted 
above the map (orange), as are the heavy chain binding site (dark blue; C-terminus) and 
the region with which the dynein regulators, p150 (dynactin) and NudE, interact (dark 























*****************  First splice site
********************  Second splice site
Figure 1.10: Alternative splice isoforms of human dynein intermediate chain genes
Various splice isoforms are shown for human IC-1 and IC-2. A, Sequence alignment of an
N-terminal portion of the three IC-1 splice isoforms (IC-1A, IC-1B and IC-1C which are
645, 628 and 608 amino acids in length, respectively) and three IC-2 splice isoforms (IC-
2A, IC-2B and IC-2C which are 638, 632 and 612 amino acids in length, respectively),
revealing the regions that are alternatively spliced. IC-1A and IC-2A proteins arise from
unspliced, full-length transcripts, IC-1B and IC-2B proteins arise from splicing at the first
splice site, and IC-1C and IC-2C proteins arise from splicing at both the first and second
splice sites. Alignment was performed using the Clustal Omega program via UniProt. B,
Schematic summarising the alternate splice sites (red) at the N-terminal ends of IC-1 and




intestine, ovary, testis, prostate, thymus, spleen, and mammary epithelial cells (Horikawa et 
al, 2001). Therefore, the expression pattern of IC-1 may vary between humans and other 
species. 
 
Like the LICs, the IC isoforms seem to give rise to distinct dynein complexes with isoform-
specific cargoes and functions. Interestingly, in axons only dynein containing the IC-2C 
isoform was associated with fast anterograde axonal transport of membrane bounded 
organelles linked to kinesin, whereas all other IC isoforms were associated with the slow 
component b (Dillman et al, 1996). This may suggest that dynein composed of IC-2C may 
function in neurons to provide a reverse motor during fast anterograde transport in the event 
that obstructions are encountered (Pfister, 2015). Furthermore, dynein complexes containing 
IC-1B specifically interact with and transport neurotrophic factor receptor TrkB-containing 
signalling endosomes, whereas IC-2C does not associate with TrkB (Ha et al, 2008). 
Furthermore, dynein with IC-1B was more likely to co-localise with Rab7-positive 
endosomes than dynein with IC-2C, whereas the opposite was true for mitochondria, which 
had a greater association with dynein containing IC-2C (Mitchell et al, 2012). Again, these 
differential functions of IC isoform-specific dynein subsets are only relevant to neuronal 
type cells where more than one isoform is expressed, demonstrating the importance of 
intracellular transport and the high level of regulation and functional diversity of dynein 
required in these long, polarised cells. This is reiterated by the fact that neurological defects 
are generally the predominant phenotype of mutations in the dynein complex, emphasising 
that the long distance transport within axons is already pushing dynein to maximal capacity 
(Hafezparast et al, 2003; Ilieva et al, 2008; Pfister, 2015). 
 
Another important aspect of dynein regulation is through phosphorylation of the ICs. 
Adjacent to the N-terminal coiled-coil domain, there is a serine rich region near the 
alternative splicing sites on the ICs (Figure 1.9). Here, a number of phosphorylation events 
have been described. Phosphorylation has been shown to occur on Ser80 of IC-1B and the 
equivalent residue Ser81 of IC-2C, which is stimulated by EGF (Pullikuth et al, 2013) and 
was found to be phosphorylated by ERK1/2 (Mitchell et al, 2012). This modification seems 
to promote binding of dynein to signalling endosomes, as the corresponding alanine 
mutations significantly reduced co-localisation of the ICs to these organelles. Interestingly, 
phosphorylation at Ser81 of IC-2C does not appear to regulate binding of dynein to 
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mitochondria, suggesting that this site does not regulate binding of dynein to all cargoes 
(Mitchell et al, 2012).  
 
Furthermore, Ser84 phosphorylation on IC-2C appears to disrupt binding of the IC to the 
p150 subunit of the dynactin complex, which may contribute to a reduction in dynein-
mediated transport (Vaughan et al, 2001). Phosphorylation of Thr89 also prevents binding 
of dynein to dynactin p150, but appears to be stimulated during early mitosis and 
concomitantly increases dynein binding to another adaptor protein, ZW10 (Whyte et al, 
2008). This event then promotes the localisation of dynein to kinetochores during mitosis, 
and Thr89 is subsequently dephosphorylated during metaphase to allow dynein to re-interact 
with dynactin and translocate towards the spindle poles to initiate anaphase (Whyte et al, 
2008).  
 
Interestingly, a recent comprehensive study performed to identify IC phosphorylation events 
by mass spectrometry, using neuronal cells and tissues, identified a total of six sites on IC-2 
and eight sites on IC-1 (unpublished work from ‘Zhang et al., in preparation’, described in 
Pfister (2015)). The six IC-2 phosphorylation sites were reported to reside within the N-
terminal serine rich region where the previously characterised sites lie (Figure 1.9). 
Fascinatingly, however, it was documented that only four of the identified IC-1 
phosphorylation sites are conserved with IC-2 and lie within the serine rich region, whereas 
the other four sites are unique to IC-1 and are located further downstream: one is near the 
LC8 binding site, one is within the IC dimerisation domain and one is located at the C-
terminus (Zhang et al., in preparation). As this study is not yet published, the exact location 
of these sites was not disclosed, but this information will undoubtedly provide insight into 
the differential regulation of the IC isoforms by phosphorylation. 
 
 
1.4.4    Regulators of dynein 
 
Dynein could not achieve many of its cellular functions by acting alone; in fact, most of its 
roles require a myriad of different proteins and complexes. As such, important regulators of 
dynein – dynactin, Lis1 and NudE/Nudel – are described below. Although some of these 
regulators are not directly examined by the studies undertaken in this thesis, knowledge of 
their roles provides greater context to the functions of dynein in the cell. 
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1.4.4.1    Dynactin 
 
Dynactin is an essential regulator of dynein as, since its discovery, it has been implicated in 
almost all of the cellular functions dynein performs (Schroer, 2004). Interestingly, dynactin 
itself is a large 1.2 MDa multi-subunit complex, making it almost as large as the dynein 
complex (see Figure 1.11). It interacts with the N-terminus of the dynein IC via its p150 
subunit. As discussed previously, dynactin was found to be involved in recruiting dynein to 
the microtubule plus-ends to initiate retrograde-directed transport of cargoes, and this 
process is driven by the recruitment of dynactin to plus-end binding proteins via the CAP-
Gly domain of its p150 subunit (Figure 1.11) (Lloyd et al, 2012; Moughamian & Holzbaur, 
2012; Moughamian et al, 2013). Upon initiation of dynein-driven retrograde transport, 
dynactin has also been implicated in activating dynein motility and increasing dynein 
processivity (Cianfrocco et al, 2015; Kardon & Vale, 2009). Although it appears that 
dynactin alone can achieve increases in dynein processivity along microtubules (Ayloo et al, 
2014; Kardon et al, 2009), recent detailed structural studies have revealed how the 
combinatorial binding of dynactin and another cargo adaptor (BICD2) to dynein can induce 
changes in symmetry and conformation of the complexes to promote dynein activity and 
processivity (Cianfrocco et al, 2015).  
 
Another fundamental role of dynactin is to act as an adaptor to tether cargo to the dynein 
complex for transport. The ARP1 filament of dynactin (Figure 1.11) binds directly to βIII 
spectrin, which is a protein found on the cytosolic surface of the Golgi and other cellular 
membranes transported by dynein (Holleran et al, 2001; Muresan et al, 2001). The p150 
subunit of dynactin also mediates dynein-cargo interactions via direct binding to a number 
of membrane proteins associated with lysosomes, endosomes and transport vesicles budding 
from the ER (Allan, 2011; Kardon & Vale, 2009). Furthermore, dynactin p50 has been 
implicated in binding to, and facilitating the transport of secretary organelles, as well as 
mediating recruitment of dynactin, and hence dynein, to the kinetochore (Allan, 2011; 






Figure 1.11: The dynactin complex 
A, Schematic illustrating the subunit composition of the dynactin complex. The actin-
related protein 1 (Arp1) filament (red) forms a central, actin-like scaffold and can interact 
with many cellular cargoes. CapZ (green) and Arp11 (yellow) act as actin-capping pro-
teins at the Arp1 plus and minus ends, respectively. Arp11 also interacts with the p25/p27 
(brown) and p62 (orange) subunits to form a heterotetrameric complex at the Arp1 minus 
end. Dynamitin (p50) exists as a tetramer and is important for complex structure as well 
as forming interactions with dynein adaptor proteins. The p24/22 subunit binds directly to 
dynamitin and p150. The p150 subunit dimer contains N-terminal microtubule binding 
domains, and it is also the subunit through which dynactin interacts with dynein. Figure 
adapted from Schroer (2004). B, Representation of how the dynein and dynactin com-
plexes interact to transport cargo along microtubules in a retrograde direction. The two 
complexes interact via the dynein intermediate chain (yellow) and dynactin p150 subunit 
(double black lines). Dynactin binds to the cargo via the Arp1 filament (transparent cir-













1.4.4.2    Lis1 and NudE/Nudel 
 
Lissencephaly 1 (Lis1) and Nuclear distribution protein E (NudE)/NudE-like (Nudel) are 
important, ubiquitous regulators of dynein and have been implicated in regulating many 
dynein functions, including nuclear and centrosome positioning, spindle pole organisation 
during mitosis, as well as organelle and mRNA transport (Dix et al, 2013; Liang et al, 2004; 
Moon et al, 2014; Moughamian et al, 2013; Tsai et al, 2007). Lis1 forms a homodimer and 
is the only known dynein regulator to bind to dynein via the HC motor domain (Cianfrocco 
et al, 2015). Upon binding to the motor domain, Lis1 sterically alters the normal progression 
of dynein’s mechanochemical cycle such that it prevents a detachment signal and thus 
promotes prolonged microtubule attachment (Huang et al, 2012; Toropova et al, 2014). 
 
NudE and Nudel are highly homologous proteins that interact at their N-terminus with the 
dynein IC and interact at their C-terminus with Lis1 (Cianfrocco et al, 2015). Hence, they 
are thought to predominantly play a tethering role to regulate and maintain the interaction 
between dynein and Lis1. Indeed, overexpression of Lis1 can partially rescue defects owing 
to a loss of NudE (Efimov, 2003; Li et al, 2005). Lis1 has been implicated in recruiting 
dynein to microtubule plus ends, as well as in initiation of dynein motility towards the 
minus ends, but the exact role and mechanism by which this occurs seems to be species-
dependent and requires further characterisation (Cianfrocco et al, 2015; Kardon & Vale, 
2009). Lis1-NudE and Lis1-Nudel complexes have also been shown to play important roles 
in recruiting dynein to the mitotic kinetochore, as NudE/Nudel and the Rod/ZW10/Zwilch 
(RZZ) complex can bind directly to kinetochore proteins to then recruit other dynein 
adaptors, and dynein itself (Kardon & Vale, 2009). 
 
Indeed, the number of different regulator proteins and complexes that bind to, tether, recruit 
and regulate dynein is rather complex. However, it is interesting to note that purified 
mammalian dynein is largely inactive in vitro, but in the same system the addition of 
dynactin plus one of the many cargo-specific adaptor proteins known to interact with dynein 
was sufficient to form a highly processive motile complex, as seen in cells (McKenney et al, 
2014). Therefore, the system of retrograde-directed transport by dynein is highly regulated, 
and depending on the cargo to be transported, appropriate adaptor proteins will recruit 




1.5 Aims  
 
The roles of SK2 are complex and still not entirely understood. There is evidence in the 
literature to suggest that the physiological and pathophysiological roles of SK2 may differ, 
where it generally seems to promote cell death and yet in a cancer setting it can be pro-
tumourigenic. However, unlike SK1, high level overexpression of SK2 does not induce 
neoplastic transformation, highlighting the importance of better understanding this enzyme 
in order to effectively target SK2 as a therapeutic option to treat cancer. As discussed, the 
subcellular localisation of the SKs, and hence the localisation of S1P production, appear 
critical in determining their function. Hence, the studies outlined in this thesis are aimed at 
examining the true functions of SK2 in cancer, and characterising novel mechanisms that 
regulate the subcellular localisation of SK2. 
 
Specifically, the aims of these studies were to: 
1) Investigate the role of SK2 in neoplastic transformation and tumourigenesis 
2) Characterise and examine the functional relevance of the novel interaction between 
SK2 and DYNC1I2. 


















































Chapter 2. General Materials and Methods 
 
2.1 Cell culture, transfection and lysate preparation 
 
Human embryonic kidney (HEK293, HEK293-C18 and HEK293T) cells and human 
cervical cancer (HeLa) cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Gibco, Thermo Fisher Scientific, Waltham, MA, USA), containing 10% heat-
inactivated fetal bovine serum (FBS; Bovogen, East Keilor, VIC, Australia), 1 mM HEPES, 
penicillin (1.2 mg/ml) and streptomycin (1.6 mg/ml). Primary mouse embryonic fibroblasts 
(MEFs) were generated from both wildtype (WT) C57/Bl6 and Sphk2-/- C57/Bl6 (Mizugishi 
et al, 2005) mouse embryos at 14.5 days post coitum. The fibroblasts were isolated and 
cultured as described above. NIH3T3 mouse fibroblasts were also cultured as above, except 
using 10% heat-inactivated donor bovine serum with iron (DBS; Gibco, Thermo Fisher 
Scientific). U-87 MG and U-251 MG human glioblastoma cells were cultured in Minimum 
essential media (MEM; Gibco, Thermo Fisher Scientific), containing 10% FBS, 2mM L-
glutamine, 1mM sodium pyruvate, 1% non-essential amino acids, penicillin (1.2 mg/ml) and 
streptomycin (1.6 mg/ml). All cells were grown at 37°C with 5% CO2 in a humidified 
incubator, except the primary MEFs which were grown in 10% CO2. 
 
Cells were transiently transfected at 80% confluence using Lipofectamine™ 2000 (Thermo 
Fisher Scientific) as per the manufacturer’s protocol. 24-48 hr after transfection, cells were 
harvested by scraping into cold phosphate buffered saline (PBS), and unless otherwise 
indicated, cell pellets were resuspended in extraction buffer (EB; 50 mM Tris-HCl buffer 
(pH 7.4) containing 150 mM NaCl, 10% glycerol, 1 mM EDTA, 0.05% Triton X-100, 2 
mM Na3VO4, 10 mM NaF, 10 mM β-glycerophosphate, 1 mM DTT and complete protease 
inhibitor cocktail (Roche)). Cells were lysed by sonication (four cycles of 30 sec on/off; 
high setting) using a Bioruptor bath sonicator (Diagenode, Seraing, Liège, Belgium). 
Lysates were clarified by centrifugation at 17,000 x g for 15 min and 4°C. Total protein 
concentration of cell lysates was determined by a Bradford protein assay (Bio-Rad 






2.2 Mouse tissue lysate preparation 
 
Mouse tissue was harvested into a 1.5 ml tube on ice and manually homogenized in cold 
extraction buffer using a pestle (Axygen, Corning, Corning, NY, USA). Tissue was then 
subjected to freeze/thawing in liquid nitrogen and sonication, and lysates were then clarified 
by centrifugation at 17,000 × g for 15 min at 4°C. 
 
 
2.3 Cloning of mammalian expression constructs 
 
The following mammalian expression constructs used in these studies were previously 
generated in the Pitson Laboratory: pcDNA3-SK2(FLAG), pcDNA3-SK2 ∆10P(FLAG), 
pcDNA3-SK2 ∆9P(FLAG), pcDNA3-SK2 ∆6P(FLAG), pcDNA3-SK2 ∆4P(FLAG), 
pcDNA3-SK2 S363A(FLAG), pcDNA3-SK2 S398A(FLAG), pcDNA3-SK2 
S437A(FLAG), pcDNA3-SK2 S441A(FLAG), pcDNA3-SK2 S448A(FLAG), pcDNA3-
DYNC1I2(HA), pcDNA3-DYNC1I1(HA), pcDNA3-DYNC1I2 1-250(HA), pcDNA3-
DYNC1I2 251-612(HA), pcDNA3-DYNC1I2 1-439(HA), pcDNA3-DYNC1I2 440-
612(HA), pET17b-DYNC1I2(His), pCX4NEO-DYNC1I1:EGFP. More detailed methods for 
any constructs generated by myself during the scope of my PhD are included in the specific 





For immunoprecipitation of over-expressed protein, cells were lysed in IP lysis buffer (50 
mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl, 1% (w/v) sodium deoxycholate, 
0.1% (w/v) SDS, 10% glycerol, 1% Triton X-100, 10 mM Na3VO4, 10 mM NaF, and 
protease inhibitor cocktail (Roche, Basel, Switzerland)). Lysates were sonicated and 
clarified (as above). 100 µl of lysate was aliquoted and made up to 170 µl in IP lysis buffer. 
20 µl of diluted lysate was removed and kept for protein expression levels. The remaining 
150 µl of lysate was used for immunoprecipitation, using the µMACS magnetic system 
(Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly, 2-4 µg of antibody (specific 
antibody details are given below and in figure legends) was added to the lysate, in addition 
to 50 µl Protein G µbeads. The lysate was gently mixed and left on ice for 30 min. µMACS 
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columns were mounted to magnetic stands and equilibrated with 200 µl IP lysis buffer. 
Lysate was then applied to the columns and bound µbeads were washed with 4 x 200 µl IP 
lysis buffer. A final wash with 100 µl low salt buffer (20 mM Tris-HCl (pH 7.5)) was 
performed. 20 µl hot 1x SDS sample buffer (1 mM Tris-HCl (pH 8.0), 1 mM EDTA, 20 
mM DTT, 1% (w/v) SDS, 10% glycerol and 0.02% (w/v) bromophenol blue) was applied to 
the columns and incubated for 5 min. Proteins were then eluted from the µbeads by addition 
of 50 µl hot 1x SDS sample buffer, and collected in eppendorf 1.5 ml tubes ready for SDS-
PAGE analysis.  
 
To perform immunoprecipitation of overexpressed FLAG-tagged SK2 from lysates co-
expressing DYNC1I1, a pre-clear of the lysate was required (to reduce non-specific binding 
of DYNC1I1 to the µbeads) prior to performing co-immunoprecipitation. Briefly, after 
preparation of the diluted lysate (170 µl), 35 µl of Protein G µbeads were added (without 
antibody), mixed and incubated on ice for 30 min. Lysate was then applied to equilibrated 
columns and flow-through was collected in an eppendorf tube. 20 µl of this pre-cleared 
lysate was removed and kept for protein expression levels, and the remaining lysate was 
used for co-immunoprecipitation, as above. 
 
For immunoprecipitation of endogenous SK2, cells were lysed in extraction buffer (without 
DTT), sonicated and clarified. 1 mg of lysate was then incubated with 4 µg anti-SK2 
antibody and 50 µl each of Protein G and Protein A µbeads (100 µl total beads). The 
protocol was then continued as above, with extraction buffer (without DTT) being used for 
column equilibration and 4 x 200 µl washes. Immunoprecipitation of endogenous SK2 from 
cleared mouse brain tissue lysate was performed essentially as described above for cultured 
cells, except the 4 x 200 µl column washes were performed using a high salt wash buffer 
(50 mM Tris-HCl (pH 8.0), 500 mM NaCl, 1% NP-40) to reduce non-specific protein 





SDS sample buffer was added to lysates of equal protein, giving a final concentration of 1 
mM Tris-HCl (pH 8.0), 1 mM EDTA, 20 mM DTT, 1% (w/v) SDS, 10% glycerol and 
0.02% (w/v) bromophenol blue. Samples were then heated to 100ºC for 5 min, briefly 
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centrifuged and separated by SDS-PAGE on either Criterion™ XT Bis-Tris 4-12% gradient 
gels (Bio-Rad Laboratories) or freshly-poured 10% SDS-polyacrylamide gels. 
Kaleidoscope™ Precision Plus protein standards (Bio-Rad Laboratories) were used to 
estimate protein molecular mass. Proteins were then transferred to nitrocellulose membrane 
(Pall Life Sciences, Pensacola, FL, USA). Membranes were blocked using Odyssey® 
Blocking Buffer (LI-COR, Lincoln, NE, USA) prior to incubation with appropriate primary 
antibodies. Proteins were visualised using IRDye® secondary antibodies and the Odyssey® 
CLx infrared imaging system (LI-COR). Alternatively, membranes were blocked in PBS 
containing 5% (w/v) skim milk powder and 0.1% Triton X-100, and subsequent to primary 
antibody incubation, proteins were visualised using horseradish peroxidise (HRP)-
conjugated secondary antibodies and enhanced chemiluminescent (ECL) substrate (GE 
Healthcare Life Sciences, Parramatta, NSW, Australia) on the ImageQuant LAS 4000 





The following commercial primary antibodies were utilised at dilutions recommended by 
the manufacturer, unless otherwise stated: mouse monoclonal anti-FLAG (Clone M2 
#F3165, Sigma-Aldrich, St. Louis, MO, USA), rabbit polyclonal anti-FLAG (#2368, Cell 
Signaling Technology, Danvers, MA, USA), rabbit monoclonal anti-FLAG (#14793, Cell 
Signaling Technology), mouse monoclonal anti-HA (#H3663, Sigma-Aldrich), rabbit anti-
SK2 (#17096-1-AP, Proteintech, Rosemont, IL, USA), rabbit anti-SK2 (#SP4621, ECM 
Biosciences, Versailles, KY, USA), rabbit anti-SK1 (#SP1621, ECM Biosciences), mouse 
anti-α-tubulin (#ab7291, Abcam, Cambridge, MA, USA), goat anti-GFP (#600-101-215, 
Rockland Immunochemicals, Limerick, PA, USA), rabbit anti-phospho-p44/42 MAPK 
(ERK1/2) Thr202/Tyr204 (#9101, Cell Signaling Technology), rabbit anti-p44/42 MAPK 
(ERK1/2) (#9102, Cell Signaling Technology), rabbit anti-phospho-AKT Ser473 (#9271, 
Cell Signaling Technology), rabbit anti-AKT (#9272, Cell Signaling Technology), mouse 
anti-Ki-67 (#VP-K452, Vector Labs, Burlingame, CA, USA), mouse monoclonal anti-
DYNC1IC (clone 74.1, #MAB1618, Millipore, Bayswater, VIC, Australia), rabbit anti-
DYNC1I1 (#13808-1-AP, Proteintech), rabbit anti-DYNC1I2 (#ab96288, Abcam), rabbit 
monoclonal anti-DYNC1LIC1 (#ab157468, Abcam), mouse monoclonal anti-dynactin p150 
(#SC-135890, Santa Cruz Biotechnology, Dallas, TX, USA) and goat anti-PECAM-1 
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(CD31; #SC-1506 Santa Cruz Biotechnology). IRDye® secondary antibodies (1:10,000, 
800CW and 680RD; LI-COR) were utilised in conjunction with the Odyssey® CLx infrared 
imaging system (LI-COR), and HRP-conjugated secondary antibodies (10,000; Pierce, 
Thermo Fisher Scientific) were used with the ImageQuant LAS 4000 imaging system (GE 
Healthcare Life Sciences). 
 
 
2.7 RNA preparation and cDNA synthesis 
 
To isolate RNA, cultured cells were pelleted and lysed in 1 ml TRIzol (Thermo Fisher 
Scientific). Lysate was centrifuged at 12,000 x g for 10 min at 4˚C, and supernatant was 
collected. After a 5 min incubation at room temperature, 200 µl chloroform was added and 
mixed by shaking vigorously for 15 sec. Samples were left at room temperature for 5 min, 
and phases were then separated by centrifugation at 12,000 x g for 15 min at 4˚C. The top 
aqueous phase was collected, 500 µl isopropanol was added and RNA was then precipitated 
at -20˚C for 1 hr. Samples were centrifuged at 12,000 x g for 10 min at 4˚C to pellet the 
RNA. The supernatant was discarded, the pellet washed with fresh 75% ethanol (RNase-
free) and then reconstituted in RNase-free water. RNA concentration was determined using 
a NanoDrop spectrophotometer (Thermo Fisher Scientific), and 1 µg RNA was then used as 
a template to synthesise cDNA using the QuantiTect reverse transcription kit (Qiagen, 
Hilden, Germany).   
 
 
2.8 Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) 
 
qRT-PCR was performed using a QuantiTect SYBR Green PCR kit (Qiagen). Primer 
sequences are as follows: hDYNC1I1 forward primer TAAAGTTGGCCAGGACTCAG, 
hDYNC1I1 reverse primer CCAGGGCTCTTTCAATTACC, hDYNC1I2 forward primer 
CCAGTTATGGCTCAACCCAA, hDYNC1I2 reverse primer 
TCAGAGTGCAAGATTTGTTGC, hSK2 forward primer 
TGGCAGTGGTGTAAGAACCA, hSK2 reverse primer CAGTCAGGGCGATCTAGGAG, 
hGAPDH forward primer ACCCAGAAGACTGTGGATGG, hGAPDH reverse primer 
CAGTGAGCTTCCCGTTCAG. Each reaction contained 2 µl RNase-free H2O, 5 µl 
QuantiTect SYBR Green PCR Master Mix (Qiagen), 0.5 µl forward primer (at 100 ng/µl), 
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0.5 µl reverse primer (at 100 ng/µl), and 2 µl cDNA (diluted 1:5 in RNase-free H2O). qPCR 
reactions were performed on a Rotor-Gene 6000 RealTime PCR machine (Corbett Life 
Sciences, Qiagen), using the following protocol: 50°C for 2 min, 95°C for 15 min, 48 cycles 
of denaturing at 95°C for 30 sec, annealing at 58°C for 21 sec, and extension at 72°C for 15 
sec, and finally 72°C for 30 sec. Melt curves were then determined by increasing 
temperature from 72°C  to 99°C, increasing by 1°C every 5 sec. Relative levels of target 
genes were analysed using the Rotor-Gene software (Qiagen) and normalised to the levels 
of GAPDH. Comparative quantitation was performed using an internal calibrator cDNA 
which was included in each experiment.  
 
 
2.9 Generating and purifying recombinant proteins 
 
To make recombinant full-length IC-2 protein, Escherichia coli BL21 cells transformed 
with pET17b-DYNC1I2(His) plasmid were grown overnight in Luria broth containing 100 
µg/ml ampicillin and 50 µg/ml chloramphenicol at 37°C with shaking. The cultures were 
then diluted 1 in 10 into the same medium and grown at 37°C with shaking for 1 hr or until 
reaching an OD600 of ~0.6 - 0.8. Expression of the IC-2(His) protein was induced by the 
addition of isopropyl 1-thio-β-D-galactopyranoside (IPTG) to a final concentration of 200 
µM, and the culture was incubated for an additional 3 hr at 30°C with shaking. The cells 
were harvested by centrifugation at 6000 × g for 15 min at 4°C, resuspended in Buffer A (50 
mM NaH2PO4 (pH 8.0), 300 mM NaCl, 20 mM imidazole, 10% glycerol, complete protease 
inhibitor cocktail) containing 1% Triton X-100, left on ice for 20 min and then lysed by 
probe sonication (six pulses 10 sec on/off at 50% amplification). The lysate was clarified by 
centrifugation at 17,000 × g for 20 min at 4°C to remove cell debris. Nickel-Sepharose™ 6 
Fast Flow beads (GE Healthcare Life Sciences) were added to the clarified lysate as a 50% 
slurry in Buffer A, and the mixture was incubated at 4°C for 1 hr with constant agitation. 
The nickel-sepharose beads were collected in an equilibrated 20 ml chromatography column 
(BioRad), washed three times with cold Buffer A, and IC-2(His) protein was then eluted 
from the beads in sequential elution fractions using Buffer B (50 mM NaH2PO4 (pH 8.0), 
300 mM NaCl, 500 mM imidazole, 10% glycerol, complete protease inhibitor cocktail). The 
amount of IC-2(His) protein in each elution was quantified with Coomassie Brilliant Blue 




To generate and purify SK2 protein, HEK293 cells were transiently transfected with 
pCDNA3-SK2(FLAG) vector, and 24 hr later cells were harvested in cold PBS. Cell pellets 
were resuspended in EB containing 1% Triton X-100, and lysed by three rounds of 
freeze/thawing in liquid nitrogen. Lysates were clarified by centrifugation at 17,000 × g for 
15 min at 4°C. To immunoprecipitate SK2(FLAG) proteins, 500 µl clarified lysate was 
added to 25 µl equivalent volume of packed FLAG-agarose beads (Sigma-Aldrich), and the 
mixture was incubated at 4°C for 1 hr with constant agitation. FLAG-agarose beads were 
pelleted by centrifugation at 6,000 × g for 30 sec and washed three times in EB containing 
1% Triton X-100. SK2(FLAG)-bound agarose beads were subsequently used in pull-down 
assays or, to quantify the amount of bound protein, 2x SDS sample buffer was added to the 
beads and proteins were subjected to SDS-PAGE analyses with BSA standards and staining 
with Coomassie Brilliant Blue. 
 
 
2.10 Pull-down assays 
 
Pull-down analyses were performed by incubating 1 µg recombinant IC-2(His) protein 
(described above) diluted in EB with ~500 ng of purified SK2(FLAG) protein bound to 
FLAG-agarose beads. The proteins were incubated for 2 hr at 4°C with constant agitation. 
The FLAG-agarose beads were pelleted by centrifugation at 6,000 × g and washed three 
times in EB, and bound proteins were then resolved by SDS-PAGE and visualised by 
immunoblotting. SK2 was detected using anti-FLAG antibodies whilst recombinant IC-2 
was detected using anti-6xHis antibodies. 
 
 
2.11 Sphingosine kinase activity assays 
 
SK2 activity was determined using D-erythro-sphingosine (Biomol, Hamburg, Germany) 
and [γ32P]ATP (Perkin Elmer, Waltham, MA, USA) as substrates under isoform-selective 
assay conditions, as previously described (Pitman et al, 2012). Briefly, 20 µl of cell lysate 
(containing 5 µg of overexpressed protein or 50 µg of endogenous protein, and Triton X-
100-free EB) was mixed with 80 µl of assay buffer (100 mM Tris/HCl (pH 7.4), 150 mM 




µM BSA-solubilised sphingosine, and 0.5 mM 4-deoxypyridoxine. Samples were vortexed 
and incubated at 37°C for 30 min. The reaction was stopped by the addition of 270 µl 
chloroform/methanol/conc. HCl solution (100:200:1, v/v), followed by 70 µl chloroform 
and 20 µl 5 M KCl. Samples were vortexed and the aqueous/methanol and chloroform 
phases were separated by centrifugation at 17,000 x g for 5 min. The upper 
aqueous/methanol layer was removed by aspiration and 50 µl of the remaining chloroform 
phase was spotted onto a thin layer chromatography (TLC) plate (Silica gel 60; Sigma-
Aldrich). The plate was developed in butanol/ethanol/acetic acid/water (8:2:1:2, v/v) 
solvent, dried and exposed to a phosphor screen (Amersham Biosciences, GE Healthcare 
Life Sciences). The spots containing radiolabel-incorporated sphingosine-1-phosphate were 
imaged using a Typhoon phosphorimager (GE Healthcare Life Sciences), and quantified 
using ImageQuant software (GE Healthcare Life Sciences). A unit (U) of SK2 activity was 
defined as the amount of enzyme required to produce 1 pmol S1P/min/mg protein. 
 
 
2.12 Focus formation assays 
 
Focus formation assays were performed as described previously (Zhu et al, 2017). Briefly, 
NIH3T3 mouse fibroblasts were cultured to form monolayers in 6-well plates in DMEM 
with 1% DBS (Gibco, Thermo Fisher Scientific), and media was replenished every 2-3 days 
for a total of 3 weeks. Cells were then fixed in methanol, foci were stained with 
bromophenol blue, and images were taken using the Odyssey® CLx infrared imaging 
system (LI-COR), using the 680 nm (red) channel. 
 
 
2.13 Colony formation in soft agar 
 
Colony formation assays in soft agar were performed as previously described (Pitman et al, 
2015). Briefly, cells were trypsinised, resuspended in complete growth media and mixed 
with DMEM containing low gelling temperature agarose (0.33% (w/v) final; Sigma-
Aldrich). This was overlaid onto 0.5% (w/v) low gelling temperature agarose in DMEM, 
pre-set in 6-well plates. Plates were then incubated at 37°C with 5% CO2, and an additional 
layer of growth media/0.33% agarose gel was added weekly. After 14-21 days, colonies 
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were imaged using an Olympus MVX10 microscope (Tokyo, Japan) and quantified either 





Cells in complete growth media were seeded onto poly-L-lysine (Sigma-Aldrich) coated 
coverslips in 12-well plates, or into poly-L-lysine coated 8- or 16-well chamber slides, and 
incubated overnight at 37°C with 5% CO2. After the appropriate treatments (transfection, 
serum-deprivation, etc), the media was then aspirated from the cells, the cells washed with 
PBS, and fixed with 4% paraformaldehyde for 10 min. Fixed cells were then washed twice 
with 0.1% Triton X-100 in PBS and permeabilised by a further 10 min incubation in Triton 
X-100/PBS. Cells were then blocked with 3% BSA (in 0.1% Triton X-100/PBS) for 10-30 
min. Primary antibodies diluted in BSA/Triton X-100/PBS were added to the cells and 
incubated for 1 hr at room temperature. Cells were washed four times with Triton X-
100/PBS. Secondary antibodies diluted in BSA/Triton X-100/PBS were added to the cells 
and incubated in the dark for 1 hr at room temperature. Cells were washed four times with 
Triton X-100/PBS and once more with PBS. For nuclear staining, DAPI (0.2 µg/ml in PBS) 
was added to the cells for 5 min in the dark. Finally, the cells were washed twice with PBS 
and mounted onto slides in fluorescent mounting medium (Dako, Agilent Technologies, 
Santa Clara, CA, USA). Cell images were taken using a Zeiss LSM 700 Confocal 
microscope (Jena, Germany), and gains were kept constant within each experiment. 
 
 
2.15 Immunohistochemistry on tumour tissue sections 
 
For immunohistological staining of PECAM-1 (CD31) expression, tumours were paraffin-
fixed and sectioned, and citrate buffer antigen retrieval was performed, followed by 
quenching endogenous peroxidase activity with 3% hydrogen peroxide. Sections were then 
blocked with rabbit serum/PBS for 60 min at room temperature, and incubated with 133 
ng/ml goat polyclonal antibody to PECAM-1 (CD31; Santa Cruz Biotechnology), or goat 
IgG isotype control, overnight at 4°C. Biotinylated rabbit anti-goat secondary antibody 
(1:500; Abcam) was incubated for 35 min at room temperature, followed by incubation with 
VECTASTAIN Elite ABC Reagent (Vector Labs) for 30 min at room temperature, and 
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peroxidase substrate solution. Sections were counterstained with Mayer’s haematoxylin, 
mounted using DPX mounting medium (Sigma-Aldrich) and imaged on an EVOS XL light 
microscope (Thermo Fisher Scientific) at 20x magnification.  
 
Immunohistological staining of overexpressed FLAG-tagged SK2 within tumour sections 
was performed as above, with the following modifications. Sections were blocked with goat 
serum/PBS and incubated with 150 ng/ml rabbit polyclonal FLAG antibody (Cell Signaling 
Technology), or rabbit IgG isotype control, overnight at 4°C. Biotinylated goat anti-rabbit 
secondary antibody (1:500; Vector Labs) was incubated for 35 min at room temperature. 
 
 
2.16 Animal ethics 
 
Experiments involving mice were conducted according to the guidelines from the Australian 
code of practice for the care and use of animals for scientific purposes 7th Edition, 2004, 
and with approval from the SA Pathology/CALHN Animal Ethics Committee (approval 

































Most of the data from this chapter has been published as: 
 
Neubauer HA and Pitson SM (2017) Validation of commercially available sphingosine 
kinase 2 antibodies for use in immunoblotting, immunoprecipitation and 
immunofluorescence. F1000Research, 5: 2825; doi: 10.12688/f1000research.10336.2. 
 


















Sphingosine kinase 2 (SK2) is a ubiquitously expressed lipid kinase that has important, 
albeit complex and poorly understood roles in regulating cell survival and cell death. In 
addition to being able to promote cell cycle arrest and apoptosis under certain conditions, it 
also appears to play a role in cancer. Therefore, well validated and reliable tools are required 
to study and better understand the true functions of SK2. In-house polyclonal SK2 antisera 
raised against amino acids 35-52 of human SK2a had previously been generated by the 
Pitson Laboratory, and this chapter describes the affinity-purification and subsequent testing 
of this in-house SK2 antibody. Furthermore, two commercially available SK2 antibodies 
were examined and compared: a rabbit polyclonal antibody from Proteintech that recognizes 
amino acids 266-618 of human SK2a, and a rabbit polyclonal antibody from ECM 
Biosciences that recognizes amino acids 36-52 of human SK2a. The performance of these 
antibodies was examined for use in immunoblotting, immunoprecipitation and 
immunofluorescence staining of endogenous SK2, using human HEK293 and HeLa cell 
lines, as well as mouse embryonic fibroblasts (MEFs). Furthermore, the specificity of these 
antibodies to the target protein was assessed through the use of siRNA-mediated SK2 
knockdown and SK2 knockout (Sphk2-/-) MEFs. The findings of this study demonstrate that 
the in-house SK2 antibody can detect endogenous SK2 by immunoblot, but also has 
extensive cross-reactivity to other proteins, making it not ideal for this application. 
Furthermore, the in-house SK2 antibody was not able to immunoprecipitate endogenous 
SK2, and it produced substantial non-specific staining by immunofluorescence, making it 
unsuitable for these applications. Notably, the Proteintech anti-SK2 antibody reproducibly 
displayed sensitivity and selectivity towards SK2 in immunoblot analyses, whilst the 
detection of non-specific proteins made it unsuitable for immunoprecipitation and 
immunofluorescence. Conversely, the ECM Biosciences anti-SK2 antibody was 
reproducibly superior for SK2 immunoprecipitation and detection by immunofluorescence 
staining, whereas it is not ideal for immunoblotting as it produces various non-specific 
bands. Overall, from this validation study, suitable tools were identified to enable 






Sphingolipids are an important family of cellular molecules that form critical structural 
components of cell membranes, as well as perform numerous signaling functions (Pitson, 
2011). Of the many enzymes responsible for the biosynthesis and metabolism of 
sphingolipids, the sphingosine kinases (SKs) are of particular interest to study as they 
catalyze the formation of sphingosine-1-phosphate (S1P), and in doing so can promote cell 
survival, proliferation, migration and angiogenesis (Pyne & Pyne, 2010). Both sphingosine 
kinases, SK1 and SK2, have been shown to be upregulated in various human cancers and 
both have documented roles in mediating oncogenesis (Neubauer et al, 2016; Xia et al, 
2000). However, where SK1 and its roles in cancer development are relatively well 
characterized, SK2 remains somewhat enigmatic as, in addition to the pro-cancer functions 
it shares with SK1, SK2 can also facilitate cell cycle arrest and cell death (Chipuk et al, 
2012; Okada et al, 2005).  
 
SK2 is ubiquitously expressed in all cells and tissues, but is expressed most highly in the 
liver, kidney and brain (Liu et al, 2000). At the mitochondria, SK2-generated S1P has been 
proposed to facilitate the activation of Bak and subsequent mitochondrial membrane 
permeabilisation and cytochrome c release (Chipuk et al, 2012). Notably, SK2 can also 
function as an epigenetic regulator, where S1P produced by nuclear-localized SK2 can 
inhibit the activity of histone deacetylases 1/2 resulting in increased transcription of specific 
genes, such as cyclin-dependent kinase inhibitor p21 and transcriptional regulator c-fos 
(Hait et al, 2009). As SK1 does not appear to localize as prominently to these internal 
organelles, it is believed that the subcellular localization of SK2 is critical for the additional 
functions it performs. However, the mechanisms regulating the localization and functions of 
SK2, allowing it to switch between pro-apoptotic and pro-survival under certain conditions, 
remain poorly understood. 
 
In order to study SK2 and better characterize its roles in normal cells as well as in cancer, 
reliable and properly validated tools are required. Antibody-based methods, such as 
immunoblotting (IB), immunoprecipitation (IP) and immunofluorescence (IF), are 
particularly useful as tools to examine and visualize important aspects of SK2 biology, like 
subcellular localization, expression and interaction with regulatory proteins. At the 
commencement of these studies, there were no validated commercially available SK2-
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specific antibodies in our Laboratory that were able to detect endogenous levels of SK2, and 
many published studies describing the detection of endogenous SK2 using antibody-based 
methods had generated and affinity-purified their own in-house SK2 antibodies (Hait et al, 
2005; Igarashi et al, 2003). As the detection and isolation of endogenous SK2 was required, 
it was of interest to validate specific SK2 antibodies that were suitable for use in various 
applications. As such, this chapter describes the affinity-purification of SK2 antisera 
generated by the Pitson Laboratory, and the subsequent validation of this in-house SK2 
antibody, as well as two recently available commercial SK2 antibodies, for use in IB, IP and 
IF using various human and mouse cells lines. The in-house antibody is a rabbit polyclonal 
SK2 antibody raised against a synthetic peptide corresponding to amino acids 35-52 of 
human SK2a. The two commercially available antibodies examined were a rabbit polyclonal 
SK2 antibody from Proteintech, which was raised against amino acids 266-618 of 
recombinant human SK2a, and a rabbit polyclonal SK2 antibody from ECM Biosciences, 
which was raised against a synthetic peptide corresponding to amino acids 36-52 of human 
SK2a. Although these antibodies have not previously been properly validated, the 
Proteintech SK2 antibody has been previously utilized in one publication for IB (Liu et al, 
2016b), and the ECM Biosciences SK2 antibody has been used in multiple publications for 
IB (Bruno et al, 2015; Liu et al, 2016a; Sun et al, 2016a; Wallington-Beddoe et al, 2014) 
and for IF (Reid et al, 2015).  
 
 
3.3 Specific Materials and Methods 
 
3.3.1 Affinity purification of SK2 antisera 
 
Polyclonal anti-SK2 antibodies, previously generated by the Pitson Laboratory, were raised 
in rabbits against the SK2 peptide H-CSQALHIQRLRPKPEARPR-OH (amino acid 
residues 35-52 of human SK2a) conjugated to maleimide-activated keyhole limpet 
hemocyanin (KLH; Pierce). To affinity purify these antibodies from the rabbit serum, an 
SK2 peptide affinity column was prepared by adding 1 ml SulfoLink™ Coupling Gel 50% 
slurry (Pierce) to a disposable column (BioRad) and equilibrating with 50 mM Tris/HCl (pH 
8.5) containing 5 mM EDTA. 1 mg SK2 peptide H-CSQALHIQRLRPKPEARPR-OH 
(ChinaPeptides, Shanghai China) in 50 mM Tris/HCl (pH 8.5) containing 5 mM EDTA was 
added to the drained and capped column, mixed by gentle inversion for 15 min at room 
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temperature, and incubated for a further 30 min at room temperature to allow the iodoacetyl 
groups on the SulfoLink resin to react with the N-terminal cysteine of the peptide. The 
column was then drained and washed with 50 mM Tris/HCl (pH 8.5) containing 5 mM 
EDTA. To quench unreacted iodoacetyl groups on the SulfoLink resin, 1 mg cysteine was 
added to the capped column, mixed by gentle inversion for 15 min at room temperature, and 
incubated for a further 30 min at room temperature. The column was drained and washed 
with 50 mM Tris/HCl (pH 7.5) containing 1 M NaCl, then stored in 50 mM Tris/HCl (pH 
7.5) containing 0.05% NaN3 at 4°C overnight.  
 
To purify the antisera, the column was equilibrated with cold 10 mM Tris/HCl (pH 7.5), 
drained and capped, and 2 ml 10 mM Tris/HCl (pH 7.5) along with 2 ml serum were then 
added and mixed by gentle inversion at 4°C for 1 hr. The column was drained and washed 
with 10 mM Tris/HCl (pH 7.5) (eluate discarded). An additional wash with 10 mM Tris/HCl 
(pH 7.5) containing 0.5 M NaCl was performed and discarded. The column was then 
washed with 5 ml 100 mM glycine (pH 2.5) and the eluate was collected in a tube 
containing 2 ml 1 M Tris/HCl (pH 8.0) (purified anti-SK2 antibodies). The column was then 
washed firstly with 10 mM Tris/HCl (pH 8.8) (eluate discarded), then with 5 ml 100 mM 
Na2PO4 (pH 11) (eluate collected in tube containing purified anti-SK2 antibodies), and 
lastly with 10 mM Tris/HCl (pH 7.5) (eluate discarded). Total collected purified anti-SK2 
antibodies were precipitated by diluting 1:2 in 100% saturated ammonium sulphate (pH 
7.4), mixing by gentle inversion, and storing at 4°C overnight. Antibodies were then 
centrifuged at 46,000 x g for 45 min at 4°C, supernatant was discarded, and remaining 
purified anti-SK2 antibodies were resuspended in 500 µl 100% saturated ammonium 
sulphate (with 0.05% NaN3) and stored at 4°C.  
 
 
3.3.2 Commercial antibodies 
 
The following commercially available SK2 antibodies were utilised: rabbit polyclonal anti-
SK2 (ECM Biosciences; anti-Sphingosine Kinase 2 (N-terminal region); #SP4621, lot #1) 
and rabbit polyclonal anti-SK2 (Proteintech Group, Inc; anti-SPHK2; #17096-1-AP, lot 
#00010361). The ECM Biosciences SK2 antibody was raised against a synthetic peptide 
coupled to keyhole limpet hemocyanin (KLH), corresponding to amino acids 36-52 of 
human SK2a, and was affinity purified with the SK2 peptide (without KLH). It is reported 
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by the manufacturer to have cross-reactivity with rat and mouse SK2 [human, mouse and rat 
SK2 share 100% sequence identity in this region (determined using the align tool and 
protein sequences from www.uniprot.org)], and has been assessed by the manufacturer for 
use in IB and enzyme-linked immunosorbent assay (ELISA). The Proteintech SK2 antibody 
was raised against truncated recombinant GST-tagged human SK2a (amino acid residues 
266-618 generated in Escherichia coli using the PGEX-4T plasmid). The SK2 target 
antibodies were then affinity purified using 6xHis-tagged antigen protein (to remove GST-
specific antibodies) and then again with the immunising GST-tagged antigen protein. It is 
reported to have cross-reactivity with rat and mouse SK2 [80.2% sequence identity between 
human and mouse SK2, and 80.2% sequence identity between human and rat SK2 in this 
region (determined using the align tool and protein sequences from www.uniprot.org)], and 
according to the manufacturer can be employed for IB, ELISA, IP and 
immunohistochemistry. Mouse anti-α-tubulin (DM1A; Abcam; #ab7291) is a mouse 




3.3.3 siRNA knockdown of SK2 
 
siRNA-mediated knockdown of SK2 was performed using human SPHK2 siGENOME 
SMARTpool siRNA (Dharmacon), which targets the following sequences: 
CCACUGCCCUCACCUGUCU, GCUCCUCCAUGGCGAGUUU, 
GAGACGGGCUGCUCCAUGA, CAAGGCAGCUCUACACUCA. Cells were seeded and 
grown to a cell density of approximately 50%, and cells were then transfected with 30 nM 
(final concentration) of either hSK2 siRNA or siGENOME non-targeting siRNA pool, using 
Lipofectamine RNAiMAX as per the manufacturer’s protocol (Life Technologies). Cells 











3.4.1 Testing the in-house affinity-purified SK2 rabbit polyclonal antibody 
 
The SK2 antisera previously generated and collected by the Pitson Laboratory was raised 
against a peptide sequence corresponding to amino acids 35-52 of SK2a, as this peptide 
sequence had been used to generate SK2-specific antibodies by other groups in published 
studies detecting endogenous SK2 (Hait et al, 2005; Igarashi et al, 2003). The antisera was 
affinity-purified using an SK2 peptide affinity column, and the resulting in-house SK2 
antibody (herein referred to as HN12) was utilised in IB, IP and IF. 
   
 
3.4.1.1    Testing the SK2 antibody HN12 for the detection of endogenous SK2 by 
immunoblot  
 
Firstly, the HN12 SK2 antibody was utilised in IB analyses to examine its specificity and 
selectivity towards endogenous SK2. As shown in Figure 3.1, HN12 was able to detect 
overexpressed SK2 very well, and importantly, HN12 demonstrated selectivity for SK2 as it 
did not detect overexpressed SK1. An additional band was detected at the same size as SK2 
(~69 kDa) in lysates from cells transfected with empty vector as well as lysates from cells 
overexpressing SK1, suggesting that HN12 may have detected endogenous SK2 (Figure 
3.1). To validate if this band was indeed endogenous SK2, HEK293 and HeLa cells were 
subjected to siRNA-mediated knockdown of SK2, which resulted in 50% knockdown of 
SK2 mRNA levels in both cell lines (Figure 3.2A). IB analyses were then performed on 
these lysates using HN12. In agreement with Figure 3.1, a band was detected in HEK293 
lysate at the correct size for SK2, but this band was, at most, only slightly reduced in the 
SK2-knockdown lysate (Figure 3.2B). Conversely, no detectable endogenous SK2 band was 
present in the HeLa lysates, however this may not be surprising as HeLa cells have less SK2 
than HEK293 cells, at least at the mRNA level (Figure 3.2A).  
 
To further examine the ability of HN12 to detect endogenous SK2, lysates from wildtype 
and Sphk2-/- MEFs were also subjected to IB analyses using HN12, negating the issues of 
incomplete knockdown often observed with siRNA. Indeed, a band was detected in the 
wildtype MEF lysate that was completely absent in the Sphk2-/- MEF lysate (Figure 3.2C),
Figure 3.1: Affinity purified HN12 SK2 antibody detects overexpressed, and
potentially endogenous, SK2 by immunoblot
HEK293T cells were transfected with vectors encoding FLAG-tagged SK2, FLAG-tagged
SK1, or empty vector (EV). The cells were harvested 24 hr later and the lysates were
subjected to SDS-PAGE and immunoblot analyses using affinity purified in-house anti-


















































































Figure 3.2: Affinity purified HN12 SK2 antibody detects endogenous SK2 by
immunoblot in some cell lines, but is nonspecific
A and B, HEK293-c18 and HeLa cells were transfected with either negative control siRNA
(si-Neg) or SK2 siRNA (si-SK2). After 48 hr, half of the cells were used for (A) qRT-PCR
analyses of SK2 mRNA levels (comparative quantitation; normalised to GAPDH and
HEK293 si-Neg), and the other half of the cells were used for (B) lysate preparation, SDS-
PAGE and immunoblot analyses using affinity-purified in-house HN12 anti-SK2
antibodies, or anti-tubulin antibodies. Data in (A) were collected and analysed by Wenying
Zhu and Elferaan Quatermass. Images shown are representative of 1-2 independent
experiments. C, Lysates made from wildtype (WT) or Sphk2-/- MEFs were subjected to
SDS-PAGE and immunoblot analyses using affinity-purified in-house HN12 anti-SK2







confirming that HN12 can detect endogenous SK2. However, in all three cell types tested, a 
substantial number of non-specific bands were present, some of which were more intense 
than the SK2 band (Figure 3.2B and C). Therefore, although HN12 may detect endogenous 
SK2 by IB, it is not an ideal antibody to use for this application. 
 
 
3.4.1.2    Testing the SK2 antibody HN12 for use in the immunoprecipitation of 
endogenous SK2 
 
In testing the use of HN12 in other applications, it was of interest to determine if this SK2 
antibody could IP endogenous SK2 from cell lysates. IP was performed using HN12 in 
HEK293 cell lysates, followed by IB analyses with HN12. A faint band at the correct size 
for SK2 appeared to be immunoprecipitated by HN12, and this band was somewhat weaker 
in lysate from cells subjected to siRNA-mediated knockdown of SK2 (Figure 3.3). 
However, the same band was present even in the absence of HN12 (Figure 3.3), suggesting 
that the bands observed may be endogenous SK2 non-specifically binding to the beads. 
Given that there was no enrichment of SK2 observed above non-specific levels by IP with 
HN12, despite a large amount of antibody being used, it is apparent that HN12 is not 
suitable for IP of endogenous SK2.  
 
 
3.4.1.3    Testing the SK2 antibody HN12 for the detection of endogenous SK2 by 
immunofluorescence 
 
IF is a very useful and commonly used technique to visualise the subcellular localisation of 
a target protein, and given that the localisation of SK2 seems to dictate its function, 
validating a specific SK2 antibody for use in IF was critical. As such, HeLa cells were 
subjected to either scrambled control siRNA or SK2-specific siRNA, and then analysed by 
IF with HN12 and confocal microscopy. As seen in Figure 3.4A, the ‘SK2’ staining 
appeared predominantly cytoplasmic, with strong peri-nuclear puncta. However, these 
puncta were also present in cells with SK2 knockdown, although the cytoplasmic staining 
was diminished (Figure 3.4A). To negate issues of incomplete knockdown by siRNA, 
wildtype and Sphk2-/- MEFs were also analysed by IF as above. In these cells, SK2 seemed 














Figure 3.3: Affinity-purified SK2 antibody HN12 cannot immunoprecipitate
endogenous SK2
HEK293-c18 cells were transfected with either negative control siRNA (si-Neg) or SK2
siRNA (si-SK2). After 48 hr, SK2 was immunoprecipitated from lysates using affinity-
purified HN12 anti-SK2 antibodies. The resulting immunoprecipitate, as well as
overexpressed SK2 lysate as a positive control [SK2(FLAG)], were subjected to SDS-
PAGE and immunoblot analyses using HN12 anti-SK2 antibodies. Image shown is
representative of two independent experiments.
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Figure 3.4: Affinity-purified SK2 antibody HN12 is not suitable for use in
immunofluorescence
A, HeLa cells were transfected with either negative control siRNA (si-Neg) or SK2 siRNA
(si-SK2). After 48 hr, endogenous SK2 was visualised by immunofluorescence and
confocal microscopy, using anti-SK2 HN12 antibodies. B, Wildtype (WT) or Sphk2-/-
MEFs were seeded and endogenous SK2 was visualised by immunofluorescence and
confocal microscopy, using anti-SK2 HN12 antibodies. Nuclei were stained with DAPI
(blue). Images shown are representative of more than 100 cells, from 1-2 independent

















the nucleus (Figure 3.4B). However, very little difference in the cytoplasmic and nuclear 
staining was observed in the Sphk2-/- MEFs, and the nuclear puncta staining was slightly 
decreased but not absent (Figure 3.4B). Therefore, it cannot be concluded that the staining 
detected by HN12 is specifically endogenous SK2, and as such, it was concluded that this 
antibody would not be ideal to use for IF studies. 
 
 
3.4.2 Validating commercially-available SK2 polyclonal antibodies  
 
As it was important to possess a validated SK2 antibody to detect endogenous SK2 in 
multiple applications, and given that the in-house SK2 antibody HN12 was only able to 
detect endogenous SK2 by IB with low specificity, two additional newly available 
commercial SK2 antibodies were examined. 
 
 
3.4.2.1    Proteintech SK2 antibody demonstrates target specificity and sensitivity by 
immunoblot 
 
Both commercial SK2 antibodies examined in the present study are reported by their 
respective manufacturers to be able to detect endogenous SK2 by IB. To determine the 
selectivity of the anti-SK2 antibodies, IB analyses were performed using two human cell 
lines (HEK293 and HeLa) that had been treated with either scrambled control or SK2-
directed siRNA, as well as WT and Sphk2-/- MEFs. The Proteintech anti-SK2 antibody 
detected a single prominent band at the correct molecular weight for SK2 (~65 kDa), which 
was decreased or absent in the knockdown and knockout lines (Figure 3.5A). Some faint 
non-specific bands were also detected in both the WT and Sphk2-/- MEF lysates by this 
antibody, which were not observed in the human cell lines. The ECM Biosciences anti-SK2 
antibody did not appear to be very sensitive towards SK2, as no band was detected at the 
expected size in the HeLa lysates, and only very faint bands were present in the HEK293 
and MEF lysates that were reduced or absent in the knockdown or knockout lines (Figure 
3.5B). Furthermore, numerous prominent non-specific bands were present in all lysates, 
particularly in the MEF lines, indicating a lack of selectivity of this antibody towards SK2. 
Therefore, the Proteintech anti-SK2 antibody appears to be superior for use in IB,
Figure 3.5: Immunoblot analyses of endogenous SK2 in multiple cell lines using two














































Immunoblot analyses of lysates from HEK293 and HeLa cells treated with scrambled
control siRNA (si-Neg) or SK2 siRNA (si-SK2), and lysates from wildtype (WT) or
Sphk2-/- MEFs. An equal amount (40 µg) of total protein from each sample was run in
duplicate. After transferring to nitrocellulose and blocking, the membrane was separated
and duplicate samples were probed with either (A) Proteintech rabbit anti-SK2 antibody
or (B) ECM Biosciences rabbit anti-SK2 antibody. SK2 membranes were imaged using a
4 min exposure. The expected band size for SK2 is ∼65 kDa. Membranes were re-probed
with mouse anti-α-tubulin antibodies as a loading control (2 min exposure), and α-tubulin
was detected at 55 kDa as expected. Consistent results were observed from 2-3 (HEK293




demonstrating both selectivity and sensitivity in the detection of endogenous SK2, 
particularly in the human cell lines tested. 
 
 
3.4.2.2     ECM Biosciences SK2 antibody is able to specifically immunoprecipitate SK2 
 
It was also examined whether either of the commercial anti-SK2 antibodies could 
immunoprecipitate SK2 from cell lysates. The Proteintech anti-SK2 antibody is suggested 
by the manufacturer to be useful for IP, whereas to our knowledge the ECM Biosciences 
anti-SK2 antibody has not been previously tested for use in this application. Initially, using 
lysates from HEK293 cells, it was found that the Proteintech anti-SK2 antibody was 
sometimes able to IP a band at the correct size for SK2 (Figure 3.6A); however this was not 
consistent with each experimental repeat and other proteins were also immunoprecipitated 
to a varying extent by this antibody that were not present in the IgG isotype control. 
 
Conversely, the ECM Biosciences anti-SK2 antibody was able to consistently and cleanly IP 
a protein of the same size as SK2 from cell lysates, with almost no non-specific bands 
observed (Figure 3.6B). The protein immunoprecipitated by the ECM Biosciences antibody 
was considerably enriched from the cell lysate and was strongly detectable by this antibody, 
which was unable to detect SK2 in the lysate input sample, consistent with Figure 3.5B. To 
determine if this band was in fact SK2, the ECM Biosciences anti-SK2 antibody was then 
used to immunoprecipitate SK2 from HEK293 lysates treated with either scrambled control 
or SK2-directed siRNA. SK2 knockdown consistently resulted in reduced intensity of the 
band enriched by this antibody (Figure 3.6C), confirming that the ECM Biosciences anti-
SK2 antibody can selectively IP endogenous SK2. 
 
 
3.4.2.3      ECM Biosciences SK2 antibody can specifically detect SK2 by 
immunofluorescence staining 
 
Finally, it was examined whether these commercially available SK2 antibodies could 
selectively detect SK2 by IF. Neither antibody has been reported to be tested for use in IF 
by their respective manufacturers; however, the Proteintech SK2 antibody is recommended 
for immunohistochemistry. Using IF staining methods routinely performed in the Pitson
Figure 3.6: Comparison of two commercially available rabbit polyclonal anti-SK2









































SK2 was immunoprecipitated from HEK293 cell lysate using either (A) Proteintech rabbit
anti-SK2 antibody or (B) ECM Biosciences rabbit anti-SK2 antibody. Normal rabbit IgG
antibody was used as an isotype control. Immunoprecipitates (and 40 µg lysate input) were
subjected to immunoblot analyses and probed with (A) Proteintech rabbit anti-SK2
antibody or (B) ECM Biosciences rabbit anti-SK2 antibody. Membranes were imaged
using a 4 min exposure. Images are representative of three independent experiments for
each antibody. C, SK2 was immunoprecipitated from HEK293 cell lysates (of equal
protein) that had been treated with scrambled control siRNA (si-Neg) or SK2 siRNA (si-
SK2), using ECM Biosciences rabbit anti-SK2 antibody. Immunoprecipitates were
subjected to immunoblot analyses and probed with ECM Biosciences rabbit anti-SK2
antibody. Membrane was imaged using a 4 min exposure. Image is representative of three




Laboratory, the two anti-SK2 antibodies were compared using HeLa, HEK293 and MEF 
cell lines. The Proteintech anti-SK2 antibody produced minimal staining in all cell lines 
tested (Figure 3.7), and consequently there was no observable differences between the 
control cells and those with SK2 knockdown (in the human cell lines) or SK2 knockout (in 
the Sphk2-/- MEF line).  
 
The ECM Biosciences anti-SK2 antibody did result in consistently observable staining in 
HeLa and HEK293 cells, which was substantially reduced upon knockdown of SK2 (Figure 
3.7A and B). Hence, in these cells the ECM Biosciences antibody was able to selectively 
detect SK2 by IF. Interestingly, in HeLa cells SK2 detected by the ECM Biosciences 
antibody was predominantly nuclear with some peri-nuclear/cytoplasmic localization, 
whereas in HEK293 cells SK2 was cytoplasmic and nuclear-exclusion, which is consistent 
with previous reports for these cell lines (Igarashi et al, 2003). However, the ECM 
Biosciences anti-SK2 antibody produced very strong peri-nuclear staining/puncta in both 
the WT and Sphk2-/- MEF lines (Figure 3.7C), suggesting that this staining was not specific 
for SK2 and represents non-specific binding to other proteins in this cell type. Increased 
non-specific binding of both SK2 antibodies to other proteins in the MEF lines was also 
observed when used for IB, so this cell type may not be suitable for use with these 
antibodies. It will remain to be determined if the same level of non-specificity is also 





It can be difficult to find commercially available antibodies that are sensitive, but also 
selective enough to detect or isolate endogenous levels of a protein of interest. The Pitson 
Laboratory had previously sought to generate in-house SK2 polyclonal antisera in order to 
provide a tool with which to detect, purify and examine the localisation of endogenous SK2. 
The SK2 peptide antigen used to generate the polyclonal SK2 antisera had previously been 
used and published by other groups, and the resulting purified SK2 antibodies had been 
utilised in a number of applications, including IB, IP and IF (Hait et al, 2005; Igarashi et al, 
2003). This would seem to be an optimal sequence within SK2 to raise an antibody against 
as it is one of the regions in SK2 not conserved in SK1, which provides isoform selectivity. 










Figure 3.7: Immunofluorescence staining analyses of endogenous SK2 in multiple cell 
lines using two commercially available rabbit polyclonal anti-SK2 antibodies 
(A) HeLa or (B) HEK293 cells were treated with scrambled control siRNA (si-Neg) or SK2 
siRNA (si-SK2), and endogenous SK2 (green) was visualised by immunofluorescence 
staining and confocal microscopy, using Proteintech rabbit anti-SK2 antibody or ECM 
Biosciences rabbit anti-SK2 antibody. C, Wildtype (WT) or Sphk2-/- MEFs were seeded, and 
endogenous SK2 (green) was visualised by immunofluorescence staining and confocal 
microscopy, using Proteintech rabbit anti-SK2 antibody or ECM Biosciences rabbit anti-
SK2 antibody. Nuclei were stained with DAPI (blue). For each cell line, background 
staining was examined by staining cells (si-Neg or WT cells) with secondary antibody and 
DAPI only, and collecting images using both 488nm and 405nm lasers (SK2 + DAPI). 
Images were taken at 40x magnification; scale bars = 10 µm. Images shown are 
representative of more than 100 cells from each experiment, and these results were 











































region, and no post-translational modifications have been reported within this sequence 
(Hornbeck et al, 2015), which may otherwise block antibody binding in physiological 
settings. In the studies described here, the in-house SK2 antiserum was affinity-purified 
(HN12) and found to detect endogenous SK2, amongst other non-specific bands, by IB. 
However, HN12 could not successfully IP SK2, nor could it cleanly detect SK2 by IF. 
Additional affinity-purification of the SK2 antisera may be beneficial in an attempt to 
remove/reduce the non-specific antibodies present in the polyclonal pool, which may 
increase the sensitivity and selectivity of this antibody. Similarly, Hait et al. used their 
affinity-purified SK2 antibody for IB analyses, and multiple bands were detected, but a ~70 
kDa band was observed and confirmed to be endogenous SK2 by siRNA-mediated 
knockdown (Hait et al, 2005). Igarashi and colleagues validated the specificity of their 
polyclonal SK2 antibody for use in IP by demonstrating that the immunoprecipitate had SK 
activity, and co-incubation of the lysate with the SK2 antibody as well as immunogen 
peptide ablated this activity (Igarashi et al, 2003). However, IB analyses of the 
immunoprecipitates using their SK2 antibody resulted in many prominent bands, one of 
which ran at the correct size for SK2 and was thus deemed to be endogenous SK2, without 
further validation. Furthermore, no validation of their SK2 antibody was performed when 
utilising it for IF detection of endogenous SK2 (Igarashi et al, 2003). Therefore, it is 
difficult to conclude whether the affinity-purified SK2 antibody generated by this group, 
which was raised against the same peptide sequence as HN12, is in fact suitable for use in 
the published applications.  
 
At the commencement of these studies, very few commercially available antibodies claimed 
to be able to detect endogenous levels of SK2. Furthermore, commercially available 
antibodies raised against the SKs can be notorious for not being very sensitive or selective. 
However, more recent published studies have reported the use of different commercial SK2 
antibodies, sometimes without proper controls or validation of selectivity. Two commercial 
SK2 antibodies were obtained and their selectivity towards SK2 was examined in multiple 
applications using siRNA-mediated SK2 knockdown or Sphk2-/- MEF lines.  
 
The SK2 antibody from Proteintech was able to consistently detect a prominent band at the 
correct molecular weight by IB, and this band was confirmed to be SK2 by knockdown and 
knockout analyses, confirming the specificity of this antibody. The Proteintech antibody 
also resulted in virtually no non-specific detection of any other proteins in the HEK293 and 
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HeLa lysates, but some additional faint bands were present in the MEF lines. This antibody 
has been tested by IB on various mouse tissue lysates by the manufacturer and many of 
these also gave rise to non-specific bands, so this will need to be considered and further 
validation may be required if this antibody is intended for use with mouse cells or tissues. 
Occasionally more than one band was detected in the human cell lines by the Proteintech 
SK2 antibody, but these bands also seemed to be reduced by SK2 knockdown. There are 
two characterized human SK2 isoforms (Neubauer & Pitson, 2013), so these bands may 
represent different SK2 variants and/or post-translationally modified forms of SK2.  
 
In contrast, the present results revealed that the sensitivity of the ECM Biosciences antibody 
towards SK2 by IB was poor, with a faint band detected only in the HEK293 and MEF lines 
that was not present in the knockdown/knockout lysates. Furthermore, the ECM Biosciences 
SK2 antibody produced many intense non-specific bands in all cell lines tested, 
demonstrating poor selectivity. This antibody has been used for IB analyses in multiple 
publications (Bruno et al, 2015; Liu et al, 2016a; Sun et al, 2016a; Wallington-Beddoe et al, 
2014), suggesting that it may be more suitable with other cell/tissue systems or conditions 
not tested here. However, in agreement with the current findings, the IB analysis performed 
by the manufacturer also showed various prominent non-specific bands in HeLa lysates. 
Therefore, these data demonstrate that the ECM Biosciences SK2 antibody is not ideal for 
this application. 
 
However, the ECM Biosciences anti-SK2 antibody was superior for the IP of endogenous 
SK2, as it was able to cleanly and substantially enrich the protein from lysates and was 
confirmed by SK2-specific knockdown to be selective for SK2 in this application. This 
antibody will therefore be a useful tool to study SK2 function and regulation, as it can be 
applied to other applications requiring IP, such as chromatin-IP (ChIP) and rapid 
immunoprecipitation mass spectrometry of endogenous protein (RIME). In the present 
study, the Proteintech anti-SK2 antibody was inconsistent in its ability to IP protein at the 
correct size for SK2, and other bands of equal intensity were sometimes present.  
 
Similarly, the ECM Biosciences anti-SK2 antibody was able to selectively detect 
endogenous SK2 by IF staining in two human cell lines, HeLa and HEK293 cells. 
Furthermore, the observed localization of SK2 in these two cells lines was consistent with 
previous reports (Igarashi et al, 2003). The selectivity of this antibody was validated by 
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knockdown of SK2 in these cell lines, where most of the staining was reduced. A very small 
level of staining was still visible after SK2 siRNA treatment, possibly owing to the 
inherently incomplete nature of siRNA-mediated knockdown. However, this could not be 
corroborated with SK2 knockout using the MEF lines, as considerable non-specific staining 
was present in this cell type, as was found for IB. Using identical methods, there was 
minimal staining observed using the Proteintech anti-SK2 antibody for IF, and therefore the 
selectivity of this antibody towards SK2 in this application could not be properly examined. 
  
During this study, methods routinely used in the Pitson Laboratory were employed, and 
where applicable, recommendations from the manufacturers for antibody dilutions and 
concentrations were followed. It is possible that further optimization for these antibodies 
may allow them to perform better in the applications where they were deemed not optimal. 
However, as one of the main aims of this study was to directly compare the performance of 
these two antibodies, and given at least one of the antibodies performed well for each 
application using the standard methods, further optimization was not performed.  
 
Overall, based on the data from this study, the Proteintech SK2 antibody was optimal and 
suitable for use in IB, as it demonstrated selectivity and sensitivity towards endogenous SK2 
in the human cell lines tested. Furthermore, the ECM Biosciences SK2 antibody is suitable 
for IP of endogenous SK2 and for visualizing SK2 by IF methods. Both antibodies detected 
non-specific proteins by IB and IF in the mouse fibroblasts used, and hence further 
validation will be required to determine if this is the case for other mouse cells or tissues. In 
line with these results, all subsequent results chapters utilising IB analyses to detect 
endogenous SK2 were performed using the Proteintech SK2 polyclonal antibody, and all IP 

























Most of the data from this chapter has been published as: 
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While both human sphingosine kinases (SK1 and SK2) catalyse the generation of the 
pleiotropic signalling lipid sphingosine-1-phosphate, these enzymes appear to be 
functionally distinct. SK1 has well described roles in promoting cell survival, proliferation 
and neoplastic transformation. The roles of SK2, and its contribution to cancer, however, are 
much less clear. Some studies have suggested an anti-proliferative/pro-apoptotic function 
for SK2, while others indicate it has a pro-survival role and its inhibition can have anti-
cancer effects. Our analysis of gene expression data revealed that SK2 is upregulated in 
many human cancers, but only to a small extent (up to 2.5-fold over normal tissue). Based 
on these findings, we examined the effect of different levels of cellular SK2 and showed 
that high-level overexpression reduced cell proliferation and survival, and increased cellular 
ceramide levels. In contrast, however, low-level SK2 overexpression promoted cell survival 
and proliferation, and induced neoplastic transformation in vivo. These findings coincided 
with decreased nuclear localisation and increased plasma membrane localisation of SK2, as 
well as increases in extracellular S1P formation. Hence, we have shown for the first time 
that SK2 can have a direct role in promoting oncogenesis, supporting the use of SK2-

















The sphingosine kinases (SKs) catalyse the conversion of sphingosine to sphingosine-1-
phosphate (S1P). Given that sphingosine and its precursor, ceramide, are pro-apoptotic 
molecules, and S1P mediates cell survival and proliferation (Pitson, 2011; Pyne & Pyne, 
2010), the SKs are considered critical regulators of the balance between cell death and cell 
survival, and represent promising targets for anti-cancer therapies (Pitman & Pitson, 2010). 
The two mammalian SKs, SK1 and SK2, share high sequence similarity and both possess 
constitutive catalytic activity, but generally show distinct subcellular localisation (Neubauer 
& Pitson, 2013). 
 
The role of SK1 in cancer is well characterised and has been extensively reviewed 
(Heffernan-Stroud & Obeid, 2013; Pitson, 2011; Pyne & Pyne, 2010), with high SK1 
expression observed in many different cancers (Bayerl et al, 2008; French et al, 2003; 
Kawamori et al, 2006; Malavaud et al, 2010) and often correlating with poorer patient 
survival (Li et al, 2008; Ruckhaberle et al, 2008; Van Brocklyn et al, 2005). SK1 
overexpression promotes neoplastic transformation and tumourigenesis (Xia et al, 2000), 
and notably, targeting SK1 has been shown to attenuate tumour growth in numerous animal 
models (French et al, 2003; Ju et al, 2016; Nagahashi et al, 2012; Pchejetski et al, 2008; 
Ponnusamy et al, 2012). In contrast, the contribution of SK2 to cancer is unclear. 
Surprisingly, despite both enzymes catalysing the same reaction, most studies examining 
SK2 function have found that it has an opposite role to SK1, and can promote cell cycle 
arrest and apoptosis (Chipuk et al, 2012; Igarashi et al, 2003; Liu et al, 2003; Maceyka et al, 
2005; Okada et al, 2005). Although most of these studies utilised high-level overexpression 
systems, functional analysis of endogenous SK2 has supported this role in promoting cell 
death (Chipuk et al, 2012; Hofmann et al, 2008; Okada et al, 2005). Most notably, nuclear-
localised SK2 has been shown to act as an epigenetic regulator, through S1P-mediated 
inhibition of HDAC1/2 activity and increased transcription of p21 and c-fos (Hait et al, 
2009). 
 
Despite the general notion that SK2 is pro-apoptotic, a number of studies have emerged that 
demonstrate a role for SK2 in promoting cancer. Knockdown of SK2 expression has been 
shown to enhance apoptosis and chemosensitise many cancer cell types (Nemoto et al, 
2009; Sankala et al, 2007; Schnitzer et al, 2009; Van Brocklyn et al, 2005). In fact, targeting 
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SK2 in a range of cancer cell lines appears to have more of an anti-cancer effect than 
targeting SK1 (Gao & Smith, 2011; Van Brocklyn et al, 2005). Strikingly, several in vivo 
studies have reported that targeting SK2 significantly attenuated tumour growth in a range 
of human xenografts models in mice (Chumanevich et al, 2010; French et al, 2010; Liu et al, 
2013; Wallington-Beddoe et al, 2014; Weigert et al, 2009). Increased SK2 expression levels 
also correlate with disease progression in NSCLC (Wang et al, 2014b) and multiple 
myeloma (Venkata et al, 2014), and poorer survival in NSCLC patients (Wang et al, 2014b). 
Recent work also suggests that SK2 can play a role in increasing telomerase activity 
(Panneer Selvam et al, 2015), promoting the upregulation of c-Myc via regulation of 
HDAC1/2 (Wallington-Beddoe et al, 2014), and facilitating the activation of ERM proteins 
to promote EGF-induced cancer cell invasion (Adada et al, 2015), all of which may 
contribute to cancer development and progression.  
 
Although there is an emerging body of evidence suggesting that SK2 can play a role in 
cancer development, this is complicated by the known role of SK2 in facilitating cell death, 
and that, unlike SK1, SK2 overexpression has never been shown to promote neoplastic 
transformation and tumourigenesis. Here, I demonstrate for the first time that low-level SK2 
overexpression, similar to that observed in numerous cancers, can promote cell 
proliferation, survival and neoplastic transformation, and that these levels of SK2 
overexpression alone can drive tumourigenesis in vivo.  
 
 
4.3 Preliminary data leading to this study 
 
Previously in the Pitson Laboratory, HEK293 Flp-In T-Rex cells had been engineered to 
express FLAG-tagged SK2 or SK1 in a doxycycline-inducible, concentration-dependent 
manner (Pham et al, 2008). Therefore, by using different doxycycline concentrations in the 
culture media, low and high SK2 and SK1 overexpression could be achieved, as determined 
by isoform-specific activity (Figure 4.1A) and protein expression (Figure 4.1B). These cells 
had then been utilised to assess the effect of varying levels of SK overexpression on cell 
proliferation and survival. In agreement with previous studies, overexpression of SK2 at 
high levels (over 200-fold) in this system resulted in decreased cell proliferation and an 
increase in cell death (Figure 4.1C and D). Strikingly, however, when SK2 was 












Figure 4.1: Low-level SK2 overexpression promotes cell survival and proliferation, 
whereas high-level SK2 overexpression promotes cell death  
A, SK1 and SK2-specific activity upon doxycycline-induced low- and high-level 
overexpression in HEK293 Flp-In TRex cells. Data shown are mean (± range) of a 
representative experiment (of more than three independent experiments) with duplicate data 
points. B, Lysates from the HEK293 Flp-In TRex cells with doxycycline-induced low- and 
high-level overexpression of SK1 or SK2, or empty vector, were subjected to immunoblot 
analyses with antibodies against FLAG and α-tubulin. Blots shown are representative of at 
least three independent experiments. C, Measurement of cell proliferation (by BrdU 
incorporation) in HEK293 Flp-In TRex cells with doxycycline-induced low- and high-level 
overexpression of SK1 or SK2, or empty vector. Data shown are mean (± SEM), n = 3-4. D, 
Measurement of cell death (by DAPI staining and quantification of nuclear fragmentation) 
in HEK293 Flp-In TRex cells with doxycycline-induced low- and high-level overexpression 
of SK1 or SK2, or empty vector. Data shown are mean (± SEM), n = 4-5. Data shown in C 










































































































increase in cell proliferation and a decrease in cell death (Figure 4.1C and D). Notably, 
these findings were unique to SK2, with both low- and high-level overexpression of SK1 
resulting in a consistent increase in cell survival and proliferation (Figure 4.1C and D). 
 
Given that SK1 has known roles in promoting neoplastic transformation and oncogenesis 
(Xia et al, 2000), and that low-level overexpression of SK2 appeared to phenocopy the 
survival and proliferative advantages of SK1 overexpression, it was then examined if low-
level SK2 overexpression could also induce neoplastic transformation. In contrast to mouse 
cells, neoplastic transformation of human cells is well known to require multiple oncogenes 
(Hahn et al, 1999), meaning their use in these type of studies is problematic. Thus, to 
examine the oncogenic potential of SK2, NIH3T3 mouse fibroblasts were transfected with a 
pcDNA3 vector encoding SK2 as well as green fluorescent protein (GFP) via an internal 
ribosome entry site (IRES) such that GFP and SK2 expression were linked. A series of cell 
lines stably expressing different levels of SK2 were then isolated through the sorting of cells 
for differential GFP expression. The resulting stable cell lines were then validated through 
the analysis of SK2-specific activity and exogenous SK2 protein levels, which revealed 
overexpression of SK2 at 5-fold, 10-fold, 15-fold and 370-fold over endogenous levels, 
designated ‘very low’, ‘low’, ‘mid’ and ‘high’ level SK2 overexpression, respectively 
(Figure 4.2A).  
 
These SK2 cell lines, and their respective GFP-alone control cell lines, were then utilised in 
focus formation assays to assess their ability to overcome contact inhibition as a measure of 
neoplastic transformation. Strikingly, cell lines with ‘very low’, ‘low’ and ‘mid’-level SK2 
overexpression formed foci, whereas cells with ‘high’-level SK2 overexpression, or vector 
control cells, did not (Figure 4.2B). Therefore, it appeared that low, close to physiological 
levels of SK2 overexpression could indeed promote neoplastic transformation in vitro. It 
was then of interest to subcutaneously inject these cell lines into the flanks of NOD/SCID 
mice to determine if the low SK2-overexpressing cells could display full neoplastic 
transformation through tumour formation in vivo. However, it became apparent that the 
CMV promoter driving the stable overexpression of SK2 from the pcDNA3 vector was 
being silenced over time in these mouse fibroblast cells, as previously observed (Haase et al, 
2010; Meilinger et al, 2009). As such, the precise levels of low SK2 overexpression required 
could not be maintained long enough to test in vivo tumourigenesis. Therefore, to truly 
interrogate the role of SK2 in driving tumourigenesis in vivo, a new system was required to
Figure 4.2: SK2 overexpressed at low levels can promote neoplastic transformation in
vitro
A, SK2-specific activity of NIH3T3 pcDNA3 cell lines stably expressing ‘very low’ (5-
fold), ‘low’ (10-fold), ‘mid’ (15-fold) or ‘high’ (370-fold) levels of SK2 overexpression
(above endogenous levels), or corresponding empty vector controls. Data shown are mean
(± range) of duplicate data points from a representative experiment. B, Focus formation
assays testing contact inhibition of the NIH3T3 vector or SK2 overexpressing cell lines.
Images shown are representative of at least three independent experiments, each performed
in duplicate, using at least three independently generated sets of stable lines. Data were
generated by Julia Dobbins, Dr Huasheng Chan and Dr Tamara Leclercq (Centre for
Cancer Biology, Adelaide).






































enable long-lasting stable overexpression of SK2 in NIH3T3 mouse fibroblasts, which is the 
focus of this chapter. 
 
 
4.4 Specific Materials and Methods 
 
4.4.1 Generation of expression constructs 
 
The pCX-EGFP construct was obtained from (Okabe et al, 1997), and was modified by Paul 
Moretti (Pitson Laboratory). Initially, the EGFP was replaced with a polylinker following 
digestion with EcoRI and ligation of annealed kinased oligonucleotides 5'-
AATTCGGTACCGAGCTCGCTAGCGCGGCCGCCTCGAGC-3' and 5'-
AATTGCTCGAGGCGGCCGCGCTAGCGAGCTCGGTACCG-3', to produce pCX4. 
pCX4-IRES EGFP was then generated by subcloning the IRES EGFP cassette from 
pcDNA3-IRES EGFP (Pham et al, 2014) with EcoRI and NotI. I then generated pCX4-
SK2(FLAG) IRES EGFP by cloning in FLAG-tagged human SK2a (Roberts et al, 2004) 
following digestion with EcoRI. 
 
To generate pCX4NEO IRES EGFP, a blunted SalI and EcoRI cassette from pCX4 (described 
above), encompassing the chicken β-actin promoter, was used to replace the CMV promoter 
of pcDNA3-IRES EGFP (Pham et al, 2014) following blunted BglII and EcoRI digestion. 
pCX4NEO-SK2(FLAG) IRES EGFP was then produced by cloning in FLAG-tagged human 
SK2a (Roberts et al, 2004) with EcoRI. 
 
 
4.4.2 Generating cell lines 
 
To generate NIH3T3 stable cell lines with varying levels of constitutive SK2 
overexpression, NIH3T3 mouse fibroblasts were transfected with an SK2 expression 
construct (pCX4-SK2(FLAG) IRES EGFP or pCX4NEO-SK2(FLAG) IRES EGFP), or the 
corresponding empty vector, using Lipofectamine™ 2000 (Invitrogen) as per the 
manufacturer’s protocol. 48 hr after transfection, the cells were sorted for GFP-positive cells 
using a MoFlo Astrios cell sorter (Beckman Coulter). For the pCX4 vector, a stable GFP-
positive cell population was obtained by sorting for GFP another two times. For the 
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pCX4NEO vector, a stable pooled cell line was obtained by selection with G418 (0.8mg/ml). 
The stable GFP-positive pooled line was then sorted on four separate narrow gates of 
varying GFP intensity, to produce new stable lines depicted as ‘very low’, ‘low’, ‘mid’ and 
‘high’, for both the SK2 and empty vector lines. The average SK2 expression levels of each 
line were determined by SK2-specific activity assays, and if the desired level of SK2 
overexpression for any line had not been achieved, the line was resorted on four separate 
narrow gates of varying GFP intensity, as above, until suitable lines had been generated. 
These new stable lines were then analysed by flow cytometry to confirm that the desired 
narrow GFP-expression levels were obtained as expected. 
 
 
4.4.3 In vivo subcutaneous tumour model 
 
The NIH3T3 cell lines expressing varying levels of SK2 were trypsinised and washed in 
PBS, and 1x106 cells were injected in 200 µl of PBS subcutaneously into the flank of 8-
week old female NOD/SCID mice. The empty vector cells with low GFP expression were 
selected as a representative control group. Mice were left for 18 days and were examined 
daily to monitor tumour formation. On day 19, all mice were humanely killed and tumours 
were excised. Half of each tumour was fixed in 10% formalin, paraffin embedded and 
sectioned. The remaining half was homogenised using a pestle (Axygen) in extraction buffer 
(recipe described in Chapter 2), subjected to freeze/thawing in liquid nitrogen and 
sonication, and lysates were clarified by centrifugation at 17,000 × g for 15 min at 4°C. 
 
 
4.4.4 Extracellular S1P formation assay 
 
The rate of extracellular S1P formation from intact vector control ‘low’, SK2 ‘low’ and SK2 
‘high’ NIH3T3 stable cell lines was determined essentially as previously described (Sun et 
al, 2016b). Briefly, cells were seeded in equal numbers at 80% confluence (in 20 cm2 
dishes), and media was replaced with DMEM containing 0.5% DBS and incubated for a 
further 16 h. Cells were then labeled with 0.5 µCi of [3H]-sphingosine (Perkin-Elmer, 
Rowville, VIC, Australia) for 30 min, after which the conditioned media was collected. 




4.4.5 Immunofluorescence  
 
For dual immunofluorescence staining of overexpressed FLAG-tagged SK2 and Ki-67 on 
the formalin-fixed paraffin-embedded tumour tissue samples, sections were de-waxed, 
rehydrated, and antigen retrieval was performed by boiling in citrate buffer for 30 min. 
Sections were blocked in 10% goat serum diluted in CAS-Block (Thermo Fisher Scientific) 
for 30 min. Following blocking, sections were incubated overnight at 4°C with mouse 
monoclonal anti-Ki-67 antibody (1:20; Vector Labs) and rabbit polyclonal anti-FLAG 
antibody (1:100; Cell Signaling Technology) diluted together in 10% goat serum/CAS-
Block. Sections were then incubated for 1 hr at room temperature with goat anti-mouse 
AlexaFluor 488 (1:400) and goat anti-rabbit AlexaFluor 594 (1:400) secondary antibodies 
(Thermo Fisher Scientific) diluted together in 10% goat serum/CAS-Block. Labelled 
sections were then mounted in Vectashield mounting medium containing DAPI (Vector 
Labs) and were imaged using a Carl Zeiss LSM 700 confocal microscope (Jena, Germany).  
 
To examine the subcellular localisation of overexpressed FLAG-tagged SK2, NIH3T3 SK2 
‘low’ and ‘high’ stable cell lines were seeded onto 8-well glass chamber slides (Nalge Nunc 
International) coated with poly-L-lysine (Sigma-Aldrich) at 4x104 cells/well, and grown 
overnight in DMEM with 10% DBS. Media was then removed and replaced with DMEM 
containing 0.5% DBS, and cells were cultured for a further 16 h. Immunofluorescence 
staining protocol was then performed as detailed in chapter 2 (General Methods), with the 
following modifications. After fixing and permeabilising, cells were blocked in 5% goat 
serum in PBS with 0.1% Triton X-100 for 60 min. Rabbit anti-FLAG antibody (1:200; 
#14793, Cell Signaling Technology) and mouse anti-γ-catenin antibody (1:500; BD 
Biosciences) were incubated for 1.5 hr at room temperature, followed by goat anti-rabbit 
AlexaFluor 594 and goat anti-mouse AlexaFluor 488 secondary antibodies (1:500; Thermo 
Fisher Scientific) for 1 h.  
 
 
4.4.6 Sphingolipid analyses by liquid chromatography–mass spectrometry 
 
Vector control ‘low’, SK2 ‘low’ and SK2 ‘high’ NIH3T3 stable cell lines were grown in 
DMEM with 10% DBS to 80% confluence, media was replaced with DMEM containing 
0.5% DBS and cells were cultured for 16 h. Cells were trypsinised, quenched and washed in 
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PBS. Cells were pelleted in quadruplicate with 8.8x106 cells per sample, and intracellular 
sphingolipid species were analysed by LC-MS, as previously described (Aurelio et al, 2016) 
with the following minor modifications. Prepared samples were injected onto an Ascentis 
Express C18 column (Supelco Analytical, Bellefonte, PA, USA), and non-natural 
sphingolipid internal standards were added to each sample to allow relative quantification. 





4.5.1 Generation of NIH3T3 cell lines with varying levels of stable SK2 
overexpression 
 
Given that the NIH3T3 mouse fibroblast cells utilised for neoplastic transformation studies 
were able to silence protein expression driven by a CMV promoter over time, I needed to 
develop a system whereby SK2 expression could be driven by a different, more stable 
promoter that would not be silenced in murine cells. The pCX vector drives protein 
expression via a chicken β-actin promoter and contains a CMV enhancer and an intron, and 
has been shown to provide stable transgene expression in mice (Okabe et al, 1997). I 
therefore subcloned cDNA encoding human SK2a as well as EGFP driven by an IRES into 
the pCX4 vector, which was then further modified to contain neomycin resistance to assist 
with stable cell selection (pCX4NEO-SK2). Stable NIH3T3 SK2 or empty vector pooled cell 
lines were made in the presence of G418, and then cell lines with varying levels of SK2 
overexpression, or GFP alone, were generated by gating on different GFP expression levels 
as described above (Figure 4.3). These lines were then assessed using SK2-specific activity 
assays to determine if the desired levels of SK2 overexpression had been achieved. 
Surprisingly, where previous attempts using the pcDNA3 vector had yielded SK2 
overexpression levels as low as 5-fold over endogenous (Figure 4.2A), the lowest level of 
SK2 overexpression obtained using the pCX4NEO construct was around 80-fold over 
endogenous levels (Figure 4.4), even after an attempt to re-sort on the lowest possible levels 
of GFP. 
 
As the previously generated stable pooled pcDNA3 cell lines had not utilised antibiotic 






Figure 4.3: Generating cell lines with differential SK2 overexpression by gating on
varying levels of GFP intensity using FACS
The NIH3T3 pooled stable cell lines expressing SK2 and GFP, or GFP alone (empty
vector), were sorted on four separate narrow gates of varying GFP intensity (colored
boxes), to produce new stable lines depicted as ‘very low’, ‘low’, ‘mid’ and ‘high’. These
new stable lines were then analysed by flow cytometry to confirm that the desired narrow
GFP-expression levels were obtained as expected. GFP-negative control cells are depicted





























































Figure 4.4: SK2 activity of pCX4NEO NIH3T3 stable cell lines
SK2-specific activity of NIH3T3 pCX4NEO cell lines stably expressing SK2 or empty
vector. Data shown are mean (± range) from one experiment with duplicate data points.
Low Low





hypothesised that the G418 selection may have been preferentially selecting for cells with a 
higher copy number integration of the plasmid, and hence, greater resistance to the 
antibiotic and consequently higher GFP and SK2 expression levels. The antibiotic resistance 
was not a requirement for the process of generating the cell lines, and so a new stable 
NIH3T3 pooled cell line was made using the pCX4 plasmid (containing SK2 or vector 
alone) without G418 selection, but just by sorting three times for GFP-positive cells. The 
pooled lines were then gated as described in Figure 4.3, and this time SK2 overexpression 
was achieved as low as 10-fold over endogenous levels, ranging up to 20-fold, 40-fold and 
575-fold overexpression (Figure 4.5). 
 
To ensure that these pCX4 cell lines would be more suitable than the previous pcDNA3 cell 
lines for long-term stable SK2 overexpression, I examined the changes in SK2 activity over 
one month of culturing (approximately 12 passages), and also after freezing and then 
thawing from liquid nitrogen. The freeze/thawing of the cell lines did somewhat affect SK2 
expression, decreasing SK2-specific activity by only 13% for the ‘high’ cell line but 
decreasing SK2 activity by 42% for the ‘very low’ cell line (Figure 4.6). Passaging the cells 
for one month further decreased exogenous SK2 expression, from as little as 12% for the 
‘high’ cell line to as much as 43% for the ‘mid’ cell line (Figure 4.6). However, these final 
levels of SK2 overexpression (5-fold, 10-fold, 20-fold and 440-fold over endogenous levels) 
were still very suitable for examining the role of SK2 in oncogenesis in vitro and in vivo. 
Furthermore, a similar length of passaging of the pcDNA3 cell lines had previously resulted 
in virtually undetectable SK2 overexpression, making these pCX4 NIH3T3 stable cell lines 
far superior and suitable for further in vivo studies. 
 
 
4.5.2 SK2 can elicit oncogenic signalling and promote neoplastic transformation in 
vitro 
 
Biochemical analysis of the pCX4 NIH3T3 stable cell lines revealed that ‘low’ SK2 
overexpression resulted in the activation of oncogenic signalling pathways, as demonstrated 
by an increase in phospho-AKT and phospho-ERK1/2 levels (Figure 4.7). Conversely, the 
‘mid’ and ‘high’-level SK2 overexpression caused a downregulation of phospho-ERK1/2 
signalling (Figure 4.7), in agreement with high-level SK2 overexpression attenuating cell 


















































Figure 4.5: SK2 activity and protein levels in the pCX4 NIH3T3 stable cell lines
A, SK2-specific activity of NIH3T3 pCX4 cell lines stably expressing ‘very low’ (10-fold),
‘low’ (20-fold), ‘mid’ (40-fold) or ‘high’ (575-fold) levels of SK2 overexpression (above
endogenous levels), or corresponding empty vector controls. Data shown are mean (±
range) of duplicate data points from a representative experiment (of three independent
experiments). B, Lysates from the NIH3T3 empty vector or SK2-overexpressing pCX4 cell
lines were subjected to immunoblot analyses with antibodies against FLAG, GFP and α-








































































































































Figure 4.6: Stability of SK2 overexpression in the pCX4 stable cell lines after
freeze/thawing and passaging
SK2-specific activity of the NIH3T3 empty vector or SK2-overexpressing pCX4 cell lines
after the original sort (A), then after thawing cells from storage in liquid nitrogen (B) and
then after one month of passaging in culture (C). Data shown for all graphs are mean (±






























1 0.97 1.58 0.96 0.94 pAKT / AKT
1 0.99 1.63 0.63 0.44 pERK / ERK
Figure 4.7: SK2 overexpressed at low levels can elicit oncogenic signalling
Lysates from the NIH3T3 vector or SK2-overexpressing cell lines were subjected to
immunoblot analyses and probed with antibodies against phospho-AKT, total AKT,
phospho-ERK1/2, total ERK1/2, FLAG, GFP, SK1 and α-tubulin. Vect = empty vector
with ‘low’ level GFP expression, chosen as a representative control. Densitometry was
performed to quantify phospho-AKT and phospho-ERK band intensities, and is presented
as a ratio of total AKT and ERK levels, respectively, and is normalised to vector. Blots





SK2-overexpressing NIH3T3 cell lines, as compared to vector control cells (Figure 4.7), 
confirming that these observed changes to oncogenic signalling pathways were not a 
consequence of altered SK1 expression.  
 
As it had been previously shown using the pcDNA3 NIH3T3 cell lines that low-level SK2 
overexpression could allow cells to overcome contact inhibition and become transformed 
(Figure 4.2), I then examined these new pCX4 NIH3T3 stable cell lines in another in vitro 
assay of neoplastic cell transformation, testing the anchorage-independent growth of cells 
through their ability to form colonies in soft agar. In this more stringent assay, only the 
‘very-low’ SK2-overexpressing cells were able to form colonies (Figure 4.8). Together, 
these data confirm that low-level SK2 overexpression can elicit oncogenic signalling and 
induce neoplastic transformation of cells. 
 
 
4.5.3 Low level SK2 overexpression can drive tumour formation in vivo 
 
Given that SK2 could promote neoplastic growth in vitro, I next examined if this 
represented full neoplastic transformation through analysing the ability of these cells to 
form tumours in vivo. Hence, the series of cell lines with differential levels of SK2 
overexpression were subcutaneously engrafted into the flanks of NOD/SCID mice, and the 
development of tumours assessed. Consistent with the in vitro data, cells with either ‘very 
low’ or ‘low’ SK2 overexpression resulted in efficient tumour formation in mice (Table 
4.1). In stark contrast, however, cells with either ‘mid’ or ‘high’ SK2 overexpression 
showed minimal tumour growth (Table 4.1). All tumours were vascularised, as determined 
by CD31 staining, and showed morphology characteristic of fibrosarcoma (Figure 4.9). 
Notably, the tumours that developed from the ‘very low’ SK2 cells were significantly larger 
than all other tumours formed (Figure 4.10). Overall, these results demonstrate for the first 
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Figure 4.8: ‘Very low’-level SK2 overexpression can promote anchorage-
independent growth of cells
Anchorage-independent growth of the NIH3T3 pCX4 vector or SK2-overexpressing cell
lines were tested using colony formation assays in soft agar. A, Total number of colonies
per well were quantified and the average number of colonies for duplicate wells from one
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Table 4.1: Low-level SK2 overexpression results in efficient tumour formation
Table summarising the number of mice with tumours per cell line, 18 days post-cell
injection. Mice were injected with NIH3T3 cell lines stably overexpressing ‘very low’ (5-
fold), ‘low’ (10-fold), ‘mid’ (20-fold) or ‘high’ (440-fold) levels of SK2 (above
endogenous levels). Empty vector cells with ‘low’ level GFP expression were chosen as a
representative control.
100
Figure 4.9: Tumours formed from the in vivo transformation of NIH3T3 cells
overexpressing SK2 are vascularised and characteristic of fibrosarcoma
A, The presence of vasculature within the tumour tissue sections was examined by
PECAM-1 (CD31) staining. Representative image is shown at 20x magnification. Scale
bar = 100 µm. B, Morphology of the tumour tissue sections is shown by hematoxylin and
eosin staining. The image on the right is a 20x magnification of the area framed in the





























Figure 4.10: ‘Very low’-level SK2 overexpression results in the formation of
significantly larger tumours
Images (A) and weights (B) of the excised tumours from each group of NIH3T3 SK2-
overexpressing stable cell lines. Statistics denote a significant increase in the weights of
SK2 ‘very low’ tumours compared to tumours from the SK2 ‘low’, ‘mid’ and ‘high’




4.5.4 Less than 5-fold SK2 overexpression is optimal for promoting tumourigenesis, 
which is observed in many human cancers 
 
Although the SK2-expressing cells engrafted into mice were fractionated based on their 
GFP (and therefore SK2) expression, these cells remained pools of clones. While this 
obviates potential defects associated with plasmid integration into the genomes of individual 
clones, it meant that the level of SK2 overexpression observed for each line was an average 
of all cells within that line. Thus, I examined the expression levels of SK2 within the 
resulting tumours. Notably, every tumour that developed from the ‘very low’, ‘low’ and 
‘mid’ SK2 overexpressing cells all possessed very similar levels of SK2 protein and 
catalytic activity (Figure 4.11). Indeed, by comparison to the parental fibroblast cells, it 
appears that tumour formation resulted preferentially from cells within the pools with less 
than 5-fold SK2 overexpression (Figure 4.11). This finding suggests that this level of SK2 
represents the optimal level to promote oncogenic signalling and tumourigenesis. These 
results perhaps explain why only one tumour formed from the ‘mid’ SK2-expressing cells, 
as within this pool of cells there would likely be fewer low SK2-expressing clones 
compared with the ‘low’ and ‘very low’ groups. 
 
Given that our studies have demonstrated that low, less than 5-fold SK2 overexpression can 
promote oncogenic signalling, as well as neoplastic transformation in vitro and in vivo, it 
was of interest to examine whether SK2 is overexpressed to such levels in human cancers. 
Despite numerous studies examining the targeting of SK2 in cancer, broad analysis of SK2 
expression in cancer had not been previously performed. Thus, I examined SK2 expression 
in a wide range of human cancers using the public gene expression data sets in the 
Oncomine database (Rhodes et al, 2004). SK2 was found to be significantly elevated in 
studies from a broad range of human cancers, including bladder, melanoma, esophageal, 
breast, lymphoma and leukemia (Figure 4.12A). Interestingly, however, this cancer-
associated elevation in SK2 was only modest, with up to 2.5-fold higher levels of SK2 
compared with the corresponding normal tissues. This fits nicely with my data 
demonstrating that similar, low-level SK2 overexpression can promote tumourigenesis. 
Notably, both SK1 and SK2 were upregulated in three independent datasets for diffuse large 
B-cell lymphoma (Figure 4.12B), but there was no apparent general correlation between 
SK2 and SK1 upregulation in the other tumours examined. Indeed, in most other tumour 






















































Figure 4.11: Less than 5-fold SK2 overexpression is optimal for promoting
tumourigenesis in vivo
A, SK2-specific activity from the tumour lysates was measured and graphed as mean (±
range) of duplicate samples. These data were plotted alongside data of SK2 activity from
the engrafted cell lines, which was transformed from Figure 4.6C as specific-activity
(pmol S1P/min/mg protein) for the purposes of comparison. B, Tumour tissue lysates
were subjected to immunoblot analyses with antibodies against FLAG, α-tubulin and
GFP. Dashed lines indicate where lanes from the same immunoblots have been spliced






























































































































Figure 4.12: SK2 is upregulated in human cancers
A, Box plots showing human cancers with significant (p<1x10-4) upregulation of SK2 mRNA levels. N = normal tissue; C = cancerous tissue.
Data were extracted from the Oncomine database, from the following studies: study 1: Sanchez-Carbayo Bladder, study 2: Talantov
Melanoma, study 3: Kim Esophagus, study 4: Finak Breast, study 5: Curtis Breast, study 6: TCGA Breast, study 7: Compagno Lymphoma,
study 8: Haferlach Leukemia. B, Heat maps showing significant (p<1x10-4) changes in SK2 and SK1 mRNA levels in the human cancer






















downregulated (Figure 4.12B). 
 
 
4.5.5 Examining tumour formation from the ‘high’ SK2 overexpressing cells 
 
Unexpectedly, the ‘high’ SK2-overexpressing cells also resulted in one tumour forming. 
Further analyses, however, revealed that cells within this tumour were not actively 
proliferating, whereas cells within the tumours generated from ‘very low’ SK2-expressing 
cells were highly positive for the proliferation marker Ki-67 (Figure 4.13). Furthermore, the 
level of SK2 overexpression within the ‘high’ SK2 tumour was quite heterogeneous, with 
only small patches of cells with high levels of SK2 protein (Figure 4.14). In fact, the 
majority of the tumour was comprised of cells with low SK2 overexpression similar in level 
to that seen in the tumours arising from ‘very low’ SK2-expressing cells (Figure 4.14). 
Therefore, again, it is possible that a small population of cells within the original ‘high’ cell 
pool drifted to low-level SK2 overexpression and initiated tumour formation, thus 
supporting the growth of some of the high SK2-expressing cells. Indeed, our previous data 
demonstrating that low SK2 overexpression supported enhanced cell proliferation and 
survival, while high SK2 overexpression had the opposite effect suggests that the high SK2-




4.5.6 Differential levels of SK2 overexpression alter its subcellular localisation and 
sphingolipid metabolism 
 
It is well established that the subcellular localisation of the SKs, and hence the 
compartmentalisation of S1P formation within the cell, plays an important role in the 
function of these enzymes (Siow & Wattenberg, 2011). The oncogenic role of SK1 requires 
its translocation to the plasma membrane, a location that results in increased extracellular 
S1P production (Pitson et al, 2005). Furthermore, the localisation of SK2 to the nucleus, ER 
or mitochondria appears to promote its anti-proliferative, pro-apoptotic functions (Chipuk et 
al, 2012; Hait et al, 2009; Igarashi et al, 2003; Maceyka et al, 2005). Thus, I examined the 
localisation of SK2 when stably overexpressed at low and high levels. In the ‘high’ SK2-
expressing cells, SK2 was strongly nuclear-localised (Figure 4.15), 
Figure 4.13: Cells within the ‘very-low’ SK2 tumours are actively proliferating, but
cells within the ‘high’ SK2 tumour are not
Dual immunofluorescence staining of overexpressed FLAG-tagged SK2 (red) and the
proliferation marker Ki-67 (green) was performed on the SK2 tumours. Nuclei were
stained with DAPI (blue). At least five random fields of view were imaged per tumour
and representative images are shown. Scale bar = 50 µm. Staining was performed by Dr














Figure 4.14: Levels of SK2 overexpression are heterogeneous in the SK2 ‘high’
tumour
Expression of ectopically expressed SK2 protein within the tumour tissue sections was
examined by immunohistochemical staining for the FLAG epitope of this protein.
Multiple images were taken for each tumour, at 20x magnification, and a representative
field of view is shown. Scale bar = 100 µm. Arrow denotes a representative area of











































































Figure 4.15: Differential levels of SK2 overexpression alter its subcellular
localisation
A, The subcellular localisation of FLAG-tagged SK2 (red) in the NIH3T3 stable ‘low’ and
‘high’ SK2-overexpressing cells was examined by immunofluorescence staining, using
FLAG antibody. Nuclei were stained with DAPI (blue) and cell membranes were stained
with an antibody against γ-catenin (green). Images are representative of cells observed
from three independent experiments. Arrows denote representative plasma membrane
localisation of ‘low’ SK2. Scale bar = 10 µm. B and C, Cells from (A) were visualised by
confocal microscopy and scored based on the presence or absence of either (B) distinct
nuclear FLAG-tagged SK2 staining, or (C) plasma membrane (PM)-localised FLAG-
tagged SK2 staining. A minimum of 200 cells were scored per well. Data were graphed as
mean (± SD) of triplicate wells from a single experiment, representative of three






























































in agreement with previous reports for this cell type (Igarashi et al, 2003). In the ‘low’ SK2-
expressing cells, however, SK2 was more evenly distributed throughout the cell, and 
showed a significant increase in its plasma membrane localisation (Figure 4.15). 
Furthermore, the formation of extracellular S1P was significantly higher from cells with 
‘low’-level SK2 overexpression compared to vector control cells (Figure 4.16A), consistent 
with our observations of increased SK2 at the plasma membrane in these cells. Interestingly, 
‘high’-level SK2 overexpression resulted in a further increase in extracellular S1P formation 
(Figure 4.16A), but this was only a modest doubling compared with the ‘low’ SK2 cells, 
despite these cells having greater than 400-fold more SK2 activity. 
 
Sphingolipid analysis revealed, somewhat surprisingly, that ‘low’-level SK2 overexpression 
had very little effect on the intracellular levels of S1P, ceramides, dihydroceramides, 
sphingomyelins or dihydrosphingomyelins (Figure 4.16B-E), with the only change noted 
being a small increase in sphingosine. In contrast, ‘high’-level SK2 overexpression resulted 
in a significant increase in a range of ceramide species, sphingomyelins and 
dihydrosphingomyelins, as well as sphingosine (Figure 4.16C-E), in line with a previous 
report demonstrating that overexpressed SK2 partially localised to the ER, and S1P 
produced here could feed into an ER/golgi-associated ‘salvage pathway’ to generate pro-
apoptotic sphingosine and ceramide, as well as sphingomyelin (Maceyka et al, 2005). The 
increase in ceramides and sphingosine are likely to contribute, at least in part, to the anti-
proliferative and pro-cell death role of SK2 in these ‘high’ overexpression cells, with the 
increase in extracellular S1P formation that was observed in these cells (Figure 4.16A) 





Despite the conflicting data in the literature, the findings from this study demonstrate that, 
like SK1, SK2 can have a physiological role in promoting cell survival and proliferation, 
potentially through plasma membrane localisation. This is perhaps not surprising, as the 
individual genetic deletion of either SK1 or SK2 in mice does not result in any gross 
phenotypic abnormalities (Allende et al, 2004; Zemann et al, 2007), whereas the double 












Figure 4.16: Differential levels of SK2 overexpression alter the levels of extracellular 
and intracellular sphingolipids 
A, The rate of extracellular S1P formation from intact vector control ‘low’, SK2 ‘low’ and 
SK2 ‘high’ NIH3T3 stable cell lines was determined. Analyses were performed in triplicate 
and data are graphed as mean (± SD). Statistics denote significant increases in extracellular 
S1P compared to vector control cells (* p<0.05, ** p<0.01; Student’s unpaired two-tailed t-
test). B-E, Intracellular sphingolipid species from the above cell lines were analysed by LC-
MS. Data are graphed as mean (± SD) of quadruplicate samples for (B) individual 
dihydroceramide species, (C) individual ceramide species, sphingosine (Sph) and 
sphingosine-1-phosphate (S1P), (D) total sphingomyelin levels, and (E) total 
dihydrosphingomyelin levels. Statistics denote significant increases in lipids compared to 
vector control cells (* p<0.05, ** p<0.01, *** p<0.001; Student’s unpaired two-tailed t-
test). LC-MS analysis of cell pellets was performed by Dr Darren Creek and Amanda 







































































































































































































































































































































redundancy between the two proteins. Like SK1, there are no mutations in SK2 linked to 
cancer, however it has been suggested that cancer cells can display a ‘non-oncogene 
addiction’ for SK1 (Pyne & Pyne, 2010; Vadas et al, 2008). Given that I have now shown 
that SK2 can promote neoplastic transformation and tumourigenesis, and is upregulated in 
many human cancers, coupled with the anti-cancer efficacy of SK2-selective inhibitors 
leads me to postulate that a non-oncogene addiction may apply for both SKs in cancer. 
Indeed, targeting both SK isoforms may be the best strategy to overcome tissue and cell 
type-specific differences in the roles of the SKs in different cancers, and in agreement, dual 
SK1/SK2 inhibitors show significant decreases in tumour burden in vivo (French et al, 2006; 
Pitman et al, 2015). 
 
One of the most intriguing findings from this study is the observation that SK2 function can 
dramatically switch, depending on its expression level, from being pro-survival and pro-
proliferative to pro-cell death and anti-proliferative. While it could be argued that high-level 
overexpression is non-physiological, and may generate artefacts, it is notable that previous 
studies have shown that SK2 can have physiological roles in promoting cell cycle arrest and 
apoptosis when localised to organelles such as the nucleus and mitochondria (Chipuk et al, 
2012; Hait et al, 2009). Clearly, under normal conditions these pro-death roles are likely 
kept under tight regulation, so it remains possible that high-level overexpression 
circumvents these regulatory mechanisms. This high-level overexpression of SK2, for 
example, may lead to altered protein-protein interactions or post-translational modifications, 
altering the subcellular localisation of SK2, from the plasma membrane to cellular 
organelles such as the nucleus, in favour of promoting cell death. Indeed, it has been 
previously reported that when transiently overexpressed, SK2 could interact with and 
sequester the pro-survival Bcl-xL protein (Liu et al, 2003), suggesting a possible mechanism 
for the pro-apoptotic phenotype we observed with high-level SK2 overexpression. However, 
despite multiple attempts, I was unable to detect an interaction between Bcl-xL and SK2 in 
the NIH3T3 stable cell lines (data not shown), suggesting that this proposed interaction was 
unlikely to mediate the observed phenotype. Intriguingly, there appears to be a window 
whereby low-level SK2 upregulation confers a survival and proliferative advantage to the 
cell without inducing these pro-apoptotic functions. Whether a different subset of post-
translational modifications and/or protein-protein interactions drive the differences in 
subcellular localisation and function observed with low versus high SK2 overexpression 
will require further interrogation.  
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To add further complexity, other studies have demonstrated that nuclear SK2 can contribute 
to cancer progression through the stabilisation of telomerase and promotion of c-Myc 
expression (Panneer Selvam et al, 2015; Wallington-Beddoe et al, 2014). In the present 
study, SK2 was observed in the nucleus when overexpressed at high levels, and yet here it 
had an opposite, anti-proliferative role, which is also well documented (Hait et al, 2009; 
Igarashi et al, 2003). It is unclear how SK2 can have such vastly different functions within 
the same organelle, but it suggests that there must be additional factors regulating these 
processes. Indeed, the regulatory mechanisms controlling this enzyme remain an important, 
but currently largely unanswered question (Neubauer & Pitson, 2013). Notably, SK1 
remains pro-survival and pro-proliferative even at high-level overexpression, likely due to 
its different subcellular localisation to SK2 and consequent contribution to different 
sphingolipid pools within the cell. In line with this, previous studies have shown that 
artificially targeting SK1 to the ER can render it pro-apoptotic, like SK2 (Maceyka et al, 
2005). 
 
Interestingly, while cells with 20-fold (‘mid’) SK2 overexpression were able to form foci in 
vitro, they had decreased levels of phospho-ERK1/2 and did not efficiently form tumours in 
vivo. This may indicate that this level of SK2 overexpression is at the upper limit of the 
‘window’ whereby SK2 switches from being tumourigenic to having predominantly anti-
proliferative functions. Conversely, 5-fold (‘very low’) SK2 overexpression resulted in no 
appreciable changes in phospho-ERK1/2 or phospho-AKT levels, and yet these cells 
developed the largest tumours in vivo. It is therefore possible that S1P-mediated 
angiogenesis and tumour vascularisation played more of an important role in the 
development of these tumours, given that low-level overexpression of SK2 resulted in 
plasma membrane localisation and increased formation of extracellular S1P, which is a key 
regulator of angiogenesis (Takabe & Spiegel, 2014). These observed differences also 
highlight the importance of employing in vivo models for assessment of full neoplastic 
transformation. Furthermore, it was surprising that ‘high’-level SK2 overexpression resulted 
in a doubling in extracellular S1P production as compared to the ‘low’-SK2 overexpressing 
cells, despite ‘high’ SK2 overexpression resulting in decreased survival and proliferative 
signalling, and increases in pro-apoptotic sphingolipid species. Notably, Weigert et al. 
previously reported that transient overexpression of SK2 resulted in a substantial increase in 
S1P released from apoptotic cells as a result of SK2 being cleaved by caspase-1 and 
secreted from the cell (Weigert et al, 2010). This may, in part, explain our observed increase 
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in extracellular S1P in the SK2 ‘high’ cells, which was clearly not able to facilitate any 
overall pro-survival or proliferative stimulus in these cells.  
 
It should be noted that Liang et al. found a significant increase in colitis-associated tumour 
development in SK2 knockout mice, when compared to wildtype mice (Liang et al, 2013), 
suggesting that SK2 may function as a tumour suppressor in this model. However, these 
findings are likely to be an indirect effect as it was also shown in the study that the global 
genetic loss of SK2 caused an upregulation of both S1P receptor 1 and SK1 levels in the 
colon, with a concomitant increase in circulating and colonic S1P (Liang et al, 2013). SK1 
has been previously shown to contribute to colon carcinogenesis (Kawamori et al, 2009) and 
indeed, the increase in severity of colitis in the SK2 knockout mice was ablated by the SK1-
specific inhibitor SK1-I (Liang et al, 2013). Furthermore, the proposed tumour-suppressive 
role of SK2 in negatively regulating pro-tumourigenic SK1 levels is not recapitulated with 
SK2-selective inhibitors, which show efficacy in decreasing tumour burden in murine 
xenograft models (Chumanevich et al, 2010; French et al, 2010; Liu et al, 2013; Wallington-
Beddoe et al, 2014). 
 
Evidently the true functions of SK2 are complex and are also likely to be tissue- and cell 
type-specific. However, from the findings of this study it is clear that SK2 represents an 
important target in cancer and future work to better understand how SK2 is regulated will be 

























Characterising the Interaction between 
























Chapter 5. Characterising the Interaction between Sphingosine Kinase 2 




While the two mammalian sphingosine kinases, SK1 and SK2, both catalyse the generation 
of pro-survival sphingosine-1-phosphate, their roles vary dependent on their different 
subcellular localisation. SK1 is generally found in the cytoplasm or at the plasma membrane 
where it can promote cell proliferation and survival. However, where SK2 appears to have a 
similar function to SK1 at the plasma membrane, when localised to internal organelles such 
as the nucleus, endoplasmic reticulum or mitochondria, SK2 can mediate cell death. 
Although SK2 has recently been implicated in cancer initiation and progression, it is 
currently unclear how the subcellular localisation of SK2 is regulated. Here, a novel 
interaction between SK2 and the intermediate chain subunit of the retrograde-directed 
transport motor complex, cytoplasmic dynein (DYNC1I; IC), is reported. This interaction 
between SK2 and dynein is shown to have a physiological role in facilitating transport of 
SK2 away from the plasma membrane. Furthermore, the dynein intermediate chain isoform 
IC-1 is dramatically downregulated in patient samples of glioblastoma multiforme (GBM), 
where low expression of IC-1 correlates with poorer patient survival. Notably, low IC-1 
expression in GBM cells coincided with more SK2 localised to the plasma membrane, 
where it has been implicated in oncogenesis. Strikingly, re-expression of IC-1 in these cells 
reduced plasma membrane localised-SK2 and extracellular S1P formation, and decreased 
tumour growth and tumour-associated angiogenesis in vivo. Thus, these findings 
demonstrate a novel tumour-suppressive function of dynein IC-1, and uncover new 
mechanistic insights into SK2 regulation, which may have implications in targeting this 












Sphingosine-1-phosphate (S1P) is an important signalling lipid that can regulate a vast 
number of cellular processes, including cell survival, proliferation, apoptosis, migration and 
differentiation (Pitson, 2011; Pyne & Pyne, 2010). S1P is produced in the cell from the 
phosphorylation of sphingosine by the sphingosine kinases (SKs), SK1 and SK2. Many of 
the extracellular and intracellular signalling pathways activated by S1P promote cell 
survival and proliferation, whereas sphingosine, and its precursor ceramide, are both pro-
apoptotic molecules (Newton et al, 2015). Therefore, by modulating the relative levels of 
these lipids, the SKs play an important role in determining cell fate. Interestingly, despite 
both enzymes catalysing the formation of the same product, S1P, SK1 and SK2 appear to 
have both overlapping as well as divergent functions within the cell (Neubauer & Pitson, 
2013; Pitson, 2011), with these differing functions seemingly dictated by their differential 
subcellular localisation (Siow & Wattenberg, 2011). 
 
SK1 is largely a cytoplasmic protein, but it has previously been shown that upon 
phosphorylation and activation, SK1 can be translocated to the plasma membrane (Pitson et 
al, 2003) where it can facilitate pro-survival, pro-proliferative signalling (Jarman et al, 2010; 
Pitson et al, 2003; Pitson et al, 2005; Zhu et al, 2017). As such, targeting SK1 has 
demonstrated anti-tumour effects (recently reviewed in (Pitman et al, 2016)). Similarly, I 
demonstrated in Chapter 4 that SK2 can play a role in mediating tumourigenesis, and it too 
was found to be localised to the plasma membrane to increase S1P levels in this setting. The 
role of SK2 in cancer is still being elucidated; many studies have implicated SK2 in 
promoting tumour growth, and the molecular mechanisms involved are beginning to be 
revealed (reviewed in (Neubauer & Pitson, 2013)). However, unlike SK1, SK2 can also 
promote cell cycle arrest and cell death under certain conditions, and these functions appear 
to require changes to the subcellular localisation of this enzyme. SK2 possesses both nuclear 
localisation and export sequences (NLS and NES) (Ding et al, 2007; Igarashi et al, 2003), 
and is in fact localised to the nucleus in many cell types. Here, SK2 can promote cell cycle 
arrest and cell death (Igarashi et al, 2003; Okada et al, 2005), potentially through HDAC1/2 
inhibition and the subsequent transcriptional upregulation of p21 and c-fos (Hait et al, 
2009). Furthermore, it was reported that S1P production by SK2 at the ER resulted in the 
induction of apoptosis (Maceyka et al, 2005), and S1P produced by mitochondrial-localised 
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SK2 has been implicated in Bid-mediated Bak activation and cytochrome c release (Chipuk 
et al, 2012).  
 
Therefore, it is evident that the subcellular localisation of the SKs, and hence the 
compartmentalisation of S1P production within the cell, can alter their function and impact 
on the fate of the cell. Specifically, SK2 localisation to the nucleus and internal organelles 
within the cell seems to confer pro-apoptotic, anti-proliferative functions, whereas 
localisation to the plasma membrane drives pro-proliferative and oncogenic signalling. 
However, the mechanisms regulating the transport of SK2 between various cellular 
compartments in order to effect changes in its functions are currently unexplored.  
 
In this chapter, I examined cytoplasmic dynein 1 intermediate chain (DYNC1I; IC) as a 
novel SK2-interacting protein, and demonstrated that SK2 physiologically interacts with the 
cytoplasmic dynein motor complex in cells and is transported by dynein in a retrograde 
direction away from the cell periphery. Furthermore, I report a dramatic downregulation of 
dynein intermediate chain IC-1 in glioblastoma multiforme (GBM), which correlates with 
poorer patient survival, and demonstrate that lower IC-1 expression in GBM cells coincides 
with more SK2 localised to the plasma membrane. Notably, re-expression of IC-1 in GBM 
cells reduced plasma membrane-localised SK2 and extracellular S1P formation, and 
strikingly, decreased tumour growth and tumour-associated angiogenesis in vivo, 
highlighting a novel tumour-suppressive function of dynein IC-1 that may be linked with 
regulating SK2 subcellular localisation.  
 
 
5.3 Preliminary data leading to this study 
 
It was of interest to identify novel mechanisms of SK2 regulation, and as such, the Pitson 
Laboratory previously performed a yeast two-hybrid screen to examine SK2-interacting 
proteins. Using full-length SK2b as the bait and a C-terminal human normalised cDNA 
library as the prey, under stringent conditions, a putative SK2-interacting protein was 
detected and identified as cytoplasmic dynein 1 intermediate chain 2 (IC-2). The interaction 
between SK2 and IC-2 was subsequently confirmed in mammalian cells by co-
immunoprecipitation of the overexpressed proteins (Figure 5.1). Hence, the focus of this 
chapter was the functional characterisation of this interaction. 
IB: anti-HA (IC-2) 
IB: anti-FLAG (SK2) 
IB: anti-HA (IC-2) Lysate 
IP: anti-FLAG 
(SK2) 
IC-2 - - + + 
EV SK2 
Figure 5.1: SK2 and IC-2 interact when overexpressed in mammalian cells 
HEK293-C18 cells were transfected with empty vector (EV) or HA-tagged IC-2, either 
alone or in combination with FLAG-tagged SK2. SK2 was immunoprecipitated from cell 
lysates with anti-FLAG antibodies, and co-immunoprecipitated IC-2 was detected by im-
munoblotting with anti-HA antibodies. Expression levels of IC-2 in the lysates were con-
firmed by immunoblotting with anti-HA antibodies (Lysate). Immunoprecipitates were 
also probed with anti-FLAG antibodies to confirm pull-down of SK2. Blots shown are 




5.4 Specific Materials and Methods 
 
5.4.1 Yeast two-hybrid screen 
 
Yeast two-hybrid screening was performed using the Matchmaker Gold Gal4 Two-Hybrid 
System (Clontech, Takara, Mountain View, CA, USA) according to the manufacturer's 
instructions. The bait construct, containing full-length human SK2b cDNA cloned into 
pGBKT7 in-frame with the Gal4 DNA-binding domain, was transformed 
into Saccharomyces cerevisiae strain AH109. Mating was performed using a Mate & 
Plate™ universal human normalised cDNA library in pGADT7 (Clontech), transformed into 
S. cerevisiae strain Y187. A total of 1 x 106 clones were screened for growth on yeast 
synthetic dropout (SD) medium lacking adenine, tryptophan, leucine and histidine. Total 
plasmid DNA was then isolated from surviving His+Ade+ colonies, transformed into E. 
coli JM109, amplified and screened for false positives by transformation of these isolated 
library plasmids into S. cerevisiae AH109 containing either pGBKT7-SK2b or pGBKT7 
vector alone. Confirmed positive interactions were identified as those enabling yeast growth 
on SD medium lacking adenine, tryptophan, leucine and histidine only in the presence of 
pGBKT7-SK2b, as well as enabling expression of β-galactosidase. The identity of positive 
SK2b-interacting proteins was confirmed by digestion of plasmid DNA with EcoRI and 
XhoI, followed by sequencing of the isolated cDNA. 
 
 
5.4.2 siRNA knock-down of IC-2 
 
siRNA-mediated knockdown of IC-2 was performed using human DYNC1I2 ON-
TARGETplus SMARTpool siRNA (Dharmacon), which targets the following sequences: 
GUA AAG CUU UGG ACA ACU A, GAU GUU AUG UGG UCA CCU A, GCA UUU 
CUG UGG AGG GUA A, and GUG GUU AGU UGU UUG GAU U. Cells were seeded 
and grown to a cell density of approximately 50%, and cells were then transfected with 30 
nM (final concentration) of either hDYNC1I2 siRNA or ON-TARGETplus non-targeting 
siRNA pool, using Lipofectamine RNAiMAX as per the manufacturer’s protocol (Thermo 





5.4.3 Duolink® protein interaction assay 
 
HEK293 cells were seeded at 1x104 cells/well into 16-well Nunc™ Lab-Tek™ chamber 
slides (Thermo Fisher Scientific) that had been coated with poly-L-lysine (Sigma-Aldrich). 
Cells were incubated in DMEM growth medium for 48 hr. Protein-protein interactions were 
then visualized using the Duolink® in situ proximity ligation assay (PLA) kit, as per the 
manufacturer’s instructions (Sigma-Aldrich). Briefly, cells were washed in PBS, fixed in 
4% paraformaldehyde for 10 min, and permeabilised in PBS with 0.1% Triton X-100 for 10 
min. Blocking was performed using the blocking reagent provided with the kit. Cells were 
incubated with an antibody recognizing SK2 (1:300; ECM Biosciences) and an antibody 
specific to the dynein intermediate chains (1:300; Millipore) for 1 hr at room temperature. 
PLA was then performed, slides were dried and coverslips were mounted using mounting 
medium with DAPI (provided with the kit). Interactions were visualized and imaged using a 




5.4.4 Generating stable cell lines 
 
To generate stable cell lines expressing IC-1 as a GFP-fusion protein, U-251 cells were 
transfected with an IC-1:GFP expression construct (pCX3NEO-DYNC1I1:EGFP), or the 
corresponding empty vector, using Lipofectamine™ 2000 (Thermo Fisher Scientific) as per 
the manufacturer’s protocol. 48 hr after transfection, the cells were sorted for low-level 
GFP-positive cells using a FACSAria II cell sorter (BD Biosciences, Franklin Lakes, NJ, 
USA). Stable GFP-positive pooled cell populations were obtained by sorting for GFP 
another two times over three weeks. The stable U-251 cell lines were then analysed by 




5.4.5 In vivo subcutaneous tumour model 
 
The U-251 cell lines stably-expressing IC-1:GFP or GFP alone (vector) were trypsinised 
and washed in PBS, and 5x106 cells were injected in 200 µl of PBS subcutaneously into the 
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flank of 9 week old female NOD/SCID mice. Mice were examined daily to monitor tumour 
formation, and calliper measurements of palpable tumours were taken. On day 30 post cell 
injection, all mice were humanely killed and tumours were excised. A portion of each 
tumour was fixed in 10% formalin, paraffin embedded and sectioned. The remaining tumour 
tissue was homogenized using a pestle (Axygen) in extraction buffer, subjected to 
freeze/thawing in liquid nitrogen and sonication, and lysates were clarified by centrifugation 





5.5.1 Characterising the SK2 binding site on dynein IC-2 
 
Apart from the dynein HC, all other characterised interacting partners of the dynein ICs bind 
within the N-terminal portion of the protein (Cai et al, 2010; Pfister, 2015; Whyte et al, 
2008). However, it was the C-terminal 173 amino acid portion of IC-2 (residues 440-612) 
that was identified from the yeast two-hybrid screen to interact with SK2. Therefore, it was 
of interest to interrogate the binding site of SK2 on IC-2. Initially to examine this, a C-
terminal truncation of IC-2 identical to the fragment identified in the yeast two-hybrid was 
co-expressed with SK2 in cells (440-612), and the remaining N-terminal portion of the 
protein was also co-expressed with SK2 as a control (1-439). SK2 was then 
immunoprecipitated and, surprisingly, both the N- and C-terminal fragments of IC-2 were 
strongly and cleanly co-immunoprecipitated, the N-terminal fragment slightly more so 
(Figure 5.2).  
 
The ICs contain seven WD40 domain repeats spanning the C-terminal half of the protein, 
and these domains are known to mediate protein-protein interactions (Stirnimann et al, 
2010). Therefore, it was speculated that, because the 1-439 and 440-612 truncations of IC-2 
each contain three of these WD40 repeats, if SK2 does bind to the C-terminus via these 
domains then perhaps this is why it can interact with both fragments. Thus, to determine if 
SK2 does interact with the WD40 repeat domains of IC-2, new IC-2 truncations were 
generated to separate the C-terminal half of the protein with all seven WD40 repeats (251-
612) from the N-terminus that contains no WD40 repeats (1-250). However, upon repeating 
the co-immunoprecipitation of these fragments with SK2, SK2 was still able to cleanly


















Figure 5.2: Mapping the SK2 interaction site on dynein intermediate chain 2 
The domain map of full length dynein intermediate chain 2 (IC-2) is shown at the top of 
the figure (from Figure 1.9). Along the left are the amino acid sequences of the IC-2 trun-
cations, or full-length (FL). In green are graphical representations of the lengths of the IC-
2 truncations, to scale with the full-length domain map above. On the right are im-
munoblots showing interactions between FLAG-tagged SK2 and the HA-tagged IC-2 
polypeptides. HEK293 cells were transfected with HA-tagged IC-2 fragments alone (IC-
2), or in combination with FLAG-tagged SK2 (IC-2 + SK2). SK2 was immunoprecipi-
tated from lysates with anti-FLAG antibodies, and co-immunoprecipitated IC-2 fragments 
were detected by immunoblot with anti-HA antibodies (left panels). Green bars indicate 
successful co-immunoprecipitation of each HA-tagged IC-2 fragment with FLAG-tagged 
SK2. Expression levels of full-length IC-2 or truncations in the lysates are shown in the 
middle panels (Lysates (HA)), and equal expression of SK2 in the co-transfected lysates 
is shown in the panels on the right (Lysates (FLAG)). Images shown are representative of 




interact with both regions of the IC-2 protein, again albeit slightly more with the N-terminal 
fragment given there was less input protein compared to the C-terminal 251-612 fragment 
(Figure 5.2). Therefore, from these data, identifying the SK2 binding site on IC-2 is 
inconclusive. 
 
Another possibility is that, because dynein is a large complex made up of various dimeric 
subunits, the N-terminal fragments of IC-2 expressed in cells may be dimerising with 
endogenous full-length IC-2 protein (the dimerisation domain is within residues 151-211 of 
IC-2C (Lo et al, 2006); Figure 5.2), and the C-terminal mutants may still interact with the 
dynein HC. Therefore, SK2 may still be binding to a full-length endogenous IC-2 and 
consequently appear to be interacting with any truncated mutants that are also bound within 
the complex. So, in order to examine the direct binding of SK2 with IC-2 and the truncation 
mutants, in vitro recombinant pull-down assays were employed. Initially, SK2 was 
overexpressed in HEK293 cells and immunoprecipitated under stringent conditions such 
that no other proteins were bound (Figure 5.3A), and full-length IC-2 was generated in 
bacteria and purified (Figure 5.3B). The SK2-bound beads were then incubated with 
recombinant IC-2 to determine if an interaction would occur. However, no discernible level 
of IC-2 could be detected from the SK2-bead complexes (Figure 5.3C). Therefore, although 
these recombinant pull-downs are preliminary and would need to be repeated and optimized, 
these data may suggest that SK2 and IC-2 require more physiological conditions to form an 
interaction (i.e. in intact cells), or that the interaction may require other subunits of the 
dynein complex and/or the dynactin complex.  
 
 
5.5.2 SK2 interacts more strongly with the IC-1 intermediate chain isoform 
 
There are two mammalian cytoplasmic dynein IC isoforms, the ubiquitously expressed IC-2 
identified in the yeast two-hybrid, and IC-1 which is expressed most abundantly in the brain 
(Horikawa et al, 2001; Kuta et al, 2010; Myers et al, 2007). Thus, the interaction of SK2 
with IC-1 was also examined by co-immunoprecipitation. Interestingly, compared to IC-2, 
the interaction between SK2 and IC-1 was more prevalent (Figure 5.4), potentially 
suggesting an important isoform-specific role for IC-1 in interacting with SK2.  
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Figure 5.3: SK2 and IC-2 do not appear to directly interact in vitro 
A, HEK293 cells were transfected with FLAG-tagged SK2 or empty vector. SK2 was im-
munoprecipitated from lysates with FLAG antibody-conjugated agarose beads, and pro-
tein bound to beads was then subjected to SDS-PAGE and stained with coomassie blue. 
B, His-tagged recombinant IC-2 made in bacteria was purified using nickel-sepharose, 
and was then repeatedly eluted from the beads (E1-E5). Samples from each elution were 
subjected to SDS-PAGE and either stained with coomassie blue, or analysed by im-
munoblot with anti-His antibodies. C, HEK293 cells were transfected with FLAG-tagged 
SK2 or empty vector. SK2 was immunoprecipitated from lysates with FLAG antibody-
conjugated agarose beads, and SK2-bound beads were then incubated with recombinant 
His-tagged IC-2. Proteins bound to the beads were then subjected to SDS-PAGE, and any 
IC-2 bound was detected by immunoblot with anti-His antibodies. The presence or ab-
sence of SK2 pulled-down by the beads was confirmed by immunoblot with anti-FLAG 
antibodies, and samples of recombinant IC-2 equivalent to those added to the beads were 
also analysed by immunoblot using anti-His antibodies (input). Experiment was only per-
formed once; hc = heavy chain; lc = light chain. 
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Figure 5.4: SK2 interacts more strongly with the dynein IC-1 isoform 
HEK293-c18 cells were transfected with empty vector (EV) or a vector encoding FLAG-
tagged SK2, either alone or in combination with vectors encoding HA-tagged IC-1 or HA
-tagged IC-2. Lysates were pre-cleared with Protein G µbeads. SK2 was immunoprecipi-
tated from cell lysates with anti-FLAG antibodies, and co-immunoprecipitated IC was 
detected by immunoblotting with anti-HA antibodies. Expression levels of IC in the lys-
ates were confirmed by immunoblotting with anti-HA antibodies (Lysate). Immunopre-
cipitates were also probed with anti-FLAG antibodies to confirm pull-down of SK2. Blots 




5.5.3 The interaction between SK2 and dynein is physiological 
 
Next, it was important to move to an endogenous system to confirm that the SK2-IC 
interaction is physiologically relevant. As such, endogenous SK2 was immunoprecipitated 
from mouse brain lysate, which demonstrated a clear co-immunoprecipitation of 
endogenous dynein ICs with SK2 (Figure 5.5). Given that the ICs are found physiologically 
as dimeric subunits of the dynein complex, the presence of these proteins within the SK2 
immunocomplexes was examined. Indeed, this showed an association of SK2 with the 
dynein light intermediate chain (LIC) subunit, as well as the p150 subunit from the dynactin 
complex (Figure 5.5), a regulatory complex that plays an important role in facilitating 
almost all dynein functions (Schroer, 2004). Therefore, it would appear that SK2 can 
physiologically interact with the dynein complex. 
 
Immunofluorescence staining of endogenous SK2 and dynein ICs in HEK293 cells was then 
performed to examine their localisation, and consistent with their physiological interaction, 
both proteins showed considerable subcellular co-localisation which was mainly at 
cytoplasmic and peri-nuclear regions (Figure 5.6A). Further confirmation of the 
physiological interaction of endogenous SK2 and dynein ICs was also obtained by in situ 
proximity ligation assays (PLAs) which demonstrated a clear SK2-IC interaction, again, 
mainly at cytoplasmic and peri-nuclear regions (Figure 5.6B). Appropriate single antibody 
controls were used to confirm that detection of both proteins together was required to 
produce the PLA signals (Figure 5.6B). Taken together, these data demonstrate that SK2 
interacts with dynein IC as a part of the physiological dynein complex in cells. 
 
 
5.5.4 SK2 subcellular localisation is regulated by dynein 
 
The interaction and subcellular localisation of SK2-IC complexes is consistent with the role 
of dynein in transporting its cargo in a retrograde direction along microtubules, which 
eventually accumulate at the MTOC located in close proximity to the nucleus (Barker et al, 
2016; Kardon & Vale, 2009). Given that SK2 appears to co-localise with dynein IC mainly 
in peri-nuclear regions of the cell, it was of interest to determine if dynein is involved in the 
retrograde-directed transport of SK2. To examine this, siRNA-mediated knockdown of IC-2 
was performed using HeLa cells, as knockdown of this single subunit has been shown to
Figure 5.5: Endogenous SK2 interacts with dynein and dynactin complexes in mouse 
brain  
SK2 was immunoprecipitated from whole mouse brain lysate using anti-SK2 antibodies 
(ECM Biosciences). Co-immunoprecipitated dynein intermediate chains (IC), light inter-
mediate chain 1 (LIC-1) and dynactin p150 were detected by immunoblotting with anti-
IC, anti-LIC1 and anti-dynactin p150 antibodies, respectively. Expression levels of these 
proteins in the mouse brain lysate were confirmed by immunoblot analyses with their re-
spective antibodies (Lysate). Lysates and immunoprecipitates were also probed with anti-
SK2 antibodies to confirm expression and pull-down of SK2. Asterisk designates the 













Figure 5.6: Co-localisation of endogenous SK2 and IC  
A, Immunofluorescence staining and confocal microscopy demonstrating co-localisation 
of SK2 and dynein IC in HEK293 cells grown in 10% serum. SK2 (green) was detected 
using anti-SK2 antibodies (1:300; ECM Biosciences) and dynein IC (red) was detected 
using anti-IC antibodies (1:300; Millipore). Nuclei were stained with DAPI (blue). Im-
ages are representative of at least 100 cells, from three independent experiments. Scale 
bar = 10 μm. B, Immunofluorescence staining and confocal microscopy demonstrating 
direct interactions between SK2 and dynein IC, using the Duolink® in situ PLA system 
with anti-SK2 (1:300; ECM Biosciences) and anti-IC antibodies (1:300; Millipore) in 
HEK293 cells grown in 10% serum (top panels). Each red dot indicates a single direct 
interaction, and arrows denote peri-nuclear clusters of the interacting proteins. Nuclei 
were stained with DAPI (blue). Differential interference contrast images are also shown 
(bottom panels). Images are representative of at least 100 cells, from three independent 
experiments. Scale bar = 10 μm. 
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disrupt the dynein complex and its functions, and HeLa cells contain no detectable IC-1 to 
compensate for the loss of IC-2 protein (Palmer et al, 2009). Interestingly, low levels of IC-
1 mRNA could be detected in HeLa cells (Figure 5.7A), but no IC protein was detectable by 
immunoblot with pan-IC antibodies upon IC-2 knockdown (Figure 5.7B), suggesting that 
IC-1 is not translated, and thus, not functional in these cells. 
 
Consistent with the localisation of endogenous SK2 in HEK293 cells, FLAG-tagged SK2 
overexpressed in HeLa cells appeared to have a predominantly peri-nuclear localisation, 
which again seemed to co-localise with endogenous IC-2 (Figure 5.8A). Upon RNAi-
mediated knockdown of IC-2, the peri-nuclear localisation of SK2 was lost in the majority 
of cells (Figure 5.8B and C), and interestingly, strong plasma membrane localisation of SK2 
was observed upon IC-2 knockdown in a subset of cells (Figure 5.8B and D). Therefore, 
these data suggest that SK2 is transported as a dynein cargo in a retrograde direction, as 
disruption of dynein through the loss of IC-2 results in a loss of peri-nuclear SK2 and, in 
some cases, an accumulation of SK2 at the cell periphery. 
 
 
5.5.5 Dynein IC-1 is downregulated in glioblastoma multiforme and correlates with 
poor patient survival 
 
At the plasma membrane, S1P produced by the SKs can be exported from the cell where it 
can act on a family of five S1P receptors to promote cell survival and proliferation, as well 
as contribute to oncogenic signalling pathways (Pitson, 2011; Pyne & Pyne, 2010). This role 
is well established for SK1 (Pitson et al, 2005), and I have now demonstrated a role for SK2 
in mediating oncogenesis, which coincided with increased localisation of SK2 at the plasma 
membrane and increased extracellular S1P formation (Chapter 4). Therefore, it was 
intriguing to observe an increase in plasma membrane-localised SK2 upon dynein IC 
knockdown, raising the question of whether downregulation of the dynein ICs could 
contribute to an oncogenic phenotype. 
 
To explore this, a broad gene expression analysis of both IC-1 and IC-2 was performed on a 
panel of different human cancers, using public gene expression data sets available from the 























































Figure 5.7: Expression of IC-1 in cultured human cell lines
A, Relative IC-1 and IC-2 mRNA levels in HEK293-c18 and HeLa cells, as determined by
qRT-PCR (comparative quantitation, normalised to GAPDH). Graphs are plotted as mean
(± SEM) of data from three independent experiments. B, Immunoblot analyses of pan
dynein IC protein expression in lysates from HeLa cells transfected with negative control
siRNA (si Neg) or IC-2 siRNA (si IC-2) for 48 hr, using anti-IC (Millipore) antibodies.
Immunoblotting for α-tubulin was performed as a loading control. Blots shown are














































































Figure 5.8: Dynein regulates the subcellular localisation of SK2
Immunofluorescence staining and confocal microscopy of HeLa cells transfected with
FLAG-tagged SK2 and either (A) negative control siRNA (si Neg) or (B) IC-2 siRNA (si
IC-2) for 48 hr. SK2 (red) was detected using anti-FLAG antibodies (1:4000; Sigma) and
IC-2 (green) was detected using anti-IC-2 antibodies (1:250; Abcam). Nuclei were stained
with DAPI (blue). Images are representative of at least 200 cells observed from three
independent experiments. Scale bar = 10µm. (C,D) Cells described above were visualised
by confocal microscopy and scored based on the presence or absence of either (C) distinct
peri-nuclear FLAG-tagged SK2 staining, or (D) plasma membrane (PM)-localised FLAG-
tagged SK2 staining. A minimum of 200 cells were scored per treatment. Data were
graphed as mean (± SD) of triplicate wells from a single experiment, and were





downregulated, compared to the corresponding normal tissues, in a vast range of different 
cancers, including brain, ovarian, bladder, prostate, colon, breast, uterine, cervical and 
lymphoma (Figure 5.9A). Importantly, IC-2 gene expression levels in these cancer data sets 
were generally unaltered, compared to the corresponding normal tissues (Figure 5.10), 
demonstrating that there is no substantial compensation for IC-1 loss across these cancer 
types. As IC-1 expression is found to be highest in brain tissues [Figure 5.9A and (Horikawa 
et al, 2001; Myers et al, 2007)], it was particularly notable that a dramatic 17-fold 
downregulation in IC-1 expression occurred in glioblastoma multiforme (GBM) patient 
samples compared to normal brain tissue (Figure 5.9B). Interestingly, this was not specific 
to a particular GBM subtype, as IC-1 expression was similarly downregulated in all four 
subtypes of GBM (Verhaak et al, 2010), whereas IC-2 expression was unchanged across all 
(Figure 5.11). Kaplan-Meier survival analysis of patients with GBM also demonstrated that 
low expression of IC-1 correlated with poorer overall survival compared to patients with 
high IC-1 expression (Figure 5.9C). Together, these analyses suggest that IC-1 may play a 
tumour suppressor role in cancer, and particularly in GBM. 
 
 
5.5.6 Decreased IC-1 expression levels in U-251 cells correlates with plasma 
membrane localisation of SK2  
 
To examine the mechanisms behind the potential role of IC-1 as a tumour suppressor in 
GBM, the expression of IC-1 was initially examined in commonly used GBM cell lines, U-
87 and U-251. Notably, U-251 cells had significantly lower levels of IC-1 mRNA (Figure 
5.12A) and protein (Figure 5.12B) compared with U-87 cells, whereas SK2 protein levels 
were largely unchanged. Therefore, using these cell lines with varying levels of IC-1, the 
role of this protein in regulating the subcellular localisation of SK2 in GBM was examined. 
 
Since I observed SK2 localised to the plasma membrane with IC-2 knockdown (Figure 5.8B 
and D), I reasoned that the low levels of IC-1 observed in the U-251 cells may result in 
increased and/or prolonged localisation of SK2 at the plasma membrane. Indeed, examining 
the localisation of endogenous SK2 by immunofluorescence staining demonstrated 
prominent plasma membrane localisation of SK2 in U-251 cells (Figure 5.12C and D). In 
contrast, SK2 was not detected at the plasma membrane in U-87 cells, consistent with 








Figure 5.9: Dynein IC-1 is downregulated in GBM, which correlates with poorer 
patient survival 
A, Box plots showing human cancers with significant (p<1x10-4) downregulation of IC-1 
mRNA levels. Data were extracted from the Oncomine database, from the following studies 
(left to right): 1, TCGA Brain (Glioblastoma); 2, Murat Brain (Glioblastoma); 3, Sun Brain 
(Glioblastoma, Oligodendroglioma, Anaplastic Astrocytoma); 4, Yoshihara Ovarian 
(Ovarian Serous Adenocarcinoma); 5, Sanchez-Carbayo Bladder 2 (Infiltrating Bladder 
Urothelial Carcinoma, Superficial Bladder Cancer); 6, Lee Bladder (Superficial Bladder 
Cancer); 7, Welsh Prostate (Prostate Carcinoma); 8, Lapointe Prostate (Prostate 
Carcinoma); 9, Taylor Prostate 3 (Prostate Carcinoma); 10, TCGA Colorectal (Colon 
Adenocarcinoma); 11, TCGA Breast (Invasive Ductal Breast Carcinoma, Invasive Lobular 
Breast Carcinoma, Invasive Breast Carcinoma, Mixed Lobular and Ductal Breast 
Carcinoma); 12, Finak Breast (Invasive Breast Carcinoma Stroma); 13, Curtis Breast 
(Mucinous Breast Carcinoma, Invasive Lobular Breast Carcinoma, Invasive Ductal Breast 
Carcinoma, Tubular Breast Carcinoma); 14, Crabtree Uterus (Uterine Corpus Leiomyoma); 
15, Pyeon Multi-cancer (Cervical Cancer); 16, Compagno Lymphoma (Activated B-Cell-
Like Diffuse Large B-Cell Lymphoma). B, TCGA brain dataset showing 17-fold 
downregulation of IC-1 mRNA levels in human glioblastoma multiforme (GBM) patients, 
compared with levels in normal brain tissue. Significance (p<0.0001) was determined using 
a Student’s unpaired two-tailed t-test. (C) IC-1 mRNA expression levels and survival data 
from human GBM patients were obtained from the REMBRANDT dataset, and Kaplan-
Meier survival curves were plotted for patients in the bottom (low IC-1) and top (high IC-1) 
10% of IC-1 expression levels. Significance (p<0.05) was determined using a two-sided log-
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Figure 5.10: IC-2 expression does not vary considerably in human cancer patient data
sets where IC-1 is downregulated
Box plots showing human cancers with significant (p<1x10-4) changes in IC-2 mRNA
levels, as compared to normal tissues. Data were extracted from the Oncomine database
(details of studies used are described in Figure 5.9). n/s denotes no significant change in































































Normal Classical Mesenchymal Neural Proneural
Figure 5.11: IC-1 is significantly downregulated in all GBM subtypes, whereas IC-2
expression is unchanged
Box plots showing (A) IC-1 and (B) IC-2 mRNA levels in human patient samples from the
four GBM subtypes: Classical, Mesenchymal, Neural and Proneural, as compared to
normal brain tissue. Data were extracted from the TCGA Glioblastoma data set, from the
expression box plot (Affymetrix Human Exon 1.0 ST) platform available from the Project
Betastasis database (**** p<0.0001; Student’s unpaired two-tailed t-test; n/s denotes no












Figure 5.12: Decreased IC-1 expression levels in U-251 cells correlates with plasma 
membrane localisation of SK2  
A, Relative IC-1 and SK2 mRNA expression levels in U-87 and U-251 human GBM cell 
lines. Gene expression levels were determined by qRT-PCR (comparative quantitation, 
normalised to GAPDH). Graphs are plotted as mean (± SEM) of data from three 
independent experiments (* p<0.05; ** p<0.01; Student’s unpaired two-tailed t-test). B, 
Immunoblot analyses of IC-1 and SK2 protein expression in U-87 and U-251 cell lines, 
using anti-IC-1 (Proteintech) and anti-SK2 (Proteintech) antibodies. Immunoblotting for α-
tubulin was performed as a loading control. Blots are representative of three independent 
experiments. C, Immunofluorescence staining and confocal microscopy showing 
endogenous SK2 localisation in U-87 and U-251 GBM cells. SK2 (green) was detected 
using anti-SK2 antibodies (1:300; ECM Biosciences), and nuclei were stained with DAPI 
(blue). Arrows denote distinct plasma membrane localisation of SK2. Scale bar = 10 µm. D, 
Cells described above were visualised by confocal microscopy and scored based on the 
presence or absence of distinct plasma membrane (PM)-localised SK2 staining. A minimum 
of 200 cells were scored per cell type. Data were graphed as mean (± SEM) from three 














































































































IC-1 in regulating SK2 subcellular localisation. A comprehensive analysis of different GBM 
models deemed the U-251 cell line to more closely resemble human disease, at least in in 
vivo rodent xenograft models, compared with the U-87 cell line (Jacobs et al, 2011). In line 
with this, U-251 cells contain genetic alterations commonly associated with human GBM, 
such as loss-of-function mutant p53 and overexpression of the epidermal growth factor 
receptor (EGFR) (Verhaak et al, 2010), that are not present in U-87 cells (Jacobs et al, 
2011). Hence, U-251 cells were utilized to examine the interplay between plasma-
membrane localised SK2 and lower IC-1 expression. 
 
 
5.5.7 Re-expression of IC-1 in U-251 cells results in reduced plasma membrane 
localisation of SK2 and decreased extracellular S1P formation 
 
Next, I examined whether re-expression of IC-1 in U-251 cells was sufficient to reduce SK2 
localisation at the plasma membrane, and whether this would in turn reduce the oncogenic 
potential of these cells. Other studies have reported stable expression of GFP-fused IC-1 and 
have shown that it is still able to incorporate functionally into the dynein complex (Ha et al, 
2008; Zhang et al, 2002). As such, I generated U-251 cells with stable, low-level expression 
of IC-1:GFP, or GFP alone, and confirmed the expression of the fusion protein to be similar 
to the level of endogenous dynein IC by immunoblot (Figure 5.13A). Furthermore, as 
shown in Figure 5.13B, the IC-1:GFP fusion protein had a largely cytoplasmic and peri-
nuclear localisation pattern, similar to endogenous dynein IC (Figure 5.6A and Figure 
5.8A). To confirm that IC-1:GFP was incorporating into endogenous dynein complexes, I 
immunoprecipitated IC-1:GFP from U-251 cell lysates using its GFP-tag, and was able to 
show successful pull-down of endogenous dynein IC and LIC-1 subunits (Figure 5.13C). 
Furthermore, immunofluorescence staining of LIC-1 in the IC-1:GFP-expressing U-251 
cells demonstrated a high level of co-localisation between LIC-1 and IC-1:GFP (Figure 
5.13D). Therefore, IC-1:GFP expressed in U-251 cells was successfully forming dimers 
with endogenous IC and incorporating into endogenous dynein complexes. 
 
I next examined the localisation of SK2 in the U-251 GBM cells re-expressing IC-1:GFP. 
Strikingly, where the GFP control cells had prominent plasma membrane localisation of 
SK2 as seen previously, this localisation of SK2 was significantly decreased in cells 









Figure 5.13: Low-level exogenous IC-1:GFP incorporates into endogenous dynein 
complexes 
A, Lysates from parental U-251 cells, or U-251 stable cell lines expressing GFP alone 
(empty vector; EV) or IC-1:GFP, were subjected to immunoblot analyses with antibodies 
against dynein IC and α-tubulin. Blots shown are representative of three independent 
experiments. B, U-251 cells stably expressing GFP (EV) or IC-1:GFP were imaged using 
confocal microscopy, and exogenous proteins were visualised via their GFP tag (green). 
Nuclei were stained with DAPI (blue). Images are representative of more than 100 cells, 
from three independent experiments. Scale bar = 10 µm. C, Lysates were prepared from U-
251 cells stably expressing GFP alone (EV) or IC-1:GFP, and these exogenous proteins 
were then immunoprecipitated using anti-GFP antibodies. Co-immunoprecipitated 
endogenous dynein intermediate chains (IC) and light intermediate chain 1 (LIC-1) were 
detected by immunoblotting with anti-IC and anti-LIC1 antibodies, respectively. Expression 
levels of these proteins in the lysates were also confirmed by immunoblotting with their 
respective antibodies (Lysate). Lysates and immunoprecipitates were probed with anti-GFP 
antibodies to confirm expression and pull-down of IC-1:GFP or GFP. Blots shown are 
representative of three independent experiments. D, Co-localisation of IC-1:GFP and 
endogenous dynein light intermediate chain 1 (LIC-1) in the U-251 stable cell line was 
demonstrated by confocal microscopy. IC-1:GFP was visualised via its GFP tag (green) and 
LIC-1 via immunofluorescence staining of the endogenous protein using anti-LIC1 
antibodies (red; 1:250; Abcam). Nuclei were stained with DAPI (blue). Images are 

























































Figure 5.14: Expressing IC-1:GFP in U-251 cells reduces plasma membrane-localised
SK2 and extracellular S1P production


























































vector; EV) or IC-1:GFP was examined by confocal microscopy. IC-1:GFP or GFP were
visualised via their GFP tag (green) and SK2 via immunofluorescence staining of the
endogenous protein using anti-SK2 antibodies (red; 1:300; ECM Biosciences). F-actin was
stained using Phalloidin (cyan) to accentuate the cell membrane, and nuclei were stained
with DAPI (blue). Arrows denote distinct plasma membrane localisation of SK2. Images
are representative of more than 100 cells, from three independent experiments. Scale bar =
10 µm. B, Cells described above were visualised by confocal microscopy and scored based
on the presence or absence of distinct plasma membrane (PM)-localised SK2 staining. A
minimum of 200 cells were scored per cell line. Data were graphed as mean (± SEM) from
three independent experiments (** p<0.01; Student’s unpaired two-tailed t-test). C, Rate of
extracellular S1P formation was determined from intact U-251 cells stably expressing GFP
(EV) or IC-1:GFP, and was normalised to cell number. Analyses were performed in





plasma membrane, there was also a significant reduction in extracellular S1P formation in 
the U-251 cells expressing IC-1:GFP compared with control GFP expressing cells (Figure 
5.14C). A similar reduction in extracellular S1P levels was observed even in the presence of 
the highly selective SK1 inhibitor, PF543 (Figure 5.15), confirming that a loss of SK2, and 
not SK1, from the plasma membrane was responsible for this phenotype. Therefore, 
collectively these data demonstrate that re-expression of IC-1 in U-251 GBM cells can 
reinstate dynein-mediated translocation of SK2 away from the plasma membrane, which 
may be dampened as a result of IC-1 downregulation. 
 
 
5.5.8 Re-expression of IC-1 in U-251 cells reduces neoplastic growth in vitro and in 
vivo 
 
As plasma membrane-localised SK can promote oncogenesis (Pitson et al, 2005; Takabe & 
Spiegel, 2014), it was intriguing to hypothesize that a loss of SK2 from the plasma 
membrane, and a consequent decrease in extracellular S1P formation, in U-251 cells re-
expressing IC-1 may reduce the oncogenic potential of these GBM cells. Indeed, the U-251 
cells re-expressing IC-1 were found to have significantly attenuated neoplastic growth 
compared to control cells, as assessed by colony formation assays in soft agar (Figure 
5.16A). To determine if this reduced oncogenic potential in vitro corresponded to a decrease 
in tumour growth in vivo, U-251 cells re-expressing IC-1 (IC-1:GFP), or control U-251 cells 
expressing GFP only, were subcutaneously engrafted into the flanks of NOD/SCID mice, 
and tumour growth was measured over time. Strikingly, re-expression of IC-1 decreased the 
growth of the tumours formed by U-251 cells by 50% compared to that seen with control 
cells (Figure 5.16B). The presence of IC-1:GFP in the excised tumours was confirmed by 
immunoblot analyses using GFP antibodies (Figure 5.16C).  
 
Reduced tumour growth can be a consequence of a decrease in infiltrating blood vessels into 
the tumour, limiting nutrients and oxygen available to the tumour. Since extracellular S1P 
plays an important role in mediating angiogenesis and blood vessel infiltration into tumour 
tissue (Takabe & Spiegel, 2014), and given that I observed reduced extracellular S1P upon 
stable overexpression of IC-1 in vitro, tumour vascularisation was assessed by CD31 
staining of tumour sections. Notably, there was a significant reduction in the number of
Figure 5.15: Decrease in extracellular S1P formation resulting from IC-1




































Rate of extracellular S1P formation was determined from intact U-251 empty vector (EV)
or IC-1:GFP stable cell lines incubated with 1 µM PF543 (added to the cells at the same
time as 0.5 µCi of [3H]-sphingosine) for 40 min. Analyses were performed in quadruplicate,




















IC-1 p < 0.01
























































































Figure 5.16: Re-expression of IC-1 in U-251 cells reduces neoplastic growth in vitro
and in vivo
A, Anchorage-independent growth of U-251 cells stably expressing GFP alone (empty
vector; EV) or IC-1:GFP was tested using colony formation assays in soft agar. Average
colony numbers and size were quantified using ImageJ software, and are graphed as mean
(± SD) from quadruplicate wells of one experiment, which was representative of three
independent experiments (** p<0.01; Student’s unpaired two-tailed t-test). Representative
images of colonies from each group are shown. B, NOD/SCID mice were subcutaneously
injected with U-251 cells stably expressing IC-1:GFP, or GFP alone (EV), and calliper
measurements of palpable tumours were taken over 30 days. Mean tumour volumes are
shown (± SEM; n = 6-7 per group). Statistical analysis on all data points was performed by
two-way ANOVA. C, Equal amounts (30 µg) of total protein from the tumour tissue lysates
were subjected to immunoblot analyses with antibodies against GFP, dynein intermediate




CD31-positive vessels present in tumours formed from U-251 cells re-expressing IC-1, 





The roles and regulation of SK2 remain poorly understood. In this study I have identified 
that SK2 interacts with the cytoplasmic dynein complex, via dynein ICs, which transports 
SK2 in a retrograde direction away from the cell periphery, and thus regulates the 
subcellular localisation of SK2, which is known to be critical for the function of this 
signalling enzyme (Siow & Wattenberg, 2011). Furthermore, this newly discovered 
regulatory mechanism of SK2 appears to have implications in GBM, where I found that the 
expression of dynein IC-1 subunit is heavily downregulated, and correlates with poorer 
GBM patient survival. Indeed, my findings demonstrate an interplay between the 
downregulation of IC-1 in GBM and an increase in SK2 plasma membrane localisation, 
which was decreased by re-expression of IC-1, resulting in reduced GBM tumour growth in 
vivo. Overall, this work suggests that IC-1 can act as a tumour suppressor in GBM, and this 
role may involve the removal of SK2 from the plasma membrane to dampen extracellular 
S1P signalling.  
 
It is well accepted that the subcellular localisation of the SKs, and hence the location of S1P 
production, can give rise to various somewhat opposing signalling outcomes (Pitson, 2011; 
Siow & Wattenberg, 2011). Therefore, the cellular functions of the SKs are largely dictated 
by their subcellular localisation, which has previously been shown to be regulated by 
various interacting proteins. The calcium and integrin-binding protein CIB1 mediates the 
translocation of SK1 to the plasma membrane to promote survival and proliferative 
signalling (Jarman et al, 2010; Zhu et al, 2017), however it has not been confirmed whether 
this mechanism also regulates the plasma membrane localisation of SK2. Translocation of 
the SKs to the plasma membrane has also been reported upon IgE-mediated cross-linking of 
the FcεRI receptor on mast cells, mediated by an interaction with the Src family kinases Lyn 
and Fyn (Olivera et al, 2006). However, prior to this study, very little was known about the 
regulation of SK2 to regions of the cell where it is known to promote cell cycle arrest and 
cell death, such as the nucleus, ER and mitochondria (Chipuk et al, 2012; Hait et al, 2009; 
Igarashi et al, 2003; Maceyka et al, 2005). Therefore, uncovering mechanisms by which
















































A, Tumours derived from U-251 cells stably expressing IC-1:GFP, or GFP (empty vector;
EV), were sectioned and CD31-positive vessels were examined by immunohistochemistry
staining. Representative images for each group are shown. Scale bar = 100 µm. B, The
number of CD31-positive vessels from tumour sections described in (A) was quantified and
averaged from at least four random fields of view per tumour, at 20x magnification, and are
graphed with means (n = 6 per group; *** p<0.001; Student’s unpaired two-tailed t-test).





SK2 is translocated within the cell, particularly toward these organelles, is critical in 
understanding how the opposing roles of SK2 are regulated. As such, the studies outlined 
here have begun to decipher these mechanisms by identifying dynein as a critical regulator 
of SK2 subcellular localisation, which may therefore control many of the functions of this 
enzyme.  
 
GBM is the most common and aggressive primary malignant form of brain cancer in adults, 
where patients have a median survival of less than 15 months after diagnosis and a three-
year survival rate of 3-5% (Polivka et al, 2017; Stupp et al, 2005). The current standard of 
care for GBM patients is surgical resection of the bulk of the tumour, followed by 
radiotherapy and administration of the chemotherapeutic agent temozolomide (TMZ) (Bush 
et al, 2017; Stupp et al, 2005). However, GBM remains incurable and there is clearly a 
desperate need for new targets and more effective treatments for GBM patients. SK 
inhibitors have been proposed as promising therapeutic agents to use in combination with 
chemotherapy and/or radiotherapy in GBM (Sordillo et al, 2016), as the role of the SKs in 
mediating the conversion of pro-apoptotic ceramide, which is produced as a result of these 
therapies, to pro-proliferative S1P has been implicated in the resistance of GBM tumour 
cells to death induced by these agents (Abuhusain et al, 2013; Carpinteiro et al, 2008). S1P 
levels are elevated in GBM tissue samples compared with normal grey matter (Abuhusain et 
al, 2013), and this bioactive lipid has been shown to mediate GBM cell proliferation and 
invasiveness (Van Brocklyn et al, 2002; Van Brocklyn et al, 2003). Furthermore, glioma 
stem-like cells (GSCs), which are thought to be the drivers of disease progression and 
relapse (Bao et al, 2006), were found to produce higher levels of extracellular S1P than 
GBM cells, and extracellular S1P was found to promote GSC proliferation and stemness 
(Marfia et al, 2014; Riccitelli et al, 2013). 
 
The relative importance in GBM of the two SK isoforms that produce S1P is, however, 
somewhat unclear. While SK1 has been consistently found to be upregulated in GBM and 
its expression correlates with poor patient survival (Abuhusain et al, 2013; Bien-Moller et 
al, 2016; Van Brocklyn et al, 2005), highly selective SK1 inhibitors have had surprisingly 
inconsistent effects on reducing GBM cell proliferation and viability (Abuhusain et al, 2013; 
Kapitonov et al, 2009). The efficacy of SK2-selective inhibitors has not been examined in 
GBM, potentially because the role of SK2 in cancer is generally less well understood and, 
unlike SK1, evidence for an upregulation of SK2 in GBM is inconsistent (Abuhusain et al, 
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2013; Bien-Moller et al, 2016; Quint et al, 2014). Interestingly, however, RNAi-mediated 
knockdown of SK2 has been shown to reduce GBM cell proliferation and survival to a 
greater extent than SK1 knockdown (Van Brocklyn et al, 2005). Notably, SK2 is highly 
expressed in the brain (Liu et al, 2000); In fact, SK2 expression in the brain is considerably 
higher than SK1 expression and, as such, SK2 is responsible for the majority of S1P 
production here (Blondeau et al, 2007).  
 
Here, I have demonstrated that the plasma membrane localisation of SK2 and contribution 
to extracellular S1P production in GBM cells is negatively regulated by dynein IC-1 (Figure 
5.14), which is heavily downregulated in GBM (Figure 5.9B). These findings provide an 
explanation for why SK2 seemingly contributes to GBM cell proliferation and survival 
more so than SK1 (Van Brocklyn et al, 2005), despite SK2 expression not being upregulated 
in GBM. As SK2 can also promote ceramide production via a salvage pathway at the ER 
(Maceyka et al, 2005), it is perhaps quite logical that SK2 expression would not be 
upregulated in tissues where it is already highly expressed, such as the brain (Liu et al, 
2000), but rather cancer cells would find mechanisms to shuttle SK2 away from cellular 
compartments where it is pro-apoptotic and toward compartments like the plasma 
membrane where it can be oncogenic (Neubauer et al, 2016). My work therefore highlights 
the potential importance of examining SK2 subcellular localisation, and not simply whether 
it is upregulated, in determining if pharmacological targeting of SK2 is likely to have 
therapeutic benefits in GBM. 
 
Strikingly, I have also demonstrated that re-expression of dynein IC-1 in GBM cells resulted 
in reduced tumour growth in vivo, potentially due to decreased tumour-associated 
angiogenesis (Figure 5.16 and Figure 5.17). Drugs that target angiogenesis have emerged as 
promising anti-cancer therapeutics, and as such, the anti-angiogenic monoclonal vascular 
endothelial growth factor (VEGF) blocking antibody, bevacizumab (Avastin), has been 
approved for use in patients with recurrent GBM. Given the important role of extracellular 
S1P in mediating tumour-associated angiogenesis (Takabe & Spiegel, 2014), and in light of 
the fact that re-expression of dynein IC-1 resulted in reduced SK2-mediated extracellular 
S1P formation (Figure 5.14 and Figure 5.15), this suggests that targeting SK2 in GBM may 
have beneficial anti-angiogenic effects. Indeed, extracellular S1P produced by SK1 and 
secreted from GBM cells has been shown to mediate angiogenic signals and promote co-
cultured endothelial cell sprouting (Abuhusain et al, 2013), and so it is possible that dual 
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SK1/SK2 inhibitors may be most beneficial at blocking the angiogenic effects of S1P in this 
cancer. 
 
Another interesting concept to consider is whether the prominent plasma membrane 
localisation of SK2 observed in GBM cells is seen universally in other cancer types where 
IC-1 is found to be significantly downregulated. According to our broad gene expression 
analysis, IC-1 is significantly downregulated in many different human cancers (Figure 5.9), 
but notably, IC-1 expression levels were reduced in various subtypes of breast cancer across 
a number of datasets. SK2 has been previously shown to localise predominantly to the 
plasma membrane in MDA-MB-453 breast cancer cells, where it was found to be required 
for migration of these cells towards EGF (Hait et al, 2005). Furthermore, SK2 knockdown 
in MCF-7 breast cancer cells resulted in significantly reduced tumour growth in an in vivo 
xenograft model (Weigert et al, 2009). Therefore, it is tempting to speculate that the 
important interplay between SK2 and IC-1 observed in GBM may also occur in other 
cancers, including breast cancer, where loss of IC-1 is observed. However, given that IC-1 
is only highly expressed in the brain, heart and skeletal muscle (Horikawa et al, 2001), it 
will remain to be determined whether the ubiquitous IC-2 isoform would compensate for the 
decrease in IC-1 in other tissues. 
 
Given the critical cellular functions dynein plays in transporting cargoes and organelles, 
maintaining cellular organisation, as well as facilitating mitosis (Allan, 2011), it is 
intriguing that down-regulating a subunit of the dynein complex would be beneficial in 
cancer. It suggests that a significant reduction in IC-1 levels is not detrimental to the 
required housekeeping functions of dynein. Indeed, it is thought that the ubiquitously 
expressed IC-2 isoform is sufficient to maintain the housekeeping functions of dynein in 
most cells and tissues, whereas IC-1, being most highly expressed in the brain (Horikawa et 
al, 2001; Myers et al, 2007), facilitates additional functions required by these more 
specialised cells (Pfister, 2015).  Notably, a previous study found IC-1 to play a role in 
mediating cellular senescence (Horikawa et al, 2001).  In this study, it was found that as 
cells aged, IC-1 message levels increased over time, reaching a maximal level in senescent 
cells. Furthermore, the authors noted that the DYNC1I1 gene is located on the long arm of 
chromosome 7 where tumour suppressor genes and another senescence-inducing gene are 
mapped, and consistent with our gene expression profiling in cancer patient samples, they 
found little or no IC-1 expression in MCF-7 breast cancer cells and in BG-1 ovarian cancer 
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cells (Horikawa et al, 2001). SK2 has also more recently been implicated in regulating 
cellular senescence, where S1P produced by nuclear-localised SK2 was reported to bind to 
hTERT and prevent its degradation, thereby stabilising hTERT and preventing cell 
senescence (Panneer Selvam et al, 2015). No obvious changes in the nuclear localisation of 
SK2 were evident upon dynein IC knockdown or IC-1 overexpression in these studies (data 
not shown), but it remains to be more closely examined if the roles of IC-1 in cell 
senescence are in any way mediated by SK2 and its role in promoting hTERT stability. 
 
Furthermore, a mutation found in the dynein heavy chain (F580Y) that gives rise to spinal 
muscular atrophy with lower extremity predominance was found to negatively affect dynein 
complex assembly and processivity (Ori-McKenney et al, 2010). Interestingly, Garrett et al 
found that, upon stimulation of cells with EGF, the reduced dynein function as a result of 
this mutation led to delayed maturation and retrograde trafficking of EGF-containing 
endosomes, and consequently, sustained activation of the downstream effector of EGF-
mediated signalling, ERK1/2 (Garrett et al, 2014). It is therefore tempting to speculate 
whether other means of reducing dynein function, such as the downregulation of a 
component like IC-1, may affect a broader range of signalling pathways and responses in 
favour of cancer growth, where regulating SK2 subcellular localisation may be one such 
outcome. It may be particularly interesting, then, to explore the interplay between SK2 and 
potentially sustained EGF signalling when IC-1 is downregulated in cancer, as EGF can 
activate SK2 (Hait et al, 2007) and SK2 is required for EGF-induced migration of breast 
cancer cells (Hait et al, 2005) and EGF-mediated adhesion and invasion of cervical cancer 
cells (Adada et al, 2015). 
 
Contrastingly, a recent study reported the upregulation of cytoplasmic dynein 2 heavy chain 
1 (DHC2) upon treatment of GBM cells with TMZ, and RNAi-mediated knockdown of 
DHC2 appeared to modestly sensitize primary GBM cells to TMZ-induced cell death 
(Wang et al, 2016). The cytoplasmic dynein 1 complex, which is the focus of our work, is 
highly abundant and is found in all microtubule-containing cells where it transports various 
proteins and organelles throughout the cytoplasm, facilitates cell cycle progression and 
maintains organelle positioning (Allan, 2011; Hook & Vallee, 2006). Cytoplasmic dynein 2 
and its components, on the other hand, are best characterised for their role in retrograde 
intraflagellar transport (IFT), and consequently are almost exclusively found within and 
around the base of eukaryotic cilia and flagella to promote their assembly and maintenance 
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(Hook & Vallee, 2006; Pfister et al, 2006). Therefore, the relevance of DHC2 upregulation 
in response to TMZ treatment and potential resistance mechanisms in GBM is unclear; it 
was hypothesised that these phenotypes may be a result of the role DHC2 plays in mediating 
Hedgehog signalling, which appears to require functional cilia and IFT proteins (Huangfu & 
Anderson, 2005; Wang et al, 2016), but further work would be required to substantiate this. 
 
Additional work will be required to further understand and characterise the interaction 
between SK2 and dynein. Retrograde-directed movement of dynein results in its 
accumulation at the MTOC, and dynein is also found associated with organelles such as the 
golgi, lysosomes and endosomes (Kardon & Vale, 2009). Dynein, and the cargo that it 
transports, have been shown previously to exhibit peri-nuclear localisation (Ligon et al, 
2001; Lin & Collins, 1992) very similar to that demonstrated here by dynein IC and SK2 
(Figure 5.6A). Whether SK2 is being sequestered to specific peri-nuclear organelles, in 
either a house-keeping shuttling process or in response to certain stimuli, and how it is then 
transported away from these regions are all questions that will require further attention. 
Given that here an interaction could be detected between SK2 and dynein IC in cells without 
any additional stimuli (Figure 5.6B), this might suggest that SK2 is constitutively 
transported within the cell as a house-keeping function of dynein. Indeed, in some situations 
this may represent a negative-regulatory mechanism to prevent prolonged signalling of SK2 
at the plasma membrane. Given that re-expression of IC-1 is not a feasible therapeutic 
option, it will be of interest to explore how this interaction is regulated in order to uncover 
other potential targeting strategies.  
 
Overall, in this study I have identified a novel physiological interaction between SK2 and 
the cytoplasmic dynein complex, and have uncovered a potential new mechanism of SK2 
dysregulation in cancer, whereby modulation of dynein IC-1 expression in GBM can 
regulate SK2 subcellular localisation and ultimately affect tumourigenic potential. This 
work highlights the importance of investigating SK2 subcellular localisation, and not simply 
whether it is upregulated, in determining whether pharmacologically targeting SK2 is likely 
to have therapeutic benefits in certain cancers. As such, this study provides new mechanistic 
insights into dysregulated cellular transport and signalling in GBM, and offers a rationale 














The Role of Phosphorylation in 



























The two mammalian sphingosine kinases, SK1 and SK2, are responsible for the formation 
of the pleiotropic signaling lipid sphingosine-1-phosphate (S1P). It is well known that the 
subcellular localisation of the SKs, and hence the compartmentalisation of S1P formation 
within the cell, can alter the function of these enzymes. The SKs are known to be regulated 
by extracellular as well as intracellular stimuli, and both enzymes can undergo post-
translational modifications. Indeed, phosphorylation of SK1 at Ser225 is responsible for its 
activation, and can also facilitate its localisation to the plasma membrane. Phosphorylation 
of SK2 at Ser383 and/orSer385 has been shown to regulate its nuclear export, and 
phosphorylation of Thr578 has been proposed to result in SK2 activation. However, SK2 
possesses two regions within its sequence that are not conserved in SK1; an extended N-
terminal region and a proline-rich central domain predicted to contain multiple 
phosphorylation sites. Strikingly, through mass spectrometry analyses, the Pitson 
Laboratory previously identified ten phosphorylation sites within the unique central region 
of SK2, and seven of these sites have since been confirmed by global phosphoproteomic 
studies as being physiological phosphorylation events on endogenous SK2. In this chapter, 
the role of phosphorylation in the regulation of SK2 was examined. While initial studies 
suggested phosphorylation at Ser363 may regulate the interaction of SK2 with dynein, 
further analysis showed that phosphorylation of this site appears to regulate the subcellular 
localisation of SK2 potentially independently of dynein. Furthermore, Ser437 in SK2 was 
found to be phosphorylated by GSK3 in vitro and in cells, in a manner that appears 
dependent on a priming phosphorylation at Ser441. Furthermore, these phosphorylation 
sites may act to regulate the catalytic activity of SK2. These findings suggest that the 
regulation of SK2 by phosphorylation is likely to be more complex and important to its 









The two mammalian sphingosine kinases, SK1 and SK2, both catalyse the formation of 
S1P. Despite this, their functions within the cell appear to be somewhat divergent. SK1 is 
very well characterised as having predominantly pro-survival, pro-proliferative roles, and its 
role in promoting cancer has been extensively reviewed (Heffernan-Stroud & Obeid, 2013; 
Pitson, 2011; Pyne & Pyne, 2010). However, as discussed in Chapter 4, the functions of 
SK2 are much more complex, and although it has physiological roles in mediating cell death 
(Chipuk et al, 2012; Hofmann et al, 2008), it too appears to be able to promote survival, 
proliferation and neoplastic transformation.  
 
SK1 and SK2 are likely to have considerably different mechanisms of regulation, and it is 
evident that subcellular localisation and post-translational modifications are critical in SK 
regulation (Chan & Pitson, 2013; Siow & Wattenberg, 2011). Indeed, it is well 
characterized that phosphorylation of SK1 at a single site (Ser225) by ERK1/2 results in its 
activation (Pitson et al, 2003), and facilitates the localisation of SK1 to the plasma 
membrane, which is required for its oncogenic signalling (Pitson et al, 2005). However, this 
SK1 phosphorylation site resides within a region of the protein that is divergent in SK2, and 
hence, this activating site is not directly conserved (see Figure 6.1). Uniquely, in its central 
domain SK2 contains a proline-rich sequence of 120 amino acids that are largely absent in 
SK1. Very little is known about the structure of this region, as it shares no homology with 
any other known protein domains, and the crystal structure of SK2 is yet to be solved.  
 
Interestingly, quite a number of endogenous SK2 phosphorylation events have recently been 
reported in global phosphoproteome analyses (reviewed in Neubauer & Pitson (2013)), most 
of which have not been characterised. Twelve of these sites occur on residues within the 
unique central region of SK2, not conserved in SK1, indicating that they are likely to be 
involved in SK2-specific regulation. One of these sites, Ser351, has previously been 
implicated in SK2 activation (Hait et al, 2007). In this study, it was demonstrated that SK2 
catalytic activity is increased upon phosphorylation by ERK1 in vitro, and that S351A and 
T578A mutations ablate agonist-induced phosphorylation of SK2, as well as decrease in 
vitro phosphorylation of SK2 by ERK1. However, the critical experiment examining the 
catalytic activity of S351A and T578A after in vitro phosphorylation by ERK1 was not 
performed (Hait et al, 2007). Furthermore, Ser351 is not conserved in mouse or rat SK2, 
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making it unlikely that this residue would be responsible for SK2 activation. Therefore, 
Thr578 may be more likely involved in SK2 activation (which is not conserved in SK1), 
however, further characterisation is required to elucidate if other phosphorylation events on 
SK2 can regulate its activation. 
 
Another two phosphorylation sites within the central region of SK2 have also been 
previously studied. A novel nuclear export sequence (NES) was reported in SK2, whereby 
Ser383 and/or Ser385 were found to be phosphorylated within this sequence by PKD, to 
mediate the nuclear export of SK2 (Ding et al, 2007). Indeed, this study provided clear 
evidence for the role of PKD in SK2 nuclear export, however, the importance of these two 
specific phosphorylation sites was less clear. It was nicely demonstrated that alanine 
mutations at these two sites (S383A/S385A) blocked nuclear export of SK2 driven by PKD 
overexpression. However, the authors described that S383A alone did not prevent the 
nuclear export of SK2, whereas S385A could dampen the nuclear export but not provide 
complete nuclear retention as the double mutant did. Furthermore, the authors noted several 
other potential NESs within SK2 in addition to the one they characterised. Mutation of two 
leucine residues within one such sequence (L306A/L308A) also prevented SK2 nuclear 
export upon PMA stimulation, and yet phosphorylation on Ser383/Ser385 was detected in 
the nucleus of these cells, demonstrating that phosphorylation of these residues is not the 
only mechanism of nuclear export. Again, this study provides insight into the regulation of 
SK2 subcellular localisation by phosphorylation, but it is still a complex and incompletely 
understood area. 
 
Given that SK2 has complex opposing roles within the cell, it was of interest to better 
understand how SK2 is regulated, such as by phosphorylation. This will inevitably lead to a 
better understanding of how to control and manipulate SK2 function in order to exploit it as 
a therapeutic target. In Chapter 5, the interaction between SK2 and dynein IC was 
examined, as well as the involvement of dynein in the regulation of SK2 subcellular 
localisation. Thus, it was also of interest to understand how this interaction is regulated, and 
whether it is a constitutive interaction mediating the constant shuttling of SK2 around the 
cell, or whether it is triggered by a specific stimulus, for example, phosphorylation. 
Therefore, the focus of this chapter was to examine the role of phosphorylation in regulating 
the interaction between SK2 and dynein, and also to characterise novel SK2-specific 
phosphorylation sites.  
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Outlined in this chapter are a series of studies that examine various aspects of SK2 
phosphorylation and begin to elucidate the complex regulation of SK2 facilitated by this 
form of post-translational modification.  
 
 
6.3 Preliminary data leading to this study 
 
In order to better understand SK2-specific regulation, the Pitson Laboratory previously 
sought to identify novel SK2 phosphorylation events through mass spectrometric analysis of 
the overexpressed protein in HEK293T cells treated with phorbol esters. This study yielded 
the identification of ten phosphorylation events, all of which were located within the unique 
central domain of SK2a (Figure 6.1A). Of the ten identified sites, only one has since been 
further studied (Ser351) (Hait et al, 2007). Seven of the phosphorylation sites have been 
verified as physiological by global phosphoproteomic analyses (Hornbeck et al, 2015), and 
the remaining three sites (Ser398, Ser401, Ser430) have never been previously detected or 
documented. To determine whether these ten phosphorylation sites were likely to be the 
main sites on SK2, the Pitson Laboratory utilised site-directed mutagenesis to mutate all ten 
identified phosphorylation sites to alanine, to generate a ∆10P mutant. Metabolic labelling 
of cells expressing the ∆10P mutant with 32Pi resulted in no detectable phosphorylation of 
SK2 (Figure 6.1B), suggesting that these ten phosphorylation sites are either the main sites 
within SK2, or that any additional sites somehow require, or are regulated by these sites.  
 
Given that these phosphorylation sites are likely to represent novel, uncharacterised SK2-
specific regulatory mechanisms, it was of interest to determine if the retrograde-directed 
translocation of SK2 by dynein (examined in Chapter 5) is regulated by phosphorylation. 
Given that the retrograde-directed transport of SK2 may result in its localisation to regions 
of the cell where it is known to have pro-apoptotic roles, like the ER or mitochondria 
(Chipuk et al, 2012; Maceyka et al, 2005), it was reasoned that such an event would likely 
be tightly regulated. As such, co-immunoprecipitation experiments were performed using 
overexpressed IC-2 as well as overexpressed SK2 or various SK2 mutants where some or all 
of the ten identified phosphorylation sites were mutated to alanine (∆10P, ∆6P and ∆4P; see 
Figure 6.2A). Interestingly, less interaction was observed with IC-2 when SK2 was lacking 
at least six phosphorylation sites, whereas the interaction was comparable to wildtype SK2 
when only four phosphorylation sites were mutated (Figure 6.2B). The two extra
Figure 6.1: Identification of ten SK2 phosphorylation sites by mass spectrometry
A, HEK293T cells overexpressing FLAG-tagged SK2 were treated with 10 ng/ml PMA for






PAGE, isolated and subjected to tryptic digestion, and analysed by the Adelaide
Proteomics Facility using tandem mass spectrometry with a Q-TOF mass spectrometer. Ten
serine/threonine phosphorylation sites were identified within the unique central region of
SK2a, of which three are novel (red) and seven have since been verified by global
phosphoproteomic analyses or direct analysis and mutagenesis of overexpressed SK2
(blue). The known SK1 activating phosphorylation site (Ser225), not conserved in SK2, is
depicted (black). B, HEK293T cells were transiently transfected with FLAG-tagged SK2 or
the phosphorylation deficient mutant, SK2 ∆10P. Cells were cultured in phosphate-free
media, incubated with 32Pi (0.2 mCi/ml) for 4 hr and then treated with 10 ng/ml PMA for
30 min. SK2 was then immunoprecipitated from lysates with anti-FLAG antibodies,
subjected to SDS-PAGE and exposed to a phosphorimager screen. Immunoprecipitates
were also subjected to immunoblot analyses with anti-FLAG antibodies, to confirm SK2
expression. Dashed lines indicate where lanes from the same immunoblots have been































IC-2 +- + + + +-
EV SK2 SK2 ∆10P ∆6P ∆4P
B
Figure 6.2: Interaction between SK2 and IC-2 appears to be dependent upon SK2
phosphorylation
A, SK2 phosphorylation site mutations present in ∆10P, ∆6P and ∆4P. Those in black are
common to all three mutants, those in red are common to ∆10P and ∆6P, and those in blue
are present in ∆10P only. B, HEK293-c18 cells were co-transfected with HA-tagged IC-2
and either FLAG-tagged SK2, or FLAG-tagged SK2 mutants ∆10P, ∆6P or ∆4P. SK2 (or
mutants) were immunoprecipitated from lysates using anti-FLAG antibodies, and co-
immunoprecipitated IC-2 was detected by immunoblot analyses using anti-HA antibodies.
Expression levels of IC-2 in the lysates were confirmed by immunoblotting with anti-HA
antibodies (Lysate). Images shown are representative of three independent experiments.




phosphorylation sites mutated to alanine in the ∆6P mutant that were not mutated in the ∆4P 
mutant are Ser363 and Ser398. Therefore, it appeared that the interaction between SK2 and 
IC-2 may be regulated by SK2 phosphorylation, potentially on Ser363 and/or Ser398. 
 
 
6.4 Specific Materials and Methods 
 
6.4.1 Site-directed mutagenesis 
 
pcDNA3-SK2 S363E(FLAG) was generated by Quikchange PCR with KAPA HiFi DNA 
polymerase (Kapa Biosystems) using pcDNA3-SK2(FLAG) (Roberts et al, 2004) as 
template and the following primers: 5’-
CTGCCTCGTGCCAAGGAAGAGCTCACCCTAACCCCAGAC-3’ and 5’-
GTCTGGGGTTAGGGTGAGCTCTTCCTTGGCACGAGGCAG-3’. pcDNA3-SK2 
S363D(FLAG) was generated in the same way, using the following primers: 5’-
CCATAGCCTGCCTCGAGCCAAGGATGAGCTGACCCTAACC-3’ and 5’-
GGTTAGGGTCAGCTCATCCTTGGCTCGAGGCAGGCTATGG-3’. Sequencing verified 




6.4.2 Kinexus screen 
 
Two peptide substrates (Ser363: RLPRAKSELTLT and S363A: RLPRAKAELTLT) that 
recapitulate the polypeptide sequence surrounding Ser363 of human SK2 were generated at 
90% purity by Kinexus Bioinformatics (Vancouver, Canada). These peptides were then 
tested by Kinexus in in vitro phosphorylation assays against 46 protein kinases. Peptides 
were screened at 500 µM in duplicate measurements using a radiometric assay method. 
Strong phosphorylation was deemed to be > 100,000 counts per minute (cpm), and 






6.4.3 TUNEL apoptosis assays 
 
HeLa cells were seeded onto poly-L-lysine coated coverslips in a 12-well plate and grown 
overnight at 37°C. Cells were then either mock transfected (no DNA) or transfected with 
pcDNA3-IRES mCherry, FLAG-tagged wildtype SK2, or FLAG-tagged SK2 mutants: 
S363A, S398A, S437A, S441A or S448A. After 24 hr, media was removed and cells were 
cultured in serum-free media for another 24 hr, and mock transfected cells were treated for 
24 hr with 1 µM Staurosporine as a positive control. Cells were then fixed and apoptotic 
cells were identified using terminal deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL) technology with an in situ cell death detection kit (Fluorescein; Roche), 
performed as per the manufacturer’s instructions. Secondary labelling of exogenous proteins 
was achieved by immunofluorescence staining using mouse anti-FLAG antibodies. Cells 
were visualised by confocal microscopy, and dual TUNEL-positive / transfected cells were 





6.5.1 Characterising the regulation of SK2 by Ser363 phosphorylation 
 
6.5.1.1    Ser363 appears to regulate the interaction between SK2 and dynein IC 
 
The previous use of broad phosphorylation-deficient SK2 mutants indicated that Ser363 
and/or Ser398 may play a role in regulating the interaction between dynein IC-2 and SK2. 
Hence, it was of interest to further characterise their importance through the use of single 
point-mutants. Interestingly, co-immunoprecipitation experiments with co-expressed IC-2 
and SK2 S363A or S398A point-mutants clearly demonstrated that an alanine mutation at 
Ser363 alone could abolish the interaction, whereas mutating Ser398 had only a minimal 
effect on the interaction (Figure 6.3A). This trend was also confirmed in co-
immunoprecipitation experiments with IC-1 (Figure 6.3B), indicating that Ser363 appears to 
regulate the interaction between SK2 and both IC isoforms.  
 
To confirm that Ser363 alone is responsible for this phenotype, and that the alanine 
mutation on Ser363 doesn’t subsequently interfere with the phosphorylation of another
Figure 6.3: Interaction between SK2 and dynein IC appears to be regulated by Ser363
A, HEK293-c18 cells were co-transfected with HA-tagged IC-2 and either FLAG-tagged
SK2 or FLAG-tagged SK2 mutants, S363A or S398A. SK2 (or mutants) were
immunoprecipitated from lysates using anti-FLAG antibodies, and co-immunoprecipitated
IC-2 was detected by immunoblot analyses using anti-HA antibodies. Expression levels of
IC-2 in the lysates were confirmed by immunoblot with anti-HA antibodies (Lysate). B,
Performed as in (A), except with HA-tagged IC-1. All images shown are representative of


























important site, a ∆9P mutant was employed where nine of the ten phosphorylation sites 
previously identified by the Pitson Laboratory were mutated to alanine, leaving only Ser363 
intact. Indeed, utilising this SK2 ∆9P mutant in overexpressed co-immunoprecipitation 
experiments with dynein IC-2 demonstrated that wildtype Ser363 was sufficient for the 




6.5.1.2    Mutating Ser363 to glutamate or aspartate does not appear to function as a 
phospho-mimetic 
 
In order to further demonstrate the importance of phosphorylation on a particular residue, it 
is common to substitute the residue for a glutamate or an aspartate in an attempt to 
constitutively mimic the bulky negative charge of a phosphate group (Dephoure et al, 2013; 
Hao et al, 1996). Indeed, this method has been previously shown to be successful for SK2, 
where substitutions of Ser351 and Thr578, the sites implicated in SK2 activation in response 
to EFG (Hait et al, 2007), to aspartate residues resulted in increased basal adherence levels 
and increased basal phosphorylation of ERM proteins in the absence of EGF, compared to 
WT SK2 (Adada et al, 2015). In line with this, both glutamate and aspartate mutants at the 
Ser363 site (S363E and S363D) were generated for use in co-immunoprecipitation 
experiments, to determine if this would result in an increase in the interaction between SK2 
and dynein IC. However, both of these mutants resembled the S363A mutant, where the 
interaction between SK2 and IC-1 was decreased (Figure 6.5). Hence, S363E and S363D 
were not able to mimic the potential role of phosphorylated Ser363 in promoting the 
interaction between SK2 and dynein IC. 
 
 
6.5.1.3    Ser363 regulates the subcellular localisation of SK2 
 
Given that Ser363 appeared to regulate the interaction between SK2 and dynein IC, and as 
examined in Chapter 5, dynein can translocate SK2 in a retrograde direction within the cell,  
it was therefore hypothesised that modulation of Ser363 would result in changes to SK2 
subcellular localisation. Accordingly, wildtype SK2 or various mutants were overexpressed 











Figure 6.4: Other SK2 phosphorylation sites do not regulate the interaction with IC-2
HEK293-c18 cells were co-transfected with HA-tagged IC-2 and either FLAG-tagged SK2
or FLAG-tagged SK2 mutants, S363A or ∆9P. SK2 (or mutants) were immunoprecipitated
from lysates using anti-FLAG antibodies, and co-immunoprecipitated IC-2 was detected
by immunoblot analyses using anti-HA antibodies. Expression levels of IC-2 in the lysates
were confirmed by immunoblotting with anti-HA antibodies (Lysate). Images shown are






















Figure 6.5: Glutamate/aspartate substitutions to Ser363 do not appear to act as
phospho-mimetics to enhance the interaction with IC
A, HEK293-c18 cells were co-transfected with HA-tagged IC-2 and either FLAG-tagged
SK2 or FLAG-tagged SK2 mutants, S363A, S363E or S363D. SK2 (or mutants) were
immunoprecipitated from lysates using anti-FLAG antibodies, and co-immunoprecipitated
IC-2 was detected by immunoblot analyses using anti-HA antibodies. Expression levels of
IC-2 in the lysates were confirmed by immunoblotting with anti-HA antibodies (Lysate).
Images shown are representative of three independent experiments. B, Performed as in (A),
except with HA-tagged IC-1. Experiment was only performed once.




microscopy. Strikingly, where wildtype SK2 was localised predominantly in the cytoplasm 
of the cells, the S363A variant was very distinctly nuclear localised (Figure 6.6). The S363E 
and S363D mutant proteins were also localised mainly to the nucleus like the S363A 
mutant, demonstrating again that they are not functioning as ‘phospho-mimetics’, in 
agreement with the co-immunoprecipitation experiments performed in Figure 6.5. 
Interestingly, ablation of all ten phosphorylation sites identified in the Pitson Laboratory 
(∆10P), which included Ser363, localised SK2 to the nucleus. The conversion, however, of 
only Ser363 back to wildtype in this mutant (∆9P) resulted in an almost exclusively 
cytoplasmic localisation of SK2 (Figure 6.6). These data suggest that Ser363 is an important 
regulator of SK2 subcellular localisation, such that this site may act to facilitate the nuclear 
export of SK2, potentially via phosphorylation.   
 
 
6.5.1.4    The effects of S363A on SK2 binding to dynein IC may be an artefact of its 
altered localisation 
 
It was expected that if Ser363 regulates the interaction between SK2 and dynein, and dynein 
can transport SK2 in a retrograde direction (Chapter 5), then modulating Ser363 would 
result in changes to SK2 localisation. This was in fact observed, but, according to this 
rationale it would be expected that the S363A mutation would result in a decreased 
interaction between SK2 and dynein and a consequent decrease in retrograde-directed 
transport of SK2, potentially leading to an accumulation of SK2 at the plus-ends of the cell 
(i.e. the cell periphery). However, quite the opposite was observed, with S363A being 
strongly localised to the nucleus (Figure 6.6). This then posed the following questions: (i) is 
SK2 S363A retained in the nucleus because it is no longer being transported by dynein, or 
(ii) is SK2 S363A no longer able to interact with dynein IC because it is trapped exclusively 
in the nucleus? If the former is true, then it would suggest that dynein transports SK2 out of 
the nucleus in an anterograde direction, which, based on existing knowledge of dynein 
function, is unlikely (Allan, 2011; Vale, 2003). However, the latter scenario would suggest 
that Ser363 may not directly regulate the interaction between SK2 and dynein IC, but rather 
that mutation of Ser363 to alanine simply results in a physical separation of SK2 and dynein 


















SK2 WT S363A S363E
S363D ∆9P ∆10P
Figure 6.6: Ser363 regulates the subcellular localisation of SK2
A, HEK293 cells were transfected with FLAG-tagged wildtype SK2 or mutants, S363A,
S363E, S363D, ∆9P or ∆10P. After 48 hr, exogenous SK2 or mutants were visualised by
immunofluorescence and confocal microscopy, using mouse anti-FLAG antibodies. Scale
bar = 10 µm. B, Using confocal microscopy, cells from (A) were scored visually as having
either predominantly cytoplasmic localisation (C > N), equal cytoplasmic and nuclear
localisation (C = N), or predominantly nuclear localisation (N > C). A minimum of 200
cells were scored per treatment. Data shown is from one experiment, and is representative
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To identify which of these two scenarios is correct, firstly the subcellular localisation of 
overexpressed IC in the cell was assessed. To that end, HEK293 cells were co-transfected 
with IC-2 and either wildtype SK2 or S363A mutant, and their localisation was visualized 
by immunofluorescence and confocal microscopy. IC-2 displayed clear nuclear-exclusion, 
and there was a high level of cytoplasmic co-localisation between wildtype SK2 and IC-2 
(Figure 6.7A). In contrast, the increased nuclear localisation of the S363A mutant meant 
there was considerably less co-localisation between S363A and IC-2 (Figure 6.7A). This 
result, therefore, favours the notion that the decrease in binding observed between S363A 
and dynein IC is due to the physical separation of the two proteins within the cell. However, 
this theory would imply that there is a need for SK2 and dynein IC to form an interaction 
within the cell prior to cell lysis and co-immunoprecipitation. Otherwise, upon lysis and 
disruption of the nuclear membrane, IC and S363A would then be in the vicinity to form an 
interaction. Thus, to test whether an interaction between SK2 and IC could be formed post 
cell lysis, HEK293 cells were separately transfected with either SK2 or IC-2, and lysates 
from these cells were then mixed in a 1:1 ratio and incubated prior to co-
immunoprecipitation. Notably, in contrast to the SK2-IC complex observed following co-
expression of the proteins, no interaction between the two proteins could be detected when 
combined in vitro following cell lysis (Figure 6.7B).  
 
Although, due to time restraints, this experiment was only performed once and requires 
further confirmation, such a result may not be surprising, as SK2 appears to interact with IC 
and the dynein complex in conjunction with the dynactin complex (as shown in Chapter 5). 
Therefore, an interaction between SK2 and these complexes is quite likely to require an 
intact cell in order for these proteins to come together physiologically, as dynein-mediated 
retrograde transport of cargoes generally requires the initial recruitment of dynein to the 
microtubule plus ends, which can involve the coordinated assembly of many additional 
components such as kinesis, dynactin and microtubule plus end-tracking proteins 
(Cianfrocco et al, 2015). If true, it would suggest that the interaction between SK2 and 
dynein IC is not directly regulated by Ser363, but that Ser363 regulates the subcellular 
localisation of SK2 via other mechanisms. It therefore remains to be determined if the 




Figure 6.7: Ser363 is likely to regulate the subcellular localisation of SK2
independently of dynein
A, HEK293-c18 cells were co-transfected with HA-tagged IC-2 in combination with either
FLAG-tagged wildtype SK2, or S363A mutant. After 48 hr, exogenous proteins were
visualised by immunofluorescence and confocal microscopy using mouse anti-FLAG
antibodies (to detect SK2 and S363A) and rabbit anti-HA antibodies (to detect IC-2). Scale
bar = 10 μm. B, HEK293-c18 cells were transfected with HA-tagged IC-2 or FLAG-tagged
SK2, or co-transfected with both (Co). 100 μl of lysate from each of the singly-transfected
cells were mixed gently for 2 hr at 4°C (Mix). SK2 was then immunoprecipitated from all
lysates using anti-FLAG antibodies, and co-immunoprecipitated IC-2 was detected by
immunoblot analyses using anti-HA antibodies. Expression levels of IC-2 in the lysates

















6.5.1.5    Ser363 regulates SK2 catalytic activity 
 
Given that Ser363 clearly regulates the subcellular localisation of SK2, potentially via 
phosphorylation of this site, it was of interest to determine if this residue could also regulate 
other aspects of SK2 function, such as its catalytic activity. Overexpression of the S363A 
mutant in HEK293 cells resulted in a doubling in SK2 catalytic activity compared to 
wildtype SK2 (Figure 6.8), suggesting that Ser363 phosphorylation may act to negatively-
regulate the catalytic activity of SK2 either directly or indirectly via changes in subcellular 
localisation. Since the proportion of overexpressed wildtype SK2 that was phosphorylated 
on Ser363 was not known, the S363E and S363D mutants were utilized as potential 
phospho-mimetics in order to analyse the activity of SK2 when Ser363 was constitutively 
‘phosphorylated’. However, although this experiment was only performed once, similarly to 
the modulation of SK2 localisation (Figure 6.6), these mutants phenocopied the S363A 
mutant and displayed an increase in SK2 activity (Figure 6.8), again implying that they do 
not function as phospho-mimetics.  
 
 
6.5.1.6    Screening candidate kinases that phosphorylate Ser363 on SK2 
 
From the studies described above, it was clear that identifying the kinase responsible for 
phosphorylating Ser363 would be beneficial in understanding SK2 regulation. Unlike the 
other nine phosphorylation sites identified within the unique central region of SK2 (Figure 
6.1), Ser363 is the only site that doesn’t conform to the consensus motif for a proline-
directed protein kinase [i.e. serine/threonine that is immediately followed by a proline (Lu et 
al, 2002)]. This gives it a unique set of candidate kinases and also raises the possibility that 
it may be regulated in a manner different to the other sites.  
 
Given that Ser363 appears to be a physiological SK2 phosphorylation site (Hornbeck et al, 
2015), it was of interest to identify the kinase responsible, and so Kinexus Bioinformatics 
was employed to perform in vitro kinase screens. Initially, a list of the top 50 candidate 
kinases was generated by Kinexus, based on consensus motif algorithms matching the 
residues surrounding Ser363. Of these 50 kinases, 41 were available for testing by Kinexus. 
We selected an additional five kinases (PKAc-α, PKAc-β, PKAc-γ, ROCK1 and ROCK2) to 































Figure 6.8: Ablation of Ser363 phosphorylation significantly increases SK2 catalytic
activity
HEK293 cells were transfected with either wildtype SK2, S363A, S363E or S363D
mutants, and 48 hr later lysates were subjected to SK2-specific activity assays. Activity
was normalised to expression levels of the exogenous proteins, as determined by
immunoblot analyses using anti-FLAG antibodies (panel below). Data are mean (± SD) of





were then screened by Kinexus in in vitro phosphorylation assays for their ability to 
phosphorylate a synthetic peptide generated from the SK2 sequence containing Ser363 
(RLPRAKSELTLT). The 46 kinases were also assayed using a control peptide, with Ser363 
converted to a non-phosphorylatable alanine residue, to validate the specificity of the 
kinases to this site. The ability of each kinase to phosphorylate the wildtype and mutant 
peptides was quantified and is shown in Figure 6.9. Kinexus deemed greater than 100,000 
counts per minute (cpm) as strong phosphorylation of the substrate peptide, and specificity 
of the kinases to Ser363 phosphorylation was determined by inclusion of the S363A mutant 
control peptide. 
 
There were eleven kinases from seven different kinase families that demonstrated both 
strong phosphorylation of Ser363 in vitro as well as specificity to this site (see Table 6.1): 
AMP-activated protein kinase 1 and 2 (AMPK-α1 and AMPK-α2), brain-specific 
serine/threonine kinase 1 and 2 (BRSK1 and BRSK2), death-associated protein kinase 3 
(DAPK3), mitogen-activated protein kinase (MAPK)-activated protein kinase 2 
(MAPKAPK2), proto-oncogene serine/threonine-protein kinase Pim-1 and -3 (PIM1 and 
PIM3), ribosomal s6 kinase p90rsk (RSK1; also MAPKAPK1), and serum/glucocorticoid 
regulated kinase 2 and 3 (SGK2 and SGK3). Of these kinases, the strongest phosphorylation 
of Ser363 was by AMPK-α2, and the greatest specificity to Ser363 was observed for RSK1 
(only 3% phosphorylation of the S363A peptide observed). Unfortunately, due to time 
constraints, further testing of these candidate kinases in in vitro phosphorylation assays 
using full-length SK2 protein was not performed. 
 
 
6.5.2 The pro-apoptotic role of SK2 may be regulated by phosphorylation 
 
Although many of the studies demonstrating a pro-apoptotic role for SK2 have utilised 
overexpression systems (Liu et al, 2003; Maceyka et al, 2005), which are likely to alter the 
normal physiological subcellular localisation of SK2 and possibly override other regulatory 
mechanisms, it appears the pro-apoptotic function of SK2 is not simply an artefact of 
overexpression (Chipuk et al, 2012; Hofmann et al, 2008; Okada et al, 2005). Therefore, 
identifying the mechanisms that allow SK2 to switch from its pro-survival to pro-apoptotic 
roles would be of interest. For example, it would potentially allow targeting of only the 











Figure 6.9: Kinexus Bioinformatics screen identifying candidate kinases that 
phosphorylate SK2 at Ser363 in vitro 
Two peptide substrates (one containing wildtype S363: RLPRAKSELTLT, the other 
containing the A363 mutation: RLPRAKAELTLT) were tested in in vitro phosphorylation 
assays against 46 protein kinases. Peptides were screened at 500 µM in duplicate 
measurements using the radiometric assay method. Graph shows level of phosphorylation, 
in counts per minute (cpm), of both wildtype (blue bars) and mutant (red bars) peptides by 
the 46 kinases. Kinases resulting in phosphorylation of the wildtype peptide greater than 
100,000 cpm were considered to strongly phosphorylate S363 (dotted line). Peptide 
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Table 6.1: Kinase family members found to strongly and specifically phosphorylate 
Ser363 in vitro 
Kinase Family 
Specific kinase(s) found to strongly 
phosphorylate Ser363 in vitro 
AMP-activated protein kinases AMPK-α1 and AMPK-α2 
Brain-specific serine/threonine kinases BRSK1 and BRSK2 
Death-associated protein kinases DAPK3 
Mitogen-activated protein kinase 
(MAPK)-activated protein kinases 
MAPKAPK2 and MAPKAPK1 (also RSK1) 
Proto-oncogene serine/threonine-
protein kinases 
PIM1 and PIM3 
Ribosomal s6 kinase p90rsk RSK1 (also MAPKAPK1) 














in cancer cells that may be reliant on SK2-driven survival and proliferation. One such 
mechanism to control SK2 function is the modulation of its subcellular localisation (Siow & 
Wattenberg, 2011), which, as discussed in Chapter 5, may involve dynein-mediated 
translocation. It was also of interest to identify whether one or more of the uncharacterised 
SK2 phosphorylation sites may regulate its pro-apoptotic role. Thus, multiple SK2 point 
mutants were assessed for their ability to induce apoptosis.  
 
As it has been well documented that overexpression of SK2 results in increased apoptosis 
compared to vector alone (Liu et al, 2003; Maceyka et al, 2005), overexpression of wildtype 
SK2 was initially used as a positive control to optimise methods of quantifying apoptosis. 
Various well validated methods were employed using a number of different cell lines to 
assess apoptosis, and such methods included quantifying fragmented nuclei by DAPI 
staining, flow cytometric assessment of annexin V and propidium iodide staining of intact 
cells as well as caspase 3 activation using NucView™ Caspase 3 substrate, and TUNEL 
assays. However, despite efforts to optimise these methods, considerable variability was 
observed between experimental repeats, but the reasons for this are unclear. The expected 
increase in apoptosis with wildtype SK2 overexpression was best observed using TUNEL 
apoptosis assays, however due to time constraints, subsequent assays using the full array of 
SK2 point mutants were only performed once and would therefore need to be repeated. 
 
With this in mind, cells overexpressing SK2 with an alanine mutation at either Ser363 or 
Ser437 showed increased levels of apoptosis compared with wildtype SK2, whereas 
overexpression of SK2 with an alanine mutation at Ser398 appeared to abolish the SK2-
mediated increase in apoptosis (Figure 6.10). Furthermore, mutation of Ser441 to alanine 
also reduced the level of apoptosis but to a lesser extent than S398A (Figure 6.10). 
Therefore Ser398, and possibly Ser441, may act to promote or activate the pro-apoptotic 
role of SK2, however as these were findings from a single experiment, caution must be 
taken in interpreting these data.  
 
 
6.5.3 SK2 is phosphorylated at a novel site by GSK3 
 
The SK2 phosphorylation sites examined above for their roles in apoptosis are either 
























Figure 6.10: Phosphorylation may regulate the pro-apoptotic role of SK2
HeLa cells were transfected with either pcDNA3-IRES mCherry, FLAG-tagged wildtype
SK2, or FLAG-tagged SK2 mutants S363A, S398A, S437A, S441A or S448A. Cells were
cultured in serum-free media for 24 hr, and untransfected cells were treated for 24 hr with 1
µM Staurosporine as a positive control. Cells were then fixed and a TUNEL apoptosis
assay was performed, followed by labelling of exogenous proteins by immunofluorescence
using anti-FLAG antibodies. Cells were visualised by confocal microscopy, and dual
TUNEL-positive / transfected cells were quantified in a blinded manner. A minimum of




perfectly to a consensus motif found on substrates of glycogen synthase kinase 3 (GSK3; 
Figure 6.11A), whereby a priming phosphorylation event is required four residues 
downstream in order for GSK3 to dock and subsequently phosphorylate the second N-
terminal site (Cole, 2012). Therefore, it was hypothesised that SK2 could be phosphorylated 
by GSK3 at Ser437, and this phosphorylation would be dependent on a priming 
phosphorylation event at Ser441. To test this, in vitro radiolabel phosphorylation assays 
were employed using wildtype SK2, or S437A or S441A mutants immunoprecipitated from 
cell lysates (performed by Dr. Adam Cole, Garvan Institute, Sydney). Indeed, recombinant 
GSK3 was able to phosphorylate SK2 in vitro, and this phosphorylation was significantly 
reduced when Ser437 or Ser441 were mutated to alanine (Figure 6.11B and C). Notably, 
when SK2-overexpressing cells were treated with the selective GSK3 inhibitor, CT99021 
(Ring et al, 2003), to eliminate any endogenous GSK3 phosphorylation of SK2 prior to cell 
lysis, a doubling in SK2 phosphorylation by recombinant GSK3 was observed (Figure 
6.11B and C). This demonstrates that SK2 is in fact a substrate of endogenous GSK3 and 
SK2 can be phosphorylated by GSK3 in cells.   
 
In order to further characterise this novel GSK3 phosphorylation site, it was of interest to 
determine whether Ser437, or the priming site Ser441, had any effect on SK2 catalytic 
activity. Therefore, cells overexpressing these mutants, or wildtype SK2, were utilised in 
SK2-specific activity assays. As observed in Figure 6.12, rendering these residues non-
phosphorylatable modestly, but significantly, increased SK2 catalytic activity by ~50% as 
compared to wildtype SK2. Hence, it appears that phosphorylation of SK2 at these sites may 





6.6.1 Involvement of Ser363 in regulating the interaction between SK2 and dynein IC 
 
This chapter examined the role of phosphorylation in SK2 regulation. There are a large 
number of uncharacterised phosphorylation sites in SK2 that have been identified in the 
Pitson Laboratory (Figure 6.1) and/or by global phosphoproteome analyses, that are likely 
to provide complex and potentially coordinated regulatory mechanisms to reflect the 




SK2 sequence431 PDPLLSSPPGSPKAALH 447
SPPxSP
Figure 6.11: GSK3 phosphorylates SK2 on Ser437 in vitro and in cells
A, SK2 contains a sequence within its central domain that matches the GSK3 substrate
consensus motif. The GSK3 phosphorylation site (red) as well as the required priming site
(+4 position; blue) are indicated. B, HEK293 cells were transfected with FLAG-tagged
SK2 (WT) or FLAG-tagged SK2 mutants, S437A or S441A. Cells transfected with
wildtype SK2 were then either left untreated or treated with the GSK3 inhibitor CT99021
(CT). SK2 (or mutants) were then immunoprecipitated from lysates using anti-FLAG
antibodies, and subjected to in vitro kinase assays with recombinant GSK3 and γ32P-
ATP. Expression of SK2 and mutants in the immunoprecipitates was confirmed by SDS-
PAGE and staining with coomassie brilliant blue R250 (CBR-250). C, Phosphorylation of
wildtype or mutant SK2 by GSK3 was quantified and normalised to protein expression.


























Figure 6.12: Ablation of Ser437 or Ser441 phosphorylation significantly increases SK2
catalytic activity
HEK293 cells were transfected with either wildtype SK2, or SK2 mutants S437A or
S441A. After 48 hr, lysates were subjected to SK2-specific activity assays. Activity was
normalised to expression levels of the exogenous proteins, as determined by immunoblot
analyses using anti-FLAG antibodies (panel below). Dashed lines indicate where lanes
from the same immunoblot have been spliced together to aid interpretation. Data are





predominantly examined in this chapter, Ser363, was regulating the interaction between 
SK2 and dynein IC (Figure 6.3). However, further characterisation revealed that the 
observed reduction in binding of the SK2 mutant S363A with dynein IC was likely due to 
an indirect mechanism as a result of the isolation of these two proteins in different 
subcellular compartments (Figure 6.7). This would perhaps explain why some variability in 
the levels of interaction between IC and SK2 S363A were occasionally observed, ranging 
from almost completely abolished to only slightly reduced from wildtype (data not shown). 
This observation would likely have coincided with the levels of nuclear localised S363A 
mutant and consequently, the amount of protein in contact with dynein IC within the cell. 
 
Since Ser363 phosphorylation does not appear to directly control the association of SK2 
with dynein, future work will be required to characterise the regulation of this interaction. It 
remains possible that phosphorylation of SK2 at other sites may play a role in regulating this 
interaction, and these should be screened by in vitro pull-down assays to prevent any 
artefacts of altered SK2 localisation. However, it is also feasible that phosphorylation of the 
dynein IC may regulate its interaction with SK2, as a number of phosphorylation sites have 
been documented within the serine-rich region at the N-terminus of the protein (Figure 1.9). 
Specifically, phosphorylation of Ser81 and Ser84 on IC-2 appear to regulate the binding of 
dynein to certain cargoes for transport (Mitchell et al, 2012; Vaughan et al, 2001). On the 
contrary, the interaction between SK2 and dynein may be regulated by phosphorylation-
independent mechanisms, such as by other post-translational modifications.  
 
6.6.2 The role of Ser363 in the regulation of SK2 subcellular localisation 
 
From the data in this study, it appears that Ser363 regulates the subcellular localisation of 
SK2, such that SK2 is sequestered to the nucleus when this site is mutated to alanine (Figure 
6.6). It is tempting to speculate that phosphorylation of this site may be the mechanism 
regulating SK2 nuclear localisation, although other possibilities exist, such that Ser363 may 
form a critical residue involved in a kinase binding motif to regulate other SK2 
phosphorylation sites, for example. Ser363 may also serve as an important residue in 
regulating or maintaining a specific conformation of the NES on SK2 through interactions 
with other residues, or it may regulate binding of SK2 to other proteins involved in 




However, SK2 has been previously found to be phosphorylated endogenously on Ser363 in 
cells (Hornbeck et al, 2015). Indeed, the nuclear-localisation phenotype resulting from the 
S363A mutant is reminiscent of the previous study characterising the nuclear export of SK2, 
which was reported to be regulated by PKD-mediated phosphorylation of Ser383 and/or 
Ser385 within a novel nuclear export sequence (Ding et al, 2007). Similarly to S363A, when 
these two residues were mutated to alanine, SK2 was almost exclusively nuclear, suggesting 
that Ser363 may also be involved in SK2 nuclear export. It would therefore be of interest to 
determine if Ser363 is also phosphorylated to regulate SK2 nuclear export in a similar 
manner as the residues reported by Ding et al. Although, if Ser363 is being phosphorylated 
to regulate SK2 nuclear localisation, it cannot be ruled out that it is simply preventing 
nuclear import, and this would need to be examined in future work. Notably, however, like 
the SK2 nuclear export regulation site Ser385, Ser363 also perfectly matches the PKD 
minimal consensus motif of LxRxx(p)S/T (Nishikawa et al, 1997). Furthermore, again like 
Ser385, Ser363 resides within a sequence that contains a number of hydrophobic leucine 
residues, a hallmark of the nuclear export sequence motif: Hx2-3Hx2-3HxH (where H is a 
hydrophobic residue, generally leucine but can also be isoleucine, methionine, 
phenylalanine, or valine, X is any amino acid, and the subscript numbers indicate the 
possible number of repeats) (Ishizawa et al, 2015). Although the sequence surrounding 
Ser363 is missing the second hydrophobic residue in the motif, it has been reported that as 
little as a third of experimentally-validated NESs match the above motif (la Cour et al, 
2003). Therefore, given that PKD was clearly implicated in promoting the nuclear export of 
SK2, and it was documented that SK2 possesses multiple putative NESs, of which at least 
two appear to be functional (Ding et al, 2007), it is possible that Ser363 may also be 
phosphorylated by PKD to regulate the nuclear export of SK2. As discussed further below, 
PKD was not included in the broad kinase screen, so in vitro phosphorylation of Ser363 
using PKD will need to be performed. Furthermore, whether the sequence surrounding 
Ser363 is a bona fide NES, and whether it acts redundantly or in cooperation with the NES 
charactered previously (Ding et al, 2007) requires further investigation. 
 
6.6.3 The role of Ser363 in the regulation of SK2 catalytic activity 
 
Mutating Ser363 to alanine also resulted in an increase in SK2 catalytic activity (Figure 
6.8), again potentially due to a loss of phosphorylation at this site. The observations that an 
increase in catalytic activity and change in subcellular localisation occurred when Ser363 
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was mutated to alanine, without any further stimulation of the cells, may suggest that there 
is basal phosphorylation of wildtype SK2. This would fit with the hypothesis of Ser363 
being a modulator of the basal nucleo/cytoplasmic shuttling of SK2. However, it is also 
possible that this basal phenotype could also be an artefact of overexpression, where the 
high cellular levels of SK2 protein may facilitate its basal phosphorylation at sites normally 
only phosphorylated under certain circumstances. Therefore, to validate this potential basal 
effect of Ser363 phosphorylation on SK2 activity and localisation, it would be of interest to 
generate an inducible cell line where low-level overexpression of SK2 with a S363A 
mutation could be achieved through titrating levels of doxycycline, as previously achieved 
in the Pitson Laboratory (Pham et al (2008), and Chapter 3). Furthermore, for a completely 
physiological setting, CRISPR/Cas9 gene editing could be employed to insert an alanine 
mutation into Ser363, as well as a C-terminal FLAG-tag, within the endogenous SK2 gene 
in cells. Therefore, SK2 localisation and activity in these cells could be analysed and 
compared to wildtype cells to determine the physiological effects of Ser363 
phosphorylation. 
 
6.6.4 Substitutions of Ser363 to glutamate and aspartate 
 
Through the use of glutamate and aspartate substitutions, an attempt was made to 
constitutively mimic phosphorylation of Ser363 in order to further characterise the role of 
this potential phosphorylation site. However, these mutants (S363E and S363D) displayed a 
localisation phenotype and activity level similar to the S363A mutant (Figure 6.6 and Figure 
6.8). It is possible that Ser363 may be regulating SK2 in a phosphorylation-independent 
manner, in which case substitution to glutamate or aspartate would likely still abolish this 
function. However, if Ser363 is regulating SK2 through phosphorylation, then in this case 
glutamate and aspartate were unsuccessful at recapitulating the appropriate size and charge 
of a phospho-serine. Although the differences in the size and charge of a phospho-serine 
compared with a glutamate/aspartate residue are only subtle, and they have been shown to 
successfully mimic phosphorylation of certain proteins including SK2 (Adada et al, 2015), it 
has been reported that even small differences in charge and size can lead to changes in 
hydrogen bonding and overall protein conformation (Ng et al, 2010). Consequently, the 
hydrogen bonding that occurs due to the presence of a phosphate group can be lost when a 
glutamate is substituted, and hence the function of the phosphorylation will not be 
recapitulated. Therefore, in order to further characterise the function of this site in the 
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future, in vitro phosphorylation of recombinant SK2 on Ser363 or stimulating endogenous 
phosphorylation of this site in cells would be informative, however the identity of the kinase 
responsible will be required.  
 
6.6.5 Screening candidate kinases responsible for Ser363 phosphorylation 
 
The in vitro kinase screen performed provided eleven candidate kinases that were able to 
strongly, and selectively, phosphorylate Ser363 in SK2-derived peptides. This number is 
quite high, likely due to the use of a short peptide as opposed to full-length protein and the 
relatively high concentration of peptide used, undoubtedly resulting in false-positives. 
Interestingly, AMP-activated protein kinase (AMPK) was the top candidate with the 
strongest phosphorylation of Ser363 (Figure 6.9). Both isoforms of the catalytic domain 
(AMPK-α1 and AMPK-α2) were able to phosphorylate Ser363 in vitro. AMPK is an 
important, ubiquitously expressed, energy-sensing kinase that, when the cell is experiencing 
energy stress and the AMP:ATP ratio is high, becomes activated through binding to AMP to 
promote catabolic pathways to restore energy homeostasis (Hardie et al, 2015). However, 
there appear to be other less well characterised roles of AMPK, including a requirement of 
AMPK for normal cell cycle progression, and conflicting roles in both supporting and 
preventing cancer progression (Dasgupta & Chhipa, 2015), both of which would be 
interesting in the context of SK2 regulation by phosphorylation. AMPK has a very well 
defined substrate recognition motif, where some flexibility can be tolerated but most 
substrates possess the sequence LxRSx(p)S/TxxxL (Hardie et al, 2015). Aside from the 
polar residue at the -2 position [which is the least critical residue (Hardie et al, 2015)], 
Ser363 perfectly matches this motif (LPRAKpSELTL).  
 
Interestingly, another kinase family closely related to AMPK, BRSK, was also able to 
strongly phosphorylate SK2 at Ser363 in vitro. BRSK, also known as SAD or AMPK-
related kinase, is not as well characterised as AMPK but has known roles in promoting 
neuronal cell polarity, likely via its role in phosphorylating tau to regulate microtubule 
organisation (Kishi et al, 2005; Yoshida & Goedert, 2012). The specific expression of 
BRSKs in the brain and nervous system makes them an interesting candidate kinase for SK2 
phosphorylation, as SK2 is also highly expressed in brain (Liu et al, 2000) and preferentially 
interacts with the predominantly neuronal-expressed dynein IC-1 (Chapter 5), highlighting 
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that SK2 may have additional brain-specific functions that require brain-specific regulatory 
mechanisms.  
 
DAPK would also make an interesting candidate kinase for SK2 regulation, as it is a well 
characterised tumour suppressor with various roles in mediating interferon-γ induced 
apoptosis, promoting anoikis and suppressing cell motility (Huang et al, 2014). Intriguingly, 
DAPK3, the isoform found to strongly phosphorylate Ser363 in vitro (Figure 6.9), does not 
possess the Ca2+/CaM autoregulatory domain found on DAPK1 and DAPK2, but instead 
possesses an NLS and a leucine zipper, and has unique nuclear functions as well as roles in 
mitochondrial mediated apoptosis and autophagy (Shiloh et al, 2014). As SK2 has also been 
shown to mediate cell death at these localisations (Chipuk et al, 2012; Okada et al, 2005), it 
would be fitting for SK2 to be regulated by DAPK3. However, DAPK1 and DAPK2 could 
also phosphorylate Ser363 specifically in vitro, albeit to a lesser extent than DAPK3 (Figure 
6.9), and so if DAPK is the kinase responsible for phosphorylation of this site, it would be 
of interest to examine the involvement of each isoform.  
 
Another set of candidate kinases include the MAPK-activated protein kinases, which 
encompass MAPKAPK2 and RSK1. Interestingly, canonical activation of the RSKs occurs 
via ERK1/2 whereas canonical activation of the MAPKAPKs is mediated by p38 (Gaestel, 
2016). As such, RSKs have been shown to promote cell proliferation, cell growth, protein 
synthesis and cell survival, and they generally translocate to and signal from the nucleus 
upon mitogenic stimulation (Cargnello & Roux, 2011). Furthermore, MAPKAPK2 is 
activated by stress stimuli and, in contrast to the RSKs, is exported out of the nucleus to the 
cytoplasm upon stimulation, where it acts to facilitate cytokine production, cell migration, 
actin remodelling, cell cycle control and gene expression (Cargnello & Roux, 2011). Given 
that Ser363 appears to be involved in SK2 transport out of the nucleus, where it has anti-
proliferative functions (Hait et al, 2009; Igarashi et al, 2003), it is perhaps more plausible 
that a pro-proliferative kinase like RSK1 that signals from the nucleus would be a more 
likely candidate. 
 
The possibility of SK2 regulation by PIM kinases is intriguing, as PIM kinases are proto-
oncogenes that mediate cell cycle progression, cell survival, transcriptional upregulation, 
protein synthesis and cellular metabolism, and are frequently upregulated in various cancers 
(Alvarado et al, 2012; Bullock et al, 2005). Fascinatingly, PIM kinases do not possess a 
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kinase regulatory domain, and so they are likely to be constitutively active following 
translation (Alvarado et al, 2012). In line with this, Ser363 phosphorylation has been 
detected in 34 different phosphoproteomic studies (Hornbeck et al, 2015), suggesting that it 
may be a prevalent modification. Furthermore, like RSK1, the pro-proliferative functions of 
the PIM kinases make them logical candidates for Ser363 phosphorylation. Similarly, the 
SGKs are also involved in the regulation of important processes such as cell growth, 
proliferation, survival and migration, with additional functions including involvement in 
locomotive behaviour, cellular stress, and transport of ions, nutrients and amino acids 
(Bruhn et al, 2010). Interestingly, the SGKs exhibit structural similarity to AKT and are 
activated downstream of the PI3K pathway, and they also interact at various levels with the 
Ras/Raf/ERK pathway (Tessier & Woodgett, 2006) As such, the SGKs have also been 
found to contribute to tumourigenesis (Bruhn et al, 2010). Unlike the PIM kinases, however, 
the SGKs translocate to the nucleus upon growth factor stimulation (Buse et al, 1999).  
 
The substrate consensus motifs for each of the seven kinase families demonstrating strong 
phosphorylation of Ser363 in vitro are listed in Table 6.2. The amino acid sequence 
surrounding Ser363 on SK2 is also provided to demonstrate how well each consensus motif 
suits this site. However, it should be noted that some of the kinases’ known substrates 
themselves do not match the consensus motifs well [e.g. DAPK; Lin et al (2010)], and so 
this does not seem to be a good indicator of whether or not a protein will be a bona fide 
substrate. 
 
Notably, ROCK2 was able to phosphorylate both the wildtype and the alanine mutant 
peptides very strongly (Figure 6.9), indicating that it must be phosphorylating another 
residue on the peptides, possibly Thr366 and/or Thr368. Interestingly, ROCK1 was also 
able to phosphorylate both the wildtype and S363A peptides, but to a lesser extent than 
ROCK2. As Thr368 lies directly upstream of a proline residue in SK2, the proline residue 
had been specifically excluded from the peptide sequences used for the in vitro kinase 
assays in order to prevent background phosphorylation of Thr368 by proline-directed 
kinases (although ROCK is not a member of this family of kinases). Mass spectrometric-
based phosphorylation studies have reported Thr366 as being physiologically 
phosphorylated in Jurkat cells treated with the protein phosphatase inhibitors calyculin and 
pervanadate (Hornbeck et al, 2015). Thr368 was also found to be endogenously 









Table 6.2: Substrate consensus motifs of the candidate kinases for Ser363 
phosphorylation on SK2 
Kinase Family Consensus Motif SK2 sequence Reference 
AMPK LxRSxS/TxxxL LPRAKSELTL (Hardie et al, 2015) 
BRSK R/KxxS/T LPRAKSELTL (Yoshida & Goedert, 2012) 
DAPK KRRxxS/T LPRAKSELTL (Lin et al, 2010) 
MAPKAPK ΦxRxL/NS/TΦ LPRAKSELTL (Cargnello & Roux, 2011) 
PIM RxRHxS/T LPRAKSELTL (Bullock et al, 2005) 
RSK R/KxRxxS LPRAKSELTL (Cargnello & Roux, 2011) 
SGK RxRxxS/T LPRAKSELTL (Kobayashi & Cohen, 1999) 
PKD LxRxxS/T LPRAKSELTL (Nishikawa et al, 1997) 
Underlined residues in the SK2 sequence designate residues that match the consensus motif. 














phosphorylation of this site was also detected previously by the Pitson Laboratory using 
overexpressed SK2 (Figure 6.1). Neither of these threonine residues match the ROCK 
substrate consensus motif (R/Kx(p)S/T or R/Kxx(p)S/T) (Amano et al, 2010), however, 
other bona fide ROCK substrates (e.g. Calponin) also deviate from this sequence (Kaneko et 
al, 2000). Furthermore, neither Thr366 nor Thr368 are conserved in mouse or rat SK2, and 
hence phosphorylation at these sites would likely represent human-specific regulatory 
modifications of SK2. 
 
Future work will require the validation of these kinases by in vitro phosphorylation assays, 
using recombinant full-length SK2 and a S363A mutant (or T366A and T368A mutants for 
ROCK), and ultimately the use of selective inhibitors and activating compounds specific for 
the kinase of interest in cell-based assays. Unfortunately, PKD was not included in this 
kinase screen as, surprisingly, it was not selected by Kinexus as being in the top 50 
candidate kinases for this site. However, given that PKD mediates the nuclear export of SK2 
(Ding et al, 2007), and Ser363 matches the PKD consensus motif (Nishikawa et al, 1997), 
PKD should also be included in future kinase validation assays. 
 
6.6.6 Examining phosphorylation sites as potential regulators of the pro-apoptotic 
role of SK2 
 
Any molecule that plays a role in mediating apoptosis must be appropriately regulated to 
ensure that this function is only activated when cell death is required. However, although 
SK2 has known roles in mediating cell death (Chipuk et al, 2012; Hofmann et al, 2008; 
Okada et al, 2005), the mechanisms through which this function is regulated are not clear. 
SK2 was previously proposed to possess a BH3 domain which can interact with Bcl-xL to 
mediate the intrinsic mitochondrial apoptosis pathway (Liu et al, 2003). However, these 
studies employed high level SK2 overexpression and so the physiological relevance of this 
domain, and how it may be regulated, remains to be addressed.  
 
It was of particular interest to determine if any of the uncharacterised SK2-specific 
phosphorylation sites within the unique central region were able to regulate the pro-
apoptotic role of SK2. Although preliminary, the results from these studies are suggestive 
that phosphorylation of Ser363 or Ser437 may act to prevent the pro-apoptotic function of 
SK2 (Figure 6.10). These assays will need to be repeated to validate these findings, 
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however, given that the localisation data suggests that Ser363 phosphorylation may promote 
SK2 nuclear export, it would be quite appropriate for Ser363 phosphorylation to also 
prevent cell death as SK2 has been previously shown to promote cell cycle arrest in the 
nucleus (Hait et al, 2009; Igarashi et al, 2003). This is purely speculative and considerable 
work will be required to validate these hypotheses.  
 
Furthermore, the data also suggest that phosphorylation at Ser398 or Ser441 may drive the 
pro-apoptotic role of SK2, as when these sites were mutated to alanine the percentage of 
apoptotic cells resembled that of the empty vector cells (Figure 6.10). Again, this will 
require further validation. Interestingly, Ser398 phosphorylation was previously detected on 
overexpressed SK2 by the Pitson Laboratory (Figure 6.1), however phosphorylation of this 
site has not been detected endogenously and has not been otherwise characterised.  
 
Upon future validation of these results, if the pro-apoptotic role of SK2 is in fact regulated 
by phosphorylation, it would be intriguing to examine how this regulation occurs. It could 
be likely to involve changes in subcellular localisation, which is critical for SK2 function 
(Siow & Wattenberg, 2011), and/or modulation of SK2 interacting with binding partners. It 
would also be interesting to determine if more than one site is involved in such regulation 
(as the preliminary data may suggest), and if so, whether they act in a co-ordinated manner 
or whether individual phosphorylation events could regulate slightly different functions of 
SK2, dependent on the pro-apoptotic stimuli presented. For example, SK2 is known to 
mediate cell cycle arrest in the nucleus (Hait et al, 2009; Igarashi et al, 2003), and apoptosis 
at the ER (Maceyka et al, 2005) and mitochondria (Chipuk et al, 2012; Liu et al, 2003), but 
it is unknown whether different regulatory mechanisms dictate where SK2-mediated cell 
death occurs in the cell. It would be very interesting to pursue this further. 
 
6.6.7 Phosphorylation of SK2 by GSK3 
 
Through collaboration with Dr. Adam Cole (Garvan Institute, Sydney), it was demonstrated 
that SK2 is a bona fide substrate of GSK3 in vitro and in cells (Figure 6.11). GSK3 is a 
ubiquitously-expressed proline-directed kinase with particularly high expression in the brain 
(Cole, 2012). Rather unusually, GSK3 is constitutively active in resting/unstimulated cells, 
and is in fact inhibited by a number of extracellular stimuli, including growth factors, 
insulin and serum (Kaidanovich-Beilin & Woodgett, 2011). Furthermore, GSK3 generally 
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requires another kinase to ‘prime’ its substrate in order to bind to and phosphorylate it 
(Kennelly & Krebs, 1991), however an acidic residue in place of a priming phosphorylation 
site can sometime suffice (Beurel et al, 2015). Previously reported priming kinases include 
cyclin-dependent kinase-5 (CDK-5), PAR-1 (microtubule affinity-regulating kinase; MARK 
in mammals), casein kinase 1 and 2 (CK1 and CK2), protein kinase A (PKA), and protein 
kinase C (PKC) (Kaidanovich-Beilin & Woodgett, 2011). 
 
In agreement with the constitutive activity of GSK3 in cells, there was evidence of basal 
phosphorylation of SK2 at Ser437 by endogenous GSK3, as application of the GSK3 
inhibitor CT99021 to cells, to prevent endogenous phosphorylation, resulted in a doubling 
of SK2 phosphorylation by recombinant GSK3 in vitro (Figure 6.11). This would imply that 
the ‘priming’ kinase must also be constitutively active, although it will need to be 
determined if this observed basal phosphorylation of SK2 is simply an artefact of 
overexpression. Such high cellular levels of SK2 protein could potentially facilitate basal 
phosphorylation at sites normally only phosphorylated under certain circumstances, for 
example when a priming kinase is activated. 
 
The concept of constitutive basal phosphorylation of SK2 by GSK3 is intriguing, and raises 
the possibility that de-phosphorylation of this site may also be an important regulatory 
mechanism of SK2. GSK3 is generally considered to be pro-apoptotic, as a number of 
GSK3 substrates that promote cell proliferation and survival are negatively regulated by 
GKS3-mediated phosphorylation (Cole, 2012; Sutherland, 2011). Furthermore, GSK3 can 
promote the intrinsic apoptosis pathway (Beurel & Jope, 2006). Perhaps basal GSK3 
phosphorylation suppresses the pro-survival/proliferative, oncogenic role of SK2. Or, if this 
phosphorylation event is not constitutive, then it is possible that GSK3 phosphorylation of 
SK2 might be triggered to promote the pro-apoptotic role of SK2. The preliminary apoptosis 
data is conflicting, where preventing SK2 phosphorylation of the GSK3 priming site Ser441 
by mutation to alanine appeared to prevent SK2-mediated apoptosis, whereas alanine 
mutation of the GSK3 phosphorylation site Ser437 seemed to enhance this function (Figure 
6.10). Hence, it will be interesting to validate the apoptosis data in order to examine the 
potential role of GSK3 in regulating the pro-apoptotic role of SK2.  
 
Notably, as shown in Figure 6.11B, SK2 protein expression levels substantially decreased 
upon use of the GSK3 inhibitor CT99021, and upon alanine substitution of the two residues 
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involved in GSK3 phosphorylation, Ser437 and Ser441. This may represent a novel role of 
GSK3-mediated phosphorylation in maintaining the stability of SK2 protein. Indeed, this 
has been previously observed for other GSK3 substrates, where phosphorylation of Axin by 
GSK3 results in increased Axin protein stability (Yamamoto et al, 1999), although the exact 
mechanisms are unclear but may involve the dissociation of Axin from Adenomatous 
Polyposis Coli (APC), resulting in less degradation of Axin (Pronobis et al, 2015; Takacs et 
al, 2008). Furthermore, it was proposed that GSK3-mediated phosphorylation of p130 
Retinoblastoma protein increases its stability when cells are undergoing quiescence, but this 
stabilisation of p130 does not appear to involve changes in proteasome-mediated 
degradation (Litovchick et al, 2004). It will therefore be of interest to further explore the 
possibility of GSK3-mediated SK2 protein stabilisation, and determine the mechanisms at 
play and how SK2 function might be affected. It should also be noted that the non-
phosphorylatable priming site mutant, S441A, resulted in 3-fold less phosphorylation of 
SK2 by GSK3 in vitro than the direct GSK3 site mutant S437A (Figure 6.11C). The reason 
for this is unclear but could potentially involve changes to SK2 conformation. 
 
Interestingly, while the GSK3 phosphorylation site Ser437 is conserved in SK2 across many 
mammalian species, including human, chimpanzee, dog, cow, mouse and rat, the priming 
phosphorylation site likely required by GSK3, Ser441 (in human), is divergent in some 
species (Figure 6.13A). Compared to the minimal consensus motif used by GSK3 (Beurel et 
al, 2015), mouse and rat SK2 do not possess a functional priming site, whereas bovine SK2 
acquired a threonine residue, and canine, chimpanzee and human possess a serine residue at 
this site (Figure 6.13A). Interestingly, the acquisition of a potentially functional priming 
phosphorylation site appears to have occurred in line with other evolutionary changes to the 
SK2 sequence, as demonstrated by a phylogenetic tree showing the relationships between 
SK2 sequences of the different species (Figure 6.13B). As there are no acidic residues in 
place of the serine/threonine to mimic a priming phosphorylation in rodents, it is unlikely 
that the GSK3 site is functional in these species, but this would require further examination. 
Therefore, similarly to Thr366 and Thr368, phosphorylation of SK2 by GSK3 at Ser437 
does not appear to be an evolutionarily conserved regulatory mechanism. Why SK2 has 
acquired additional phosphorylation sites in higher-order mammals, and whether these 
pertain to functions specifically involving the longer SK2b isoform not found in rodents, 




Human SK2 425 GDAPLSPDPLLSSPPGSPKAALHSPVSEGA 454
SxxxS
Mouse SK2 426 GDAPLSPDPLLPSSPNALKTAQLSPIAEGP 455
Rat SK2 426 GDAPLSPDPLLPSSPNAFKTAQLSPIAEGP 455
Bovine SK2 460 GDAPLSPDPLLPSPPGTPKAAQLSPISEGA 489
Canine SK2 528 GDAPLSPDPLLPSPPSSPKAALLSPITEGV 557
Chimpanzee SK2 506 DA---L--SDALSSPGSPKAALHSPVSEGA 535















Figure 6.13: Sequence alignment of SK2 from various species showing conservation of
the GSK3 phosphorylation and priming sites
A, Amino acid sequence alignment of SK2 is shown from human, chimpanzee, canine,
bovine, murine and rat SK2 sequences. The canonical SK2 sequences were used for all
species, except human where SK2a was used in order to keep numbering consistent. The
GSK3 phosphorylation site and the priming phosphorylation site are highlighted in red and
blue, respectively. The GSK3 minimal consensus motif is shown above. B, Phylogenetic
tree showing the evolutionary relationships of SK2 sequences between different species.
The ‘priming site’ residue for each species (from A) is overlayed. Sequence alignments and




Similarly to the S363A SK2 mutant, the non-phosphorylatable S437A and S441A mutants 
had higher catalytic activity than wildtype SK2 (Figure 6.12). Therefore, these data suggest 
that phosphorylation at these sites may act to decrease SK2 activity in cells, although further 
investigation is required to confirm that phosphorylation is in fact involved in these 
observed changes in SK2 activity. Given that the S363A mutant resulted in a similar 
phenotype (Figure 6.8), it will need to be determined whether these sites are all acting 
independently to regulate SK2, or whether there may be some interplay allowing the loss of 
one site to co-ordinately act on other sites.  
 
It is interesting to note that when overexpressed in cells, SK2 has four-fold less specific 
activity than SK1 (Roberts et al, 2004). Examining the kinetics of the SKs overexpressed in 
cells revealed that their Km values for sphingosine were equivalent, whereas the catalytic 
efficiency (kcat/Km) of SK1 is approximately 1.3-fold higher than that of SK2 (Billich et al, 
2003). Therefore, it is tempting to speculate that the naturally lower activity of SK2 may be 
due, at least in part, to this array of SK2-specific phosphorylation events within its unique 
central region that may act to lower its activity. The basal catalytic efficiency of non-
phosphorylated SK1 and SK2 made in E. coli have not previously been analysed together 
for comparison. Furthermore, the crystal structure of SK2 has not yet been solved, and as 
there is no sequence similarity of the ~130 residue proline-rich central domain to any other 
known protein, the conformation of this region and whether or not it could physically 
interact with and modulate the catalytic domains, cannot currently be determined. It is, 
however, predicted to be a disordered loop (Wang et al, 2014a). Nevertheless, it is rather 
fascinating to speculate that SK2 may have lower basal activity than SK1 as a result of its 
collection of regulatory phosphorylation sites. Whether the reason for this potential 
evolutionary downregulation of SK2 activity is because of its differential subcellular 
localisation and additional pro-apoptotic roles would require further investigation. 
 
Notably, in contrast to my findings, Hait et al previously reported that the S441A mutant 
had only 35% of the activity of wildtype SK2 (Hait et al, 2007), suggesting that 
phosphorylation of this site may increase SK2 activity. However, this previous study did not 
appear to normalise the activity of SK2 or the S441A mutant to their expression levels in the 
lysates, and since the S441A mutant does not express as well as wildtype SK2 (Figure 6.11 






The studies outlined in this chapter aimed to provide a better understanding of SK2 
regulation by phosphorylation. While, due to time constraints, some of these results are 
preliminary, they touch on the level of complexity of SK2 phosphorylation and provide a 
number of avenues to further investigate how SK2 localisation, function and activity may all 
be differentially regulated by different signalling pathways. What is clear is that there is still 
a substantial amount of work required to truly understand how these regulatory mechanisms 
are co-ordinated, and how they may be potentially manipulated in order to develop 




























































Chapter 7. General Discussion 
 
Despite first being identified almost two decades ago, the functions and regulation of SK2 
still remain rather poorly understood. Unlike SK1, which has well established roles in 
promoting cell survival, proliferation and oncogenesis (Newton et al, 2015; Pitson, 2011; 
Pyne & Pyne, 2010), SK2 has generally been perceived to be pro-apoptotic and to promote 
cell cycle arrest (Hait et al, 2009; Igarashi et al, 2003; Liu et al, 2003). However, conflicting 
evidence has emerged suggesting that SK2 can also play a role in cancer, as knockdown or 
inhibition of SK2 can reduce cancer cell growth and proliferation, and tumour growth in 
vivo (French et al, 2010; Liu et al, 2013; Panneer Selvam et al, 2015; Weigert et al, 2009). 
Despite this, at the beginning of the studies outlined in this thesis it still remained to be 
determined whether, like SK1, SK2 could in fact drive neoplastic transformation and 
tumourigenesis. Furthermore, the subcellular localisation of SK2 is thought to be critical for 
its functions, as the production of S1P at different organelles within the cell can induce 
varying functional outcomes (Siow & Wattenberg, 2011). Indeed, where SK1 is generally 
localised to the cytoplasm and plasma membrane, SK2 is often found localised to the 
nucleus, ER and mitochondria, suggesting that its additional functional complexity may 
arise from its localisation to these organelles. Therefore, given the clearly complex and 
poorly understood roles of SK2 in cancer, the goal of the studies outlined in this thesis were 
to interrogate the role of SK2 in promoting oncogenesis, as well as to better understand how 
SK2 is regulated and localised within the cell.    
 
 
7.1 SK2 can mediate oncogenesis 
 
Given that SK1 and SK2 both catalyse the production of S1P from sphingosine, and given 
that there is evidence of functional redundancy between these enzymes as demonstrated by 
individual genetic knockout of each gene (Allende et al, 2004; Mizugishi et al, 2005; 
Zemann et al, 2007), it would perhaps be expected that SK2 could mediate oncogenesis 
through S1P production like SK1. However, where overexpression of SK1 in NIH3T3 
mouse fibroblasts leads to neoplastic transformation of these cells (Xia et al, 2000), 
overexpression of SK2 in these cells had previously been shown to decrease proliferation 
and promote apoptosis (Igarashi et al, 2003; Liu et al, 2003; Maceyka et al, 2005). This was 
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not consistent with more recent reports hinting a role for SK2 in promoting cancer, through 
knockdown or inhibition of the endogenous protein, which suggested that perhaps a more 
physiological system needed to be employed to interrogate the true roles of SK2 in cancer.  
 
In this study, we were able to demonstrate that low, much closer to physiological levels of 
SK2 overexpression in NIH3T3 fibroblasts could induce neoplastic transformation in vitro 
and could promote tumour formation in vivo. This was a significant finding, as it is the first 
to finally confirm that SK2 can mediate oncogenesis and that the previously observed anti-
cancer effects of SK2 knockdown or inhibition are likely to be specific to SK2 and not the 
result of off-target effects or other affected downstream mediators. I also demonstrated that, 
consistent with previous findings, the subcellular localisation of SK2 seemed to change in 
line with its opposing functions. When overexpressed at low levels (10-fold over 
endogenous levels), there was a significant increase in plasma membrane-localised SK2, as 
well as a significant increase in extracellular S1P formation. Whereas when overexpressed 
at high levels (~400-fold over endogenous levels), SK2 was found more strongly localised 
to the nucleus.  
 
These findings highlight the importance of using physiologically relevant systems and tools 
to explore the roles of SK2. However, it is unclear whether the anti-proliferative, pro-
apoptotic functions of SK2 that have been proposed from studies using non-physiological 
high-level overexpression are real or artifacts of these systems. Indeed, there have been 
studies demonstrating that siRNA-mediated knockdown of endogenous SK2 in HEK293 
cells or MEFs prevented apoptosis induced by TNFα (Chipuk et al, 2012; Okada et al, 
2005). Similar results were observed upon staurosporine-induced apoptosis in mesangial 
cells taken from Sphk2-/- mice (Hofmann et al, 2008). These studies would suggest that SK2 
does have physiological roles in promoting apoptosis, however it cannot be ruled out that 
this function of SK2 may be cell type dependent (as two of the studies used renal cells) or 
may be more prevalent earlier in development (since human embryonic kidney cells and 
mouse embryonic fibroblasts were used). These studies reported endogenous SK2 
localisation to the nucleus and mitochondria (Chipuk et al, 2012; Okada et al, 2005), which 
is consistent, at least for nuclear-localisation, with reports from high-level overexpression 
studies of SK2 mediating cell cycle arrest and cell death (Igarashi et al, 2003; Okada et al, 
2005). However, it is unclear whether reports of overexpressed SK2 promoting apoptosis 
when localised to the ER (Maceyka et al, 2005), and inducing apoptosis through a putative 
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BH3 domain and interaction with Bcl-xL (Liu et al, 2003) are physiological roles of SK2 or 
artifacts of overexpression. High-level overexpression can mis-localise proteins and can also 
force protein-protein interactions that may otherwise not occur naturally (Berggard et al, 
2007; Lalonde et al, 2008). As many of the initial studies examining and characterising SK2 
function and localisation employed high-level overexpression systems, it seems necessary 
that as the roles of SK2 are appearing more complex, care will need to be taken to ensure 
that the systems and tools used to dissect SK2 functions are as physiological and relevant as 
possible.  
 
In this study, we demonstrated that low-level overexpression of the SK2a isoform can 
induce neoplastic transformation. SK2a is by far the best characterised SK2 isoform and is 
the isoform most commonly used in the literature. However, it would be of interest to 
examine whether the larger, human-specific isoform SK2b can also have the same effects. It 
was reported that SK2b is the predominant form of SK2 in various human tissues and cell 
lines, and serum deprivation resulted in increased expression of SK2b (Okada et al, 2005). 
Using high-level overexpression in HEK293 cells, it was shown that serum-withdrawal 
induced the translocation of SK2b to the nucleus in a small proportion of cells, and this 
coincided with a decrease in cell proliferation, whereas SK2a decreased cell proliferation in 
both the presence and absence of serum (Okada et al, 2005). It is tempting to suggest that 
this role of SK2a is an artifact of overexpression in this cell type, as it mediated cell cycle 
arrest even in the absence of any anti-proliferative stimuli, and we have shown that SK2a is 
capable of inducing neoplastic transformation. As SK2b seems to be the predominant 
isoform found in human cells, and as it only promotes cell cycle arrest upon stressful 
stimuli, perhaps it is the main isoform mediating cell death. It would therefore be of interest 
to determine whether SK2b can also localise to the plasma membrane to mediate 
oncogenesis, or whether this role is unique to SK2a. However, the relevance of SK2b being 
present in human cells but not in mice (Okada et al, 2005) is still unclear, but this would 
suggest that SK2a must be capable of fulfilling all of the functions SK2 is required to 
perform. Additional roles unique to SK2b, if any exist, remain to be elucidated. Of note, it 
was previously demonstrated, using SK2b, that the N-terminus of SK2 (residues ~1-175) 
contains a lipid binding domain that can interact with phosphoinositides and facilitate 
localisation of SK2 to intracellular membranes and the nucleus (Don & Rosen, 2009). 
Although similar characterisation of lipid binding was not performed using SK2a, it appears 
that deletion of more than the first 77 amino acids is required to completely abrogate lipid 
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binding of SK2b (Don & Rosen, 2009), suggesting that the first 36 residues unique to SK2b 
are alone unlikely to mediate these interactions and that this lipid binding domain may also 
be present in SK2a. 
 
 
7.1.1 Managing a double-edged sword in cancer 
 
Since the discovery of the first SK2-selective inhibitor, ABC294640, there has been an 
interest in targeting SK2 in cancer. Indeed, pharmacologically targeting SK2 has been found 
to have anti-cancer effects in many different human xenograft models in mice (French et al, 
2010; Liu et al, 2013; Panneer Selvam et al, 2015). As such, ABC294640 (Yeliva®) is 
currently in clinical trials for patients with advanced solid tumours and refractory/relapsed 
diffuse large B-cell lymphoma, with plans to soon commence trials for patients with 
multiple myeloma and advanced hepatocellular carcinoma. However, as discussed further 
below, ABC294640 has since been reported to target other proteins and enzymes in addition 
to SK2, such as dihydroceramide desaturase (Des1) (McNaughton et al, 2016). 
Nevertheless, the literature would suggest that targeting SK2 in cancer cells and in vivo 
models is therapeutically beneficial; however there has been very little mechanistic data to 
explain why such outcomes would be expected from targeting an enzyme that is generally 
considered to be pro-apoptotic.  
 
Our findings here demonstrating that SK2 can induce neoplastic transformation provide the 
first solid evidence that SK2 plays an important role in carcinogenesis, and validate the use 
of SK2-targeting agents in cancer. However, many questions now remain to be elucidated. 
What is the functional relevance of low-level SK2 overexpression, and why does it mediate 
oncogenesis when high-level overexpression does not? I found that SK2 is significantly 
upregulated in some human cancers, although this was generally a rather modest 
upregulation and certainly SK2 is not found to be upregulated as frequently as SK1 (Rhodes 
et al, 2004). It is tempting to speculate that due to the additional physiological pro-apoptotic 
roles of SK2, it would not be advantageous for a cancer cell to have SK2 upregulated too 
much, unlike SK1 and other known cancer-promoting proteins that have only pro-
proliferative roles. It is then of interest to know, what is the critical ‘tipping-point’ level of 
SK2, below which it is oncogenic but above which it would induce cell death? My studies 
would perhaps suggest that this point is somewhere between 10- and 20-fold above 
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endogenous levels, as 10-fold overexpression induced oncogenic signalling and efficient 
tumour formation in vivo, whereas 20-fold overexpression did not. This is, however, still an 
artificial system and whether this would translate to a physiological setting is unclear, but 
such levels of SK2 overexpression have certainly not been reported in human cancer patient 
samples.  
 
It is interesting to consider that the exact level of SK2 that represents the ‘tipping-point’ will 
likely be tissue- and cell-type dependent, based on the basal, normal expression of SK2 in 
that tissue. In fact, it is rather intriguing to note that there seems to be a correlation between 
the normal level of SK2 expression in a given tissue and whether SK2 will be up- or down-
regulated, or unchanged, in cancers that develop from that tissue. For example, in tissues 
where SK2 is relatively highly expressed, such as the kidney and liver (Liu et al, 2000), SK2 
expression is actually commonly downregulated in cancers of those tissues (Figure 7.1). 
This could suggest that the pro-apoptotic role of SK2 may be more prevalent or ‘primed’ in 
these tissue types. Indeed, the physiological role of SK2 in mediating cell death has been 
demonstrated using renal cells (Hofmann et al, 2008; Okada et al, 2005). On the other hand, 
SK2 has been found to be significantly upregulated in cancers that have developed from 
tissues where SK2 is not as highly expressed, such as breast and esophagus (Figure 7.1). 
This may suggest that SK2 has more of a pro-proliferative, pro-survival role in these tissue 
types and may represent a promising target in these cancers.  
 
However, this trend was not observed for all cancers where a significant up- or 
downregulation of SK2 had been reported (i.e. colon; Figure 7.1). Of course, there is likely 
to be other factors at play in addition to SK2 expression levels, for example where SK2 is 
localised within the cell and the concurrent up- or downregulation of proteins involved in 
SK2 regulation, such as IC-1. Nevertheless, it is likely that the balance between the 
opposing roles of SK2 may vary in different tissues, and as suggested by Figure 7.1, this 
may result in different changes to SK2 expression in cancer which could potentially have 
implications in the benefits of targeting SK2 in certain cancers. Clearly much work is still 
required to understand the interplay between the opposing roles of SK2 in different tissues, 
however this knowledge may be the key to understanding which cancers will respond best 
to SK2 inhibition. 
 
Figure 7.1: Relative expression of SK2 in normal tissues compared with correspond-
ing cancerous tissues 
Heat maps showing SK2 mRNA levels in various normal human tissues (left), and fold-
changes in SK2 mRNA levels in cancerous tissues (right). Data were extracted from the 
Oncomine database; median SK2 expression in normal tissues (log2 median-centred in-
tensity) was taken from the Roth Normal 2 dataset, and significant (p<1x10-4) changes in 
SK2 expression levels in cancerous tissues (fold-change compared with normal tissues) 
were extracted from the following datasets: Gumz Renal, Mas Liver, Finak Breast, TCGA 
Colorectal and Kim Esophagus. Heat maps were generated using Morpheus online soft-
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Further studies will be required to determine the effects of low- and high-level SK2 
overexpression and why they mediate different functional outcomes. Overexpression in this 
system is of course not physiological, but if we can use it as a tool to identify the changes 
that are occurring to the regulatory mechanisms governing SK2 function and localisation, in 
settings where SK2 is oncogenic or pro-apoptotic, then we can further examine these 
mechanisms in systems that are more physiologically relevant. Although SK2 upregulation 
in cancer has not been observed as high as 10-fold or even 5-fold over endogenous levels, 
overexpression at these levels still triggered the oncogenic role of SK2 suggesting that the 
physiological changes and mechanisms that regulate this role were activated. A change in 
SK2 subcellular localisation in favour of the plasma membrane was observed, but other 
mechanisms could potentially include changes to SK2 post-translational modifications 
and/or protein-protein interactions. Therefore, it would be of interest to use this system of 
graded SK2 overexpression in the future to isolate SK2 protein from the various cell lines 
and perform mass spectrometry to identify phosphorylated residues, as well as use methods 
to identify novel SK2-interacting proteins such as rapid immunoprecipitation mass 
spectrometry of endogenous protein (RIME). 
 
This knowledge would be very insightful, as I hypothesize that a different subset of the 
uncharacterised sites on SK2 will become phosphorylated to mediate its oncogenic role, 
whereas different phosphorylation sites will facilitate its pro-apoptotic role. Similarly, SK2 
may interact with specific proteins to mediate oncogenesis but may switch to interact with 
other proteins when it is triggered to promote cell death. This could potentially explain why 
high-level overexpression results in the pro-apoptotic role of SK2 becoming dominant, as 
overexpression can force phosphorylation events and protein-protein interactions to occur in 
the absence of their normal stimuli. Therefore, in a system with high-levels of SK2, 
inadvertently triggering cell death would likely override any other potentially pro-
proliferative signals that are simultaneously activated. Understanding such regulatory 
mechanisms governing SK2, and their distinct roles in the interplay between oncogenesis 
and cell death, would be a major step forward in understanding this complex enzyme, and 
would uncover new ways in which SK2 function could be targeted in cancer. 
 
It is interesting to note that there are reports of other proteins within the cell that also have 
anti-proliferative functions, and yet have been found to be physiologically overexpressed in 
cancer and linked with higher-grade tumours. The p16Ink4a protein is generally considered a 
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tumour suppressor that has widely studied roles in negatively regulating cell cycle 
progression, by inhibiting S phase (Romagosa et al, 2011). However, it has been 
documented that, where anti-proliferative p16Ink4a would normally be expressed at lower 
levels and localised to the nucleus, in some cancers p16Ink4a has been found overexpressed 
and localised more to the cytoplasm (Evangelou et al, 2004). This increased ratio of 
cytoplasmic:nuclear localisation of p16Ink4a has been linked to poorer prognosis in some 
cancers (Romagosa et al, 2011), and interestingly, the increased accumulation of 
‘oncogenic’ p16Ink4a in the cytoplasm has been attributed to altered post-translational 
modifications and interactions with other proteins (Nilsson & Landberg, 2006; Souza-
Rodrigues et al, 2007). Although this scenario does not involve high-level overexpression 
like that used for SK2, it does demonstrate that increased levels of a protein can cause it to 
undergo changes in subcellular localisation, in response to altered modifications and 
interacting-partners, to perform a completely opposing function, as hypothesized for SK2. 
Notably, other proteins such as p27, PTEN and protein arginine methyltransferase 5 
(PRMT5) have also been documented to undergo translocations to different subcellular 
compartments in cancer settings, in order to perform other secondary functions (Gu et al, 
2012; Kim et al, 2009; Lobo et al, 2008). As SK2 has been shown to have physiological 
roles in mediating cell death, without the use of high-level overexpression (Chipuk et al, 
2012; Hofmann et al, 2008; Okada et al, 2005), it is tempting to speculate that the primary 
house-keeping function of SK2 may be to mediate cell cycle arrest and cell death but 
overexpression in cancer may provide additional oncogenic roles in different cellular 
compartments.    
 
In fact, there are many known examples of ‘moonlighting’ proteins – proteins that possess a 
primary function but appear to have evolved to perform additional, diverse secondary 
functions (Jeffery, 2003). Often these proteins carry out their secondary functions at 
different subcellular locations. In this sense, SK2 could be considered a moonlighting 
protein, as it appears to share some functional redundancy with SK1, but unlike SK1, it also 
appears to have acquired an additional pro-apoptotic function, likely facilitated by the 
additional unique N-terminal and central domains in its sequence. Often the secondary 
functions of moonlighting enzymes do not require their primary catalytic function (Jeffery, 
2003). However, in the case of SK2, the role of S1P production in mediating its roles in cell 
death has not been properly interrogated, for example through the use of the catalytically 
inactive G212D mutation. It has been suggested that catalytic activity is not required for the 
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induction of apoptosis via the putative BH3 domain of SK2, however disrupting SK2 
activity whilst maintaining the BH3 domain via use of an N-terminal truncated form of SK2 
reduced the levels of apoptosis by 50% (Liu et al, 2003).  
 
 
7.2 The role of dynein in regulating SK2 subcellular localisation 
 
In these studies, I have demonstrated that SK2 interacts physiologically with the 
cytoplasmic dynein motor complex, and further, that this interaction appears to mediate the 
retrograde-directed transport of SK2. For an enzyme whose subcellular localisation has a 
significant impact on its functions, uncovering mechanisms by which SK2 is localised 
within the cell provides a considerable step forward in better understanding SK2. 
 
Despite attempts to characterise the specific binding site of SK2 on dynein IC-2, I was 
unable to conclusively determine where SK2 interacts. This will require future 
characterisation, as understanding where SK2 binds to the dynein complex will potentially 
provide insights into how this interaction is regulated. IC-2 was first identified as a putative 
SK2-interacting protein from a yeast two-hybrid screen, as a 173 amino acid C-terminal 
truncated fragment (residues 440-612 of IC-2). Therefore, it would perhaps be expected that 
SK2 would interact with the C-terminus of IC-2. However, this region of dynein IC contains 
multiple WD40 repeat domains that fold into a beta propeller structure, and it is where IC 
forms an interaction with the HC subunit (Vale, 2003). Furthermore, no cargo of the dynein 
complex have previously been found to bind to the C-terminal end of IC; all previously 
identified cargo interact with the IC N-terminus or via regulators such as dynactin, which 
also binds IC at the N-terminus (Pfister, 2015). Indeed, yeast do possess both dynein and 
dynactin complexes (Pfister et al, 2006; Schroer, 2004), and so it cannot be ruled out that 
endogenous subunits may have facilitated a bridging of the interaction between the bait, 
SK2, and the prey, C-terminal IC-2, to produce a positive interaction. As dynein HC subunit 
dimers bind two IC subunits (Kardon & Vale, 2009), it is possible that a yeast HC dimer 
may have bound one endogenous full-length IC as well as truncated prey IC-2, where bait 
SK2 could have then interacted with the N-terminus of the full-length IC to activate 
transcription (yeast IC protein, known as Pac11, shares 44% amino acid sequence similarity 
with human IC-2C, and yeast HC shares 62% amino acid sequence similarity with human 
dynein HC). Hence, optimizing methods to examine the interaction in vitro using purified 
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recombinant proteins will be insightful. Of course, it is also possible that SK2 does interact 
with the C-terminus of IC, as the beta propeller structure of the WD40 repeat domains is 
such that it may be able to interact with other proteins as well as the HC (Vale, 2003). This 
would be a novel finding and will require further investigation. 
 
 
7.2.1 The involvement of IC-1 versus IC-2: roles in brain function and disease 
 
Intriguingly, I found that SK2 seems to interact more robustly with the IC-1 isoform 
compared with the IC-2 isoform. This observation may hint at where SK2 interacts within 
the IC sequence; IC-1 and IC-2 share 76% amino acid sequence identity, but the majority of 
the differences within their sequences come from the N-termini (Figure 7.2). Therefore, the 
fact that differential binding was observed between SK2 and these two isoforms may 
suggest that SK2 interacts with a sequence within the N-terminus of IC-1 that is more 
divergent in IC-2, and therefore results in a less prevalent interaction. However, it is also 
possible that the interaction between SK2 and IC may not be constitutive and may be 
regulated by isoform-specific post-translational modifications or other interacting regulatory 
proteins, thus altering the preference for SK2 binding to IC-1 over IC-2.  
 
Isoform-specific phosphorylation sites have been reported for the dynein ICs, which may 
confer selectivity in their binding-partners. A number of phosphorylation events have been 
detected on IC-2 by mass spectrometry, all of which are restricted to the N-terminal half of 
the protein and most occur within the serine-rich region (residues 80-105) (Lo et al, 2006), 
with others found spanning the IC dimerisation domain and light chain binding sites 
(Hornbeck et al, 2015). IC-1 was also found to be phosphorylated at a number of these 
conserved sites within the serine-rich region, but interestingly, IC-1 is also phosphorylated 
at additional sites not conserved in IC-2, found within regions flanking the light chain 
binding sites and the IC dimerisation domain (Ser148, Thr159, Ser162), and notably, at the 
C-terminus (Ser618; see Figure 7.2) (Hornbeck et al, 2015). Again, given that SK2 seems to 
bind differentially to IC-1 and IC-2, it will be of interest to investigate the potential role of 
isoform-specific IC phosphorylation on SK2 binding. Indeed, isoform-selective cargoes 
have been reported previously, where dynein complexes containing the isoform IC-1B (see 
section 1.4.3 and Figure 1.10 in Chapter 1 for a description of IC splice isoforms) were 
more likely than complexes containing IC-2C to transport Rab7-containing endosomes and
208 
 
IC-1B  MSDKSDLKAELERKKQRLAQIREEKKRKEEERKKKEADMQ-QKKEPVQDDSDLDRKRRET   59  
IC-2C  MSDKSELKAELERKKQRLAQIREEKKRKEEERKKKETDQKKEAVAPVQEESDLEKKRREA   60 
 
IC-1B  EALLQSIGISPEPPLVPTPMSPSSKSVSTPSEAGSQDSGDLGPLTRTLQWDTDPSVLQLQ  119  
IC-2C  EALLQSMGLTPESPIVPPPMSPSSKSVSTPSEAGSQDSGDGAVGS---------------  105  
 
IC-1B  SDSELGRRLHKLGVSKVTQVDFLPREVVSYSKETQTPLATHQSEEDEEDEEMVESKVGQD  179  
IC-2C  -----RRGPIKLGMAKITQVDFPPREIVTYTKETQTPVMAQPKEDEEEDDDVVAPKPPIE  160  
 
IC-1B  SELENQ--DKKQEVKEAPPRELTEEEKQQILHSEEFLIFFDRTIRVIERALAEDSDIFFD  237  
IC-2C  PEEEKTLKKDEENDSKAPPHELTEEEKQQILHSEEFLSFFDHSTRIVERALSEQINIFFD  220  
 
IC-1B  YSGRELEEKDGDVQAGANLSFNRQFYDEHWSKHRVVTCMDWSLQYPELMVASYNNNEDAP  297  
IC-2C  YSGRDLEDKEGEIQAGAKLSLNRQFFDERWSKHRVVSCLDWSSQYPELLVASYNNNEDAP  280  
 
IC-1B  HEPDGVALVWNMKFKKTTPEYVFHCQSSVMSVCFARFHPNLVVGGTYSGQIVLWDNRSHR  357  
IC-2C  HEPDGVALVWNMKYKKTTPEYVFHCQSAVMSATFAKFHPNLVVGGTYSGQIVLWDNRSNK  340  
 
IC-1B  RTPVQRTPLSAAAHTHPVYCVNVVGTQNAHNLITVSTDGKMCSWSLDMLSTPQESMELVY  417  
IC-2C  RTPVQRTPLSAAAHTHPVYCVNVVGTQNAHNLISISTDGKICSWSLDMLSHPQDSMELVH  400  
 
IC-1B  NKSKPVAVTGMAFPTGDVNNFVVGSEEGTVYTACRHGSKAGIGEVFEGHQGPVTGINCHM  477  
IC-2C  KQSKAVAVTSMSFPVGDVNNFVVGSEEGSVYTACRHGSKAGISEMFEGHQGPITGIHCHA  460  
 
IC-1B  AVGPIDFSHLFVTSSFDWTVKLWTTKHNKPLYSFEDNADYVYDVMWSPVHPALFACVDGM  537  
IC-2C  AVGAVDFSHLFVTSSFDWTVKLWTTKNNKPLYSFEDNADYVYDVMWSPTHPALFACVDGM  520 
 
IC-1B  GRLDLWNLNNDTEVPTASVAIEGASALNRVRWAQAGKEVAVGDSEGRIWVYDVGE-LAVP  596  
IC-2C  GRLDLWNLNNDTEVPTASISVEGNPALNRVRWTHSGREIAVGDSEGQIVIYDVGEQIAVP  580 
 
IC-1B  HNDEWTRFARTLVEIRANRADSEEEGTVELSA                              628  





























Figure 7.2: Sequence alignment of human IC-1 and IC-2 
Amino acid sequence alignment of the human IC-1B and IC-2C isoforms (performed using 
the Clustal Omega program via UniProt). Regions containing identical residues between the 
two isoforms are highlighted in grey. Phosphorylation events that have been detected on 
human IC-1 by mass spectrometry are circled; red denotes those that have also been 
detected on IC-2, green denotes phosphorylation sites unique to IC-1. 
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signalling endosomes containing the transmembrane neurotrophin receptor kinase, TrkB 
(Ha et al, 2008; Mitchell et al, 2012). On the other hand, dynein complexes containing the 
IC-2C isoform were more likely to associate with mitochondria than complexes containing 
IC-1B (Mitchell et al, 2012).  
 
The physiological relevance of SK2 interacting more robustly with IC-1 remains to be 
determined. IC-1 is, at least in mouse and rat, a predominantly neuronal-specific isoform 
(Kuta et al, 2010; Myers et al, 2007). Very few studies, however, have examined human IC-
1 tissue expression and distribution, but IC-1 expression has been detected in many non-
neuronal human tissues (Horikawa et al, 2001). Therefore, it is unclear whether the 
interaction between SK2 and IC-1 has a particularly important function in the brain, or 
whether it is a ubiquitous interaction also involving IC-2 and occurring equally in all cells 
and tissues. It is believed that the additional expression of IC-1 isoforms in neuronal cells, in 
addition to ubiquitously expressed IC-2, is to compensate for the higher demand and longer 
distances required to travel and transport cargo along axons (Pfister, 2015). Given that SK2 
is transported or sequestered by dynein in HeLa cells (Figure 5.8), and that HeLa cells do 
not have any detectable IC-1 protein (Figure 5.7 and Palmer et al, (2009)), this would 
suggest that perhaps the interaction between SK2 and dynein is ubiquitous. However, as 
SK2 is the major SK isoform expressed in the brain and is responsible for the majority of 
S1P production here (Blondeau et al, 2007; Couttas et al, 2014), it is possible that SK2 may 
require additional regulation, above that provided by ubiquitous IC-2, in this setting.  
 
Dynein is the major molecular motor responsible for retrograde axonal transport of cargoes, 
and is indispensable for the maintenance of healthy neurons and the nervous system 
(Hirokawa et al, 2010). Consequently, defects in dynein complex function have been linked 
to a plethora of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, 
Huntington’s disease and motor neuron diseases, as well as many other disorders that are 
caused by defects in other components that regulate dynein-mediated transport (Eschbach & 
Dupuis, 2011). Notably, a number of different mutations in the cytoplasmic dynein heavy 
chain gene have been found in human patients that possess a range of neurological 
abnormalities (Schiavo et al, 2013).  
 
SK2 has also been implicated in neurodegeneration, specifically in Alzheimer’s disease, the 
most common form of dementia. Conflictingly, SK2 activity has been reported as 
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significantly upregulated in the brains of Alzheimer’s disease patients (Takasugi et al, 
2011), whereas more in-depth stratification of Alzheimer’s disease progression 
demonstrated a decrease in SK2 activity with increased disease severity (Couttas et al, 
2014). The reasons for this discrepancy are unclear, but may reflect the samples and 
preparation methods used; one study measured SK2 activity normalised to SK2 protein 
levels from Tris-soluble fractions isolated from frontal cortices of diseased and non-diseased 
patients (Takasugi et al, 2011), whereas the other study examined SK2 activity from total 
homogenates of hippocampus and temporal grey matter tissues from patients with varying 
stages of disease (Couttas et al, 2014).  
 
The pathogenesis of Alzheimer’s disease is typically thought to involve two lesions, 
amyloid plaques – extracellular aggregates containing Aβ peptides – and neurofibrillary 
tangles composed of intracellular hyperphosphorylated Tau aggregates (Blennow et al, 
2006; Scheltens et al, 2016). Interestingly, inhibition or downregulation of SK2 in mouse 
neuronal cells resulted in decreased proteolytic activity of BACE1, the rate-limiting enzyme 
for Aβ production, and decreased levels of secreted Aβ (Takasugi et al, 2011). In line with 
this, S1P was found to directly interact with BACE1 and increase its activity (Takasugi et al, 
2011). BACE1 contains a transmembrane domain and shuttles between the cell surface, the 
endosomal pathway and the trans-Golgi network (Walter et al, 2001). Dynein mediates the 
retrograde transport of BACE1 to the lysosomes for degradation, hence reducing Aβ 
production (Ye & Cai, 2014). It is therefore intriguing to speculate that disruption of 
dynein-mediated retrograde axonal transport may contribute to the development of 
Alzheimer’s disease through both an accumulation of BACE1 protein as well as a reduction 
in retrograde transport of SK2, potentially resulting in increased SK2 and S1P at the 
membrane to facilitate BACE1 activity and Aβ production. Hence, SK2 may represent a 
promising therapeutic target in Alzheimer’s disease, but the mechanisms involved and the 
potential interplay with dynein will require further investigation. 
 
The downregulation of IC-1 in human cancers had not been previously reported, but 
strikingly, by mining publically available datasets I found IC-1 to be significantly 
downregulated in a range of difference cancer types. The highest level of downregulation 
was found in brain cancers, which is perhaps not surprising as it is where it has the highest 
expression in normal tissue (Horikawa et al, 2001). However, the relevance of IC-1 
downregulation in other cancer types is unclear as, although it is found to be expressed in 
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other human tissues (Horikawa et al, 2001), it has been generally considered to be neuronal-
specific in mouse and rat. Therefore, future studies will be required to examine the role of 
IC-1 in other human tissues, and specifically, to identify whether the interplay between IC-1 
downregulation and increased SK2 plasma-membrane localisation observed in GBM is also 
recapitulated in other cancer types. If it is, then this will add another layer of complexity in 
identifying cancer types where SK2 may represent a valid therapeutic target, as altered 
subcellular localisation may be as equally an important factor as overexpression. 
 
 
7.2.2 Does dynein also interact with and regulate SK1? 
 
The studies described here have focused on the interaction and regulation of SK2 with 
dynein, as dynein IC was identified in a yeast two-hybrid screen using SK2 as the bait. 
However, it will be of interest in the future to determine whether dynein can also interact 
with and regulate SK1. My data demonstrating that re-expression of IC-1 in GBM cells 
resulted in reduced extracellular S1P formation even in the presence of a potent SK1-
specific inhibitor suggests that only SK2 is being translocated by dynein, at least in this 
system. However, as SK2 is the most highly expressed SK isoform in the brain (Blondeau et 
al, 2007), it cannot be ruled out that my observations in this system were biased toward 
SK2, whereas there may be other ‘housekeeping’ roles of dynein in transporting both SK1 
and SK2 in other cell types. Moreover, the roles of dynein in regulating SK2 explored in 
Chapter 5 may be specific to a cancer setting, whereas other ‘housekeeping’ roles may exist 
in normal cells.  
 
 
7.2.3 Are other cellular processes regulated by this interaction? 
 
Due to time constraints, I was unable to delve further into the characterisation of the 
interaction between dynein and SK2, the mechanisms that regulate the interaction, and 
potential additional factors and processes that may be involved. However, from the 
literature, it appears that there are various overlapping functions shared between SK2/SK1 
and dynein, posing the question of whether the interaction between these proteins may act to 




It would be interesting to investigate the potential involvement of EGF and its receptor 
EGFR in the functional effects of SK2 and dynein interactions, as both SK2 and dynein are 
integral to EGFR signalling outcomes. SK2 has been shown to localise to the plasma 
membrane in MDA-MB-453 breast cancer cells, where it was required for the migration of 
these cells towards EGF (Hait et al, 2005). Furthermore, SK2 was found to be required for 
EGF-induced cancer cell invasion, a process involving S1P production and phosphorylation 
of ERM proteins (Adada et al, 2015). Therefore, SK2 appears to play important roles in 
mediating EGF-dependent signalling to promote cell migration and invasion, which may 
have implications in the metastasis of cancer cells. EGF has been found to activate SK2 
localised to the membrane fraction in cells (Hait et al, 2005), and notably, EGF stimulated 
an increase in S1P secretion from GBM stem cells, which was found to play a role in 
maintaining their proliferation and stemness (Marfia et al, 2014). Approximately 50% of 
GBM patient tumours possess amplification of EGFR (across all GBM subtypes, for the 
Classical subtype alone it is as high as 95%) (Verhaak et al, 2010), making EGF/EGFR an 
important signalling axis in GBM.  
 
Dynein also plays an important role in EGF signalling. Dynein IC-2 is phosphorylated by 
ERK1/2 at Ser81 in response to EGF (Pullikuth et al, 2013), and this phosphorylation event 
recruits dynein to signalling endosomes (Mitchell et al, 2012). Dynein mediates the 
transport of internalised, activated EGFR through the endosomal pathway to the lysosomes 
for degradation (Garrett et al, 2014; Taub et al, 2007). Indeed, mutations in the dynein 
heavy chain result in sustained EGF/MAPK signalling (Garrett et al, 2014). It is therefore 
possible that the highly significant downregulation of IC-1 in GBM patient samples 
observed in my studies may result in reduced dynein function and sustained signalling of 
both SK2, which is critical for aspects of EGF signalling, and EGFR at the cell periphery, 
working in concert with EGFR upregulation to mediate pro-proliferative signalling. Thus, it 
would be of interest to examine EGF/EGFR signalling and degradation, and EGF-induced 
cell migration and invasion in the U-251 cell lines ectopically expressing IC-1, or the 
control cells, to examine potential co-localisation of SK2 with EGFR.  
 
Dynein has well characterised roles in mediating endocytic trafficking and autophagy, 
which are particularly important for maintaining healthy functioning neurons. Dynein 
mediates the retrograde-directed transport of late endosomes and enhances 
endosomal/lysosomal membrane trafficking (Cai et al, 2010). The molecular motor also 
213 
 
mediates important aspects of autophagy, as it is critical for the movement of 
autophagosomes towards lysosomes, which are usually localised in close proximity to the 
centrosome (Kimura et al, 2008), and for autophagosome-lysosome fusion (Ravikumar et al, 
2005). Notably, many of the neurological diseases described above that develop in response 
to mutations or defects in dynein function are found to have defective autophagy or protein 
aggregate-clearance pathways (Eschbach & Dupuis, 2011), and hence, it is critical that these 
pathways are well understood and characterised. 
 
The SKs have been implicated in regulating endocytic trafficking, although the exact 
mechanisms involved are still being elucidated. It is accepted that the balance of lipids such 
as cholesterol and sphingolipids in the cell membrane can affect endocytic trafficking 
processes, and experimental perturbations to these lipid compositions can induce endocytic 
trafficking (Shen et al, 2014). Addition of sphingosine and sphingosine-like molecules were 
found to induce endocytosis and fusion of vesicles to form enlarged late endosomes, and 
this endosomal fusion was found to be dependent on SK1 but, surprisingly, independent of 
its catalytic activity (Lima et al, 2017; Young et al, 2016). However, later stages of the 
endocytic pathway involving endosomal maturation and processing were found to be 
dependent on SK1 activity (Young et al, 2016). Furthermore, SK1 was found to co-localise 
with early and late endosomes, as well as autophagosomes in neurons, where it was found to 
mediate autophagy in a manner dependent on S1P production (Moruno Manchon et al, 
2015). In another study, both SK2 and SK1 were found to localise to early endocytic 
intermediates, and both were shown to be required for recycling of transferrin-containing 
endosomes (Shen et al, 2014). However, specifically SK2, but not SK1, was implicated in 
S1P production in multivesicular endosomes to constitutively activate associated S1P 
receptors to mediate endosome maturation, cargo sorting and exosomal release of vesicles 
(Kajimoto et al, 2013).  
 
It should be noted that the studies implicating only SK1 in regulating endocytic trafficking 
did not actually examine SK2, but they did note that SK2 is likely to share compensatory 
functions (Lima et al, 2017; Young et al, 2016). There is additional literature to suggest an 
involvement of SK2 in autophagy, as inhibition of SK2 induced autophagic cell death in 
kidney, prostate and breast cancer cell lines (Beljanski et al, 2010), as well as in T-cell acute 
lymphoblastic leukemia (T-ALL) cell lines (Evangelisti et al, 2014). The same autophagic 
mechanism of cell death was also observed in kidney carcinoma cells in vivo when an SK2 
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inhibitor was administered (Beljanski et al, 2010). However, care must be taken in 
interpreting these data, as both inhibitors used in these studies, ABC294640 and ROME, 
are, like most other SK inhibitors, sphingosine-like molecules (French et al, 2010; Lim et al, 
2011). Therefore, as discussed above, the lipid-like nature of these drugs may perturb the 
balance of lipids in cellular membranes, resulting in a non-physiological induction of vesicle 
and endosome formation and trafficking (Lima et al, 2017; Shen et al, 2014; Young et al, 
2016). Furthermore, ABC294640 has many known targets in addition to SK2 (Pitman et al, 
2016). Nevertheless, it is clear that the SKs play a role in endocytic trafficking and 
autophagy, and whether there is crosstalk between the SKs and dynein in regulating these 
processes remains to be examined. 
 
SK2 has also been previously implicated in cell cycle regulation, a cellular process that 
dynein plays important roles in mediating (Kardon & Vale, 2009). SK2 has been implicated 
in promoting cell cycle arrest in the nucleus (Igarashi et al, 2003), and it was shown that 
S1P produced by SK2 in the nucleus can alter epigenetic modifications at the promoter of 
the gene encoding cyclin-dependent kinase inhibitor p21, resulting in its increased 
transcription (Hait et al, 2009). However, my co-localisation studies did not demonstrate a 
specific strong interaction between SK2 and dynein in the nucleus, as one would expect if 
they interact to perform functions involving the cell cycle. Although, as I did not examine 
synchronized cells or particular phases of the cell cycle, this may not have been apparent in 
my system.  
 
In addition, the SKs were previously reported to localise to the centrosome, in conjunction 
with S1P5, and it was suggested that they may play a role in regulating mitosis here, 
although this has not specifically been examined (Gillies et al, 2009). Dynein accumulates at 
the centrosome, being the main microtubule organizing centre in metazoan cells (Barker et 
al, 2016), and may therefore interact with SK2 there, or transport SK2 there under certain 
conditions. Indeed, I did observe co-localisation of SK2 and dynein IC at distinct peri-
nuclear regions, however due to time constraints I was not able to examine potential co-
staining with specific organelle markers. The involvement of S1P5 is intriguing, as its 
expression is mostly restricted to brain and skin (Anliker & Chun, 2004), and interestingly 
its expression levels have been found to correlate significantly with poorer survival in GBM 
patients (Quint et al, 2014). Therefore, the potential intracellular role of S1P5 in modulating 
cell cycle in GBM, and any involvement of SK2 and dynein in this process, could warrant 
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further investigation. Indeed, a very recent mechanistic study has reported that S1P, 
signalling extracellularly via S1P5, can activate the PI3K-AKT pathway and polo-like kinase 
1 to promote mitotic progression, which in the case of exogenous S1P addition or SK 
overexpression, overrides the spindle assembly checkpoint and results in chromosome 
segregation defects (Andrieu et al, 2017). There is evidence to suggest that dysregulation of 
the mitotic-spindle checkpoint can promote aneuploidy, a form of genetic instability 
commonly observed in cancers, termed chromosomal instability (CIN) (Bharadwaj & Yu, 
2004; Jallepalli & Lengauer, 2001). Therefore, these findings have interesting implications 
in cancer, where the SKs are often upregulated (Heffernan-Stroud & Obeid, 2013; Neubauer 
et al, 2016), and increased S1P production may therefore give rise to increased CIN, a 
known driver of tumourigenesis (Jallepalli & Lengauer, 2001). In this study it was shown 
that both SK1 and SK2 can play an equivalent role in this S1P-mediated effect, despite the 
paper focusing predominantly on SK1 (Andrieu et al, 2017). However, an intracellular role 
for S1P5 at the centrosome still remains to be explored. Notably, a role for nuclear S1P2 in 




7.3 Regulation of SK2 by phosphorylation 
 
The studies outlined in Chapter 6 aimed to examine SK2 regulation by novel, previously 
uncharacterized phosphorylation sites. However, there is still a vast amount of work 
required in this area. Given that there are clearly some functional redundancies between 
SK1 and SK2, it is fascinating that the main activating phosphorylation site on SK1, Ser225, 
is not directly conserved in SK2 (Pitson, 2011; Pitson et al, 2003). It is also intriguing that 
the proposed activating phosphorylation site on SK2, Thr578 (Hait et al, 2007), has never 
been detected by mass spectrometry on endogenous SK2 (Hornbeck et al, 2015), nor was it 
detected by our previous mass spectrometry analyses of overexpressed SK2. However, it is 
possible that the peptide containing this modification may not be suitable for detection by 
these methods. Nevertheless, further work is required to understand SK2 regulation by 
phosphorylation. 
 
The Ser363 residue has been shown to be phosphorylated on endogenous SK2 by 37 studies 
employing mass spectrometry analyses (Hornbeck et al, 2015). It is therefore likely to be a 
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common, potentially important modification of SK2. While many of these studies were 
examining a broad range of pathways, cell types and conditions, making it difficult to 
narrow down the potential function of this modification, it is interesting to note that Ser363 
phosphorylation was found to be significantly increased upon use of the AMPK activator 
AICAR, as determined by SILAC labeling and quantitative phosphoproteomic analysis 
(Hoffman et al, 2015). Furthermore, another group detected Ser363 phosphorylation by 
using a phospho-(Ser/Thr) AMPK substrate antibody to purify peptides prior to LCMS 
(Hornbeck et al, 2015). Notably, AMPK was ranked as the lead candidate kinase for Ser363 
phosphorylation from the Kinexus in vitro phosphorylation screen, and as such, future 
studies should validate whether AMPK is the kinase responsible for phosphorylating SK2 at 
Ser363.  
 
Interestingly, phosphorylation and binding prediction software predicts that, in addition to 
AMPK being a likely candidate kinase for Ser363 phosphorylation, phospho-Ser363 is also 
predicted to be a binding site for the pro-survival 14-3-3 chaperone protein (Obenauer et al, 
2003). 14-3-3 has known roles in binding to phospho-client proteins and mediating their 
transport out of the nucleus via a 14-3-3 NES (Rittinger et al, 1999) or by sequestering them 
in the cytoplasm (Grozinger & Schreiber, 2000), which fits with the hypothesis and my data 
suggesting that Ser363 is involved in SK2 nuclear export or exclusion from the nucleus. As 
predicted, phospho-Ser363 fits the requirements of a 14-3-3 binding motif; the most 
common motif is Rxx(pS/pT)xP, where the +2 proline residue appears to be dispensable in 
more than half of client proteins (Johnson et al, 2010). Ser363 has an arginine at the -3 
position but does not contain the +2 proline residue. Generally 14-3-3 will bind to its clients 
within a flexible region (Johnson et al, 2010), and indeed Ser363 resides within the unique 
central domain of SK2 that is predicted to be disordered (Wang et al, 2014a). As 14-3-3 is a 
dimeric protein, it generally binds to two phospho-residues on the client protein, where the 
two binding sites need to be at least 15 residues apart to allow for the conformation required 
to bind each dimer (Johnson et al, 2010). It is tempting to speculate that the second 
phospho-residue binding site on SK2 may be Ser383 or Ser385, the phosphorylation sites 
20-22 residues downstream of Ser363 that were previously reported to regulate SK2 nuclear 
export (Ding et al, 2007). This would explain why manipulating these sites generates the 
same phenotype as mutating Ser363 to alanine, if they are both involved in 14-3-3 binding 
to be exported from the nucleus. The PKD-mediated export of SK2 from the nucleus 
involving Ser383/Ser385 was shown to be CRM1 dependent (Ding et al, 2007), however 
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14-3-3 contains an NES and does transport clients from the nucleus in a CRM1-dependent 
manner (Lopez-Girona et al, 1999; Rittinger et al, 1999).  
 
AMPK is known to shuttle between the cytoplasm and the nucleus (Kodiha et al, 2007), and 
can therefore phosphorylate nuclear substrates. Notably, another 14-3-3 client protein, 
CREB-regulated transcription coactivator 2 (CRTC2; also TORC2), can be phosphorylated 
by AMPK which promotes 14-3-3 binding at this site and sequestration of CRTC2 to the 
cytoplasm (Koo et al, 2005; Screaton et al, 2004). However, upon dephosphorylation of this 
site, CRTC2 no longer binds to 14-3-3 and can translocate to the nucleus in order to perform 
its roles in transcriptional regulation (Koo et al, 2005; Screaton et al, 2004). As SK2 also 
has nuclear roles in regulating transcription (Hait et al, 2009; Nagahashi et al, 2015; 
Wallington-Beddoe et al, 2014), this could represent an interesting mechanism of regulating 
SK2 nuclear localisation and it will be of interest to determine whether SK2 is regulated in 
this manner involving Ser363, AMPK and 14-3-3.  
 
Through collaboration with Dr. Adam Cole (Garvan Institute of Medical Research, Sydney), 
we were able to identify SK2 as a novel substrate of GSK3 in vitro and in cells. Due to time 
constraints, however, no further characterisation of the GSK3 phosphorylation site, Ser437, 
or the associated priming site, Ser441, was performed. This will be a particularly interesting 
modification to examine in the future, as GSK3 is highly expressed in the brain and, like 
SK2 and dynein as discussed above, has been implicated in various neurological diseases 
such as Alzheimer’s disease (Cole, 2012). Therefore, again it will be interesting to 
determine whether there is an interplay between SK2 regulation by GSK3 and its interaction 
with dynein, and if so, whether this has specific implications in the brain. 
 
 
7.4 Implications for targeting SK2 in cancer 
 
Evidence is now building to suggest that SK2 is a therapeutically valid target in cancer. 
Indeed, from the accumulating studies demonstrating reduced tumour growth upon SK2 
knockdown or inhibition (French et al, 2010; Liu et al, 2013; Panneer Selvam et al, 2015; 
Weigert et al, 2009), it doesn’t appear that its pro-apoptotic roles are causing any negative 
or complicating effects upon its targeting in cancer. However, this will require further 
examination, as the roles of SK2 may vary in different tissues and cell types, and as 
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discussed previously, there are some cancer types where SK2 does appear to be 
predominantly downregulated (Figure 7.1). If SK2 switches to having more of an oncogenic 
role in cancer cells, but in normal cells or certain cell types its pro-apoptotic role is more 
dominant, then this could have potentially negative implications for blocking SK2 
systemically. On the other hand, this may in fact provide a beneficial therapeutic window, 
where SK2 is more dispensable in normal cells but cancer cells perish because they rely 
more upon the oncogenic signalling SK2 provides (a non-oncogene addiction as previously 
described for SK1 (Vadas et al, 2008)). Therefore, better understanding of the complexity of 
SK2 and its roles and regulation may assist in developing better strategies to target only the 
oncogenic pool of SK2, which may reduce or prevent any potential side effects of broadly 
targeting SK2. 
 
The SKs have gained interest as therapeutic targets in GBM. It is well accepted that 
resistance to radiotherapy and chemotherapy can involve mechanisms to metabolise and 
clear the excess pro-apoptotic ceramide that is produced from these treatments (Senchenkov 
et al, 2001; Sordillo et al, 2016), and hence targeting SK in combination with these therapies 
can overcome this resistance (Bektas et al, 2009; Riccitelli et al, 2013). Notably, elevated 
levels of S1P are found in GBM tumours compared to normal brain tissue (Abuhusain et al, 
2013), and SK1 has been shown to be overexpressed in GBM and its expression correlates 
with poor patient survival (Abuhusain et al, 2013; Van Brocklyn et al, 2005). However, all 
of the in vivo studies have been performed using either SK1-specific or dual SK1/SK2 
inhibitors, but not SK2-selective inhibitors, despite its genetic knockdown inducing GBM 
cell death in vitro (Van Brocklyn et al, 2005). Granted, SK2 is not consistently found to be 
overexpressed in GBM, however my studies suggest that it may still play an important role 
in the production of S1P and potentially, therefore, in resistance to current therapies. Again, 
this may depend heavily on the subcellular localisation of SK2, as it may contribute towards 
metabolizing ceramide to S1P when at the plasma membrane, when IC-1 is downregulated, 
but it has also been shown to contribute to ceramide production via a salvage pathway at the 
ER (Maceyka et al, 2005). Therefore, inhibition of SK2 in GBM may be beneficial, and 
should be examined in future studies. However, it will also be of interest to explore other 
avenues of targeting only oncogenic SK2, potentially by manipulating regulators that dictate 
its subcellular localisation. Unfortunately, increasing cellular IC-1 levels in GBM or 
manipulating dynein in any way is not feasible as a therapeutic approach, but a better 
understanding of how the interaction is regulated, for example through phosphorylation, 
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may lead to new strategies to target kinases or phosphatases to increase the interaction 
between SK2 and dynein and drive SK2 away from the plasma membrane. Building on my 
in vivo studies, it will also be of interest to employ a more physiological orthotopic model of 
GBM to explore the therapeutic benefit of targeting SK2 as well as SK2 regulation by 
dynein. 
 
A current problem in the field is a lack of truly SK2-specific inhibitors. ABC294640, which 
is currently in clinical trials for various solid and non-solid cancers, was originally pitched 
as an SK2-selective inhibitor (French et al, 2010). However, it is now known that 
ABC294640 has a plethora of additional targets that are either inhibited or degraded by the 
drug, including Des1 and SK1 (McNaughton et al, 2016). Although this complicates the fact 
of whether or not the anti-tumour properties of this compound are mediated by SK2 
inhibition, and care must be taken in linking its effects to SK2 biology, it is likely that the 
multiple targets it has are what makes it effective. An array of more potent SK2-selective 
inhibitors have recently been developed that seem to more closely recapitulate phenotypes 
observed with the genetic knockout of SK2, such as SLR080811, SLM6031434, 
SLP120701, and the most potent and selective to date, SLC4101431 (Ki = 90 nM, 100-fold 
SK2 selectivity) (Childress et al, 2017; Kharel et al, 2015; Kharel et al, 2012; Patwardhan et 
al, 2015). However, these drugs have not yet been utilised in in vivo xenograft models. 
Other as yet biologically uncharacterised potent SK2-selective inhibitors have also been 
recently reported, namely 27c and 27d (Schnute et al, 2017). Hopefully this range of newly 
developed tools will assist in exploring the roles of SK2 in cancer. 
 
 
7.5 Concluding remarks 
 
Overall, the studies outlined in this thesis have contributed new knowledge to the complex 
field of SK2 biology, and how its roles and regulation may be altered in cancer. There is, 
however, much still to discover and understand about this enigmatic enzyme, and as 
highlighted by my work, the field should move away from systems that use high-level 
overexpression to ensure that correct interpretations are made about SK2 function. From my 
work, we now know that SK2 can contribute to oncogenesis and can initiate neoplastic 
transformation when overexpressed at low levels, which coincides with plasma membrane 
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localisation and extracellular S1P production. Further, a novel interaction between SK2 and 
dynein IC revealed that dynein can transport SK2 in a retrograde direction, away from the 
plasma membrane, which appears to have implications in GBM where downregulation of 
IC-1 correlates with SK2 plasma membrane localisation. Finally, novel SK2 
phosphorylation events were explored, where Ser363 appears to regulate SK2 nuclear 
localisation, and other SK2 phosphorylation sites may control its pro-apoptotic functions. 
These findings are illustrated in Figure 7.3. 
 
Some of the key questions in SK2 biology that I believe will be critical to explore in the 
future include: (1) How are the nuclear roles of SK2 regulated, allowing it to mediate cell 
cycle arrest but also stabilize hTERT and regulate epigenetic modifications and transcription 
of genes involved in various pathways? (2) What are the tissue-specific roles of SK2 and 
how does this affect its roles in cancer? (3) How is SK2 intricately regulated by 
phosphorylation? Are all identified phosphorylation sites physiological and do they act 
individually or in concert to regulate various SK2 functions? Addressing these questions 












































Figure 7.3: Model of SK2 functions and regulation
SK2 can localise to organelles such as the mitochondria, endoplasmic reticulum and
nucleus, where it has been reported to have predominantly pro-apoptotic and anti-
proliferative functions. I have shown that SK2 can mediate survival and proliferative
signalling, and drive neoplastic transformation, and these functions coincide with enhanced
plasma membrane localisation of SK2 and increased extracellular S1P production.
Furthermore, I have shown that cytoplasmic dynein can mediate the retrograde-directed
transport of SK2, from the plasma membrane to peri-nuclear regions of the cell. I
hypothesise that SK2 subcellular localisation and function can be regulated by various
phosphorylation events, where certain phosphorylation sites will mediate its plasma
membrane localisation and proliferative functions, and others will promote its apoptotic
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The bioactive sphingolipids ceramide, sphingosine and sphingosine-1-phos-
phate (S1P) are important signalling molecules that regulate a diverse array
of cellular processes. Most notably, the balance of the levels of these three
sphingolipids in cells, termed the ‘sphingolipid rheostat’, can dictate cell
fate, where ceramide and sphingosine enhance apoptosis and S1P promotes
cell survival and proliferation. The sphingosine kinases (SKs) catalyse the
production of S1P from sphingosine and are therefore central regulators of
the sphingolipid rheostat and attractive targets for cancer therapy. Two
SKs exist in humans: SK1 and SK2. SK1 has been extensively studied and
there is a large body of evidence to demonstrate its role in promoting cell
survival, proliferation and neoplastic transformation. SK1 is also elevated
in many human cancers which appears to contribute to carcinogenesis, che-
motherapeutic resistance and poor patient outcome. SK2, however, has not
been as well characterized, and there are contradictions in the key physio-
logical functions that have been proposed for this isoform. Despite this,
many studies are now emerging that implicate SK2 in key roles in a variety
of diseases, including the development of a range of solid tumours. Here,
we review the literature examining SK2, its physiological and pathophysio-
logical functions, the current knowledge of its regulation, and recent devel-
opments in targeting this complex enzyme.
Introduction
Sphingolipids have emerged as important signalling
molecules that can regulate a vast range of cellular
processes, including cell survival, proliferation, migra-
tion, differentiation and inflammation [1–3]. Although
many enzymes are involved in regulating the relative
levels of the sphingolipids, the sphingosine kinases
(SKs) SK1 and SK2 are of particular interest as their
activity can be dynamically regulated by external
stimuli [4]. As a result, altering the levels or activity of
the SKs can play a key role in controlling cell fate,
making them attractive targets in the development of
cancer therapeutics [4–9]. Indeed, given its unequivocal
role in promoting cell survival and proliferation,
targeting SK1 has proved effective in attenuating
tumour growth and progression in a range of cancer
models (reviewed in [5]). However, investigating the
Abbreviations
dhS1P, dihydro-sphingosine-1-phosphate; dhSph, dihydrosphingosine; EGF, epidermal growth factor; ER, endoplasmic reticulum; ERK1/2,
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therapeutic potential of targeting SK2 in cancer has
only very recently gained momentum, and although
the findings are promising, the mechanisms behind
SK2 function and regulation remain poorly under-
stood. Indeed, the current literature focuses largely on
SK1, and although the exact cellular roles of SK2 are
yet to be deciphered, what is currently known about
this isoform suggests that its functions and mecha-
nisms of regulation are extremely complex. Here, we
review what is currently known about SK2 function
and regulation in both physiological and pathophysio-
logical settings, and the recent developments made in
targeting this SK isoform.
Sphingosine-1-phosphate (S1P) and
sphingolipid signalling
S1P is a biologically active phospholipid that is
derived from a network of sphingolipid synthesis and
degradation pathways [4]. Ceramide resides at the
centre of this network and can be deacylated by
ceramidase to form sphingosine, which can in turn
be phosphorylated by the SKs to produce S1P
(Fig. 1). The aforementioned reactions are reversible
and the only exit point from the cycle is the irrevers-
ible degradation of S1P to hexadecenal and
phosphoethanolamine. S1P acts as both an extracellu-
lar and intracellular signalling molecule through a
range of different pathways [10]. It can be trans-
ported out of the cell where it exists in high nanom-
olar concentrations in the blood [11,12]. This export
is mediated by members of the ABC transporter fam-
ily [13,14] and, more recently noted, by spinster
homolog 2 [15]. Upon exit from the cell, S1P can
bind to and activate a family of five G-protein cou-
pled receptors (GPCRs), referred to as S1P1–5 [16], to
elicit autocrine or paracrine signalling. Interestingly,
recent evidence suggests that S1P may engage its
GPCRs by lateral diffusion within the outer leaflet of
the plasma membrane rather than directly from the
extracellular space [17]. The S1P receptors are cou-
pled to various heterotrimeric G proteins, which sub-
sequently activate a number of downstream signalling
pathways via the modulation of extracellular-signal-
regulated kinases 1/2 (ERK1/2), small GTPases (Rac
and Rho), the phosphoinositide 3-kinase (PI3K)/AKT
pathway and phospholipase C (PLC), ultimately
modulating cell proliferation, survival and migration
[6,18]. These responses can vary in a cell- or tissue-
specific manner as a result of the differential expres-
sion of the S1P receptors and the various G proteins




































Fig. 1. Sphingolipid synthesis and
degradation pathways. Sphingolipid
structures are shown with the key enzymes
that catalyse their synthesis and
degradation.
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In addition to its extracellular signalling roles, S1P
can also act directly on a number of intracellular tar-
gets. Specifically, S1P has been shown to directly inhibit
histone deacetylase (HDAC) 1/2 activity [20], activate
the E3 ubiquitin ligase activity of tumour necrosis fac-
tor (TNF) receptor-associated factor 2 (TRAF2) [21],
interact with prohibitin 2 to mediate mitochondrial res-
piration [22] and possibly modulate the activity of
p21-activated kinase 1 [23]. A recent study also sug-
gested that S1P may contribute to cytochrome c release
from mitochondria via modulation of BAK, although
the direct interaction of S1P with BAK was not
described [24]. Through the activation of these varied
signalling pathways, S1P can act to promote cell sur-
vival, proliferation and migration, as well as regulate
differentiation, angiogenesis and inflammation
[6,25,26]. Interestingly, an intracellular role for the
S1P5 GPCR has also been proposed, where the colocal-
ization of the receptor and SKs to centrosomes may
indicate a novel function in regulating cell division [27].
In contrast to S1P, the sphingolipids ceramide and
sphingosine, which both lie directly upstream of S1P
in the sphingolipid biosynthetic pathway (Fig. 1), are
promoters of apoptosis. Ceramide has been found to
directly activate a number of protein targets that
appear to mediate its pro-apoptotic functions, includ-
ing protein phosphatases 1 [28], 2A [28] and 2C [29],
protein kinase C (PKC) f [30,31], the kinase suppres-
sor of ras [32] and cathepsin D [33]. Furthermore,
sphingosine can bind to and initiate the phosphoryla-
tion and inactivation of the pro-survival adaptor pro-
tein 14-3-3 [34]. Given these opposing functions, the
current dogma is that a delicate balance must be main-
tained between the relative levels of pro-apoptotic
ceramide and sphingosine and pro-survival S1P, with
this equilibrium, referred to as the ‘sphingolipid rheo-
stat’, playing an important role in dictating cell fate
[6,35]. SK is a central regulator of this equilibrium,
residing at the critical junction between pro-prolifera-
tive, pro-survival S1P and pro-apoptotic sphingosine
and ceramide (Fig. 1). Therefore, understanding how
SKs are regulated is important to understand their role
not only in controlling cell fate but also in aberrant
survival and proliferative signalling in disease states
like cancer. Indeed, there are a multitude of studies
that implicate S1P and the SKs in cancer development,
survival and metastasis, and this field has been exten-
sively reviewed [4–9,36,37].
Sphingosine kinases
Two SKs exist in mammalian cells, namely SK1 and
SK2. In humans they are generated from two distinct
genes, SPHK1 and SPHK2, which are located on
chromosome 17 (17q25.2) and 19 (19q13.2), respec-
tively. Although human SK1 and SK2 vary consider-
ably in size (384 and 618 amino acids for SK1a and
SK2a, respectively) [38], they share 80% similarity and
45% overall sequence identity, with almost all of the
polypeptide sequence of SK1 aligning with regions of
the larger SK2. All known eukaryotic SKs share five
highly conserved regions within their sequence (termed
C1–C5; see Fig. 2), which appear to encompass the
regions necessary for ATP binding and catalysis [39].
The additional residues present in SK2 result from
both its extended N-terminus and an additional central
proline-rich region not found in SK1 or in any other
protein (Fig. 2). While there are currently no crystal
structures available to allow for comparisons between
the two SKs, the central proline-rich region of SK2
appears to coincide with the sphingosine binding
region of these enzymes [4]. Consistent with this,
biochemical information regarding substrate specific-
ity and inhibition of the two SKs suggests that signifi-
cant differences exist in their substrate binding
pockets. As discussed below, SK2 is more promiscuous
than SK1 in the substrates it can phosphorylate, and
several isoform-selective inhibitors that target the
sphingosine binding site of these enzymes have been
developed [47,48]. Surprisingly, due to the high degree
of sequence conservation in the putative ATP binding
regions, a recent study has also reported an ATP
competitive inhibitor that shows high selectivity for
SK1 [47], suggesting that at least some divergence
also occurs between SK1 and SK2 in this pocket.
Experimental evidence has demonstrated that the
single point mutant G212E completely abolishes SK2
catalytic activity [49] just like the comparable
G82D mutation in SK1 [50], via interfering with ATP
binding [51].
While the activity of both SK isoforms can be
enhanced by various cytokines and growth factors (see
below), both enzymes also possess intrinsic catalytic
activity independent of eukaryotic post-translational
modifications that results in cellular SK activity even
in the absence of agonist stimulation [52–54]. This
basal SK activity has been proposed to facilitate a
housekeeping role in maintaining cellular sphingosine
and ceramide levels [55].
Although both SK isoforms are ubiquitously
expressed in all human tissues, some differential
expression is apparent, with SK1 most highly
expressed in lung, spleen and leukocyte [56] whereas
SK2 is highest in the kidney and liver [38]. Further-
more, while both SKs are expressed throughout
embryonic development in the mouse, SK1 expression
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peaks earlier (E7–E11), with SK2 being more strongly
expressed in the later stages (E15–E17) [38].
Roles and regulation of SK1
Of the two SKs, SK1 is by far the most well studied.
SK1 has been widely described as a pro-survival, pro-
proliferative enzyme, demonstrated initially by studies
showing that overexpression of SK1 increases cell sur-
vival and proliferation [57] and induces neoplastic
transformation [58]. Numerous studies have implicated
SK1 in cancer development and progression, where
expression levels of SK1 are found to be upregulated
in a number of human solid tumours [59–65] and
higher SK1 expression is correlated with poor patient
prognosis [62,63,66–72]. Notably, targeting SK1 by
chemical inhibition or genetic ablation has successfully
reduced tumour growth in mice [59,71,73–80]. The
oncogenic signalling mediated by SK1 is dependent
upon its activation and translocation to the plasma
membrane [81]. SK1 is a cytoplasmic protein that,
upon agonist stimulation, can be phosphorylated by
ERK1/2 at Ser225, which results in a 14-fold increase
in catalytic activity and also facilitates the transport of
SK1 to the plasma membrane via binding to
calcium- and integrin-binding protein 1 [82,83]. Inter-
estingly, other phosphorylation-independent mecha-
nisms of SK1 translocation to the plasma membrane
have also been documented [84,85]. At this location,
SK1 catalyses the formation of S1P from plasma-mem-
brane-associated sphingosine, which appears to facili-
tate both the efficient release of S1P to act
extracellularly on cell surface S1P receptors and the
interaction with intracellular targets to mediate down-
stream signalling and promote cell survival, prolifera-
tion, migration, differentiation, angiogenesis and
inflammation [2,3,6].
Roles of SK2
SK2-induced apoptosis and growth arrest
Contrary to the roles of SK1 in pro-proliferative, pro-
survival signalling, many of the early studies examin-
ing SK2 function found that its overexpression
induced cell cycle arrest and apoptosis [49,86,87]. A
putative BH3 domain was identified within SK2, which
has been proposed to mediate its pro-apoptotic func-
tions, at least in part, through interaction with Bcl-xL,




























































Fig. 2. SK2 post-translational modifications and regulatory domains. SK2 contains two unique regions within its sequence not conserved in
SK1, or in any other protein. These regions, the N-terminus and the central proline-rich region (white), have been expanded to show the
amino acid sequence. Shaded regions represent sequences that are highly conserved in both SK1 and SK2, including the five evolutionarily
conserved regions C1–C5. The SK2b isoform is shown here. SK2 possesses an NLS within the N-terminus and an NES within the central
region. A lipid binding domain also spans the N-terminus, allowing SK2 to interact with phosphoinositides. Data from direct analysis of SK2
or from mining of global phosphoproteomic studies and the PhosphositePlus resource [40] identified a number of phosphorylation sites that
have been detected on SK2. Phosphorylation events detected in human SK2 where the site is conserved in mouse or rat SK2 sequence are
shown in red, while those not conserved in rodent SK2 are shown in white. Phosphorylation events detected in mouse or rat SK2 where
the site is conserved in the human sequence are shown in yellow. Ser355, Thr359 and Thr371 were identified in untreated HeLa cells [40].
Ser105 and Ser107 were identified in HeLa cells treated with rapamycin and EGF [41]. Ser387, Ser389, Thr404, Ser414 and Ser484 were
identified in HeLa cells treated with double thymidine block (G1- or S-phase) or nocodazole (M-phase) [42,43]. Ser399, Ser414, Ser473 and
Ser477 were identified in HEK293 cells stably transfected with angiotensin II (Ang II) type 1 receptor treated with Ang II ligand [44]. Thr402
was identified in Jurkat cells treated with calyculin and pervanadate [40]. Ser419, Ser421, Ser387 and Thr614 were identified by direct
analysis of overexpressed SK2 and validated by mutagenesis [45,46].
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SK2–Bcl-xL interaction was only demonstrated follow-
ing SK2 overexpression, however, the physiological
significance of the proposed association remains
unclear. More recently, mitochondrial localization of
SK2, and specifically S1P generation at this site, was
shown to contribute to BID-mediated activation of
BAK, and subsequent mitochondrial membrane per-
meabilization and cytochrome c release [24]. Another
recent study also demonstrated that nuclear S1P and
dihydro-S1P produced specifically by SK2 inhibited
HDAC1/2 activity, leading to increased histone acety-
lation at distinct promoters and resulting in enhanced
transcription of cyclin-dependent kinase inhibitor p21
and transcriptional regulator c-fos [20]. While this is
likely to contribute to the growth arrest previously
associated with SK2, the notion that SK2 can act as
an epigenetic and transcriptional regulator suggests
that there may be more downstream effects of its
nuclear activity yet to be elucidated.
While a number of the initial studies describing pro-
apoptotic effects of SK2 are based on data from
forced overexpression of this protein, several studies
also suggest this role for endogenous SK2. For exam-
ple, small interfering RNA (siRNA) mediated knock-
down of endogenous SK2 in HEK293 or mouse
embryonic fibroblasts prevented the induction of apop-
tosis by TNF-a [24,86], while mesangial cells taken
from SK2/ mice displayed greater resistance to
staurosporine-induced apoptosis than wild-type or
SK1/ cells [89]. Thus, these studies support the
notion that SK2 can have an opposite role to SK1 in
the control of cell survival. Indeed, the tissue distribu-
tion and developmental expression of the SKs would
also suggest that they may have differing roles.
Interestingly, although there is compelling evidence
to suggest that SK2 can have a physiological role in
mediating apoptosis, there are now many studies also
supporting a role for SK2 in promoting survival and
proliferation, much like SK1. siRNA-mediated knock-
down of SK2 has been shown to enhance apoptosis
and decrease chemotherapeutic resistance in a number
of cancer cell types [63,90–92]. Interestingly, a recent
study also proposed that nuclear S1P, produced by
SK2, can act as an antagonist to the retinoic acid
receptor b, attenuating ligand-stimulated tumour sup-
pressor effects of this nuclear receptor in human colon
carcinoma cells [93]. This is an intriguing concept, as
nuclear-localized SK2 and S1P have been shown in a
number of other studies to have exclusively anti-prolif-
erative roles [20,86,87].
Notably, there appears to be at least some func-
tional redundancy between the two enzymes as dele-
tion of either Sphk1 or Sphk2 in mice produces no
gross phenotype [94–96], and yet a double knockout of
the two genes is embryonic lethal from defects in neu-
rological and vascular development [96].
SK2 in cancer
Despite the apparent roles, in some situations, of SK2
in inducing apoptosis and growth arrest described
above, a number of studies have emerged that demon-
strate a role for SK2 in cancer promotion, similar to
SK1. Notably, targeting SK2 in a range of cancer cell
lines can have more of an anti-cancer effect than tar-
geting SK1 [63,97]. A number of in vivo studies have
reported that tumour growth can be significantly
attenuated following the genetic ablation of SK2 in
MCF-7 breast tumour xenografts [98] or the pharma-
cological inhibition of SK2 in a range of mouse
tumour models, including breast [48,99,100], kidney
[101], pancreatic [101], liver [102] and colon cancer
[103]. Furthermore, SK2 was shown to play a role in
transforming growth factor (TGF) b induced migra-
tion of oesophageal cancer cells [104] and epidermal
growth factor (EGF) induced migration of breast can-
cer cells [105], suggesting a potential role for SK2 in
metastasis.
SK2 in inflammation and immune cell regulation
The role of SK in inflammation and immune cell func-
tion has been widely investigated, with most studies
focusing on SK1 and its role in promoting inflamma-
tion. SK1 can be both post-translationally activated
and transcriptionally upregulated by a number of
inflammatory signalling molecules such as TNF-a,
interleukin (IL)-1b, interferon (IFN)-c, IgE and C5a
[106–108], and is shown to regulate monocyte, macro-
phage and neutrophil function during the inflamma-
tory response [108]. However, despite SK1 having a
clear role in promoting/enhancing inflammation, the
role of SK2 in the inflammatory response is controver-
sial, with many of the studies suggesting that SK2 may
in fact be anti-inflammatory. It was demonstrated,
using a breast cancer xenograft model, that SK2-
deficient MCF-7 cells had increased levels of pro-
inflammatory cytokines and decreased levels of
anti-inflammatory IL-10, which coincided with a
decrease in tumour growth [98]. Furthermore, unlike
SK1, siRNA-mediated knockdown of SK2 in a murine
collagen-induced arthritis model led to more aggressive
disease and production of pro-inflammatory cytokines
[109]. Notably, Samy et al. employed an adoptive
transfer model of inflammatory bowel disease (IBD)
where T-cell-deficient C.B-17 scid mice were injected
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with SK2/ T cells, and found that mice receiving
these cells had increased levels of pro-inflammatory
cytokines and worsened intestinal inflammation than
those receiving wild-type T cells, seemingly due to
enhanced IL-2 responsiveness and increased expression
of activated pSTAT5 [110]. Therefore, SK2 may play a
role in negatively regulating IL-2 signalling by attenu-
ating STAT5 activation.
In contrast to the studies described above, the
pharmacological inhibition of SK2 demonstrated
anti-inflammatory effects in murine IBD models of
ulcerative colitis [111] and Crohn’s disease [112] and in
rodent models of inflammatory arthritis [113], suggest-
ing that SK2 can promote inflammation. However, it
is intriguing that opposite effects are observed only
with the pharmacological inhibition of SK2 compared
with genetic ablation and RNA interference, suggest-
ing either that the loss of SK2 protein elicits a differ-
ent effect in comparison with its inhibition or that the
SK2-specific inhibitor may be affecting different path-
ways.
It also appears that SK2 may have opposite roles to
SK1 in mast cell function. Upon IgE-mediated cross-
linking of the FceRI receptor, the Src family kinases
Lyn and Fyn facilitate the activation and translocation
of the SKs to the plasma membrane [114]. In murine
mast cells, SK2 has emerged as the major producer of
intracellular S1P and, unlike SK1, appears to mediate
calcium influx and initiate downstream activation of
PKCa, PKCb and nuclear factor jB (NF-jB), leading
to degranulation and the production of eicosanoids
and cytokines [115]. However, in human mast cells
SK1 appears to be more important, initiating degranu-
lation, migration and cytokine production, with the
roles of SK2 seemingly limited to the production of
TNF-a and IL-6 [116]. This variation in SK function
between species is intriguing, in particular as S1P
strongly induces degranulation of human mast cells
but only weakly in murine mast cells [115,116]. It has
therefore been suggested that SK2 may function as an
intrinsic regulator of mast cell responses, independent
of the S1P receptors, whereas SK1, which is largely
responsible for the production of circulating S1P, may
regulate extrinsic mast cell responsiveness [115,116].
Indeed, sphingosine is reported to inhibit calcium
influx [117,118] and so SK2 may function, at least in
murine mast cells, by decreasing the intracellular levels
of sphingosine, thus allowing for calcium entry and
the subsequent activation of downstream signalling
pathways.
S1P plays an important role in immune cell function
by regulating lymphocyte egress from lymphoid tis-
sues, and it appears that SK2 may mediate this
response by regulating the transport and circulation of
S1P between tissues. A study by Sensken et al. demon-
strated that the uptake of blood-borne S1P into
peripheral tissues is SK2-dependent, and suggested
that intracellular SK2 may play a role in importing
S1P into cells and directing it to S1P lyase for degra-
dation and maintenance of an S1P gradient [12]. In
agreement, SK2/ mice resist lymphopenia induced in
wild-type mice by the inhibition of S1P lyase in lym-
phoid tissues [12]. This is an intriguing concept, partic-
ularly as a number of groups have reported that
SK2/ mice, surprisingly, have significantly increased
levels of plasma S1P compared with wild-type mice
[12,115,119–121]. Another obvious explanation for this
phenomenon is that SK1 may be upregulated as a
compensatory mechanism for SK2 ablation, and
indeed this has been examined with somewhat conflict-
ing results. Some studies have found no differences in
SK1 mRNA levels or activity in SK2/ mice com-
pared with wild-type mice [12,120]. Conversely, a
recent study found increased SK1 mRNA and protein
levels in SK2/ mice [121], which was proposed to
arise from a compensatory mechanism involving a
reduction of HDAC1/2 inhibition by SK2, leading to a
decrease in histone acetylation and an indirect tran-
scriptional upregulation of SK1 [20,121]. Notably,
however, transgenic mice with ubiquitous overexpres-
sion of SK1 (approximately 20-fold over endogenous)
did not show a significant increase in blood S1P levels
[122].
Interestingly, murine SK2 was found to interact with
the cytoplasmic region of the murine IL-12 receptor
b1, mediating downstream IL-12 signalling and pro-
duction of IFN-c [123]. It still remains to be elucidated
whether this interaction and function of SK2 also
occurs in humans.
SK2 in other diseases
SK2 also appears to be influential in a number of
other disease states. A recent study demonstrated that
the inhibition or downregulation of SK2 resulted in
decreased proteolytic activity of BACE1, the rate-limit-
ing enzyme for amyloid-b peptide production [124].
Targeting SK1 also had the same effect, although the
role of SK2 in this process appeared more prominent.
Interestingly, SK2 activity was also found to be upreg-
ulated in the brain of Alzheimer’s disease patients, sug-
gesting a role for SK2 in this disease [124].
There are conflicting reports on the role of SK2 in
ischaemia-reperfusion (IR) injury, although generally it
appears to play a protective role. The genetic deletion
of SK2, but not SK1, in mice significantly increased
5322 FEBS Journal 280 (2013) 5317–5336 ª 2013 FEBS
Roles, regulation and inhibitors of sphingosine kinase 2 H. A. Neubauer and S. M. Pitson
kidney damage following renal IR [125], and SK2 was
found to mediate the protective effects of ischaemic
preconditioning in cerebral [126,127] and myocardial
[128,129] IR injury. Interestingly, cerebral ischaemia
was found to increase SK2 mRNA levels in the brain
[130] and hypoxic preconditioning rapidly and tran-
siently upregulated SK2 activity and protein levels in
cerebral microvessels [127]. Conversely, however, SK2
inhibition greatly reduced liver injury and improved
survival following hepatic IR, coinciding with a reduc-
tion in liver S1P levels and mitochondrial permeabili-
zation [131], suggesting that the role of SK2 in IR
injury may be tissue-specific.
It has also been reported that the pharmacological
inhibition of SK2 resulted in reduced disease severity
in rodent models of osteoarthritis [132] and diabetic
retinopathy [133]. It therefore appears that the roles
of SK2 are complex and, as such, the dysregulation of
SK2 can facilitate the development of a number
of highly varied disease states. In this regard, SK2 is




Like SK1, the catalytic activity of SK2 can be rapidly
increased upon stimulation by a number of agonists,
including EGF [105], TNF-a [134], IL-1b [134], cross-
linking of the IgE receptor FceRI [114], and phorbol
esters [105]. Hypoxia was also found to rapidly acti-
vate SK2 in vivo [127] and in cultured lung cancer cells
[91]. Like SK1, SK2 activation can occur via phos-
phorylation by ERK1/2 [46]. In cells, agonist-induced
activation of SK2 increases its catalytic activity by
2- to 6-fold [105], which is comparable with that
observed for SK1 [83]. Interestingly, however, in vitro
phosphorylation of SK2 by ERK1 resulted in a mod-
est doubling of catalytic activity of this enzyme [46],
which is less than the 14-fold increase observed for the
same analysis of SK1 [83]. Enhanced SK2 activity fol-
lowing interaction with eukaryotic elongation factor
1A has also been described, suggesting that alternative
mechanisms of SK2 activation may occur in addition
to that involving phosphorylation [135].
Subcellular localization
The subcellular localization of the SKs, and hence the
compartmentalization of generated S1P, is widely
accepted to play an important role in dictating their
function [136,137]. It is well established that in order
for SK1 to mediate pro-survival, pro-proliferative and
oncogenic signalling it must relocalize from the cyto-
plasm to the plasma membrane [81]. By comparison,
the subcellular localization of SK2 appears to be much
more complex than for SK1, in line with its more com-
plex functions. SK2 possesses nuclear localization
(NLS) and export (NES) signals [45,87], with the NLS
positioned within the N-terminus and the NES located
within the central proline-rich region that is not con-
served in SK1 (Fig. 2). Interestingly, when localized to
the nucleus, SK2 has been shown to inhibit DNA syn-
thesis [87], as well as regulate epigenetic modifications
via interaction with and modulation of HDAC1/2 [20].
SK2 localization also appears to vary according to
both cell type and cell density. For example, SK2 pre-
dominantly localizes to the nucleus in HeLa cells
whereas in HEK293 cells it is mainly cytoplasmic [87].
Moreover, it has been described that, as COS-7 fibro-
blasts became more confluent in culture, the propor-
tion of SK2 localized to the nucleus increased [87],
suggesting that SK2 may be involved in a contact inhi-
bition response to decrease cell proliferation.
It has also been demonstrated that under stress con-
ditions SK2 localizes to the endoplasmic reticulum
(ER) [49]. S1P production at the ER can fuel the
sphingosine salvage pathway driven by ER-localized
S1P phosphatases and ceramide synthases, to ulti-
mately generate pro-apoptotic ceramide [49]. Interest-
ingly, artificially targeting SK1 to the ER or nucleus
can allow the otherwise pro-survival enzyme to pro-
mote apoptosis [49,87]. Moreover, mitochondrial local-
ization of SK2 has been shown to promote apoptosis
via S1P and BAK-dependent membrane permeabiliza-
tion and cytochrome c release [22,24]. Therefore the
additional pro-apoptotic functions of SK2 not shared
with SK1 seem to be mediated by its localization to
intracellular membranes like the ER, mitochondria
and nucleus. It should be noted that a lipid binding
domain has been identified within the N-terminal
region (residues 1–175) of SK2, not conserved in SK1
[138]. This domain was shown to be a requirement for
SK2 to interact with phosphoinositides and may there-
fore facilitate its differential localization at internal
membranes [138].
The subcellular localization of SK2 also influences
substrate availability, and recent findings suggest that
this may be another major contributor to the pro-
apoptotic function of SK2. Both SK1 and SK2 can
utilize dihydrosphingosine (dhSph) as a substrate [5].
Since dhSph is generated at internal membranes such
as the ER, SK1 targeted to the plasma membrane can-
not utilize this substrate pool [139]. Unlike S1P, the
specific role of dihydro-S1P (dhS1P) in oncogenic
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signalling is not well characterized. Interestingly, how-
ever, Hait et al. demonstrated that dhS1P and S1P
generated by SK2 in the nucleus can both inhibit
HDAC1/2 and regulate epigenetic modifications to
inhibit proliferation [20]. Furthermore, a very recent
study employing photodynamic therapy and nanopar-
ticle technology to treat solid tumours has reported
that the anti-tumour efficacy of this novel technology
is directly attributed to the production of dhS1P spe-
cifically by SK2, leading to a reduction in immune
suppressive myeloid cells expanded in response to
tumour-associated inflammation [140]. Notably, this
study also demonstrated that administering dhS1P in
tumour-bearing mice prevented tumour growth and
increased survival, as opposed to S1P which increased
tumour growth [140]. Therefore, dhS1P and S1P
appear to have opposing roles in oncogenic signalling,
dependent on their differential cellular compartmental-
ization. Again, this highlights the importance of SK2
subcellular localization and consequent access to sub-
strates in relation to its function.
While most studies have described SK2 localization
to internal organelles to either induce apoptosis or eli-
cit growth arrest, one study has shown SK2 to mediate
pro-proliferative S1P receptor signalling when localized
to the plasma membrane [141]. This process, however,
appears linked to the activation of caspase-1 in apop-
totic cells, which cleaves the N-terminus of SK2 and
allows it to be exported from the cell, potentially medi-
ated by the flipping of phosphatidylserine following
interaction of the enzyme with the plasma membrane
[141].
Post-translational modifications
Although the activating phosphorylation site in SK1
(Ser225) occurs within a region that is divergent in
SK2, studies have shown that SK2 catalytic activity
also increases following phosphorylation by ERK1/2
[46]. This activation of SK2 has been suggested to
involve the phosphorylation of Ser351 and/or Thr578
on SK2a (Ser387 and Thr614 on SK2b) [46], although
notably Ser351 is not conserved in mouse or rat SK2.
Phosphorylation of SK2 also appears to regulate its
nuclear–cytoplasmic shuttling, with protein kinase D
mediated phosphorylation of either Ser419 or Ser421
within the NES of SK2 promoting its nuclear export
[45].
Recent global phosphoproteome analyses have iden-
tified 13 other Ser/Thr phosphorylation events in
endogenous human SK2, most of which occur within
unique regions of SK2 not conserved in SK1 (Fig. 2)
[40–44]. Nine of these residues are conserved in mouse
and rat, while another three phosphorylations have
been detected in mouse and rat SK2 (see Fig. 2) but
have yet to be confirmed in human [142]. No func-
tional studies have been performed to define the regu-
latory significance of these novel phosphorylation sites.
However, it is possible that these modifications play a
role in the isoform-specific regulation of SK2 and may
therefore provide an elegant yet undoubtedly complex
mechanism to allow for the emerging functional com-
plexity of SK2.
SK2 isoforms
Two isoforms of SK2 have been described and charac-
terized [38,86]. Unless otherwise specified, in the litera-
ture ‘SK2’ generally refers to the shorter isoform
(SK2a or SK2-S), which is consequently the best char-
acterized. The larger isoform (SK2b or SK2-L) has an
additional 36 amino acids at the N-terminus and
appears to arise from the use of an alternative start
codon (Fig. 3). While not expressed in mice, SK2b
appears the predominant form of SK2 in several
human cell lines and tissues [86]. This may suggest that
C1 C2 C3 5C4CSK2a
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Fig. 3. Human sphingosine kinase 2 isoforms. All known SKs possess five evolutionarily conserved regions (labelled C1–C5) important for
catalytic activity [51]. There are two confirmed human SK2 isoforms (SK2a and SK2b) and two further putative or predicted SK2 isoforms.
Compared with SK2a (GenbankTM accession number AF245447), SK2b (RefSeq NM_020126) has an additional 36 amino acids at the
N-terminus and appears to be the most abundant human isoform [86]. SK2c (GenbankTM accession number EF107108) has an additional
N-terminal extension as well as an extended C-terminus; however, this putative isoform has only been detected at the mRNA level in some
human cells [143]. A fourth SK2 isoform (bottom) has been predicted by in silico analyses (GenbankTM accession number AK000599) and
varies considerably at the C-terminus compared with SK2a. The expression of this isoform has not been examined, but since it does not
possess the conserved C4 and C5 regions it is unlikely to have SK activity.
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in fact SK2b is physiologically the more important
human SK2 isoform, although very few studies have
specifically examined its functions. It has been demon-
strated that serum deprivation leads to an increase in
SK2b expression and promotes the translocation of
SK2b to the nucleus where it can inhibit DNA synthe-
sis [86]. Furthermore, SK2b appears to phosphorylate
some of its substrates at a higher rate than SK2a,
including FTY720 (4-fold increase) and sphingosine
(1.3-fold increase) [144]. This trend would suggest that
the N-terminal extension of SK2b may introduce a
conformational change that promotes catalytic activity
[144].
A third isoform of SK2 (SK2c; GenbankTM accession
number EF107108) has been reported, which possesses
an N-terminal extension and an additional C-terminal
sequence [143] (Fig. 3). SK2c mRNA has been
reported to be detected in some human cells, but no
other analysis of this putative SK2 isoform has been
described [143]. In silico analysis has predicted a
fourth SK2 splice variant (GenbankTM accession num-
ber AK000599) that differs from SK2a at the C-termi-
nus (from residue 256; see Fig. 3), although there is
yet no physical evidence for the existence of this SK2
isoform. Notably, this putative SK2 variant does not
possess the C4 and C5 regions proposed to contain the
sphingosine binding and catalytic residues, respectively
[4,145], which have previously been shown to be
essential for SK activity [51]. Therefore, even if this
SK2 variant was expressed it is unlikely to have SK
activity.
SK2 substrate specificity
Both SK1 and SK2 can utilize D-erythro-sphingosine
and D-erythro-dihydrosphingosine as substrates; how-
ever, SK2 appears to be more promiscuous and can
phosphorylate a range of other biological and syn-
thetic lipids with much greater efficiency than SK1 [5].
These substrates include phytosphingosine [38], x-biot-
inyl D-erythro-sphingosine [146] and, surprisingly, the
SK1-specific inhibitor D,L-threo-dihydrosphingosine
[38]. SK2 is also responsible for phosphorylating the
immunosuppressive agent FTY720, converting it to its
active form FTY720-P [144,147,148]. Although SK1
can also phosphorylate FTY720 in vitro, albeit less
efficiently than SK2 [144,147,148], levels of FTY720-P
in SK2/ mice administered FTY720 are negligible,
indicating that SK1 does not significantly contribute
to FTY720 phosphorylation in vivo [149]. The ability
of SK2 to phosphorylate a larger pool of substrates
suggests that the sphingosine binding pockets of SK1
and SK2 differ slightly in conformation. Although the
functional significance of this is currently unknown, it
has allowed for these subtle structural differences to be
exploited in the generation of isoform-specific SK
inhibitors.
SK2 inhibitors
A number of SK inhibitors have been generated which
show potential for development as therapeutics for can-
cer and some other diseases [5]. The majority of these
specifically inhibit either SK1 or both SK isoforms. In
the last few years, however, several SK2-specific inhibi-
tors have emerged that demonstrate promising thera-
peutic properties (Table 1). Notably, recently
developed potent SK1-selective inhibitors have demon-
strated surprisingly limited anti-cancer properties com-
pared with less isoform-specific SK inhibitors
[47,150,151]. This notion, coupled with the promising
anti-cancer effects of the current SK2-specific inhibitors
(described below), suggests that in some cancers SK2
may be a more important target for cancer therapy.
ABC294640
There is growing interest in the therapeutic effects of
the first described SK2-selective small molecule inhibi-
tor ABC294640 [48]. This orally bioavailable agent
specifically targets SK2 in a sphingosine-competitive
manner with a Ki of 9.8 lM. No effect was observed
with ABC294640 on SK1, or the closely related diacyl-
glycerol kinase, at concentrations up to 100 lM
[47,48]. There have been a number of studies docu-
menting the effects of this inhibitor in a range of dis-
ease models. Notably, ABC294640 has been shown to
significantly decrease tumour growth in vivo in an
array of different tumour models in mice [48,99–103].
Furthermore, ABC294640 also seems to have thera-
peutic potential for a number of other diseases, where
attenuated disease progression was observed in rodent
models of osteoarthritis [132], rheumatoid arthritis
[113], Crohn’s disease [112], ulcerative colitis [111] and
diabetic retinopathy [133]. Biochemically, ABC294640
has been reported to decrease S1P and increase cera-
mide levels in cells [47,48], decrease plasma S1P levels
in mice [102], inhibit TNF-a-induced NF-jB activation
[99], as well as inhibit the activation of STAT3, AKT
and ERK2, and decrease the expression of STAT3 and
ERK2 [47]. There are conflicting reports on the mode
of action whereby ABC294640 induces cell death, with
some studies demonstrating that apoptotic pathways
are activated [48,100] and others describing the pres-
ence of autophagy markers [47,152]. Perhaps the mech-
anism by which SK2 inhibition leads to cell death is
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tissue- and disease-specific, as different diseases may
exploit different roles of SK2, and so inhibition of
SK2 in each case may affect different pathways. Nev-
ertheless, targeting SK2 with ABC294640 appears to
have significant therapeutic potential and, as such, this
compound is currently in phase I clinical trials for the
treatment of advanced solid tumours.
Notably, in addition to its SK2 inhibitory proper-
ties, ABC294640 can also bind to the oestrogen recep-
tor and act as a partial antagonist like tamoxifen
[153]. While this additional action of ABC294640 com-
plicates some studies into the role of SK2 in disease, it
does suggest that, with dual targeting of SK2 and the
oestrogen receptor, this agent may be particularly
Table 1. Structures and inhibitory properties of SK2 inhibitors. ND, not determined.




































16  1.3 7.9  0.6 [59]
a No inhibition detected up to 100 lM.
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beneficial in the treatment of oestrogen-receptor-positive
breast cancer.
SLR080811
SLR080811 has been recently described as an SK2-spe-
cific inhibitor [119]. This agent is a competitive inhibi-
tor with respect to sphingosine, with a Ki of 1.3 lM for
SK2 and a 10-fold weaker affinity for SK1
(Ki = 12 lM). Interestingly, SLR080811 was not found
to have significant effects on survival or proliferation of
U937 human leukaemia cells, despite reducing S1P gen-
eration and total S1P levels in these cells [119]. The rea-
sons for this unexpected finding remain unclear, with
further studies required to examine whether this is spe-
cific to this cell line or a more general effect.
Notably, use of this inhibitor in vivo resulted in an
increase in blood S1P levels in wild-type mice [119],
which is the same unexpected phenomenon observed
in SK2/ mice [12,115,119,120] but different from
that observed with ABC294640 [102]. Again, the rea-
sons for these differences require further analysis.
Trans-12a
Amidine-based compounds have recently been
described as SK inhibitors [154]. To this end, a quater-
nary ammonium salt, labelled trans-12a, was synthe-
sized and found to selectively inhibit SK2 over SK1,
with Ki values of 8 and 60 lM, respectively [154]. In
U937 human leukaemia cells, trans-12a was reported to































































Fig. 4. Signalling and regulation of SK2. Activation of SK2 is mediated by ERK1/2 phosphorylation in response to a range of growth factors
and cytokines. SK2 can undergo nuclear–cytoplasmic shuttling, regulated by NLS and NES. The latter is regulated by PKD-mediated
phosphorylation, which promotes the nuclear export of SK2. In the nucleus, SK2 can interact with histone H3–HDAC1/2 complexes
following phorbol ester treatment of cells, and S1P produced by SK2 here can inhibit HDAC1/2-mediated deacetylation of histone H3 and
promote transcription of cyclin-dependent kinase inhibitor p21 and the transcriptional regulator c-fos. SK2 can also localize to the ER in
response to serum deprivation or cell density, and S1P produced here can fuel a sphingolipid ‘salvage’ pathway that ultimately results in the
generation of pro-apoptotic ceramide via ER-localized S1P phosphatase and ceramide synthase. Mitochondrial localization of SK2, and
subsequent S1P production, can mediate apoptosis via BAK-dependent membrane permeabilization and cytochrome c release. SK2 contains
a putative BH3 domain through which it can interact with, and presumably sequester, the pro-survival molecule Bcl-xL, to induce apoptosis.
The release of active SK2 from the cell can occur following cleavage at the N-terminus by caspase-1, which can then allow for the
production of extracellular S1P. Upon IgE-mediated crosslinking of the FceRI receptor, Lyn and Fyn can mediate the activation and
translocation of SK2 to the plasma membrane to initiate downstream mast cell responses. Murine SK2 has also been found to interact with
the IL-12 receptor b1, mediating downstream IL-12 signalling and production of IFN-c.
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suggesting inhibition of SK2, although there was no
detectable change in S1P levels in these cells [154].
K145
K145 is another SK2-selective inhibitor that acts in a
competitive manner with respect to sphingosine, with a
Ki of 6.4 lM [155]. No significant inhibition of SK1 or
ceramide kinase was observed by K145 at concentra-
tions up to 10 lM [155]. At 10 lM, K145 also caused a
> 40% decrease in the activity of CaMKIIb, and at
4 lM a significant decrease in phospho-ERK and phos-
pho-AKT was observed, implying that K145 may
function as a dual-pathway inhibitor [155]. Cellular
studies demonstrated that, in contrast to SLR080811,
K145 can inhibit growth and induce apoptosis in
U937 human leukaemia cells. In vivo K145 was found
to reduce tumour volume in JC mammary adenocarci-
noma and U937 leukaemia xenograft models [155],
with comparable anti-tumour activity by both oral
administration (50 mgkg1) and intraperitoneal injec-
tion (15 mgkg1).
(R)-FTY720-OMe
Lim et al. have recently synthesized an SK2-selective
inhibitor, (R)-FTY720 methyl ether, based on the
structure of the SK2-specific substrate FTY720 [156].
(R)-FTY720-OMe is a competitive inhibitor with
respect to sphingosine, inhibiting SK2 with a Ki of
16.5 lM and showing no significant inhibition of SK1
activity at 50 lM [156]. In LNCaP prostate cancer
cells, (R)-FTY720-OMe was found to decrease expres-
sion of SK2 and stimulate autophagy, but not apopto-
sis, in these cells [157].
SG-12
SG-12 was synthesized amongst a panel of 15 potential
SK2-specific inhibitors and was found to inhibit SK2
with an IC50 of 22 lM while not affecting SK1 activity
[158]. SG-12 induced cell death in CHO-K1 cells, con-
sistent with SK inhibition, but since it also inhibits
PKC the actual mechanism mediating these effects is
not clear [158]. Interestingly, it has now been proposed
that SG-12 is phosphorylated by SK2 and this modifi-
cation is critical for its ability to induce cell death [159].
SKI-II
SKI-II is one of the most commonly used SK inhibi-
tors [59]. Among numerous findings, SKI-II has been
shown to decrease S1P production and induce apoptosis
in tumour cells in vitro [59,76] and inhibit tumour
growth in a mammary adenocarcinoma xenograft
mouse model [76]. SKI-II has been used widely as a
direct SK1 inhibitor [133,160–162], although more
recent studies suggest it acts mainly to target SK1
through enhancing degradation of this enzyme
[163,164]. While commonly stated as an SK1-specific
inhibitor, analyses of this compound revealed that
SKI-II inhibits SK2 with slightly higher affinity than
SK1 (Ki values of 7.9 and 16 lM for SK2 and SK1,
respectively) [47], but, contrary to SK1, does not
induce degradation of SK2 [157].
Concluding remarks and future
perspectives
There is now considerable evidence that SK2 can phys-
iologically perform both pro- and anti-survival func-
tions in cells. It is not currently understood how this is
regulated, but it is almost certainly influenced by the
subcellular localization of SK2, which may vary
according to the cell and tissue type, disease state or
environmental stimuli. It is notable, however, that the
role for SK2 specifically in cancer and disease, as
determined by pharmacological or genetic ablation
in vivo, is overwhelmingly in support of survival and
proliferation. Therefore, despite its ability to promote
apoptosis under some conditions, it still appears that
targeting SK2 in cancer and other diseases will provide
substantial therapeutic benefits. However, as the func-
tional complexity of SK2 becomes more apparent
(Fig. 4), it stands to reason that the mechanisms regu-
lating its contrasting roles need to be identified in
order to develop therapeutics to specifically target the
pro-survival functions of this enzyme.
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Introduction
Sphingolipids are an important family of cellular molecules that 
form critical structural components of cell membranes, as well as 
performing numerous signaling functions1. Of the many enzymes 
responsible for the biosynthesis and metabolism of sphingolipids, 
the sphingosine kinases (SKs) are of particular interest to study 
as they catalyze the formation of sphingosine 1-phosphate (S1P), 
and in doing so can promote cell survival, proliferation, migration 
and angiogenesis2. Both sphingosine kinases, SK1 and SK2, have 
been shown to be upregulated in various human cancers and both 
have documented roles in mediating oncogenesis3,4. However, 
where SK1 and its roles in cancer development are relatively well 
characterized, SK2 remains somewhat enigmatic as, in addition to 
the pro-cancer functions it shares with SK1, SK2 can also facilitate 
cell cycle arrest and cell death5,6.
SK2 is ubiquitously expressed in all cells and tissues, but is 
expressed most highly in the liver, kidney and brain7. At the 
mitochondria, SK2-generated S1P has been proposed to facilitate 
the activation of Bak and subsequent mitochondrial membrane 
permeabilisation and cytochrome c release5. Notably, SK2 can 
also function as an epigenetic regulator, where S1P produced by 
nuclear-localized SK2 can inhibit the activity of histone deacety-
lases 1/2 resulting in increased transcription of specific genes, 
such as cyclin-dependent kinase inhibitor p21 and transcriptional 
regulator c-fos8. As SK1 does not appear to localize as promi-
nently to these internal organelles, it is believed that the subcellular 
localization of SK2 is critical for the additional functions it per-
forms. However, the mechanisms regulating the localization and 
functions of SK2, allowing it to switch between pro-apoptotic and 
pro-survival under certain conditions, remain poorly understood.
In order to study SK2 and better characterize its roles in normal 
cells as well as in cancer, reliable and properly validated tools 
are required. Antibody-based methods, such as immunoblotting 
(IB), immunoprecipitation (IP) and immunofluorescence (IF), are 
particularly useful as tools to examine and visualize important 
aspects of SK2 biology, like subcellular localization, expression 
and interaction with regulatory proteins. A number of groups in 
the field have taken to generating their own in-house SK2-specific 
polyclonal antibodies9,10, but to our knowledge there has been no 
systematic validation of commercially available SK2 antibodies. 
Here, we compare two commercially available SK2 antibodies, 
and validate the suitability of their use in IB, IP and IF using 
various human and mouse cells lines. We have examined a rabbit 
polyclonal SK2 antibody from Proteintech, which is raised against 
amino acids 266–618 of recombinant human SK2a, and a rabbit 
polyclonal SK2 antibody from ECM Biosciences, which is raised 
against a synthetic peptide corresponding to amino acids 36–52 of 
human SK2a. The Proteintech SK2 antibody has been previously 
utilized in one publication for IB11, and the ECM Biosciences 




The following SK2 antibodies were assessed: rabbit polyclonal anti-
SK2 (ECM Biosciences; anti-Sphingosine Kinase 2 (N-terminal 
region); #SP4621, lot #1) and rabbit polyclonal anti-SK2 
(Proteintech Group, Inc; anti-SPHK2; #17096-1-AP, lot #00010361). 
The ECM Biosciences SK2 antibody was raised against a 
synthetic peptide coupled to keyhole limpet hemocyanin (KLH), 
corresponding to amino acids 36–52 of human SK2a, and was 
affinity purified with the SK2 peptide (without KLH). It is reported 
by the manufacturer to have cross-reactivity with rat and mouse 
SK2 [human, mouse and rat SK2 share 100% sequence identity in 
this region (determined using the align tool and protein sequences 
from www.uniprot.org)], and has been assessed by the manufacturer 
for use in IB and enzyme-linked immunosorbent assay (ELISA). 
The Proteintech SK2 antibody was raised against truncated recom-
binant GST-tagged human SK2a (amino acid residues 266–618 
generated in Escherichia coli using the PGEX-4T plasmid). The 
SK2 target antibodies were then affinity purified using 6xHis-
tagged antigen protein (to remove GST-specific antibodies) and 
then again with the immunising GST-tagged antigen protein. It is 
reported to have cross-reactivity with rat and mouse SK2 [80.2% 
sequence identity between human and mouse SK2, and 80.2% 
sequence identity between human and rat SK2 in this region 
(determined using the align tool and protein sequences from 
www.uniprot.org)], and according to the manufacturer can be 
employed for IB, ELISA, IP and immunohistochemistry. Mouse 
anti-α-tubulin (DM1A; Abcam; #ab7291) is a mouse monoclonal 
antibody, which was used as a loading control for IB analyses, at a 
dilution of 1:5,000. All antibody details, including information for 
secondary antibodies used, are provided in Table 1.
Cell culture
Human embryonic kidney (HEK) 293 cells (CellBank Australia; 
#85120602) and HeLa human cervical cancer cells (ATCC; 
#CCL-2) were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Gibco, Thermo Fisher Scientific Inc.), containing 10% 
heat-inactivated fetal bovine serum (FBS; Bovagen), 1 mM HEPES, 
penicillin (1.2 mg/ml) and streptomycin (1.6 mg/ml). Cells were 
grown at 37°C with 5% CO
2
 in a humidified incubator. Primary 
mouse embryonic fibroblasts (MEFs) were generated from both 
wildtype (WT) C57/Bl6 and Sphk2-/- C57/Bl617 mouse embryos at 
14.5 days post coitum. The fibroblasts were isolated and cultured 
as described above, except they were maintained at 37°C in a 
humidified atmosphere with 10% CO
2
.
RNAi knockdown of SK2
siRNA-mediated knockdown of SK2 was performed using human 
SPHK2 siGENOME SMARTpool siRNA (Dharmacon), which 
targets the following sequences: CCACUGCCCUCACCUGUCU, 
GCUCCUCCAUGGCGAGUUU, GAGACGGGCUGCUCCAUGA, 
CAAGGCAGCUCUACACUCA. Cells were seeded and grown 
to a cell density of approximately 50%, and were then transfected 
      Amendments from Version 1
Following the reviewers’ comments, this revised version of 
the manuscript now includes additional comments in the 
Conclusion section addressing the low expression of SK2 protein 
in many cell lines, which may impact on immunoblotting and 
immunofluorescence detection. It also includes further discussion 
on the splice isoforms of human SK2. 
See referee reports
REVISED
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with 30 nM (final concentration) of either human SK2 siRNA or 
siGENOME non-targeting siRNA control pool (Dharmacon), 
using Lipofectamine RNAiMAX (Life Technologies), as per the 
manufacturer’s protocol. Cells were incubated with the siRNA 
complexes at 37°C for 48 h.
Immunoblotting
Specific details for all reagents used can be found in Table 2. 
Cells were pelleted by centrifugation (400 × g, 5 min, 4°C) and 
washed in cold phosphate buffered saline (PBS). Cell pellets were 
resuspended in extraction buffer [EB; 50 mM Tris/HCl buffer 
(pH 7.4) containing 150 mM NaCl, 10% glycerol, 1 mM EDTA, 




, 10 mM NaF, 10 mM 
β-glycerophosphate, 1 mM dithiothreitol (DTT) and protease 
inhibitor cocktail (Roche)], and lysed by bath sonication (4× 30 sec 
on/off). Lysates were clarified (17,000 × g, 15 min, 4°C) and equal 
amounts of protein [as determined by a Bradford protein assay 
(Bio-Rad Laboratories)] were mixed with 5× Laemmli sample 
buffer, boiled at 100°C for 5 min, and separated by SDS-PAGE on 
a Criterion™ XT Bis-Tris 4–12% gradient gel (Bio-Rad Labora-
tories). Proteins were then transferred to nitrocellulose membrane 
(Pall Life Sciences) at 400 mA for 1 h. Membranes were blocked 
with 5% skim milk in PBS containing 0.1% Triton X-100 (PBS-T) 
for 1 h at room temperature, with gentle rocking. Membranes were 
probed with rabbit anti-SK2 antibodies diluted in Signal Boost 
primary antibody diluent at 1:1,000 (ECM Biosciences: 1 µg/ml; 
Table 1. Details of primary and secondary antibodies.
Antibody Manufacturer Catalogue number RRID
Rabbit anti-SK2 ECM Biosciences SP4621 AB_2619719
Rabbit anti-SK2 Proteintech 17096-1-AP AB_10598479
Mouse anti-α-tubulin Abcam ab7291 AB_2241126
Goat anti-rabbit IgG HRP Thermo Fisher Scientific 31460 AB_228341
Goat anti-mouse IgG HRP Thermo Fisher Scientific 31430 AB_228307
Normal rabbit IgG Cell Signaling Technology 2729 AB_2617119
Goat anti-rabbit Alexa Fluor 488 Thermo Fisher Scientific A-11008 AB_143165
Table 2. Reagents used for immunoblotting.
Process Reagent Manufacturer Catalogue number Concentration
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Table 3. Reagents used for immunoprecipitation
Process Reagent Manufacturer Catalogue number Concentration
Magnetic Labelling (µMacs) Protein A µBeads 
Protein G µBeads
Miltenyi Biotech 130-071-001 
130-071-101
Proprietary
Washing Columns EB -DTT (described in methods) 








1× Laemmli Protein Loading 
Buffer
























Table 4. Reagents used for immunofluorescence
Process Reagent Manufacturer Catalogue number Concentration
Washing PBS 1x
Fixing Paraformaldehyde Santa Cruz 
Biotechnology
sc-281692 4% in PBS




Bovine Serum Albumin (BSA) 
PBS-T
Sigma Aldrich A7906 3% w/v
Nuclear Staining DAPI (4’,6-diamidino-2-
phenylindole)
Roche 10236276001 0.2 µg/ml in PBS
Mounting Fluorescent Mounting Medium Dako S3023 Proprietary
Proteintech: 687 ng/ml) overnight at 4°C with gentle rocking. 
Alternatively, membranes were probed with mouse anti-α-tubulin 
antibody diluted in 5% skim milk in PBS-T at 1:5,000 (200 ng/ml) 
for 1 h at room temperature, with gentle rocking. Following 
primary antibody incubation, membranes were washed 3 × 5 min 
in 5% skim milk in PBS-T at room temperature with gentle 
agitation. Membranes were probed with goat anti-rabbit 
horseradish peroxidase (HRP) secondary antibody diluted in 
Signal Boost secondary antibody diluent at 1:10,000 (40 ng/ml), or 
goat anti-mouse HRP secondary antibody diluted in 5% skim milk 
in PBS-T at 1:10,000 (40 ng/ml), for 1 h at room temperature, with 
gentle rocking. Membranes were washed 3 × 5 min in 5% skim 
milk in PBS-T at room temperature with gentle agitation, and 
proteins were visualized using enhanced chemiluminescence 
(ECL) on a LAS-4000 luminescence image analyser (Fujifilm). 
Exposure times are indicated in the figure legends for each blot.
Immunoprecipitation
HEK293 cell lysates were prepared as for immunoblotting, with 
the exclusion of DTT in the extraction buffer (EB–DTT). Protein 
concentration was determined from clarified lysates, and 800 µg 
total protein was transferred to fresh tubes and made up to 300 µl in 
EB–DTT. In total, 20 µl of diluted lysate was removed and mixed 
with 5× Laemmli sample buffer for immunoblot analysis. Immu-
noprecipitation was performed using the µMacs magnetic system 
(Miltenyi Biotec; see Table 3 for reagent details). Rabbit anti-SK2 
antibodies (4 µg; ECM Biosciences 1:75 or Proteintech 1:52) or 
rabbit IgG isotype control antibody (4 µg), as well as 50 µl each 
of Protein A and G µBeads were added to the lysate, mixed gently 
and incubated on ice for 30 min. µMacs columns were placed onto 
a magnetic stand, equilibrated with 200 µl EB–DTT, and lysate/
antibody/bead complexes were run through the columns. Columns 
were washed four times with 200 µl EB–DTT, and once with 100 µl 
low salt wash buffer, before the addition of 20 µl hot 1× Laemmli 
sample buffer for 5 min. Immunoprecipitates were then eluted with 
50 µl hot 1× Laemmli sample buffer and collected in fresh tubes. 
Samples were boiled and 25 µl was analysed by SDS-PAGE and 
immunoblotting as described above.
Immunofluorescence staining
Cell lines were seeded onto coverslips coated with poly-L-lysine 
(Sigma-Aldrich) in a 12-well plate (HEK293: 1.5 ×105 cells/well; 
HeLa: 7.5 ×104 cells/well; MEF: 3 ×104 cells/well). Cells were 
allowed to bed down overnight at 37°C in DMEM with 10% 
FBS. The following day (for HEK293 and HeLa cells), cells were 
treated with siRNA as described above, and incubated for 48 h. 
The following immunofluorescence staining protocol was then 
performed, with all steps carried out at room temperature (see 
Table 4 for reagent details). Cells were washed once in PBS, 
fixed in 4% paraformaldehyde for 10 min, washed three times in 
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PBS-T, and permeabilized for 10 min in PBS-T. Cells were then 
blocked in 3% bovine serum albumin (BSA) in PBS-T for 30 min, 
and incubated for 1 h with anti-SK2 antibodies (4 µg/ml; ECM 
Biosciences 1:250 and Proteintech 1:172) diluted in 3% BSA/ 
PBS-T. Cells were washed five times in PBS-T, and then incubated 
with goat anti-rabbit AlexaFluor 488 secondary antibody (1:500) 
for 1 h. After washing five times in PBS-T, cell nuclei were 
stained with DAPI (0.2 µg/ml) for 5 min. Cells were then washed 
twice in PBS, coverslips were partially dried and mounted onto 
slides using fluorescence mounting medium (Dako), and then 
left to set overnight. Fluorescence microscopy and imaging were 
performed using a Carl Zeiss LSM 700 confocal microscope, with 
Zen 2011 (Black Edition) version 8.1.5.484 software. All microscope 
settings, including gains, were kept constant for each cell line, 
allowing direct comparison between antibodies.
Controls
Various controls were used in these studies. Immunoprecipitations 
were performed with IgG isotype control antibody to control for 
any non-specific binding of proteins to the antibodies. Primary 
antibodies were also omitted from the immunofluorescence 
protocol to control for background fluorescence of the secondary 
antibody alone. siRNA-mediated SK2 knockdown as well as 
Sphk2-/- MEFs were utilized to verify the specificity of the SK2 
antibodies to their target.
Results
Proteintech SK2 antibody demonstrates target specificity 
and sensitivity by immunoblot
Both SK2 antibodies examined in the present study are reported 
by their respective manufacturers to be able to detect endogenous 
SK2 by IB. To determine the selectivity of the anti-SK2 antibodies, 
we performed IB analyses using two human cell lines (HEK293 
and HeLa) that had been treated with either scrambled control 
or SK2-directed siRNA, as well as WT and Sphk2-/- MEFs. The 
Proteintech anti-SK2 antibody detected a single prominent 
band at the correct molecular weight for SK2 (~65 kDa), which 
was decreased or absent in the knockdown and knockout lines 
(Figure 1A; Dataset 118). Some faint non-specific bands were also 
detected in both the WT and Sphk2-/- MEF lysates by this antibody, 
which were not observed in the human cell lines. The ECM 
Biosciences anti-SK2 antibody did not appear to be very sensitive 
towards SK2, as no band was detected at the expected size in 
the HeLa lysates, and only very faint bands were present in the 
HEK293 and MEF lysates that were reduced or absent in the 
knockdown or knockout lines (Figure 1B). Furthermore, numer-
ous prominent non-specific bands were present in all lysates, par-
ticularly in the MEF lines, indicating a lack of selectivity of this 
antibody towards SK2. Therefore, the Proteintech anti-SK2 
antibody appears to be superior for use in IB, demonstrating both 
selectivity and sensitivity in the detection of endogenous SK2, 
particularly in the human cell lines tested.
Dataset 1. Raw images of all experimental replicates for Figure 1, 
immunoblotting experiments
http://dx.doi.org/10.5256/f1000research.10336.d145416
This dataset includes uncropped blots for all experimental 
replicates that are represented in Figure 1. Treatments and 
immunoblot methods were performed as outlined in Figure 1. Blots 
were probed with Proteintech rabbit polyclonal anti-SK2 antibody 
(A–D) or ECM Biosciences rabbit polyclonal anti-SK2 antibody 
(E–H). Anti-α-tubulin antibody was used as a loading control. O/E 
SK2 = lysate from cells overexpressing SK2, used as a positive 
control to validate the correct size of SK2. Asterisks denote other 
protein bands that were probed using other antibodies not relevant 
to this study, prior to anti-α-tubulin.
Figure 1. Immunoblot analyses of endogenous SK2 in multiple cell lines using two commercially available rabbit polyclonal anti-
SK2 antibodies. Immunoblot analyses of lysates from HEK293 and HeLa cells treated with scrambled control siRNA (si-Neg) or SK2 siRNA 
(si-SK2), and lysates from wildtype (WT) or Sphk2-/- MEFs. An equal amount (40 µg) of total protein from each sample was run in duplicate. 
After transferring to nitrocellulose and blocking, the membrane was separated and duplicate samples were probed with either (A) Proteintech 
rabbit anti-SK2 antibody or (B) ECM Biosciences rabbit anti-SK2 antibody. SK2 membranes were imaged using a 4 min exposure. The 
expected band size for SK2 is ∼65 kDa. Membranes were re-probed with mouse anti-α-tubulin antibody as a loading control (2 min exposure), 
which was detected at 55 kDa as expected. Consistent results were observed from 2-3 (HEK293 and MEF) or 3-4 (HeLa) independent 
experiments for each antibody.
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ECM Biosciences SK2 antibody is able to specifically 
immunoprecipitate SK2
We also examined whether either of the commercial anti-SK2 
antibodies could immunoprecipitate SK2 from cell lysates. The 
Proteintech anti-SK2 antibody is suggested by the manufacturer to 
be useful for IP, whereas to our knowledge the ECM Biosciences 
anti-SK2 antibody has not been previously tested for use in this 
application. Initially, using lysates from HEK293 cells, we found 
that the Proteintech anti-SK2 antibody was sometimes able to IP a 
band at the correct size for SK2 (Figure 2A); however this was not 
consistent with each experimental repeat and other proteins were 
also immunoprecipitated to a varying extent by this antibody that 
were not present in the IgG isotype control (Dataset 219).
Conversely, the ECM Biosciences anti-SK2 antibody was able 
to consistently and cleanly IP a protein of the same size as SK2 
from cell lysates, with almost no non-specific bands observed 
(Figure 2B; Dataset 219). The protein immunoprecipitated by the 
ECM Biosciences antibody was considerably enriched from the 
cell lysate and was strongly detectable by this antibody, which was 
unable to detect SK2 in the lysate input sample, consistent with 
Figure 1B. To determine if this band was in fact SK2, the ECM 
Biosciences anti-SK2 antibody was then used to immunoprecipitate 
SK2 from HEK293 lysates treated with either scrambled control 
or SK2-directed siRNA. SK2 knockdown consistently resulted in 
reduced intensity of the band enriched by this antibody (Figure 2C; 
Dataset 219), confirming that the ECM Biosciences anti-SK2 
antibody can selectively IP endogenous SK2.
Dataset 2. Raw images of all experimental replicates for Figure 2, 
immunoprecipitation experiments
http://dx.doi.org/10.5256/f1000research.10336.d145417
This dataset includes uncropped blots for all experimental 
replicates that are represented in Figure 2. SK2 
immunoprecipitation from HEK293 cell lysate, and subsequent 
immunoblotting, were performed using either (A–C) Proteintech 
rabbit anti-SK2 antibody or (D–F) ECM Biosciences rabbit  
anti-SK2 antibody. (G–I) SK2 immunoprecipitation from HEK293 
cell lysates (of equal protein) treated with scrambled control 
siRNA (si-Neg) or SK2 siRNA (si-SK2), and subsequent 
immunoblotting, were performed using ECM Biosciences rabbit 
anti-SK2 antibody.
ECM Biosciences SK2 antibody can specifically detect 
SK2 by immunofluorescence staining
Finally, we examined whether these commercially available SK2 
antibodies could selectively detect SK2 by IF. Neither antibody 
has been reported to be tested for use in IF by their respective 
manufacturers; however, the Proteintech SK2 antibody is 
recommended for immunohistochemistry. Using IF staining 
methods routinely performed in our laboratory, we compared the 
two anti-SK2 antibodies using HeLa, HEK293 and MEF cell lines. 
The Proteintech anti-SK2 antibody produced minimal staining in 
all cell lines tested (Figure 3A–C), and consequently there was no 
observable differences between the control cells and those with 
SK2 knockdown (in the human cell lines) or SK2 knockout (in the 
Sphk2-/- MEF line).
Figure 2. Comparison of two commercially available rabbit polyclonal anti-SK2 antibodies for immunoprecipitation of SK2 from 
HEK293 cell lysates. SK2 was immunoprecipitated from HEK293 cell lysate using either (A) Proteintech rabbit anti-SK2 antibody or (B) ECM 
Biosciences rabbit anti-SK2 antibody. Normal rabbit IgG antibody was used as an isotype control. Immunoprecipitates (and 40 µg lysate input) 
were subjected to immunoblot analyses and probed with (A) Proteintech rabbit anti-SK2 antibody or (B) ECM Biosciences rabbit anti-SK2 
antibody. Membranes were imaged using a 4 min exposure. Images are representative of three independent experiments for each antibody. 
(C) SK2 was immunoprecipitated from HEK293 cell lysates (of equal protein) that had been treated with scrambled control siRNA (si-Neg) 
or SK2 siRNA (si-SK2), using ECM Biosciences rabbit anti-SK2 antibody. Immunoprecipitates were subjected to immunoblot analyses and 
probed with ECM Biosciences rabbit anti-SK2 antibody. Membrane was imaged using a 4 min exposure. Image is representative of three 
independent experiments. IgG h/c = IgG heavy chain.
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Figure 3. Immunofluorescence staining analyses of endogenous SK2 in multiple cell lines using two commercially available rabbit 
polyclonal anti-SK2 antibodies. (A) HeLa or (B) HEK293 cells were treated with scrambled control siRNA (si-Neg) or SK2 siRNA (si-SK2), 
and endogenous SK2 (green) was visualised by immunofluorescence staining and confocal microscopy, using Proteintech rabbit anti-SK2 
antibody or ECM Biosciences rabbit anti-SK2 antibody. (C) Wildtype (WT) or Sphk2-/- MEFs were seeded, and endogenous SK2 (green) was 
visualised by immunofluorescence staining and confocal microscopy, using Proteintech rabbit anti-SK2 antibody or ECM Biosciences rabbit 
anti-SK2 antibody. Nuclei were stained with DAPI (blue). For each cell line, background staining was examined by staining cells (si-Neg or WT 
cells) with secondary antibody and DAPI only, and collecting images using both 488nm and 405nm lasers (SK2 + DAPI). Images were taken 
at 40× magnification; scale bars = 10 µm. Images shown are representative of more than 100 cells from each experiment, and these results 
were consistent over three independent experiments for each cell line.
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The ECM Biosciences anti-SK2 antibody did result in consist-
ently observable staining in HeLa and HEK293 cells, which was 
substantially reduced upon knockdown of SK2 (Figure 3A and B; 
Dataset 320). Hence, in these cells the ECM Biosciences antibody 
was able to selectively detect SK2 by IF. Interestingly, in HeLa cells 
SK2 detected by the ECM Biosciences antibody was predominantly 
nuclear with some peri-nuclear/cytoplasmic localization, whereas in 
HEK293 cells SK2 was cytoplasmic and nuclear-exclusion, which 
is consistent with previous reports for these cell lines9. However, 
the ECM Biosciences anti-SK2 antibody produced very strong 
peri-nuclear staining/puncta in both the WT and Sphk2-/- MEF lines 
(Figure 3C), suggesting that this staining was not specific for 
SK2 and represents non-specific binding to other proteins in this 
cell type. Increased non-specific binding of both SK2 antibodies 
to other proteins in the MEF lines was also observed when used 
for IB, so this cell type may not be suitable for use with these 
antibodies. It will remain to be determined if the same level of non-
specificity is also observed in other mouse cell lines and tissues.
Dataset 3. Raw images of additional experimental replicates for 
Figure 3, immunofluorescence experiments
http://dx.doi.org/10.5256/f1000research.10336.d145418
This dataset includes additional images from experimental 
replicates that demonstrate reproducibility of the images presented 
in Figure 3. Treatments and immunofluorescence staining methods 
were performed as outlined in Figure 3. Images were taken at 40× 
magnification; scale bars = 10 µm.
Conclusion
Commercially available antibodies raised against the SKs can 
be notorious, in our experience, for not being very sensitive or 
selective. This is accentuated by the apparent low abundance of 
SK proteins in most cells, which can be in some cases hundreds of 
fold lower than when overexpressed4,21. A number of groups have 
generated their own SK-specific antibodies; however, many 
published studies have reported the use of different commercial 
SK2 antibodies, sometimes without proper controls or valida-
tion of selectivity. Hence, we have compared two commer-
cially available SK2 antibodies and evaluated their selectivity 
towards SK2 in multiple applications using siRNA-mediated SK2 
knockdown or Sphk2-/- MEF lines.
We found that the SK2 antibody from Proteintech was able to con-
sistently detect a prominent band at the correct molecular weight 
by IB, and this band was confirmed to be SK2 by knockdown and 
knockout analyses, confirming the specificity of this antibody. The 
Proteintech antibody also resulted in virtually no non-specific 
detection of any other proteins in the HEK293 and HeLa lysates, 
but some additional faint bands were present in the MEF lines. This 
antibody has been tested by IB on various mouse tissue lysates by 
the manufacturer and many of these also gave rise to non-specific 
bands, so this will need to be considered and further validation 
may be required if this antibody is intended for use with mouse 
cells or tissues. Occasionally more than one band was detected in 
the human cell lines by the Proteintech SK2 antibody, but these 
bands also seemed to be reduced by SK2 knockdown. There are 
two characterized human SK2 isoforms22, so these bands may 
represent different SK2 variants and/or post-translationally modified 
forms of SK2. Notably, although a previous report suggested 
that the mRNA of the 69 kDa SK2b (SK2-L) isoform is the 
most abundant in many human cell lines, including HeLa cells6, 
our studies clearly suggest that the SK2a (SK2-S) isoform is the 
predominant form of SK2 protein in HeLa and HEK293 cells.
In contrast, the present results revealed that the sensitivity of the 
ECM Biosciences antibody towards SK2 by IB was poor, with a 
faint band detected only in the HEK293 and MEF lines that was 
not present in the knockdown/knockout lysates. Furthermore, 
the ECM Biosciences SK2 antibody produced many intense 
non-specific bands in all cell lines tested, demonstrating poor 
selectivity. This antibody has been used for IB analyses in 
multiple publications12–15, suggesting that it may be more suit-
able with other cell/tissue systems or conditions not tested here. 
However, in agreement with our findings, the IB analysis performed 
by the manufacturer also showed various prominent non-specific 
bands in HeLa lysates. Therefore, at least in our hands, the ECM 
Biosciences SK2 antibody was not ideal for this application.
However, the ECM Biosciences anti-SK2 antibody was superior 
for the IP of endogenous SK2, as it was able to cleanly and 
substantially enrich the protein from lysates and was confirmed 
by SK2-specific knockdown to be selective for SK2 in this appli-
cation. This antibody will therefore be a useful tool to study SK2 
function and regulation, as it can be applied to other applications 
requiring IP, such as chromatin-IP (ChIP) and rapid immunopre-
cipitation mass spectrometry of endogenous protein (RIME). 
In the present study, the Proteintech anti-SK2 antibody was incon-
sistent in its ability to IP protein at the correct size for SK2, and 
other bands of equal intensity were sometimes present.
Similarly, we found that the ECM Biosciences anti-SK2 antibody 
was able to selectively detect endogenous SK2 by IF staining in 
two human cell lines, HeLa and HEK293 cells. Furthermore, the 
observed localization of SK2 in these two cells lines was consist-
ent with previous reports9. The selectivity of this antibody was 
validated by knockdown of SK2 in these cell lines, where most 
of the staining was reduced. A very small level of staining was 
still visible after SK2 siRNA treatment, possibly owing to the 
inherently incomplete nature of siRNA-mediated knockdown. 
However, we were unable to corroborate these data with SK2 
knockout using the MEF lines, as considerable non-specific 
staining was present in this cell type, as was found for IB. Using 
identical methods, there was minimal staining observed using the 
Proteintech anti-SK2 antibody for IF, and therefore the selectiv-
ity of this antibody towards SK2 in this application could not be 
properly examined.
During this study, methods routinely used in our laboratory were 
employed, and where applicable, recommendations from the 
manufacturers for antibody dilutions and concentrations were 
followed. It is possible that further optimization for these 
antibodies may allow them to perform better in the applications 
where they were deemed not optimal. However, as our main aim 
was to directly compare the performance of these two antibodies, 
and given at least one of the antibodies performed well for each 
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application using our standard methods, further optimization was 
not performed.
Overall, based on the data from this study we would recommend 
the use of the Proteintech SK2 antibody for IB, as it demonstrated 
selectivity and sensitivity towards endogenous SK2 in the human 
cell lines tested. Furthermore, we recommend the ECM Biosciences 
SK2 antibody for IP of endogenous SK2 and for visualizing SK2 
by IF methods. Furthermore, both antibodies detected non-specific 
proteins by IB and IF in the mouse fibroblasts used, and hence 
further validation will be required to determine if this is the case 
for other mouse cells or tissues.
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ABSTRACT
While both human sphingosine kinases (SK1 and SK2) catalyze the generation 
of the pleiotropic signaling lipid sphingosine 1-phosphate, these enzymes appear 
to be functionally distinct. SK1 has well described roles in promoting cell survival, 
proliferation and neoplastic transformation. The roles of SK2, and its contribution 
to cancer, however, are much less clear. Some studies have suggested an anti-
proliferative/pro-apoptotic function for SK2, while others indicate it has a pro-
survival role and its inhibition can have anti-cancer effects. Our analysis of gene 
expression data revealed that SK2 is upregulated in many human cancers, but only 
to a small extent (up to 2.5-fold over normal tissue). Based on these findings, we 
examined the effect of different levels of cellular SK2 and showed that high-level 
overexpression reduced cell proliferation and survival, and increased cellular ceramide 
levels. In contrast, however, low-level SK2 overexpression promoted cell survival and 
proliferation, and induced neoplastic transformation in vivo. These findings coincided 
with decreased nuclear localization and increased plasma membrane localization of 
SK2, as well as increases in extracellular S1P formation. Hence, we have shown for 
the first time that SK2 can have a direct role in promoting oncogenesis, supporting 
the use of SK2-specific inhibitors as anti-cancer agents.
INTRODUCTION
The sphingosine kinases (SKs) catalyze the 
conversion of sphingosine to sphingosine 1-phosphate 
(S1P). Given that sphingosine and its precursor, ceramide, 
are pro-apoptotic molecules, and S1P mediates cell 
survival and proliferation [1, 2], the SKs are considered 
critical regulators of the balance between cell death and 
cell survival, and represent promising targets for anti-
cancer therapies [3]. The two mammalian SKs, SK1 and 
SK2, share high sequence similarity and both possess 
constitutive catalytic activity, but generally show distinct 
subcellular localization [4].
The role of SK1 in cancer is well characterized 
and has been extensively reviewed [1, 2, 5], with high 
SK1 expression observed in many different cancers and 
often correlating with poorer patient survival [5]. SK1 
overexpression promotes neoplastic transformation and 
tumorigenesis [6], and notably, targeting SK1 has been 
shown to attenuate tumor growth in numerous animal 
models [3]. In contrast, the contribution of SK2 to cancer 
is unclear. Surprisingly, despite both enzymes catalyzing 
the same reaction, most studies examining SK2 function 
have found that it has an opposite role to SK1, and can 
promote cell cycle arrest and apoptosis [7-11]. Although 
most of these studies utilized high-level overexpression 
systems, functional analysis of endogenous SK2 has 
supported this role in promoting cell death [9, 11, 12]. 
Most notably, nuclear-localized SK2 has been shown 
to act as an epigenetic regulator, through S1P-mediated 
inhibition of histone deacetylase 1/2 (HDAC1/2) activity 
and increased transcription of p21 and c-fos [13].
                  Research Paper
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Despite this general notion that SK2 is pro-
apoptotic, a number of studies have emerged that 
demonstrate a role for SK2 in promoting cancer. 
Knockdown of SK2 expression has been shown to 
enhance apoptosis and chemosensitize many cancer cell 
types [14-17]. In fact, targeting SK2 in a range of cancer 
cell lines appears to have more of an anti-cancer effect 
than targeting SK1 [14, 18]. Strikingly, several in vivo 
studies have reported that targeting SK2 significantly 
attenuated tumor growth in a range of human xenograft 
models in mice [19-23]. Increased SK2 expression levels 
also correlate with disease progression in non-small cell 
lung cancer (NSCLC) [24] and multiple myeloma [25], 
and poorer survival in NSCLC patients [24]. Recent 
work also suggests that SK2 can play a role in increasing 
telomerase activity [26], promoting the upregulation of 
c-Myc via regulation of HDAC1/2 [20], and facilitating 
the activation of ezrin-radixin-moesin proteins to promote 
EGF-induced cancer cell invasion [27], all of which may 
contribute to cancer development and progression. 
Although there is an emerging body of evidence 
suggesting that SK2 can play a role in cancer development, 
this is complicated by the known role of SK2 in facilitating 
cell death, and that, unlike SK1, SK2 overexpression has 
never been shown to promote neoplastic transformation 
and tumorigenesis. Here, we demonstrate for the first 
time that low-level SK2 overexpression, similar to 
that observed in numerous cancers, can promote cell 
proliferation, survival and neoplastic transformation, and 
that these levels of SK2 overexpression alone can drive 
tumorigenesis in vivo. 
RESULTS
SK2 expression is elevated in a wide range of 
human cancers
Despite numerous studies examining the targeting of 
SK2 in cancer, broad analysis of SK2 expression in cancer 
has not been previously performed. Thus, we examined 
SK2 expression in a wide range of human cancers using 
the public gene expression datasets in the Oncomine 
database [28]. We found that SK2 is significantly elevated 
in studies from a broad range of human cancers, including 
bladder, melanoma, esophageal, breast, lymphoma and 
leukemia (Figure 1A and Supplementary Figure S1A). 
Figure 1: Low-level SK2 overexpression is observed in human cancers, and can promote cell survival and proliferation. 
A. Heat map showing human cancers where significant (p < 1x10-4) upregulation of SK2 mRNA levels have been observed in cancerous 
tissues compared with corresponding normal tissue. Data was extracted from the Oncomine database [28], where each row represents a 
cancer subtype from an individual dataset. Further detail is presented in Supplementary Figure S1A. B. SK1 and SK2-specific activity 
upon doxycycline (dox)-induced low- and high-level overexpression in HEK293 Flp-In T-Rex cells. Data shown are mean (± range) 
of duplicate data points from a representative experiment (of more than three independent experiments). C. Lysates from the HEK293 
Flp-In T-Rex cells with doxycycline-induced low- and high-level overexpression of FLAG-tagged SK1 or SK2, or empty vector, were 
subjected to immunoblot analyses with antibodies against FLAG and α-tubulin. Blots shown are representative of at least three independent 
experiments. D. Measurement of cell proliferation in HEK293 Flp-In T-Rex cells with doxycycline (dox)-induced low- and high-level 
overexpression of SK1 or SK2, or empty vector. Data shown are mean ± SEM, n = 3-4. Statistics were performed using an unpaired 
Student’s t-test (two-tailed); ***p < 0.001, ****p < 0.0001. E. Measurement of cell death in HEK293 Flp-In T-Rex cells with doxycycline 
(dox)-induced low- and high-level overexpression of SK1 or SK2, or empty vector. Data shown are mean ± SEM, n = 4-5. Statistics were 
performed using an unpaired Student’s t-test (two-tailed); **p < 0.01, ***p < 0.001.
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Interestingly, however, this cancer-associated elevation in 
SK2 was only modest, with up to 2.5-fold higher levels 
of SK2 compared with the corresponding normal tissues. 
Notably, both SK1 and SK2 were upregulated in three 
independent datasets for diffuse large B-cell lymphoma 
(Supplementary Figure S1B), but there was no apparent 
general correlation between SK2 and SK1 upregulation in 
the other tumors examined. Indeed, in most other tumor 
datasets where SK2 was upregulated, SK1 expression 
was either unaltered or significantly downregulated 
(Supplementary Figure S1B).
Low-level SK2 overexpression enhances cell 
survival and proliferation, whereas high-level 
overexpression promotes cell death
Many studies have demonstrated that high-level 
SK2 overexpression can promote cell cycle arrest and 
cell death [7-10]. However, based on the gene expression 
analysis showing only low levels of SK2 overexpression 
in human cancers, we reasoned that more informative 
functional analysis would be gained by overexpression 
Figure 2: Generation of NIH3T3 stable cell lines with varying levels of constitutive SK2 overexpression. A. The NIH3T3 
pooled stable cell line expressing SK2 and GFP, or GFP alone (empty vector), were sorted on four separate narrow gates of varying GFP 
intensity (colored boxes in top panel), to produce new stable lines depicted as ‘very low’, ‘low’, ‘mid’ and ‘high’. These new stable lines 
were then analyzed by flow cytometry to confirm that the desired narrow GFP-expression levels were obtained as expected. GFP-negative 
control cells are depicted by a dotted line. B. SK2-specific activity of NIH3T3 cell lines stably expressing ‘very low’ (5-fold), ‘low’ (10-
fold), ‘mid’ (20-fold) or ‘high’ (440-fold) levels of SK2 overexpression (above endogenous levels), or empty vector. Data are shown as 
mean (± range) of duplicate samples from a representative experiment, of at least three independent experiments. C. Lysates from the 
NIH3T3 vector or SK2 overexpressing cell lines were subjected to immunoblot analyses with antibodies against FLAG, GFP and α-tubulin. 
Blots shown are representative of at least three independent experiments.
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of SK2 at much lower levels. To investigate this, we 
utilized human embryonic kidney (HEK) 293 cells 
engineered to express FLAG-tagged SK2 or SK1 in a 
doxycycline-inducible, concentration-dependent manner. 
Using different doxycycline concentrations in the culture 
media, we could achieve low and high SK2 and SK1 
overexpression, as determined by specific-activity (Figure 
1B) and protein expression (Figure 1C). Importantly, 
endogenous SK2 and SK1 protein levels remained 
unaltered upon induction of SK1 and SK2 overexpression, 
respectively (Supplementary Figure S2A and S2B). We 
then used this system to assess the effect of varying levels 
of SK overexpression on cell proliferation and survival. In 
agreement with previous studies, overexpression of SK2 
at high levels (over 200-fold) in this system resulted in 
decreased cell proliferation and an increase in cell death 
(Figure 1D and 1E). Strikingly, however, when SK2 
was overexpressed to much lower levels (8-fold over 
endogenous), more comparable to that seen in the cancer 
expression analysis, this induced a marked increase in cell 
proliferation and a decrease in cell death (Figure 1D and 
1E). These contrasting findings clearly demonstrate that 
the cellular levels of SK2 influence its function. Notably, 
these findings were unique to SK2, with both low- and 
high-level overexpression of SK1 resulting in a consistent 
increase in cell survival and proliferation (Figure 1D and 
1E).
SK2 can elicit oncogenic signaling and promote 
neoplastic transformation in vitro
Next, we assessed if low-level overexpression 
of SK2 could also induce neoplastic transformation, as 
had been previously observed for SK1 [6]. In contrast to 
mouse cells, neoplastic transformation of human cells is 
well known to require multiple oncogenes [29], meaning 
their use in these type of studies is problematic. Thus, to 
Figure 3: SK2 overexpressed at low levels can elicit oncogenic signaling and drive neoplastic transformation in vitro. 
A. Lysates from the NIH3T3 vector or SK2-overexpressing cell lines were subjected to immunoblot analyses and probed with antibodies 
against phospho-AKT, total AKT, phospho-ERK1/2, total ERK1/2, FLAG, GFP, SK1 and α-tubulin. Vect = empty vector with ‘low’ level 
GFP expression, chosen as a representative control. Densitometry was performed to quantify phospho-AKT and phospho-ERK band 
intensities, and is presented as a ratio of total AKT and ERK levels, respectively, and is normalized to vector. Blots shown are representative 
of three independent experiments. B. Contact inhibition of the NIH3T3 vector or SK2-overexpressing cell lines was tested using focus 
formation assays. Images shown are representative of at least three independent experiments, each performed in duplicate, using at least 
three independently generated sets of stable lines. C. Number of foci per well from the experiment shown in Figure 3B were quantified and 
the mean number of foci for duplicate wells was graphed (± range).
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examine the oncogenic potential of SK2, we transfected 
NIH3T3 mouse fibroblasts with a vector encoding SK2 
as well as green fluorescent protein (GFP) via an internal 
ribosome entry site (IRES) such that GFP and SK2 
expression were linked. We then isolated a series of cell 
lines stably expressing different levels of SK2 through the 
sorting of cells for differential GFP expression (Figure 
2A). The resulting stable cell lines were then validated 
through the analysis of SK2-specific activity (Figure 
2B) and exogenous SK2 protein levels (Figure 2C), 
which revealed stable overexpression of SK2 at 5-fold, 
10-fold, 20-fold and 440-fold over endogenous levels, 
designated ‘very low’, ‘low’, ‘mid’ and ‘high’ level SK2 
overexpression, respectively. 
Biochemical analysis of these cell lines revealed 
that ‘low’ SK2 overexpression resulted in the activation 
of oncogenic signaling pathways, as demonstrated by an 
increase in phospho-AKT and phospho-ERK1/2 levels 
(Figure 3A). Conversely, the ‘mid’ and ‘high’-level SK2 
overexpression caused a downregulation of phospho-
ERK1/2 signaling (Figure 3A), in agreement with high-
level SK2 overexpression attenuating cell proliferation. 
Also consistent with the HEK293 Flp-In T-Rex 
overexpression system, endogenous SK1 protein levels 
were unchanged in the multiple SK2-overexpressing 
NIH3T3 cell lines, as compared to vector control cells 
(Figure 3A). These cells were then utilized in in vitro 
assays of neoplastic cell transformation. Notably, in focus 
formation assays, cell lines with ‘very low’, ‘low’ and 
‘mid’-level SK2 overexpression formed foci, whereas 
cells with ‘high’-level SK2 overexpression did not 
(Figure 3B and 3C). Similar results were also observed 
in colony formation assays (Supplementary Figure S3), 
demonstrating that low-level SK2 overexpression can 
promote anchorage-independent growth in soft agar. 
Together, these data demonstrate that low-level SK2 
overexpression can elicit oncogenic signaling and induce 
neoplastic transformation of cells.
Low-level SK2 overexpression can drive tumor 
formation in vivo
Given that SK2 could promote neoplastic growth in 
vitro, we next examined if this represented full neoplastic 
transformation through analyzing the ability of these 
cells to form tumors in vivo. Hence, the series of cell 
lines with differential levels of SK2 overexpression were 
subcutaneously engrafted into the flanks of NOD/SCID 
mice, and the development of tumors assessed. Consistent 
with the in vitro data, cells with either ‘very low’ or ‘low’ 
SK2 overexpression resulted in efficient tumor formation 
in mice (Figure 4A). In stark contrast, however, cells with 
either ‘mid’ or ‘high’ SK2 overexpression showed minimal 
tumor growth (Figure 4A). All tumors were vascularized, 
as determined by CD31 staining, and showed morphology 
characteristic of fibrosarcoma (Supplementary Figure 
S4A and S4B). Notably, the tumors that developed from 
the ‘very low’ SK2 cells were significantly larger than all 
other tumors formed (Figure 4B and 4C). Overall, these 
results demonstrate for the first time that through low-level 
overexpression, SK2 can drive tumorigenesis in vivo. 
Although the SK2-expressing cells engrafted into 
mice were fractionated based on their GFP (and therefore 
SK2) expression, these cells remained pools of clones. 
While this obviates potential defects associated with 
plasmid integration into the genomes of individual clones, 
it meant that the level of SK2 overexpression observed 
for each line was an average of all cells within that line. 
Thus, we examined the expression levels of SK2 within 
the resulting tumors. Notably, every tumor that developed 
from the ‘very low’, ‘low’ and ‘mid’ SK2 overexpressing 
cells all possessed very similar levels of SK2 protein 
(Figure 4D) and catalytic activity (Figure 4E). Indeed, by 
comparison to the parental fibroblast cells, it appears that 
tumor formation resulted preferentially from cells within 
the pools with less than 5-fold SK2 overexpression (Figure 
4E). This finding suggests that this level of SK2 represents 
the optimal level to promote oncogenic signaling and 
tumorigenesis, and is consistent with the low level of 
SK2 upregulation seen in many human cancers (Figure 
1A). These results perhaps explain why only one tumor 
formed from the ‘mid’ SK2-expressing cells, as within 
this pool of cells there would likely be fewer low SK2-
expressing clones compared with the ‘low’ and ‘very low’ 
groups. Unexpectedly, the ‘high’ SK2-overexpressing 
cells also resulted in one tumor forming. Further analyses, 
however, revealed that cells within this tumor were not 
actively proliferating, whereas cells within the tumors 
generated from ‘very low’ SK2-expressing cells were 
highly positive for the proliferation marker Ki-67 (Figure 
4F). Furthermore, the level of SK2 overexpression 
within the ‘high’ SK2 tumor was quite heterogeneous, 
with only small patches of cells with high levels of SK2 
protein (Figure 4G). In fact, the majority of the tumor was 
comprised of cells with low SK2 overexpression similar 
in level to that seen in the tumors arising from ‘very low’ 
SK2-expressing cells (Figure 4G). Therefore, again, it is 
possible that a small population of cells within the original 
‘high’ cell pool drifted to low-level SK2 overexpression 
and initiated tumor formation, thus supporting the growth 
of some of the high SK2-expressing cells. Indeed, our data 
demonstrating that low SK2 overexpression supported 
enhanced cell proliferation and survival, while high 
SK2 overexpression had the opposite effect suggests 
that the high SK2-expressing cells would have been 
under considerable selective pressure towards low SK2 
overexpression.
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Figure 4: Low-level SK2 overexpression can drive proliferation and tumorigenesis in vivo. NOD/SCID mice were injected 
with NIH3T3 cell lines stably overexpressing ‘very low’ (5-fold), ‘low’ (10-fold), ‘mid’ (20-fold) or ‘high’ (440-fold) levels of SK2 
(above endogenous levels). Empty vector cells with ‘low’ level GFP expression were chosen as a representative control (Vector). A. Table 
summarizing the number of mice with tumors per cell line, 18 days post-cell injection. B. Images of the excised tumors from each group 
of NIH3T3 stable SK2 cell lines. Dashed lines indicate where the same image has been spliced together to aid interpretation. C. Weights 
of the excised tumors from each group of NIH3T3 stable SK2 cell lines. Statistics denote a significant increase in the weights of SK2 ‘very 
low’ tumors compared to tumors from the SK2 ‘low’, ‘mid’ and ‘high’ groups (* p < 0.05; Student’s unpaired two-tailed t-test). D. Equal 
amounts of total protein from the tumor tissue lysates were subjected to immunoblot analyses with antibodies against FLAG, α-tubulin 
and GFP. Each lane represents a different tumor sample. Dashed lines indicate where lanes from the same immunoblots have been spliced 
together to aid interpretation. E. SK2-specific activity from the tumor lysates was measured and graphed as mean (± range) of duplicate 
samples. These data were plotted alongside data of SK2 activity from the engrafted cell lines, which was transformed from Figure 2B 
as specific-activity (pmol S1P/min/mg protein) for the purposes of comparison. F. Dual immunofluorescence staining of overexpressed 
FLAG-tagged SK2 (red) and the proliferation marker Ki-67 (green) on the SK2 tumors. Tumor sections were counterstained with DAPI to 
indicate nuclei (blue). At least five random fields of view were imaged per tumor and representative images are shown. Scale bar = 50 µm. 
G. Levels of SK2 overexpression are heterogeneous in the SK2 ‘high’ tumor. Staining of overexpressed FLAG-tagged SK2 was visualized 
by immunohistological analyses. Multiple images were taken for each tumor and a representative field of view is shown. Arrow denotes a 
representative area of heterogeneous, intense FLAG (SK2) staining in the SK2 ‘high’ tumor. Scale bar = 100 µm.
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Differential levels of SK2 overexpression alter 
its subcellular localization and sphingolipid 
metabolism
It is well established that the subcellular localization 
of the SKs, and hence the compartmentalization of S1P 
within the cell, plays an important role in the function of 
these enzymes [30]. The oncogenic role of SK1 requires 
its translocation to the plasma membrane, a location that 
results in increased extracellular S1P production [31]. 
Furthermore, the localization of SK2 to the nucleus, 
endoplasmic reticulum (ER) or mitochondria appears to 
promote its anti-proliferative, pro-apoptotic functions [7, 
8, 11, 13]. Thus, we examined the localization of SK2 
when overexpressed at low and high levels. In the ‘high’ 
SK2-expressing cells, SK2 was strongly nuclear-localized 
(Figure 5A and 5B), in agreement with previous reports 
for this cell type [7]. In the ‘low’ SK2-expressing cells, 
however, SK2 was mostly cytoplasmic, and showed a 
significant increase in its plasma membrane localization 
(Figure 5A and 5C). Furthermore, the formation of 
extracellular S1P was significantly higher from cells 
with ‘low’-level SK2 overexpression compared to vector 
control cells (Figure 6A), consistent with our observations 
of increased SK2 at the plasma membrane in these cells. 
Interestingly, ‘high’-level SK2 overexpression resulted in 
a further increase in extracellular S1P formation (Figure 
6A), but this was only a modest doubling compared with 
the ‘low’ SK2 cells, despite these cells having greater than 
400-fold more SK2 activity.
Sphingolipid analysis revealed, somewhat 
surprisingly, that ‘low’-level SK2 overexpression had 
very little effect on the intracellular levels of S1P, 
ceramides, dihydroceramides, sphingomyelins or 
dihydrosphingomyelins (Figure 6B-6E), with the only 
change noted being a small increase in sphingosine. 
In contrast, ‘high’-level SK2 overexpression resulted 
in a significant increase in a range of ceramide species, 
sphingomyelins and dihydrosphingomyelins, as well 
as sphingosine (Figure 6B, 6D and 6E), in line with a 
previous report demonstrating that overexpressed SK2 
partially localized to the ER, and S1P produced here 
could feed into an ER/golgi-associated ‘salvage pathway’ 
to generate pro-apoptotic sphingosine and ceramide, as 
well as sphingomyelin [8]. The increase in ceramides 
and sphingosine are likely to contribute, at least in part, 
to the anti-proliferative and pro-cell death role of SK2 
in these ‘high’ overexpression cells, with the increase in 
extracellular S1P formation that was observed in these 
cells (Figure 6A) possibly insufficient to override these 
effects.
Figure 5: Varying levels of SK2 overexpression affect its subcellular localization. A. The subcellular localization of FLAG-
tagged SK2 (red) in the NIH3T3 stable ‘low’ and ‘high’ SK2-overexpressing cells was examined by immunofluorescence staining, using 
FLAG antibody. Nuclei were stained with DAPI (blue) and cell membranes were stained with antibodies against γ-catenin (green). Images 
are representative of cells observed from three independent experiments. Arrows denote representative plasma membrane localization of 
‘low’ SK2. Scale bar = 10 µm. B.-C. Cells from A. were visualized by confocal microscopy and scored based on the presence or absence 
of either B. distinct nuclear FLAG-tagged SK2 staining or C. plasma membrane-localized FLAG-tagged SK2 staining. A minimum of 
200 cells were scored per well, and data were graphed as mean (± SD) of triplicate wells from a single experiment, representative of three 
independent experiments (** p < 0.01; Student’s unpaired two-tailed t-test).
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DISCUSSION
Despite the conflicting data in the literature, our 
findings demonstrate that, like SK1, SK2 can have 
a physiological role in promoting cell survival and 
proliferation, potentially through plasma membrane 
localization. This is perhaps not surprising, as the 
individual genetic deletion of either SK1 or SK2 in mice 
does not result in any gross phenotypic abnormalities [32, 
33], whereas the double knock-out mice die in utero [34], 
suggestive of at least some functional redundancy between 
the two proteins. Like SK1, there are no mutations in 
SK2 linked to cancer, however it has been suggested that 
cancer cells can display a ‘non-oncogene addiction’ for 
SK1 [2, 35]. Given that we have now shown that SK2 can 
promote neoplastic transformation and tumorigenesis, and 
is upregulated in many human cancers, coupled with the 
anti-cancer efficacy of SK2-selective inhibitors leads us 
to postulate that a non-oncogene addiction may apply for 
both SKs in cancer. Indeed, targeting both SK isoforms 
may be the best strategy to overcome tissue and cell type-
specific differences in the roles of the SKs in different 
cancers, and in agreement, dual SK1/SK2 inhibitors show 
significant decreases in tumor burden in vivo [36, 37].
One of the most intriguing findings of our study 
is the observation that SK2 function can dramatically 
switch, depending on its expression level, from being 
pro-survival and pro-proliferative to pro-cell death and 
anti-proliferative. While it could be argued that high-level 
overexpression is non-physiological, and may generate 
Figure 6: Sphingolipid metabolism is altered when SK2 is overexpressed at varying levels. A. Rate of extracellular S1P 
formation was determined from intact vector control ‘low’, SK2 ‘low’ and SK2 ‘high’ NIH3T3 stable cell lines. Analyses were performed 
in triplicate and data are graphed as mean (± SD). Statistics denote significant increases in extracellular S1P compared to vector control 
cells (* p < 0.05, ** p < 0.01; Student’s unpaired two-tailed t-test). B.-E. Intracellular sphingolipid species were analyzed by LC-MS using 
NIH3T3 vector control ‘low’, SK2 ‘low’ and SK2 ‘high’ stable cell lines. Data are graphed as mean (± SD) of quadruplicate samples for 
B. individual ceramide species, sphingosine (Sph) and sphingosine 1-phosphate (S1P), C. individual dihydroceramide species, D. total 
sphingomyelin levels, and E. total dihydrosphingomyelin levels. Statistics denote significant increases in lipids compared to vector control 
cells (* p < 0.05, ** p < 0.01, *** p < 0.001; Student’s unpaired two-tailed t-test).
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artefacts, it is notable that previous studies have shown 
that SK2 can have physiological roles in promoting cell 
cycle arrest and apoptosis when localized to organelles 
such as the nucleus and mitochondria [11, 13]. Clearly, 
under normal conditions these pro-death roles are likely 
kept under tight regulation, so it remains possible that 
high-level overexpression circumvents these regulatory 
mechanisms. This high-level overexpression of SK2, for 
example, may lead to altered protein-protein interactions 
or post-translational modifications, altering the subcellular 
localization of SK2, from the plasma membrane to cellular 
organelles such as the nucleus, in favor of promoting cell 
death. Indeed, it has been previously reported that when 
transiently overexpressed, SK2 could interact with and 
sequester the pro-survival Bcl-xL protein [10], suggesting 
a possible mechanism for the pro-apoptotic phenotype 
we observed with high-level SK2 overexpression. 
However, despite multiple attempts, we were unable 
to detect an interaction between Bcl-xL and SK2 in our 
system, suggesting that this proposed interaction was 
unlikely to mediate the observed phenotype. Intriguingly, 
there appears to be a window whereby low-level 
SK2 upregulation confers a survival and proliferative 
advantage to the cell without inducing these pro-apoptotic 
functions. Whether a different subset of post-translational 
modifications and/or protein-protein interactions drive 
the differences in subcellular localization and function 
observed with low versus high SK2 overexpression will 
require further interrogation. 
To add further complexity, other studies have 
demonstrated that nuclear SK2 can contribute to cancer 
progression through the stabilization of telomerase 
and promotion of c-Myc expression [20, 26]. In the 
present study, SK2 was observed in the nucleus when 
overexpressed at high levels, and yet here it had an 
opposite, anti-proliferative role, which is also well 
documented [7, 13]. It is unclear how SK2 can have such 
vastly different functions within the same organelle, but it 
suggests that there must be additional factors regulating 
these processes. Indeed, the regulatory mechanisms 
controlling this enzyme remain an important, but currently 
largely unanswered question [4]. Notably, SK1 remains 
pro-survival and pro-proliferative even at high-level 
overexpression, likely due to its different subcellular 
localization to SK2 and consequent contribution to 
different sphingolipid pools within the cell. In line with 
this, previous studies have shown that artificially targeting 
SK1 to the ER can render it pro-apoptotic, like SK2 [8].
Interestingly, while cells with 20-fold (‘mid’) 
SK2 overexpression were able to form foci in vitro, they 
had decreased levels of phospho-ERK1/2 and did not 
efficiently form tumors in vivo. This may indicate that this 
level of SK2 overexpression is at the upper limit of the 
‘window’ whereby SK2 switches from being tumourigenic 
to having predominantly anti-proliferative functions. 
Conversely, 5-fold (‘very low’) SK2 overexpression 
resulted in no appreciable changes in phospho-ERK1/2 
or phospho-AKT levels, and yet these cells developed 
the largest tumors in vivo. It is therefore possible that 
S1P-mediated angiogenesis and tumor vascularization 
played more of an important role in the development of 
these tumors, given that low-level overexpression of SK2 
resulted in plasma membrane localization and increased 
formation of extracellular S1P, which is a key regulator 
of angiogenesis [38]. These observed differences also 
highlight the importance of employing in vivo models for 
assessment of full neoplastic transformation. Furthermore, 
it was surprising that ‘high’-level SK2 overexpression 
resulted in a doubling in extracellular S1P production as 
compared to the ‘low’-SK2 overexpressing cells, despite 
‘high’ SK2 overexpression resulting in decreased survival 
and proliferative signaling, and increases in pro-apoptotic 
sphingolipid species. Notably, Weigert et al. previously 
reported that transient overexpression of SK2 resulted 
in a substantial increase in S1P released from apoptotic 
cells as a result of SK2 being cleaved by caspase-1 and 
secreted from the cell [39]. This may, in part, explain our 
observed increase in extracellular S1P in the SK2 ‘high’ 
cells, which was clearly not able to facilitate any overall 
pro-survival or proliferative stimulus in these cells. It 
should be noted that Liang et al. found a significant 
increase in colitis-associated tumor development in SK2 
knockout mice, when compared to wildtype mice [40], 
suggesting that SK2 may function as a tumor suppressor 
in this model. However, these findings are likely to be 
an indirect effect as it was also shown in the study that 
the global genetic loss of SK2 caused an upregulation of 
both S1P receptor 1 and SK1 levels in the colon, with a 
concomitant increase in circulating and colonic S1P [40]. 
SK1 has been previously shown to contribute to colon 
carcinogenesis [41] and indeed, the increase in severity of 
colitis in the SK2 knockout mice was ablated by the SK1-
specific inhibitor SK1-I [40]. Furthermore, the proposed 
tumor-suppressive role of SK2 in negatively regulating 
pro-tumorigenic SK1 levels is not recapitulated with SK2-
selective inhibitors, which show efficacy in decreasing 
tumor burden in murine xenograft models [20-23].
Evidently the true functions of SK2 are complex 
and are also likely to be tissue- and cell type-specific. 
However, from our findings it is clear that SK2 represents 
an important target in cancer and future work to better 
understand how SK2 is regulated will be important for the 





The following primary antibodies were utilized: 
mouse monoclonal anti-FLAG (Clone M2 #F3165, 
Sigma-Aldrich), rabbit polyclonal anti-FLAG (#2368, 
Cell Signaling Technology), rabbit monoclonal anti-
FLAG (#14793, Cell Signaling Technology), mouse anti-
α-tubulin (#ab7291, Abcam, Cambridge, MA, USA), goat 
anti-GFP (#600-101-215, Rockland Immunochemicals, 
Limerick, PA, USA), rabbit anti-SK1 (#SP1621, ECM 
Biosciences, Versailles, KY, USA), rabbit anti-SK2 
(#17096-1-AP, Proteintech, Rosemont, IL, USA), rabbit 
anti-phospho-p44/42 MAPK (ERK1/2) Thr202/Tyr204 
(#9101, Cell Signaling Technology), rabbit anti-p44/42 
MAPK (ERK1/2) (#9102, Cell Signaling Technology), 
rabbit anti-phospho-AKT Ser473 (#9271, Cell Signaling 
Technology), rabbit anti-AKT (#9272, Cell Signaling 
Technology), mouse anti-Ki-67 (#VP-K452, Vector Labs, 
Burlingame, CA, USA), mouse anti-γ-Catenin (#610253, 
BD Biosciences) and goat anti-PECAM-1 (CD31; #SC-
1506, Santa Cruz Biotechnology, Dallas, TX, USA).
Generation of cell lines
HEK293 Flp-In T-Rex cells (Invitrogen, Life 
Technologies) with doxycycline-inducible FLAG-tagged 
SK1 or SK2 expression, or empty vector, were generated 
as previously described [42]. 
To generate NIH3T3 cells with varying levels 
of constitutive SK2 overexpression, we obtained 
a pCX-EGFP construct [43] that we initially 
modified by replacing the EGFP with a polylinker 
following digestion with EcoRI and ligation of 




to produce pCX4. pCX4-IRES EGFP was then generated 
by subcloning the IRES EGFP cassette from pcDNA3-
IRES EGFP [44] with EcoRI and NotI. pCX4-SK2(FLAG) 
IRES EGFP was then made by cloning in FLAG-tagged 
human SK2a [45] following digestion with EcoRI. 
NIH3T3 mouse fibroblasts (ATCC CRL-1658) were 
transfected with pCX4-SK2(FLAG) IRES EGFP, or empty 
vector, using Lipofectamine™ 2000 (Invitrogen) as per the 
manufacturer’s protocol. 48 h after transfection, the cells 
were sorted for GFP-positive cells using a MoFlo Astrios 
cell sorter (Beckman Coulter). A stable GFP-positive cell 
population was obtained by sorting for GFP another two 
times. The stable GFP-positive pooled line was then sorted 
on four separate narrow gates of varying GFP intensity, 
to produce new stable lines depicted as ‘very low’, 
‘low’, ‘mid’ and ‘high’. These new stable lines were then 
analyzed by flow cytometry to confirm that the desired 
narrow GFP-expression levels were obtained as expected.
Cell culture
HEK293 Flp-In T-Rex cells were cultured in 
Dulbecco’s modified Eagle’s medium (Gibco, Invitrogen), 
containing 10% fetal bovine serum (Bovagen), 1 mM 
HEPES, penicillin (1.2 mg/ml) and streptomycin (1.6 
mg/ml). NIH3T3 mouse fibroblasts were cultured in 
Dulbecco’s modified Eagle’s medium (Gibco, Invitrogen), 
containing 10% donor bovine serum with iron (DBS; 
Gibco, Invitrogen), 1 mM HEPES, penicillin (1.2 mg/ml) 
and streptomycin (1.6 mg/ml). All cells were grown at 
37°C, 5% CO2 in a humidified incubator.
For doxycycline-induced low- and high-level 
overexpression of FLAG-tagged SK1 and SK2, HEK293 
Flp-In T-Rex cells were seeded, and 24 h later media was 
removed and replaced with serum-free media containing 
0.1% bovine serum albumin (BSA; Sigma Aldrich) with 
either vehicle (methanol, 0.001% v/v final), 0.5 ng/ml 
or 100 ng/ml doxycycline (Sigma Aldrich). After 24 h 
induction, cells were harvested and lysates prepared. Cell 
proliferation and cell death were determined as previously 
described [36].
Immunoblot analysis
Cells were harvested by scraping into cold phosphate 
buffered saline (PBS), and cell pellets were resuspended 
in extraction buffer (50 mM Tris-HCl buffer (pH 7.4) 
containing 150 mM NaCl, 10% glycerol, 1 mM EDTA, 
0.05% Triton X-100, 2 mM Na3VO4, 10 mM NaF, 10 mM 
β-glycerophosphate, 1 mM dithiothreitol and protease 
inhibitor cocktail (Roche)). Cells were lysed by sonication, 
and total protein concentration was determined by a 
Bradford protein assay (Bio-Rad Laboratories, Hercules, 
CA, USA). Lysates of equal protein were separated by 
SDS-PAGE on a Criterion™ XT Bis-Tris 4-12% gradient 
gel (Bio-Rad Laboratories) under reducing conditions. 
Proteins were transferred to nitrocellulose membrane 
(Pall Life Sciences, Pensacola, FL, USA). Membranes 
were blocked using Odyssey® Blocking Buffer (LI-COR, 
Lincoln, NE, USA), and subjected to immunoblotting 
with various primary antibodies. Proteins were visualized 
using IRDye® secondary antibodies and the Odyssey® 
CLx infrared imaging system (LI-COR). Densitometry 




Focus formation assays were performed as 
described previously [6]. Briefly, cells were cultured to 
form monolayers in 6-well plates in DMEM with 1% DBS 
(Gibco, Life Technologies), and media was replenished 
every 2-3 days for a total of 3 weeks. Cells were then fixed 
in methanol, foci were stained with bromophenol blue, 
and images were taken using the Odyssey® CLx infrared 
imaging system (LI-COR).
Colony formation in soft agar
Colony formation assays in soft agar were performed 
as previously described [36]. After 14-21 days, colonies 
were quantified visually using light microscopy. Colonies 
were imaged using an Olympus MVX10 microscope.
In vivo tumor model
Experiments involving mice were conducted 
according to the guidelines from the Australian code 
of practice for the care and use of animals for scientific 
purposes 7th Edition, 2004, and with approval from the 
SA Pathology/CALHN Animal Ethics Committee and the 
University of Adelaide Animal Ethics Committee. 
The NIH3T3 cell lines expressing varying levels 
of SK2 described above were trypsinized and washed 
in PBS, and 1x106 cells were injected in 200 µl of PBS 
subcutaneously into the flank of 8 week old female NOD/
SCID mice. The empty vector cells with ‘low’ GFP 
expression were selected as a representative control group. 
Mice were examined daily to monitor tumor formation. On 
day 19, all mice were humanely killed and tumors were 
excised. Half of each tumor was fixed in 10% formalin, 
paraffin embedded and sectioned. The remaining half 
was homogenized using a pestle (Axygen) in extraction 
buffer, subjected to freeze/thawing in liquid nitrogen and 
sonication, and lysates were clarified by centrifugation at 
17,000 × g for 15 min at 4°C. 
Sphingosine kinase activity assays
SK1 and SK2 activity was determined as previously 
described, using isoform-selective assay conditions [46].
Immunohistological analyses
Immunohistological staining was performed 
as previously described [36], with the following 
modifications. For PECAM-1 (CD31) expression, 
sections were blocked with rabbit serum, incubated 
with goat polyclonal antibody to PECAM-1 (Santa 
Cruz Biotechnology) at 133 ng/ml, and biotinylated 
rabbit anti-goat secondary antibody (1:500; Abcam). For 
FLAG-tagged SK2 expression, sections were blocked 
with goat serum, incubated with rabbit polyclonal FLAG 
antibody (Cell Signaling Technology) at 150 ng/ml, and 
biotinylated goat anti-rabbit secondary antibody (1:500; 
Vector Labs). Sections were visualized on an EVOS XL 
light microscope (Life Technologies) at 20x magnification.
Immunofluorescence analyses
For dual immunofluorescence staining of 
overexpressed FLAG-tagged SK2 and Ki-67 on the 
formalin-fixed paraffin-embedded tumor tissue samples, 
sections were de-waxed, rehydrated, and antigen retrieval 
was performed by boiling in citrate buffer for 30 min. 
Sections were blocked in 10% goat serum diluted in CAS-
Block (Thermo Fisher Scientific) for 30 min. Following 
blocking, sections were incubated overnight at 4°C with 
mouse monoclonal anti-Ki-67 antibody (1:20; Vector 
Labs) and rabbit polyclonal anti-FLAG antibody (1:100; 
Cell Signaling Technology) diluted together in 10% goat 
serum/CAS-Block. Sections were then incubated for 1 
h at room temperature with goat anti-mouse AlexaFluor 
488 (1:400) and goat anti-rabbit AlexaFluor 594 (1:400) 
secondary antibodies (Thermo Fisher Scientific) diluted 
together in 10% goat serum/CAS-Block. Labelled sections 
were then mounted in Vectashield mounting medium 
containing DAPI (Vector Labs) and were imaged using 
a Zeiss LSM 700 confocal microscope (Jena, Germany). 
To examine the subcellular localization of 
overexpressed FLAG-tagged SK2, NIH3T3 SK2 ‘low’ 
and ‘high’ stable cell lines were seeded onto 8-well glass 
chamber slides (Nalge Nunc International) coated with 
poly-L-lysine (Sigma-Aldrich) at 4x104 cells/well, and 
grown overnight in DMEM with 10% DBS. Media was 
then removed and replaced with DMEM containing 0.5% 
DBS, and cells were cultured for a further 16 h. Cells 
were then fixed in 4% paraformaldehyde for 10 min, 
permeabilized for 10 min in PBS with 0.1% Triton X-100, 
and blocked in 5% goat serum in PBS with 0.1% Triton 
X-100 for 60 min. Rabbit monoclonal anti-FLAG antibody 
(1:200; Cell Signaling Technology) and mouse anti-γ-
catenin antibody (1:500; BD Biosciences) were incubated 
for 1.5 h at room temperature, followed by goat anti-rabbit 
AlexaFluor 594 and goat anti-mouse AlexaFluor 488 
secondary antibodies (1:500; Thermo Fisher Scientific) 
for 1 h. Cells were counterstained with DAPI to identify 
nuclei (blue). Fluorescence microscopy and imaging were 
performed using a Zeiss LSM 700 confocal microscope. 
Measuring rate of extracellular S1P production
Rate of extracellular S1P formation from intact 
vector control ‘low’, SK2 ‘low’ and SK2 ‘high’ NIH3T3 
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stable cell lines was determined essentially as previously 
described [47]. Briefly, cells were seeded in equal 
numbers at 80% confluence (in 20 cm2 dishes), and media 
was replaced with DMEM containing 0.5% DBS and 
incubated for a further 16 h. Cells were then labelled with 
0.5 µCi of [3H]-sphingosine (Perkin-Elmer, Rowville, 
VIC, Australia) for 30 min, after which the conditioned 
media was collected. Extracellular [3H]-S1P generated in 
the conditioned medium was extracted and analyzed by 
scintillation counting.
Intracellular sphingolipid analyses
Vector control ‘low’, SK2 ‘low’ and SK2 ‘high’ 
NIH3T3 stable cell lines were grown in DMEM with 
10% DBS to 80% confluence, media was replaced with 
DMEM containing 0.5% DBS and cells were cultured 
for 16 h. Cells were trypsinized, quenched and washed in 
PBS. Cells were pelleted in quadruplicate with 8.8x106 
cells per sample, and intracellular sphingolipid species 
were analyzed by LC-MS, as previously described [48] 
with the following minor modifications. Prepared samples 
were injected onto an Ascentis Express C18 column 
(Supelco Analytical, Bellefonte, PA, USA), and non-
natural sphingolipid internal standards were added to each 
sample to allow relative quantification. Data analysis was 
performed using Tracefinder (Thermo Fisher Scientific).
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